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Infant MLL-AF4-driven pro-B Acute Lymphoblastic Leukaemia (ALL) is the 
most common leukaemia in infants. This devastating disease, which arises in 
utero, renders the infant patients with an aggressive disease and with a 5-year 
survival rate of less than 50%. It has long been speculated that along with the 
fusion protein, the foetal origin of the disease is one of the main contributing 
factors to its aggressive nature. The first aim of this work was to identify if and 
how this was the case. Towards this end, multiple RNA sequencing 
experiments were performed comparing foetal and neonatal/adult populations 
in both humans and mice. This allowed for the identification of the 
transcriptional differences between foetal and neonatal/adult cells. The results 
showed that the foetal derived cells were characterised by a proliferative and 
oncogenic nature whereas neonatal/adult cells had a mature and immune cell-
like profile. From this it can be concluded that the foetal nature of the 
leukaemia-initiating cell could support the aggressive nature of the infant 
disease. 
To address the question of whether the foetal characteristics were maintained 
in the transcriptome of the blasts, the transcriptional profile of the foetal cells 
was compared to that of blasts derived from infant patients. Interestingly, there 
was a large commonality between the two. To further investigate whether the 
common genes were critical for the disease, 21 were selected and functional 
assays performed using the SEM cell line. With this approach, several genes 
were identified deletion of which had a tremendous impact on the survival of 
the SEM cells. The genes that were shown to be critical for the SEM cells 
included PLK1, BUB1B, HSPD1, ELOVL1, CCNB1, NUTF2 and TPX2. Of 
particular interest was PLK1 because there is an inhibitor (Volasertib) available 
that is currently in phase III clinical trials. Inhibition of PLK1 using Volasertib in 
the SEM cells resulted in cell cycle arrest, which led to apoptosis. Another gene 
of interest was ELOVL1, because its knockout effect appears to be unique to 
the infant disease. Knockout of ELOVL1 in SEM resulted in apoptosis and 
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investigation into the lipidome of the knockout cells identified a dramatic 
decrease in lipids that contain very long fatty acid chains. Additionally, using 
overexpression assays, DACH1 was shown to decrease the proliferation 
potential of the SEM cells. From this data it can be concluded that the foetal 
origin of the disease could be used as a means to identify novel therapeutic 
targets.  
A further aim of this work was to investigate and understand the early disease 
stages. For this, an additional RNA sequencing experiment was performed. 
This experiment used an Mll-AF4 expressing mouse model to characterise the 
transcriptional profile of a pre-leukemic population. Of particular interest was 
Skida1 which was shown to be upregulated in the Mll-AF4 expressing cells. 
Intriguingly, SKIDA1 was also upregulated in the blasts of infants with MLL-
AF4 driven ALL compared to blasts derived from paediatric patients with the 
same disease and healthy controls. Interestingly, Skida1 belongs to the same 
family of proteins as DACH1. Intriguingly, while SKIDA1 was upregulated in 
the infant patients, DACH1 was not expressed at all. These findings suggest 
that this family of proteins could play an important role for the infant disease. 
This has been a proof of concept study where it was shown that by defining 
the transcriptome of the cell of origin of the disease and by identifying early 
molecular aberration caused by MLL-AF4 it was possible to identify novel 






Leukaemia is a cancer of the blood and like the majority of cancers it is caused 
by mutations. Typically, an accumulation of multiple mutations is required for 
the leukaemia to develop which leads to the production of abnormal cancer 
cells called blasts. In general, it takes time for an individual cancer or 
leukaemia to develop and therefore these diseases are predominantly 
associated with aging.  
Unfortunately, there is a unique set of leukaemias that run a different course 
and these type of leukaemias affect infants. These leukaemias are caused by 
a single very potent mutation where one part of one gene (called MLL) breaks 
and fuses with part of another gene (AF4). The leukaemias that arise by such 
events are called MLL-AF4-driven and occur while the infant is still in their 
mother’s womb (in utero). Unfortunately, infants with this disease have an 
extremely poor prognosis because the disease is very aggressive and, owing 
to the fact that we do not completely understand the underling biology of this 
disease, there are few therapeutic targets.  
It has long been speculated that the foetal origin of these types of leukaemias 
is what makes them unique and very different from adult leukaemias. We know 
that the cells of the developing embryo (foetal cells) are very different from 
adult cells, as they need to support the needs of a rapidly growing organism. 
They have acquired specific features, for example, we know that these cells 
divide a lot more than other cells. Although, we do have some knowledge of 
how these cells are different, we still do not have the complete picture. The 
first aim of this work was to investigate how foetal cells are different from adult 
ones. Interestingly, it was observed that the foetal cells not only divide a lot 
more than adult cells but also that they have a very oncogenic nature. This 
oncogenic nature can form a supportive environment for the initial mutation to 
flourish and lead to this aggressive infant disease.  
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Having identified these unique features of the foetal cells, the next step was to 
ensure that they are present in the blasts of the infant patients. Interestingly, 
some of them were, indeed, present suggesting that this environment seems 
to play a role not only in the disease initiation but also in its maintenance. To 
ensure that this was true, experiments were performed where the specific 
features were removed from the cells. This was achieved by removing a gene 
from a model of the infant disease. With this approach, it was observed that 
the removal of some of these features had a tremendous impact on the 
disease, as it dramatically decreased the survival of the disease model cells. 
Intriguingly, none of these features have been associated with the infant 
disease prior to this study. 
In summary, this study was able to define the foetal nature of the leukaemia 
initiating cells thereby adding to our comprehension of the underlying biology 
of this unique disease. Additionally, features were identified in the blasts of 
infant patients that were residue of the foetal cell of origin of the disease and 
removal of these features in a disease model resulted in a tremendous 
decrease in the survival of those cells. Therefore, this study serves to present 
a new approach for the identification of novel therapeutic targets for infant 







ALL Acute Lymphoblastic Leukaemia 
alphaMEM Minimum Essential Medium Eagle - Alpha Modification 
AML Acute Myeloid Leukaemia 
BCR Breakpoint cluster region 
BFP Blue fluorescent protein 
BM Bone marrow 
CAR-T chimeric antigen receptor T-cell  
Cas9 CRISPR associated protein 9 
CLP Common lymphoid progenitor 
CMP Common myeloid progenitor 
CNS Central nervous system 
CRISPR clustered regularly interspaced short palindromic repeats 
DE Differentially expressed 
DMEM Dulbecco's Modified Eagle Medium  
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DS               Double stranded 
E  Embryonic day 
 x 
EB Elution buffer 
EDTA Ethylenediaminetetraacetic acid 
ELOVL Elongation of very long chain fatty acids 
EtOH Ethanol 
FACS Fluorescent activated cell sorting 
FL Foetal liver 
FLT3L FMS-like tyrosine kinase 3 ligand 
FPKM Fragments Per Kilobase of transcript per Million 
FSC Foetal Calf Serum 
GeCKO Genome-Scale CRISPR Knock-Out 
GEO Gene expression omnibus 
GFP Green fluorescent protein 
GO Gene ontology 
GSEA Gene set enrichment analysis 
hESCs Human embryonic stem cells 
HexCer hexosyl ceramides 
HSC Haematopoietic stem cell 
HSPC Haematopoietic stem and progenitor cell 
iALL infant ALL 
IL2 Interleukin 2 
 xi 
IL7 Interleukin 7 
IMDM Iscove's Modified Dulbecco's Media  
KO Knockout 
LB Lysogeny broth  
LDAC low dose cytarobine 
LFC Log fold change 
LMPP Lymphoid primed multipotent progenitors 
LT-HSC Long term HSC 
MA4+ MLL-AF4+ 
MACS Magnetic activated cell sorting 
MBD Menin biding domain 
MDB Membrane desalting buffer 
MEP Megakaryocyte erythroid progenitor 
MLL Mixed Lineage Leukaemia 
MLL-R  Mixed lineage leukaemia - Rearrangement 
MNC Mononucleated cells 
MPP Multipotent progenitors 
padj Adjusted p value 
pALL paediatric ALL 
PB  Base pair 
 xii 
PBS Phosphate-buffered saline  
PC Post conception 
PC phosphatidylcholines 
PCA Principal component analysis 
Pen/Strep Penicillin/Streptomycin 
PHD Plant homology domain  
RCR Polymerase chain reaction 
RD Repression domain 
RIN RNA integrity number 
RNA Ribonucleic acid 
RPKM Reads Per Kilobase of transcript per Million  
RPM Rotations per minute 
RPMI Roswell Park Memorial Institute  
RT-qPCR Real-time quantitative PCR 
SCF Stem cell factor 
sgRNA single guide RNA 
SM sphingomyelin 
SNL Speckled nuclear localisation 
ST HSC Short term HSC 
TG Triglyceride 
 xiii 
TIDE Tracking of Indels by Decomposition 
TrXG Thrithorax 
VLFAs Very long fatty acids 







Declaration ................................................................................................... iii 
Acknowledgements ..................................................................................... iv 
Abstract ......................................................................................................... v 
Lay Summary .............................................................................................. vii 
Abbreviations ............................................................................................... ix 
Chapter 1 Introduction ............................................................................ 1 
1.1 Haematopoiesis ................................................................................. 1 
1.1.1 Overview of haematopoiesis ....................................................... 1 
1.1.2 Haematopoietic hierarchy ........................................................... 1 
1.1.3 Ontogeny of the haematopoietic system ..................................... 4 
1.1.4 Developmental changes in the haematopoietic system .............. 7 
1.2 Haematological malignancies .......................................................... 10 
1.3 Epidemiology of paediatric leukaemias ........................................... 11 
1.4 The Mixed Lineage Leukaemia gene .............................................. 12 
1.4.1 MLL structure and function ........................................................ 12 
1.5 MLL- rearranged leukaemias ........................................................... 16 
1.6 AF4 .................................................................................................. 17 
1.7 MLL-AF4-driven infant ALL .............................................................. 18 
1.7.1 The unique biology of MLL-AF4 infant ALL ............................... 18 
1.7.2 MLL-AF4-driven leukaemogenesis ........................................... 20 
1.7.3 Disease models ......................................................................... 22 
1.7.4 Therapeutic approaches ........................................................... 25 
1.8 Motivation and aims ......................................................................... 27 
1.8.1 Summary of aims ...................................................................... 28 
Chapter 2 Materials & methods ............................................................ 29 
2.1 Sample collection and processing ................................................... 29 
2.1.1 Collection of human foetal tissues (first and second trimester – 9 
to 20 weeks gestational age) ................................................................. 29 
 xv 
2.1.2  Collection of murine tissues ................................................... 30 
2.2 Genotyping ...................................................................................... 31 
2.3  Magnetic-activated cell sorting and flow cytometric cell sorting and 
analysis ..................................................................................................... 32 
2.3.1 Magnetic-activated cell sorting (MACS) ........................................ 32 
2.3.2 Cell staining for flow cytometric analysis and sorting ................... 33 
2.3.3 Flow cytometric analysis and sorting ............................................ 33 
2.3.4 Analysis of flow cytometry data .................................................... 33 
2.3.5 Sorting of murine LMPP ................................................................ 34 
2.3.6 Sorting of human HSC/MPP and LMPP ....................................... 36 
2.3.7 Cell Tracer .................................................................................... 37 
2.3.8 Zombie NIR™ Fixable Viability Kit ................................................ 37 
2.3.9 Cell cycle analysis ........................................................................ 38 
2.3.10 Competition assay ...................................................................... 38 
2.3.11 Migration assay ........................................................................... 39 
2.4 Clonogenic assays .............................................................................. 40 
2.4.1 Methylcellulose assay for murine lymphoid potential ................... 40 
2.4.2 Methylcellulose assay for human myeloid potential ..................... 40 
2.4.3 Clonogenic assay for human lymphoid potential .......................... 41 
2.5 RNA extraction ................................................................................. 42 
2.5.1 RNA extraction from small cell numbers ................................... 42 
2.5.2 RNA extraction from large cell numbers ................................... 43 
2.6 DNA extraction ................................................................................. 44 
2.6.1 DNA extraction .......................................................................... 44 
2.6.2 Gel extraction ............................................................................ 44 
2.6.3 PCR product purification ........................................................... 45 
2.7 RNA and DNA quantification ........................................................... 46 
 xvi 
2.7.1 RNA quantification with Agilent High Sensitivity DNA Screen 
Tape……… ............................................................................................ 46 
2.7.2 DNA quantification with Agilent High Sensitivity DNA Screen 
Tape……. .............................................................................................. 46 
2.7.3 DNA quantification with Qubit ................................................... 46 
2.7.4 DNA and RNA quantification using Nanodrop .......................... 47 
2.8 Library preparation for RNA sequencing ......................................... 48 
2.9 Cell lines and plasmids .................................................................... 51 
2.10 Transfection .................................................................................. 53 
2.10.1 Transection via nucleofection ................................................ 53 
2.10.2 Transfection with PEI for lentiviral particle production ........... 53 
2.10.3 Transfection with Fugene for lentiviral particle production ..... 54 
2.11 Virus concentration ....................................................................... 55 
2.11.1 Ultracentrifugation ....................................................................... 55 
2.11.2 Lenti-X ................................................................................... 55 
2.12 Bacteria transformation and inoculation ....................................... 56 
2.13 Plasmid DNA purification .............................................................. 56 
2.13.1 HiSpeed plasmid Maxi/Midi kit ............................................... 56 
2.13.2 MiniPrep kit ............................................................................ 57 
2.14 sgRNA design, cloning and validation .......................................... 58 
2.15 Transduction ................................................................................. 63 
2.15.1 Transduction of SEM cells ..................................................... 63 
2.15.2 Transduction of human primary cells ..................................... 63 
2.16 Real-time quantitative PCR .......................................................... 63 
2.16.1 cDNA synthesis ..................................................................... 63 
2.16.2 RT-qPCR ............................................................................... 64 
2.17 Statistics and star system ............................................................. 66 
2.18 RNA sequencing analysis pipeline ............................................... 67 
2.19 Lipidome ............................................................................................ 69 
 xvii 
Chapter 3 Defining the transcriptional profile of LMPPs in wild-type 
and Mll-AF4 expressing mouse models ................................................... 70 
3.1 Defining the transcriptional profile of foetal liver and bone marrow-
derived LMPPs. ......................................................................................... 70 
3.1.1 Introduction ............................................................................... 70 
3.1.2 Experimental design used to define the transcriptional profile of 
foetal liver and bone marrow-derived LMPPs ........................................ 72 
3.1.3 Quality control of RNA sequencing data ................................... 73 
3.1.4 Genes differentially expressed between foetal liver and bone 
marrow-derived LMPPs ......................................................................... 76 
3.1.5 The transcriptional profile of murine foetal liver and bone 
marrow-derived LMPPs ......................................................................... 83 
3.2 Molecular characterisation of the initial stages of transformation 
during the pre-leukaemic state .................................................................. 88 
3.2.1 Introduction ............................................................................... 88 
3.2.2 Experimental design used to define the transcriptional changes 
induced by Mll-AF4 during the pre-leukaemic state .............................. 89 
3.2.3 Quality control of the RNA sequencing data ............................. 90 
3.2.4 Genes differentially expressed between Mll-AF4 expressing and 
control LMPPs ....................................................................................... 94 
3.3 Discussion ....................................................................................... 99 
Chapter 4 Defining the transcriptional profile of human foetal and 
neonatal haematopoietic stem and progenitor cells. ............................ 101 
4.1 Defining the transcriptional profile of human foetal liver and cord 
blood derived HSC/MPPs ........................................................................ 101 
4.1.1 Introduction ............................................................................. 101 
4.1.2 Experimental design ................................................................ 102 
4.1.3 Quality control of RNA sequencing data ................................. 103 
 xviii 
4.1.4 Genes differentially expressed between foetal liver and cord 
blood-derived HSC/MPPs .................................................................... 106 
4.1.5 The transcriptional profile of foetal liver and cord blood-derived 
HSC/MPPs ........................................................................................... 113 
4.2 Investigation into the cell of origin of infant MLL-AF4-driven ALL . 116 
4.2.1 Introduction ............................................................................. 116 
4.2.2 Experimental design ................................................................ 116 
4.2.3 Transcriptional profile of foetal liver-derived HSC/MPPs and 
LMPPs. ................................................................................................ 118 
4.2.4 Identification of the cell of origin of infant MLL-AF4-driven 
ALL…... ................................................................................................ 120 
4.3 Use of in vitro assays to establish early disease stages using foetal 
liver-derived cells ..................................................................................... 122 
4.3.1 Experimental design ................................................................ 122 
4.3.2 In vitro B cell differentiation assay ........................................... 123 
4.4 Discussion ..................................................................................... 124 
Chapter 5 Exploiting the foetal origin of MLL-AF4-driven infant 
ALL……………… ....................................................................................... 126 
5.1 Introduction .................................................................................... 126 
5.2 Investigation of the transcriptional profile of blasts derived from 
patients with MLL-AF4-driven ALL .......................................................... 127 
5.2.1 HOXA9 and IRX1 expression defines two subgroups of the 
disease ………………………………………………………………………128 
5.3 Identification of genes common between humans and mice ......... 131 
5.4 PLK1 .............................................................................................. 134 
5.5 Use of CRISPR-Cas9 to identify novel therapeutic targets for MLL-
AF4-driven ALL ....................................................................................... 139 
5.5.1 HSPD1 .................................................................................... 144 
5.5.2 ELOVL1 ................................................................................... 146 
5.5.3 Migration assay ....................................................................... 150 
 xix 
5.6 DACH1 ........................................................................................... 152 
5.7 Discussion ..................................................................................... 155 
Chapter 6 Discussion .......................................................................... 157 
Chapter 7 Future work ........................................................................ 163 
Chapter 8 Concluding remarks .......................................................... 164 
Chapter 9 References ......................................................................... 165 
Chapter 10 Appendices ........................................................................ 197 
10.1 Appendix 1 ................................................................................. 197 
10.2 Appendix 2 ................................................................................. 209 
10.3 Appendix 3 ................................................................................. 210 
10.4 Appendix 4 ................................................................................. 249 














List of figures  
Figure 1.1| The haematopoietic hierarchy ...................................................... 2 
Figure 1.2 | Ontogeny of the human haematopoietic system ......................... 4 
Figure 1.3 | Ontogeny of murine haematopoietic system ............................... 6 
Figure 1.4 | Epidemiology of paediatric leukaemias ..................................... 11 
Figure 1.5 | The mixed lineage leukaemia gene ........................................... 12 
Figure 1.6 | Incident of the most common MLL fusion partners in infant 
leukaemias .................................................................................................... 16 
Figure 1.7 |The mutational landscape in a variety of cancers. ...................... 19 
Figure 2.1 | Schematic representation of murine LMPP sorting strategy ...... 34 
Figure 2.2 | Schematic representation of human LMPP sorting strategy ...... 36 
Figure 3.1| Experimental design used to define the transcriptional profile of 
foetal liver and adult bone marrow derived LMPPs. ..................................... 72 
Figure 3.2| Quality control of RNA sequencing libraries - pre sequencing. .. 73 
Figure 3.3| Quality control of the RNA sequencing libraries - post 
sequencing………………………………………………………… .................... 74 
Figure 3.4| Principal component analysis of foetal liver and bone marrow-
derived LMPPs. ............................................................................................. 75 
Figure 3.5| Heatmap of the top 50 differentially expressed genes between 
foetal liver (FL) and adult bone marrow (BM)-derived LMPPs. ..................... 76 
Figure 3.6|Expression of Cebpa and Mycn in foetal liver and bone marrow-
derived LMPPs. ............................................................................................. 77 
Figure 3.7| Expression of oncogenes upregulated in the foetal liver-derived 
LMPPs. ......................................................................................................... 79 
Figure 3.8 | Tumour suppressors and oncogenes upregulated in the bone 
marrow-derived LMPPs. ............................................................................... 81 
Figure 3.9| Sell expression in foetal liver and bone marrow-derived LMPPs 82 
Figure 3.10| Gene ontology of genes differentially expressed between foetal 
and bone marrow-derived LMPPs. ............................................................... 83 
 xxi 
Figure 3.11| Genes that make up the GO process “Haematopoietic or 
lymphoid organ development” in foetal liver and bone marrow derived 
LMPPs. ......................................................................................................... 85 
Figure 3.12| Gene set enrichment analysis of foetal liver derived LMPPs .... 86 
Figure 3.13| Gene set enrichment analysis of genes upregulated in the bone 
marrow derived LMPPs. ................................................................................ 87 
Figure 3.14 | Experimental design used to define the transcriptional prolife of 
Mll-AF4 expressing foetal liver LMPPs. ........................................................ 89 
Figure 3.15 | Lymphoid colony assay using Mll-AF4 expressing HSC/MPPs 
and LMPPs. .................................................................................................. 90 
Figure 3.16 | Quality control reveals an outlier amongst the libraries. .......... 91 
Figure 3.17| Quality control of the RNA sequencing libraries - post 
sequencing………………………………………………………….. .................. 92 
Figure 3.18| PCA plot and genotyping of the Mll-AF4 and control LMPPs 
RNA sequencing libraries ............................................................................. 93 
Figure 3.19 | Genes differentially expressed between Mll-AF4 expressing and 
control LMPPs ............................................................................................... 94 
Figure 3.20| Skida1 and Ago3 expression in Mll-AF4 expressing (MA4+) and 
control LMPPs. .............................................................................................. 95 
Figure 3.21 | Expression of SKIDA1 and AGO3 in the blasts of infant patients 
with MLL-AF4 driven ALL and healthy controls. (Microarray data) ............... 96 
Figure 3.22| Expression of SKIDA1 in the blasts of infant, paediatric patients 
with MLL-AF4 driven ALL and healthy controls. ........................................... 97 
Figure 3.23| Investigation into the role of SKIDA1 in MLL-AF4-driven ALL. . 98 
Figure 4.1| Experimental design used to define the transcriptional profile of 
foetal liver (FL) and cord blood (CB) derived HSC/MPPs ........................... 102 
Figure 4.2| Percentage of HSC/MPPs and LMPPs in foetal liver and cord 
blood samples. ............................................................................................ 103 
Figure 4.3| Quality control of RNA sequencing libraries. ............................ 105 
Figure 4.4| Heatmap of the top 30 differentially expressed genes between 
foetal liver (FL) and cord blood (CB)-derived HSC/MPPs. .......................... 106 
 xxii 
Figure 4.5| Cell proliferation is a predominant feature of the foetal liver-
derived cells. ............................................................................................... 107 
Figure 4.6| Genes involved in cell division upregulated in the foetal liver-
derived cells. ............................................................................................... 108 
Figure 4.7|Clonogenic and proliferation assays comparing foetal liver and 
cord blood-derived CD34+ cells. ................................................................. 109 
Figure 4.8| Expression of TOP2A and PARP1 in foetal liver (FL) and cord 
blood (CB)-derived HSC/MPPs. .................................................................. 110 
Figure 4.9| Heatmap of genes that have been previously linked with cancer 
or leukaemia. .............................................................................................. 110 
Figure 4.10| MYC and its targets were upregulated in the foetal liver-derived 
HSC/MPPs. ................................................................................................. 112 
Figure 4.11|Heatmap of tumour suppressor genes upregulated in the cord 
blood derived samples. ............................................................................... 112 
Figure 4.12|GO and GSEA of genes upregulated in the foetal liver-derived 
HSC/MPPs. ................................................................................................. 113 
Figure 4.13| GO and GSEA of genes upregulated in the cord blood-derived 
HSC/MPPs .................................................................................................. 114 
Figure 4.14| Experimental design used to define the transcriptional profile of 
foetal liver (FL) HSC/MPPs and LMPPs ..................................................... 117 
Figure 4.15| PCA of foetal liver-derived HSC/MPPs and LMPPs. .............. 118 
Figure 4.16| Genes differentially expressed between foetal liver HSC/MPPs 
and LMPPs. ................................................................................................ 118 
Figure 4.17| Gene ontology of foetal liver-derived HSC/MPPs and LMPPs.
 .................................................................................................................... 119 
Figure 4.18| Comparison of DE genes between foetal liver-derived 
HSC/MPPs and LMPPs with MLL-AF4 ChIP-seq targets. .......................... 120 
Figure 4.19| Experimental design of in vitro assays used to establish an early 
disease stage. ............................................................................................. 122 
Figure 4.20| Flow cytometric analysis of B cell differentiation assay using 
MLL-AF4-expressing and control CD34+ foetal liver-derived cells. ............ 123 
 xxiii 
Figure 5.1| RNA sequencing experiment of patients with MLL-AF4-drive ALL.
 .................................................................................................................... 127 
Figure 5.2| Top 10 loadings of PC1 that drive the clustering in Andersson et 
al. dataset. .................................................................................................. 128 
Figure 5.3| HOXA9 – IRX1 expression defines two subgroups of infant MLL-
AF4-driven ALL. .......................................................................................... 129 
Figure 5.4|PCA of foetal liver HSC/MPPs, cord blood HSC/MPPs and infant 
ALL samples. .............................................................................................. 132 
Figure 5.5| Heatmaps of genes the expression of which was at similar levels 
between the foetal liver-derived populations and infant blasts obtained from 
patients with MLL-AF4-driven ALL .............................................................. 133 
Figure 5.6| PLK1 expression. ...................................................................... 134 
Figure 5.7| Treatment of SEM cells with BI6727 (Volasertib). .................... 137 
Figure 5.8|Expression of AURKA. ............................................................... 138 
Figure 5.9| Expression of genes of interest in SEM cell line. ...................... 139 
Figure 5.10| Use of CRISPR-Cas9 approach to identify novel therapeutic 
targets. ........................................................................................................ 141 
Figure 5.11| CRISPR-Cas9 approach identified novel disease targets. ..... 142 
Figure 5.12| BUB1B expression. ................................................................. 143 
Figure 5.13| HSPD1 expression and validation. ......................................... 145 
Figure 5.14| ELOVL1 expression and knockout validation. ........................ 147 
Figure 5.15| Lipidome analysis of ELOVL1 knockout. ................................ 148 
Figure 5.16| Migration assay using SEM-Cas9. .......................................... 151 
Figure 5.17| DACH1 expression. ................................................................ 152 







List of tables 
Table 2.1 | List of antibodies for the murine LMPP sort ................................ 35 
Table 2.2| List of antibodies for the human LMPP sort ................................. 36 
Table 2.3 | List of antibodies for assessing lymphoid and myeloid potential. 41 
Table 2.4| TIDE primers used in this study ................................................... 61 
Table 2.5 |sgRNA sequences used in this study .......................................... 62 
Table 2.6 | Primers and TaqMan Assays used for this project ..................... 65 
Table 5.1| List of lipids identified from the study of the lipidome of SEM-Cas9 




   
  1 




1.1.1 Overview of haematopoiesis 
 
Blood is a fascinating tissue. In homeostasis, it comprises a plethora of 
different cell types that establish innate and acquired immunity, haemostasis 
and oxygen transport. This beautifully synchronised cell production machinery 
depends on haematopoietic stem cells (HSCs), which lie at the apex of the 
haematopoietic hierarchy, and their ability to self-renew and produce the entire 
collection of differentiated progeny. 
1.1.2 Haematopoietic hierarchy 
 
It was early in the 19th century that biologists observed under the microscope 
the existence of two different lineages in the bone marrow, lymphoid and 
myeloid. It was also at the same time, that it was speculated that those 
lineages share a common origin, a cell that would later become known as the 
haematopoietic stem cell (HSC) (Watcham et al., 2019, Doulatov et al., 2012). 
The existence of HSCs and their ability to give rise to all the different blood cell 
types was proven to be true in the  seminal work of Till, McCulloch and Becker 
in the early 1960s (Becker et al., 1963, Till and McCulloch, 1961). They 
performed pioneering experiments, using repopulation assays and X-ray 
induced chromosomal lineage tracing, to establish that the haematopoietic 
system derives from multipotent HSCs rather than from multiple lineage 
specific/committed stem cells (Becker et al., 1963, Till and Mc, 1961). These 
early findings laid the foundation for the study of blood in both homeostasis 
and disease. 
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Figure 1.1| The haematopoietic hierarchy  (Adapted from Watcham et al., 2019). The 
haematopoietic hierarchy depicted as a tree, where the top branch comprises 
multipotent cells, the middle oligopotent cells and at the bottom of the tree are located 
the terminally differentiated cells (unipotent cells).  
 
The classical view of the haematopoietic hierarchy is a tree, with HSCs at the 
top and the terminally differentiated cells at the bottom (Fig. 1.1). In a nutshell, 
our lifelong blood production relies on HSCs which, on one hand, self-renew 
or generate daughter cells and on the other hand, undergo multi-step 
differentiation in order to generate all the progeny which will go on to provide 
the terminally differentiated cells (Doulatov et al., 2012). Although it was once 
thought to be a relative uniform population, we now know that the HSC pool is 
highly heterogeneous (Laurenti and Gottgens, 2018). This heterogeneity is 
attributed to variation in the self-renewal and differentiation properties of HSCs 
(Laurenti and Gottgens, 2018). Self-renewal is assessed by the repopulation 
potential of the cells in irradiated recipients. In line with this, long-term HSCs 
(LT-HSCs) have the highest repopulation potential, which equates to a 
successful primary and secondary transplantation (Jordan and Lemischka, 
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1990, Dykstra et al., 2007). HSCs that can give rise to all the cells in the 
haematopoietic hierarchy but with progressively shorter repopulation periods 
are either short-term HSCs or multipotent progenitors (MPPs) (Oguro et al., 
2013, Kiel et al., 2005, Kent et al., 2009, Sieburg et al., 2006, Guenechea et 
al., 2001, Muller-Sieburg and Sieburg, 2006). The lymphoid-primed multipotent 
progenitors (LMPPs) have also been shown to have limited repopulation 
potential (Adolfsson et al., 2005, Boiers et al., 2013). In addition to variation in 
self-renewal potential, HSCs also differ in their lineage output potential. 
Different subgroups of HSCs show bias towards one lineage over others 
(Dykstra et al., 2007, Muller-Sieburg et al., 2004, Sanjuan-Pla et al., 2013, 
Yamamoto et al., 2013).  
Lineage commitment is a multistep process where multipotent cells choose 
their fate in response to extracellular signals (van Galen et al., 2014, Laurenti 
and Gottgens, 2018). The first step in lineage commitment, which occurs in the 
multipotent cells, is loss of the capacity to self-renew, this can be observed in 
MPPs and LMPPs (Morrison et al., 1997, Adolfsson et al., 2005). While MPPs 
have the capacity to differentiate towards all the lineages, LMPPs lack the 
ability to generate erythrocytes and megakaryocytes. Both these populations 
possess only transient repopulation capacity in mice (Morrison et al., 1997, 
Adolfsson et al., 2005). Oligopotent cells such as common myeloid progenitors 
(CMPs), granulocyte-monocyte progenitors (GMPs), common myeloid 
progenitors (CMPs) and megakaryocyte-erythroid progenitors (MEPs) will 
further commit to produce the terminally differentiated and mature cells, which 
are unipotent. The mechanism by which cell fate decisions are executed 
involves a cascade of activation/de-activation of transcriptional and epigenetic 
regulators. This cascade is initiated by extracellular signals dictating cell fate 
choices and it is thought to occur as early as within the HSC compartment (Lee 
et al., 2017, Laurenti and Gottgens, 2018) 
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1.1.3 Ontogeny of the haematopoietic system 
 
Ontogeny of the haematopoietic system begins in the developing embryo and 
is highly conserved, though not identical, in vertebrates. As the anatomy of the 
developing embryo changes, different anatomical sites are employed in the 
establishment of the haematopoietic system. The use of multiple sites for foetal 
haematopoiesis is highly conserved. In both humans and mice, developmental 
haematopoiesis occurs in two waves, a first primitive and a second definite. 
 
Figure 1.2 | Ontogeny of the human haematopoietic system (Adapted from Rowe et al., 
2016). Ontogeny of the human haematopoietic system is a multi-step process that 
occurs in multiple anatomical sites, including the yolk sac, AGM, placenta, foetal liver, 
thymus and bone marrow.  
 
The first transient wave of haematopoiesis originates outside the embryo in 
the yolk sac. In humans, this occurs around 16-18 days post conception (pc) 
with the appearance of large primitive nucleated erythrocytes and some 
occasional primitive macrophages and megakaryocytes (Fukuda, 1973, 
Luckett, 1978, Oberlin et al., 2002). Initiation of the second and definitive wave 
is marked by the appearance of intra-aortic haematopoietic clusters on the 
ventral wall of the aorta within the aorta-gonad-mesonephros (AGM) region 
around day 27 pc (Tavian et al., 1996, Tavian et al., 1999). It was in the AGM 
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and in particular, in the dorsal aorta where the first definitive HSCs/progenitors 
were isolated. The first CD34+CD45+ cells emerge in the pre-umbilical region 
of the dorsal aorta and by day 33 pc they reach several hundred  (Marshall et 
al., 1999, Ivanovs et al., 2011, Ivanovs et al., 2017).  As blood circulation has 
been established by this point (21 days pc), the next step in the haematopoietic 
ontogeny is the establishment of foetal liver haematopoiesis. In the liver 
around 27-29 days pc Tavian et al. observed seeding of growing numbers of 
CD34+CD45+ cells (Tavian et al., 1999). Recently, Oberlin et al. identified the 
existence of two phenotypically and functionally different HSCs in the human 
foetal liver embryo, one being more primitive than the other. Interestingly, the 
more primitive population exhibited a greater capacity for self-renewal, 
proliferation and differentiation (Oberlin et al., 2010). Liver colonisation occurs 
30-33 days after conception (Migliaccio et al., 1986). It is speculated, that the 
liver remains the predominant niche where HSC expansion and differentiation 
takes place until birth after which the bone marrow (BM) takes over (Charbord 
et al., 1996). In addition, stem and progenitor cells have also been identified in 
the placenta following 9 weeks of gestation (Robin et al., 2009, Muench et al., 
2017). In a recent study, it was shown that even though B-lymphopoiesis takes 
places in both the foetal liver and bone marrow; it is in the foetal bone marrow 
that B-progenitors predominantly expand. In addition, they identified a Pro B 
progenitor which was defined as CD34+CD10-CD19 which has not been 
identified in adult bone marrow (O'Byrne et al., 2019).  
Colonisation of the BM with HSCs and progenitor cells marks the end of the 
embryonic period. This is closely associated with the development of the BM 
niche. The BM niche can only be established following osteogenesis and 
vascularisation of the bones, which allows for the seeding of the BM with HSCs 
and haematopoietic progenitors (Ivanovs et al., 2017). Following birth, the BM 
is responsible for the lifelong production of blood cells.  
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Figure 1.3 | Ontogeny of murine haematopoietic system (Adapted from Rowe et al., 
2016). Ontogeny of the murine haematopoietic system is a multi-step process that 
occurs in multiple anatomical sites, including the yolk sac, AGM, placenta, foetal liver, 
thymus and bone marrow.  
 
In mice, the sequence of anatomic locations where haematopoiesis evolves is 
the same as with the human; however, due to the differences in the gestation 
period the timelines differ. In mice, the earliest primitive erythroid cells emerge 
in the yolk sac blood islands at embryonic day (E) 7.5 and, as with the human, 
these cells are essential for the oxygenation of the growing embryo (Silver and 
Palis, 1997). Following a transient definitive wave produced by the yolk sac, 
the first long term transplantable HSC emerge in the AGM around E 10.5 
(Medvinsky et al., 1993, Medvinsky and Dzierzak, 1996).  In addition to the 
AGM, the placenta and the early umbilical cord and vitelline artery are also 
implicated in the development of HSCs and are considered sources of 
haematopoietic stem cells (Ottersbach and Dzierzak, 2005, de Bruijn et al., 
2000, Gekas et al., 2005). Additionally, HSCs can be found in the liver and it 
is in the liver where they rapidly expand and, as with the human, the liver 
remains the major site for haematopoiesis until birth which the BM takes over 
(Micklem et al., 1972, Muller et al., 1994, Fleischman et al., 1982, Yoder, 2004, 
Kikuchi and Kondo, 2006).   
   
  7 
1.1.4 Developmental changes in the haematopoietic 
system  
 
It is fascinating that the entire adult haematopoietic system relies on HSCs 
generated before birth, at least in mice. Lineage tracing has been instrumental 
in deciphering the direct relationship between foetal and adult HSCs 
(Samokhvalov et al., 2007, Gothert et al., 2005, Pei et al., 2017). Interestingly, 
even though they share a common origin, foetal and adult blood cells possess 
a multitude of different characteristics.   
Starting at the apex of the haematopoietic hierarchy, it has been shown that 
foetal HSCs are highly proliferative and have a higher self-renewal capacity as 
compared to their adult counterparts (Micklem et al., 1972, Ivanovs et al., 2011, 
Rebel et al., 1996). In particular, in humans, foetal derived HSCs replicate 
every 3.5 - 4 weeks as opposed to the much slower replication of adult HSCs, 
which occurs every 40 weeks (Ivanovs et al., 2011, Catlin et al., 2011). In 
addition, the less purified CD34+CD38- haematopoietic stem and progenitor 
cell (HSPC) compartment showed the same trend of proliferation, with the 
foetal cells being more proliferative than adult cells when compared with 
repopulation assays (Holyoake et al., 1999). Notta et al. showed that the 
cloning efficiency of the CD34+ and CD34+CD38- compartments was highest 
for cells derived from the foetal liver, then from cord blood and finally from adult 
bone marrow. In this study, they measured cloning efficiency using 
methylcellulose assays and by observing whether a single cell gave rise to 
colonies from one or multiple lineages (Notta et al., 2016). Interestingly, Benz 
et al. showed that there is a higher proportion of myeloid-biased HSCs in the 
adult haematopoietic system, which is not what they observed in the foetal liver 
where all lineages were equally represented (Benz et al., 2012, Cheshier et 
al., 1999). 
In addition, to their proliferation and differentiation potential, foetal and adult 
HSCs have different requirements to maintain their stem cell nature. In 
particular, it has been shown that adult HSCs require stem cell factor (SCF) 
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for their maintenance; however, SCF is redundant for the generation and 
maintenance of foetal ones  (Bowie et al., 2007). Etv6 is also critical for the 
maintenance of adult but not foetal HSCs (Hock et al., 2004b). Conditional 
deletion of C/EBPa only affects adult HSCs by enhancing their proliferation 
potential, and this over-proliferative state has been linked to increased 
expression of N-myc, which is normally repressed by C/EBPa in adult HSCs 
(Ye et al., 2013). Additionally, Gfi1 is only critical for adult haematopoiesis as 
Gfi1 knock-out mice develop normally, but when HSCs from adult mice are 
transplanted into irradiated recipients, they show reduced repopulation activity 
(Hock et al., 2004a). Bmi1 is required for self-renewal of adult HSCs but not 
foetal (Park et al., 2003). Epigenetic regulators also influence foetal and adult 
HSCs differently. In particular, Polycomb repressive complex factors Ezh1 and 
Ezh2 exert opposing roles in adult and foetal HSCs. While loss of the former 
mainly affects adult HSCs, loss of the latter predominantly impacts foetal HSCs 
(Hidalgo et al., 2012, Mochizuki-Kashio et al., 2011). Genes that have been 
shown to be essential for maintaining the high self-renewal potential of foetal 
but not adult HSCs include Lin28b, Hmga2,  and Sox17 (Copley et al., 2013, 
Yuan et al., 2012, He et al., 2011, Kim et al., 2007). Foetal and adult HSCs 
have very different roles and this is reflected in the high self-renewal potential 
of foetal cells but also in the highly quiescent state of adult HCSs (Bowie et al., 
2006, Cheshier et al., 1999).  
A recent study applied quantitative proteomics to characterise and compare 
the proteome of murine foetal and adult HSPCs. As expected, foetal-derived 
HSPCs upregulated proteins related to cell cycle and proliferation. Adult 
HSPCs were shown to express proteins that are involved in the defence 
against viruses, bacterial and oxidative stress, but these proteins were not 
present in foetal cells. Additionally, they observed that interferon-a (INF-α) 
stimulation exerts different effects on foetal and adult HSPCs (Jassinskaja et 
al., 2017).  
Significant differences can also be observed in the differentiated cells derived 
from foetal and adult cells. One example is the variation in lymphopoiesis that 
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can be observed across development. In particular, it has been shown first in 
mice and later in humans that B-1a B-cells arise only from embryonic 
progenitors, while conventional B-2 B-cells arise from both foetal and adult 
HSCs (Kantor et al., 1992, Griffin et al., 2011, Bueno et al., 2016, Hayakawa 
et al., 1985). Additionally, marginal zone B cells arise from embryonic 
progenitors (Yoshimoto et al., 2011). Another example is differences observed 
in erythroid cells. Different globins are observed in foetal versus adult erythroid 
cells, and while primitive erythroid cells circulate in a nucleated state, this is 
not true for definitive erythroid cells which enucleate prior to entering the 
circulation (Kingsley et al., 2004). Foetal macrophages (monocytic cells) also 
differ from their adult counterparts. In particular, the former have been shown 
to secrete high amounts of proteins acting on tissue remodelling and 
angiogenesis, whereas the latter express chemokines, scavenger receptor 
and tissue degrading enzymes (Klimchenko et al., 2011, Copley and Eaves, 
2013).  
As we have seen, the cellular context in foetal and adult haematopoiesis is 
very different. In essence, it seems that foetal and adult HSPCs have 
fundamentally different regulation and behaviour, which potentially cascades 
downstream along the haematopoietic hierarchy.  Of course, we can imagine 
that these differences are not only critical for haematopoiesis, but they could 
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1.2 Haematological malignancies 
 
Haematological malignancies refer to diseases that affect the haematopoietic 
hierarchy by influencing the homeostatic processes of blood production. In 
general, there are two main groups: 1) non-malignant diseases (such as 
anaemia and myelodysplastic syndromes) and 2) malignant diseases (such as 
acute lymphoblastic leukaemia and acute myeloid leukaemia). The focus of 
this work has been acute lymphoblastic leukaemia (ALL), which affects the 
lymphoid lineages as opposed to acute myeloid leukaemia (AML) that disturbs 
the myeloid lineage. ALL is more prevalent in children while AML predominates 
in adults. This is probably due to the differences in the cellular make-up and/or 
microenvironment during which the leukaemic transformation occurs (Babovic 
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1.3 Epidemiology of paediatric leukaemias 
 
 
Figure 1.4 | Epidemiology of paediatric leukaemias  (Data obtained from Bonaventure 
et al.). a) Incidence of paediatric leukaemia 1995-2009, UK data. b) 5-year net survival 
rate of paediatric patients with ALL 1995-2009, UK data.  
 
Leukaemias are the most common malignancies in children aged 0-14, and 
the majority of the paediatric patients are burdened with ALL, which accounts 
for approximately 81% of the cases (Fig. 1.4a) (Bonaventure et al., 2017). 
Paediatric ALL can be caused by perturbations in either B or T cells; however, 
the most common type of ALL observed in paediatric patients is precursor-B 
cell ALL. Paediatric ALL, once lethal, now, with the advancements of medicine, 
the cure rates are extremely high (Greaves, 2018). A recent study showed that 
the 5-year survival rate of children aged 1-14 diagnosed with ALL was above 
90% (Fig. 1.4b) (Bonaventure et al., 2017). Long-term survival without 
recurrence of disease is the primary clinical indicator of therapeutic success 
for patients with leukaemia (Good et al., 2018). However, Bonaventure et al. 
observed that infants with the same disease suffer from a much worse 
prognosis. In this study, they attribute the lower survival rates of infants with 
ALL to the presence of rearrangements at the Mixed Lineage Leukaemia 
(MLL) gene (Bonaventure et al., 2017).  
 
   
  12 
1.4 The Mixed Lineage Leukaemia gene 
 
 
Figure 1.5 | The mixed lineage leukaemia gene (Adapted from Winters and Bernt, 2017). 
The top schematic depicts a simplified version of wild type MLL and the bottom the 
truncated MLL with the fusion partner. In the majority of MLL-R the PHD fingers, 
bromodomain, activation domain (TA) and SET domain are lost. (BCR= breakpoint 
cluster region) 
 
The Mixed Lineage Leukaemia (MLL) gene is a member of the highly 
conserved lysine (K) methyltransferase (KMT) 2 family of proteins (Krivtsov et 
al., 2017). It is the mammalian homologue of the Drosophila thrithorax gene, 
which is a member of an evolutionarily conserved family of proteins, the 
thrithorax group (TrxG) (Tkachuk et al., 1992). MLL, which at that point was 
known as ALL1, was first described in two back to back Cell papers in 1992 
(Gu et al., 1992, Tkachuk et al., 1992).  
 
1.4.1 MLL structure and function 
 
MLL is a large nuclear protein with multiple domains that is encoded on human 
chromosome 11q23 and consists of 37 exons (Tkachuk et al., 1992, Krivtsov 
et al., 2017).  Structurally, it contains, starting at the N-terminal portion of the 
protein, a domain that is critical for the interaction of MLL with Menin/LEDGF 
(Hughes et al., 2004, Milne et al., 2005, Yokoyama and Cleary, 2008). 
Following from the menin-binding domain (MDB), there are three AT hook 
motifs, which are essential for DNA binding, two speckled nuclear localization 
motifs (SNL1 and SNL2) and two repression domains (RD1 and RD2) 
   
  13 
(Tkachuk et al., 1992, Yano et al., 1997). The first repression domain displays 
homology to the DNA methyltransferase 1 (DNMT1) gene and is known as MT-
domain (MT) (Ma et al., 1993). The homology region includes the CxxC zinc 
finger motif that binds unmethylated CpG containing DNA (Birke et al., 2002, 
Ma et al., 1993). The latter has been reported to exert transcription repression 
activity (Zeleznik-Le et al., 1994). Near the centre of MLL is the plant homology 
domain (PHD) comprising of four PHD fingers with an interspersed 
bromodomain between finger 3 and 4. The third PHD finger has been shown 
to bind to lysine 4 in histone 3 (H3K4), which is critical for MLL-depended 
transcription activity (Chang et al., 2010). The PHD domains are critical for the 
function of MLL, which could either be that of a transcriptional activator or 
repressor. CYP33/PPIE isomerase is the molecular switch that allows for the 
dual role of MLL. In particular, when one of the subdomains of PHD (PHD3/4) 
is docked to the bromodomain, it allows this domain to read di-/tri-methylated 
H3K4 (me2/3) signatures within chromatin, and binding to this histone mark is 
required for MLL transcriptional activation. However, when the same domain 
binds to CYP33/PPIE, this causes a conformational change which has as a 
result the disconnection from the bromodomain and instead the binding to the 
methyl DNA binding domain (Fair et al., 2001, Hom et al., 2010, Park et al., 
2010, Milne et al., 2010, Chang et al., 2010). Finally, at the carboxy-terminus, 
MLL contains a transcription activation domain (TA) and a SET (Su(var)3-9, 
enhancer of zeste thrithorax) domain which confers the H3K4 
methyltransferase activity (Nakamura et al., 2002, Milne et al., 2002).  
 
The full-length MLL protein is post-translationally cleaved into MLLN and MLLC 
fragments by taspase1 at two conserved cleavage sites (CS1 and CS2) (Hsieh 
et al., 2003b, Hsieh et al., 2003a). Following cleavage, the two fragments 
reassemble through interaction of FYRN with the FYRC domain in order to 
form a stable complex with correct nuclear sublocalization (Hsieh et al., 
2003b). MLL is part of a large protein complex; MLLN associates with Menin 
and LEDGF, and this protein complex has been associated with increased 
transcription of differentiation/regulatory genes as well as cyclin-dependent 
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kinase inhibitors (Hughes et al., 2004, Milne et al., 2005). MLLC interacts with 
RbBP5, Ash2L, WDR5 and DPY30 in order to achieve a potent and stable 
structural platform for activation of the catalytic activity of the SEM domain 
(Dou et al., 2006, Patel et al., 2009). Additionally, MLLC recruits 
acetyltransferases MOF and CREB, which has been shown to be important for 
transcription activation of target genes (Dou et al., 2005, Ernst et al., 2001).  
 
In homeostasis, MLL is critical for mammalian development, morphogenesis 
and homeobox gene expression (Yu et al., 1998, Yu et al., 1995). Regarding 
homeobox gene expression, Yu et al. observed that Mll expression is critical 
for maintenance of Hox gene expression but not for their initiation (Yu et al., 
1998), while Milne et al. and Nakamura et al. provided evidence that Mll 
positively regulates expression of the HOXA cluster genes via its H3K4 
methyltransferase activity (Milne et al., 2002, Nakamura et al., 2002).  
 Mll heterozygous (+/-) mice showed growth retardation, skeletal deformities 
and displayed haematopoietic abnormalities (Yu et al., 1995). Mll homozygous 
(-/-) deletion was embryonic lethal, with abnormal expression of Hox genes 
and a decrease in foetal haematopoietic cells due to a decrease in 
haematopoietic precursors. In addition, haematopoietic precursors had 
reduced clonogenic potential, as observed by colony-forming unit (CFU) 
assays of foetal haematopoietic cells, but with no specific effect on the lineage 
output (Yu et al., 1995, Yagi et al., 1998, Hess et al., 1997). Ernst et al. showed, 
using chimeric embryos and repopulation assays, that Mll is essential for 
definitive haematopoiesis. In the absence of Mll, they observed a block in HSC 
development and differentiation. This block occurred at the early stages of 
haematopoiesis, as AGM-derived Mll-deficient cells had no HSC activity and 
did not contribute to foetal liver haematopoiesis (Ernst et al., 2004). McMahon 
et al. further validated this using a different Mll KO mouse model, in this study 
they observed embryonic lethality between E12.5 and 16.5 and a dramatic 
reduction in liver-derived HSC. Further to this mouse model, they also 
developed a conditional Vav-Cre-mediated mouse model, which ablates Mll 
only in the haematopoietic system. They observed that even though the 
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haematopoietic system in the bone marrow was largely unaffected, when the 
Mll-deficient cells were transplanted into lethally irradiated recipients, their 
reconstitution potential was compromised (McMahon et al., 2007).  These data 
suggest that Mll is essential for foetal haematopoiesis but is not required 
postnatally in order to maintain normal steady state. However, it is critical for 
both pre and postnatal regulation of stem cell self-renewal. Jude et al. also 
investigated the role of Mll in the adult haematopoietic system. Using an 
inducible knockout system, they observed that Mll expression was also 
essential for maintenance of adult HSCs and progenitors while committed 
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defined as a unique entity very different from other non MLL-R ALL acute 
leukaemias (Armstrong et al., 2002, Krivtsov et al., 2008).  MLL-R 
rearrangements are present in 75% of infants with ALL while they are only 
present in 1% of paediatric patients. MLL rearrangements are also present in 
infants with AML but the incidence is much lower (Fig. 1.6). The most common 
MLL-R is MLL-AF4, which is present in the majority of infants with ALL and 




AF4 (ALL1-Fused Gene from Chromosome 4 Protein) is a member of the ALF4 
family comprising four paralogous nuclear proteins including AF4, AF5q31, 
LAF4, and FMR2.  Even though AF4 is the most common translocation partner 
gene in MLL-R, LAF4 and AF5q31 have also been reported (Meyer et al., 
2018). AF4 has been shown to play a critical role in lymphoid development as 
AF4 knockout in mice results in severe impairment of the maturation of B- and 
T-cell populations; however, it does not affect other haematopoietic 
compartments even though it is expressed in cells of other haematopoietic 
lineages (Isnard et al., 2000).  
 
At the molecular level, AF4 has been shown to act as a positive regulator of 
post-transcription elongation factor b (pTEFb). PTEFb, is a heterodimer of 
Cyclin Dependent Kinase 9 (CDK9) and Cyclin T1 or T2 and is capable of 
phosphorylating the carboxy- terminal domain (CTD) of RNA polymerase II 
(RNAPII). The interaction of Af4 and pTEFb facilitates transcription elongation, 
which results in transcriptional activation (Bitoun et al., 2007).  
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1.7 MLL-AF4-driven infant ALL 
 
Infant leukaemia is defined as leukaemia diagnosed in a patient before their 
first birthday and is very rare. As mentioned earlier, the most common 
leukaemia in infants is MLL-AF4-driven ALL and patients with this 
rearrangement have an extremely poor prognosis.  
 
1.7.1 The unique biology of MLL-AF4 infant ALL 
 
Infant MLL-AF4-driven ALL occurs in an immature B - lineage precursor, which 
lacks CD10 expression and frequent co-expresses lymphoid and myeloid 
markers. From this, it has been suggested that these leukaemias arise from a 
very immature lymphoid-primed progenitor that can intrinsically differentiate 
towards both the lymphoid and myeloid lineage (Brown, 2013, Basso et al., 
1994, Bardini et al., 2015). The patients are burdened with aggressive clinical 
features including high white blood cell (WBC) counts, hepatosplenomegaly, 
central nervous system (CNS) involvement and leukaemia cutis (skin 
infiltration with leukaemic blasts) (Hilden et al., 2006, Brown, 2013). Poor 
response to prednisone and enhanced chemoresistance is also common 
amongst infant patients. Even though patients achieve complete remission 
quickly, they frequently relapse within one year of therapy (Pieters et al., 2019). 
These unique disease features led to the belief that the disease arises in utero, 
which would explain why it manifests so quickly after birth.  
There is substantial evidence supporting the in utero origin of the disease. The 
first evidence came from studies conducted in identical twins with MLL-R-
driven leukaemia, where both twins shared the same fusion sequence. The 
only plausible explanation for this was that the fusion occurred in utero in one 
twin and then metastasised to the other twin via the shared blood circulation 
due to the monochorionic placenta (Ford et al., 1993). To further support the 
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in utero origin of the disease, the same group performed retrospective analysis 
of blood spots (Guthrie cards) taken at birth from infant patients. They 
observed that the fusions were present at birth in all the patients (Gale et al., 
1997). Further to this, in a recent study, they identified the foetal liver derived 
stem and progenitor cell compartment (CD34+CD38-) as the cell of origin of 
the disease (Agraz-Doblas et al., 2019).  
 
 
Figure 1.7 |The mutational landscape in a variety of cancers.  (Data obtained from 
Andersson et al., 2015). Infants with MLL-R have one of the lowest numbers of somatic 
mutations amongst cancers. They only have a slightly higher number of mutations 
when compared to SJ Low grade glioma, which is also predominantly observed in 
young patients. 
 
At the molecular level, these patients have a silent mutational landscape 
suggesting that no other co-operating mutations are required for the 
transformation to occur (Fig. 1.7) (Andersson et al., 2015, Agraz-Doblas et al., 
2019). In these studies, they observed that there are some mutations present, 
in particular, in the PI3K-RAS signalling pathway; however, these mutations 
were sub-clonal and they were not always present in relapse.  From this data, 
it has been concluded that in infants with this disease the fusion itself is the 
main disease driver.   
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Of particular interest is the location of the chromosomal breakpoint, which in 
the majority of patients can be found between exon 9 and intron 11 of MLL. It 
should be noted that, in the majority of infants, the MLL-AF4 breakpoint is 
located within MLL intron 11 (Meyer et al., 2018). This has been attributed to 
specific molecular features that are present in this region, including a DNA 
topoisomerase II cleavage site, an apoptotic cleavage site, a strong DNase I 
hypersensitive site and an RNA polymerase II binding site (Stanulla et al., 
1997, Aplan et al., 1996, Strissel et al., 1998, Scharf et al., 2007). Therefore, 
it has been suggested that the high incidence of DNA double strand breaks in 
this location could be due to either the specifics of the chromatin structure or 
linked to transcriptional processes (Meyer et al., 2018, Scharf et al., 2007). 
Patients with breakpoints within intron 11 have a worse prognosis as 
compared to patients with upstream breakpoints.  
One very interesting aspect of MLL-AF4 epidemiology is that it can be found 
in two very different clinical settings. One setting is infants with de novo ALL, 
but it can also be found in adults with leukaemias secondary to chemotherapy 
treatment with topoisomerase II poisons. From this, it has been suggested that 
maternal exposure to environmental DNA topoisomerase II inhibitors such as 
dietary flavonoids could contribute to the risk of MLL-AF4 infant leukaemia; 
however, evidence for this is weak (Alexander et al., 2001, Spector et al., 
2005).  
 
1.7.2 MLL-AF4-driven leukaemogenesis 
 
MLL-AF4 fusion occurs when the N terminal portion of MLL fuses with AF4 to 
create a chimeric protein. The fusion proteins contain the N terminal portion of 
MLL including the MENIN binding and CXXC domains; however, the 
downstream PHD fingers and SET domain are replaced with AF4. The 
MLL/MENIN complex further binds to LEDGF, which via its PWWP domain 
allows binding to nucleosomes (Yokoyama and Cleary, 2008). The PWWP 
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domain binds to di-/trimethylated histone H3 lysine 36 (H3K36me2/3), and this 
has been associated with gene activation (Barski et al., 2007),while the CXXC 
domain of MLL binds unmethylated CpGs which are enriched in active 
promoters (Birke et al., 2002). Therefore, MLL binds at two sites, via CXXC 
and PWWP domains, and this has been shown to be critical for stable target 
binding (Eidahl et al., 2013). Additionally, there is an interaction with PAFc 
(polymerase associated factor complex) (Muntean et al., 2010, Milne et al., 
2010). These interactions have been deemed critical for leukaemogenesis as 
they recruit MLL-AF4 to gene targets (Okuda et al., 2014, Yokoyama and 
Cleary, 2008, Yokoyama et al., 2005, Muntean et al., 2010, Milne et al., 2010).  
Truncated MLL is not sufficient to initiate leukaemia and because the SET 
domain is lost, MLL fusion proteins rely on the fusion partner in order to 
activate transcription. Interestingly, AF4 and other fusion proteins AF9, AF10 
and ENL form a complex that further associates with pTEFb and DOT1L and 
leads to aberrant gene expression via aberrant recruitment of DOT1L to the 
promoters of MLL target genes (Bitoun et al., 2007, Mueller et al., 2007, 
Mueller et al., 2009, Ballabio and Milne, 2012). DOT1L controls the levels of 
H3K79me2/3, which has been associated with gene activation (Guenther et 
al., 2008, Krivtsov et al., 2008). Additionally, in a recent study it was 
established that AF4 associates with the SL1 domain of MLL, which results in 
activation of RNAPII-dependent transcription (Okuda et al., 2015). Therefore, 
MLL-AF4 fusion proteins use the N terminal domain to recognise their target 
genes and the fusion partner to stimulate transcription elongation, which leads 
to aberrant expression of target genes including RUNX1, HOXA9 and BCL2 
(Benito et al., 2015, Wilkinson et al., 2013). Interestingly, Kerry et al. further 
showed that a subset of aberrantly activated genes exhibit a unique spreading 
pattern, and those genes were deemed essential for leukaemogenesis (Kerry 
et al., 2017). Overall, MLL-AF4 expressing blasts exhibit a persistent 
expression of MLL target genes and an increase in histone H3K79 methylation 
(Krivtsov et al., 2008) 
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1.7.3 Disease models 
 
MLL-AF4 has proven difficult to model despite the fact that there is only one 
very potent disease driver. Several mouse models have been generated; 
however, we still do not have a mouse model that closely resembles the infant 
disease. The first mouse model generated was described in Chen et al., where 
they fused the human AF4 gene to mouse MLL locus. The mice in this study 
developed, after prolonged latency, mixed lymphoid/myeloid hyperplasia and 
the haematological malignancies observed were often B-cell lymphomas 
(Chen et al., 2006). The second attempt was done by Metzler et al. where they 
used conditional invertor technology in which a floxed AF4 cDNA was inserted 
into the MLL locus in the opposite orientation to transcription. Upon Cre-
recominase expression, AF4 would flip around and be expressed in a chimeric 
mouse-human Mll-AF4 fusion protein. In their model, expression of Cre-
recombinase was conditional to Rag1, Lck and CD19 expression. These mice 
developed B cell malignancies with a mature phenotype and only after a long 
latency (Metzler et al., 2006).  Barrett et al. later used the same model but used 
VE-Cadherin Cre expression to allow expression of Mll-AF4 at the stage of the 
first definitive haematopoietic cells. Using this model, they identified a pre-
leukaemic stage and established the LMPPs as the cell of origin of the disease; 
however, the mice developed B cell lymphomas after a long latency (Barrett et 
al., 2016). Another mouse model was generated, where Mll-AF4 expression 
was conditional to Mx1-Cre, and these mice developed acute B precursor cell 
leukaemia and AML, with a median latency of 131 days. Interestingly, blasts 
derived from the murine B cell precursor leukaemia were highly enriched in the 
gene expression and H3K79 profile of MLL-R patient samples (Krivtsov et al., 
2008).   
Substantial efforts have been made to model this disease using human cells. 
Montes et al. transduced human cord blood derived CD34+ cells with MLL-
AF4 lentiviral particles and observed that MLL-AF4 conferred a proliferation 
and survival advantage in vitro; however, upon transplantation into NSG mice 
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MLL-AF4 was not sufficient to initiate leukaemia (Montes et al., 2011). The 
same group enforced expression of MLL-AF4 in human embryonic stem cells 
(hESCs), which led to an upregulation of HOXA cluster genes. Upon 
differentiation, the MLL-AF4-expressing hESCs favoured an endothelial fate 
over a haematopoietic one (Bueno et al., 2012). However, Tan et al. showed 
that MLL-AF4-expressing induced pluripotent stem cells exhibit high 
repopulation potential and were able to fully reconstruct the human 
haematopoietic system in mice (Tan et al., 2018).  
The best model that we currently have was described in a recent study and 
involved fusion of the N terminus of human MLL with the murine Af4. The 
benefit of this approach was that they achieved higher viral titers and therefore 
higher transduction efficiencies. By transducing human CD34+ cord blood and 
bone marrow cells with MLL-Af4 retroviral particles and then transplanting 
them into NSG mice, they were able to initiate a pro-B ALL in vivo. The mice 
developed leukaemia by week 22 and the blasts were predominantly 
CD34+CD10-CD19+, which is a hallmark of the infant disease.  Additionally, 
they performed molecular profiling of the blasts, and indeed a large part of the 
molecular signature of the disease was recapitulated in the blasts. In particular, 
MLL-Af4 was able to co-immunoprecipitate with DOT1L and super elongation 
complex (SEC) components, and the use of DOT1L inhibitors blocked the 
disease. However, it should be noted that the blasts did not display HOXA 
cluster upregulation, which is another hallmark of the disease. Interestingly, 
when they transplanted murine haematopoietic stem and progenitor cells 
(HSPCs) expressing MLL-Af4 they observed that the mice developed AML. 
The murine leukaemia phenotype was not influenced by culturing the cells 
prior to the transplantation in lymphoid or myeloid conditions (Lin et al., 2016). 
Using the same system, the same group investigated the interaction between 
fusion proteins and the microenvironment. They observed that the MLL-Af4 
oncogenic activity was lineage-depended, suggesting that the lymphoid 
context is critical for MLL-Af4 leukaemogenesis. Additionally, they observed 
that under myeloid conditions these cells became unstable, vulnerable and 
prone to loss of self-renewal potential and lineage switching (Lin et al., 2017).  
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Much controversy exists around the importance of the reciprocal protein AF4-
MLL for the infant disease. It was recently shown that AF4-MLL was expressed 
in 45% of the infant patients and that these patients had a significantly better 
prognosis. Interestingly, they also observed a close correlation between the 
reciprocal fusion and HOXA cluster expression (Agraz-Doblas et al., 2019, 
Trentin et al., 2009). In an effort to understand the role of AF4-MLL, Bursen et 
al. transduced murine Lin-Sca+ cells with AF4-MLL and transplanted them into 
mice, which subsequently developed pro-B ALL, B/T biphenotypic leukaemia 
or mixed lineage leukaemia but with long latency. In a human setting, Kumar 
et al. used siRNA to knock down expression of AF4-MLL and also MLL-AF4 in 
two patient-derived leukaemia cell lines (SEM and RS4;11). They observed 
that loss of AF4-MLL did not affect survival, proliferation or growth of the cell 
lines; however, knockdown of MLL-AF4 resulted in cell cycle arrest and 
apoptosis (Kumar et al., 2011). However, this study was criticised for lack of 
specificity of the AF4-MLL siRNA that could lead to false negative results. 
Using primary cells, Prieto et al. observed that AF4-MLL transduction of human 
CD34+ cells exerts an enhancement effect upon transplantation albeit with no 
leukaemogenic potential (Prieto et al., 2017). Wilkinson et al. provided further 
evidence for the interaction of the two fusion proteins and the critical role of 
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1.7.4 Therapeutic approaches 
 
Infants with MLL-AF4-driven ALL suffer from a dismal prognosis. In order to 
identify optimum treatments for these patients, large collaborative efforts have 
been established, including Interfant-06 (Driessen et al., 2017, Pieters et al., 
2019). In this international clinical trial, patients were treated with intensive 
multiagent chemotherapy, followed by consolidation with myeloid-style or 
lymphoid-style chemotherapy. This was because the blasts of infants express 
both lymphoid and myeloid markers and a lineage switch has also been 
observed, where the patient relapse to AML following treatment (Pieters et al., 
2019). This was followed with either further chemotherapy or allogenic 
haematopoietic stem cell transplant. Unfortunately, the latest data from this 
study were disappointing as no improvements were observed regarding the 
outcome of the infant patients (Pieters et al., 2019). This data suggest that the 
molecular biology of the disease is unique and therefore requires novel 
therapeutic approaches.  
Toward this end, of particular interest are demethylating agents and histone 
deacetylase inhibitors, which target the abnormal epigenetic profile of the 
disease especially H3K79 methyltransferase DOT1L inhibitors (Bhatla et al., 
2012, Garrido Castro et al., 2018, Stumpel et al., 2012). Multiple small 
inhibitors of DOT1L showed promising results in preclinical models; however, 
further clinical evidence are required to establish the suitability of this treatment 
for infant patients (Daigle et al., 2013, Daigle et al., 2011).  
The critical role of the MLL-MENIN interaction presents another interesting 
therapeutic target, and several small molecules have been identified with 
promising results in vitro and in vivo (Grembecka et al., 2012, Borkin et al., 
2015). BRD4, which is a member of the BET bromodomain-containing 
proteins, has also been considered an interesting therapeutic target as 
removal of BRD4 was shown to cause a rapid downregulation of proto-
oncogene MYC; however, the specificity of such a compound is in question as 
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it appears that it targets the myeloid lineage as opposed to MLL-R (Delmore 
et al., 2011).  
HDAC inhibition has also been reported of being capable of reversing gene-
expression profiles associated with chemotherapy resistance in infant MLL-R 
ALL (Stumpel et al., 2012).  Multiple compounds have been identified to exert 
promising results in xenograft models of the disease including romidepsin and 
panobinostat, however, further studies are required to ensure safety and 
efficiency of these compounds (Cruickshank et al., 2017, Garrido Castro et al., 
2018).   
Another promising avenue is targeting the microenvironment interactions. One 
example of such treatment is the use of CXCR4 inhibition that when used in 
combination with other treatments (for example FLT3 inhibitor lestaurtinib) can 
lead to better outcome (Sison et al., 2013).  
In addition, immunotherapies directed against B-cell antigens such as 
blinatumomab (an anti-CD19 monoclonal antibody) and chimeric antigen 
receptor T (CAR-T) cells have shown high antileukaemic potential in infant 
case reports (von Stackelberg et al., 2016, Maude et al., 2018). However, 
downregulation of the CD19 antigen and lineage switching has been observed 
in infants treated with B-lineage specific therapy (Rayes et al., 2016, 
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1.8 Motivation and aims 
 
Following from the latest Interfant publication it is clear that the prognosis of 
patients with MLL-AF4-driven ALL has not improved. It is also clear that lack 
of improvement could be attributed to the unique biology of the disease that is 
not completely understood. What makes infant leukaemia a distinct entity is its 
in utero origin. Therefore, it has long been speculated that the foetal origin of 
the disease is a key contributor to the aggressive disease phenotype. As 
mentioned earlier, several studies investigated differences between foetal and 
adult haematopoietic stem and progenitor cells; however, none of the studies 
correlated their finding with the MLL-AF4-driven infant ALL.  
Therefore, the first aim of this study was to further define a foetal and 
neonatal/adult transcriptional signature in both humans and mice and use this 
approach to corroborate how the foetal origin could affect the disease 
phenotype. Additionally, I used this approach to identify genes that were 
expressed at similar levels between foetal-derived cells and blasts and 
therefore could be a residue of the foetal cell of origin. I speculated that these 
genes might be of importance for the pathogenesis of the disease and could 
therefore serve as novel therapeutic targets.  
Additionally, following on from Barrett et al. where, using an Mll-AF4 
expressing mouse model, they captured a pre-leukaemic stage and pinpointed 
LMPPs as the cells of origin of the disease, I aimed to identify genes that were 
expressed in LMPPs at the early stages of the disease and identify novel 
disease targets. 
Having identified novel disease targets using the aforementioned approaches, 
my final aim was to investigate whether these targets could exert an effect on 
the disease phenotype.   
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1.8.1 Summary of aims 
 
• Define the transcriptional profile of murine foetal and bone marrow 
derived LMPPs. 
• Compare the transcriptional profile of murine foetal derived LMPPs 
expressing Mll-AF4 with controls.  
• Define the transcriptional prolife of human foetal liver and cord blood 
derived HSC/MPPs. 
• Compare the transcriptional profile of human foetal liver derived 
HSC/MPPs with LMPPs and investigate which is the potential cell of 
origin of the disease. 
• Identify genes the expression of which was conserved across species 
and establish a list of such genes. Investigate expression of these 
genes in the blasts of infants with MLL-AF4 driven ALL. 
• Identify genes that could serve as novel therapeutic targets and use in 
vitro approaches to investigate the effect.  
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Chapter 2 Materials & methods 
 
2.1 Sample collection and processing 
 
2.1.1 Collection of human foetal tissues (first and second 
trimester – 9 to 20 weeks gestational age) 
 
Foetal tissues were obtained from second trimester foetuses undergoing 
elective surgical termination following informed consent from the patient.  
Dissection of the foetal livers was conducted by a member of the RAA/FT/001 
study and the liver was placed in PBS. The liver was mechanically disrupted 
in order to create a single cell suspension and then passed through a 40μm 
cell filter (Becton-Dickinson). The single cell suspension was washed with PBS 
with 10% FCS and 1mM EDTA (washing buffer), the samples were washed by 
centrifugation at 500xg for 5 minutes and the supernatant was removed.  
The pellet was resuspended in 40ml of washing buffer (for livers obtained from 
16 to 20 weeks of gestation, the pellet was resuspended in 80ml of washing 
buffer). In order to separate the mononucleated cells (MNC), the Ficoll™ 
(Sigma-Aldrich, Haverhill, England) gradient separation method was used. 
20ml of the cell suspension were layered over 10ml of Ficoll™ and the samples 
were centrifuged for 30 minutes at 1500rpm (with no breaks).  Following 
centrifugation, the MNC layer, which was visible, was collected with a Pasteur 
pipette and washed with at least 30ml of washing buffer at 300xg for 10 
minutes. The cell pellet was either further processed for enrichment or was 
cryopreserved in freezing medium (FSC with 10% DMSO and 1% P/S). 
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Cord blood samples obtained from the Scottish cord bank in Glasgow and the 
Cambridge stem cell biobank were already CD34 enriched and thus no further 
processing was required.  
 
2.1.2  Collection of murine tissues  
 
Heterozygous Mll-AF4loxP knock-in (Metzler et al 2006) and heterozygous 
VEC-Cre transgenic (Chen et al 2009) mice were crossed in order to produce 
Mll-AF4+ VEC-Cre+ and Mll-AF4- VEC-Cre+ embryos. Additionally, I obtained 
E14.5 embryos from wild-type C57BL6/N crosses and adult bone marrow from 
adult C57BL6/N mice (8-10 weeks old). 
After dissection of the E14.5 embryos, the liver was macroscopically identified 
and placed in a 1.5ml tube containing PBS where it was mechanically 
disrupted with a syringe into a single cell suspension. Bone marrow was 
obtained by removing and crushing the long bones (femur and tibia) of the 
adult mice. In order to ensure single cell suspension, the samples were passed 
through a 50µM filter (Wolf Laboratories). The samples were washed once with 
either PBS for the foetal liver or complete medium (PBS, 10% FSC, 1% 
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2.2 Genotyping  
 
Genotyping of the embryos for the Mll-AF4loxP knock-in and VEC-Cre 
transgenic timed mattings was performed in order to ensure the appropriate 
genotypes of each mouse embryos.  
For DNA extraction the HotSHOT method was used, where 1/5 of the embryo’s 
head was used (Truett et al., 2000). Specifically, the tissue was initially placed 
in an alkaline lysis buffer (0.04% disodium EDTA and 0.25% NaOH in water) 
and heated to 95°C at 1000rpm for 20 minutes. This was followed by addition 
of a lysis neutralisation reagent (4% 1M Tris-HCl in water). 1μl of the HotSHOT 
mixture was mixed with 12.5μl Kapa2G PCR mixture (Merck), 9μl of water and 
1.25μl of (10nM) each primer.  
Target Forward primer Reverse primer 
Vec-Cre GCC TGG CGA TCC CTG AAC ATG 
 
CCC AGG CTG ACC AAG CTG AG 
 
Mll-AF4 ATG ATG CCA CTG TGC TGT GT 
 
TCG CCT TCT TGA CGA GTT CT 
 
 
The above were placed in a thermal cycler and the following PCR conditions 
were used: 
Initial denaturation  92oC for 2 min 
Denaturation  95 °C for 15 s 
Annealing   58 °C for 15 s 
Extension   72 °C for 5 s 
Final extension  72 °C for 10 s 
Infinite hold   4 °C 
30 cycles for Mll-AF4  
35 cycles for Vec-Cre 
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The PCR products were visualised on a 1% agarose (Sigma-Aldrich) gel using 
GelRed™ (Biotium). In addition to the samples a 1000bp DNA ladder 
(Invitrogen) and also a positive and negative control were used in every gel, 
the gels were run for 20 minutes at 120V and visualised with a gel 
documentation system (Gene Flash, SYNGENE). 
 
2.3  Magnetic-activated cell sorting and flow 
cytometric cell sorting and analysis 
 
2.3.1 Magnetic-activated cell sorting (MACS)  
 
Magnetic-activated cell sorting (MACS) was used for enrichment of human 
foetal liver samples for CD34 using Miltenyi Biotec CD34 MicroBeadKit – Ultra 
Pure Human (Miltenyi Biotec). Following single cell suspension and Ficoll 
separation, foetal liver-derived MNCs were resuspended in 300µl of FACS 
buffer and 100µl of FcR Blocking Reagent and 100µl of CD34 MicroBeads 
UltraPure were added to the sample. The samples were incubated at 2-8°C for 
30 minutes, in the dark. Following incubation, the samples were washed at 
300xg for 10 minutes and the pellet was resuspended in 500µl of FACS buffer. 
The cell suspension was transferred into a LS MACS column attached to a 
magnet (which has been previously primed by allowing 3ml of FACS buffer to 
go through) and 3 x 3ml of buffer were added for washing the column 
afterwards. The flow through contained the unlabelled cells whereas the 
labelled cells were retained inside the column by the magnet. Finally, the 
column was removed from the separator and placed inside a falcon tube. 5ml 
of buffer were added to the column and the column was immediately flushed 
by firmly pushing the plunger into the column. The labelled cells obtained in 
the final step were washed and processed in accordance with the downstream 
application that they were going to be used for.   
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2.3.2 Cell staining for flow cytometric analysis and 
sorting 
 
General staining protocol: 
Cells were initially washed with FACS buffer (PBS, 2% FCS and 1% P/S). The 
pellet was then resuspended in approximately 100µl of FACS buffer for 1 
million cells. 5µl of Fc blocker agent (BD) was added and the samples were 
incubated for 10 minutes. Following the end of the 10-minute incubation 
period, the appropriate antibody cocktail (see below) was added to the 
samples and the samples were incubated for 20 minutes at 4°C, in the dark. 
1ml of FACS buffer was added to the samples and the samples were washed 
by centrifugation for 5 minutes at 2000 rpm where possible at 4°C. The pellet 
was resuspended at 200µl and the appropriate viability dye added. It should 
be noted that the appropriate compensation controls (single stained and 
fluoresce-minus-one) were used when setting up an experiment and for 
complicated sorting strategies with every experiment.  
2.3.3 Flow cytometric analysis and sorting  
Samples were analysed using a 4 laser FACSAria (Beckton Dickinson) and a 
3 laser NovoCyte (Acea Biosciences). Samples were sorted on either a 
FACSDiva or FACSAria (Beckton Dickinson).  
 
2.3.4 Analysis of flow cytometry data  
Data was analysed with FlowJo software (Tree Star). Gating strategies are as 
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2.3.5 Sorting of murine LMPP  
 
 
Figure 2.1 | Schematic representation of murine LMPP sorting strategy Viable cells 
were gated on cellsà singlets 
 
It should be noted that this protocol was established by Charlotta Böiers 
(Boiers et al., 2013). Following dissection of E14.5 foetal liver and bone 
marrow, a single cell suspension was created, the samples were washed with 
complete medium (CM) (PBS, 10% FSC and 1% P/S) and LMPPs were sorted 
for Lin-Sca1+c-kit+CD45+B220-CD19-Flt3+. A master mix of appropriate 
antibodies was created (Table 2.1) and added to the samples and controls. 
The samples were incubated at 4°C for 20 minutes and then washed with CM.  
A second staining step was required for the Flt3 and as such the samples were 
incubated with StAV-Qd655 for a further 20 min at 4°C. The samples were 
washed twice with CM and finally the viability dye SytoxGreen (Thermo Fisher 
Scientific) was added at a concentration of 1:1000. The stained pellet was 
resuspended in 300µl of FACS buffer and the samples were sorted using the 
Cell Sorter BD FACS ARIA II or BD FACS Fusion. Controls included an 
unstained control as well as single stains and fluorescence-minus-one (FMO) 
controls for all antibodies. The sorted cells were collected in CM at 4°C. After 
sorting, the samples were centrifuged at 500xg for 5 minutes at 4°C in a fixed 
angle centrifuge and the pellets immediately processed for the downstream 
application.  
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Antibody / fluorophore Clone Provider 
IL7R-PE A7T34 eBioscience 
Sca1-PB E13-161.7 Biolegent 
ckit-APCeF780 2B8 eBioscience 
CD45-AF700 30-F11 eBioscience 
Flt3-biotin A2F10 eBioscience 
B220-PECy7 RA3-6B2 Biolegend 
CD19-PECy7 1D2 Biolegend 
StAV-Qd655  Life technologies 
CD3e-APC* I45-2C11 BD 
Ter119-APC* TER119 eBioscience 
F4/80-APC* 2BM8 eBioscience 
Nk1.1-APC* PK136 BD 
Gr1-APC* RB6-8C5 BD 
SytoxGreen   Life technologies 
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2.3.6 Sorting of human HSC/MPP and LMPP 
 
 
Figure 2.2 | Schematic representation of human LMPP sorting strategy Viable cells 
were gated on cellsà singlets 
 
Human foetal liver and cord blood derived samples were initially enriched for 
CD34 using magnetic-activated cell sorting. The CD34 enriched populations 
were further sorted for haematopoietic stem and progenitor cells (HSC/MPPs) 
CD34+CD38-CD45RA- and LMPPs CD34+CD38-CD45RA+. It should be 
noted that human cord blood samples were also enriched for CD34. The 
samples were resuspended in approximately 100µl of FACS buffer for 1 million 
cells and 5µl of Fc blocker agent (Becton Dickinson) added and the samples 
were incubated for 10 minutes. A master mix of appropriate antibodies (Table 
2.2) was created and the samples were then stained and incubated for 20 
minutes at 4 °C, in the dark. The samples were washed with 1ml of FACS 
buffer and the pellet was resuspended in 300µl of buffer. DAPI (Biolegend) 
was used as a viability dye.  Following sorting, the cells were processed in an 




CD34 FITC 581 Biolegend 
CD38 PE HIT2 Biolegend 
CD45RA APC HI100 Biolegend 
Table 2.2| List of antibodies for the human LMPP sort 
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2.3.7 Cell Tracer 
 
Cell Tracer™ Far Red Cell Proliferation kit (Thermo Fisher Scientific) was used 
for in vitro cell proliferation analysis.   
The following protocol has been optimised for cell concentrations of 1x106 
cells/mL and the dye was used at a 1µM concentration. 
 1x106 cells were washed with PBS and the supernatant was removed. The 
dye, which was diluted into 1ml of PBS, was added to the cells. The cells were 
incubated for 20 minutes at room temperature, in the dark. 7ml of FACS buffer 
were added to the cells and the cells incubated for 5 minutes and then washed. 
Following the final washing, 1/3 of the cells were resuspended in FACS buffer 
for immediate analysis (day 0 of analysis) while the remaining 2/3 were placed 
in culture medium and cultured for 4 days (day 4 of analysis). Cells were 
cultured in SEM medium (RPMI (Gibco) and 10% FCS) at 37°C with 5% CO2.  
Following the 4 days incubation, the cells were washed and resuspended in 
FACS buffer for flow cytometric analysis. It should be noted that during 
analysis acquisition flow rate was less than 150 events per second. It should 
also be noted that for the day 0 time point the cells were incubated for at least 
10 minutes prior to the analysis in order to allow the CellTrace™ reagent to 
undergo acetate hydrolysis. The viability dye for this experiment was Sytox 
Orange (Life Technologies) used at 1:1000.  
 
2.3.8 Zombie NIR™ Fixable Viability Kit 
 
The Zombie fixable viability dye (Biolegend) was used to stain live cells for 
treatments that would lyse the cells such as analysis of the cell cycle.  
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The following protocol has been optimised for cell concentrations of 1x106 cells 
and the dye was at 1:100 dilution (stock solution was diluted with 100µl of 
DMSO).  
1x106 cells were washed with PBS. 1µl of the dye was diluted in 100µl of PBS. 
The cells were resuspended in 100µl of PBS containing the dye and the cells 
were incubated at room temperature for 15 minutes, in the dark. Following 
incubation, the cells were washed with FACS buffer and resuspended in FACS 
buffer ready for the cell cycle analysis.  
 
2.3.9 Cell cycle analysis 
 
Cell cycle analysis was conducted in order to observe differences in the 
number of cells present in the different phases of the cell cycle between 
treatments. It should be noted that in order to ensure that all the cells analysed 
for the cell cycle were viable, I either used the Zombie NIR™ Fixable Viability 
Kit or the cells were sorted and immediately analysed. The buffer for the cell 
cycle was made by our Flow Cytometry facility and contained 5µg/ml Dapi 
(Thermo Fisher Scientific) in 1% IGEPAL (Merck). One volume of cell cycle 
buffer was added to the cells that were resuspended in either PBS or FACS 
buffer. The mixture was incubated for 1 minute and then immediately analysed. 
It should be noted that during acquisition with the flow cytometric analyser, I 
always acquired less than 150 events per second.  
 
2.3.10 Competition assay 
 
The competition assay was used to assess the proliferation/viability potential 
of cells. In particular, it was used to assess the effect of specific sgRNAs on 
the phenotype of the SEM cells. For the competition assay, I mixed in a 1:1 
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ratio wild-type SEM cells with Cas9-GFP SEM cells and then transduced the 
cells with the sgRNA of interest. It should be noted that in all the competition 
assays I always used a positive and negative control. In order to assess the 
impact of the sgRNA I performed flow cytometric analysis of the cells at 
different time points (days 2, 6 and 12).  
 
2.3.11 Migration assay 
 
The migration assay was performed with the CRISP/R Cas9 SEM cells to 
assess whether sgRNAs could affect the migration potential of cells. For the 
assay, I generated SEM Cas9-sgRNAs cell lines, including one line for the 
negative control. All the cell lines were passaged at least once before sorting 
1x105 SEM-Cas9-sgRNA cells for the assay. Following sorting, the cells were 
washed and resuspended in culture media and incubated overnight at 37°C 
with 5% CO2. The following morning the cells were centrifuged, and all the 
media was carefully removed. A transwell (Corning, 8µm pore) was placed in 
a standard 24-well plate. The cells were resuspended in RPMI with no FCS in 
order to starve them and they were placed on top of the transwell. In order to 
create the migration gradient, 600µl of migration media (RPMI with 10% FSC 
and 100ng/ml CXCL12 -Thermo Fisher Scientific) were added to the lower well 
of the 24-well plate. The cells were allowed to migrate for 5 hours at 37°C and 
5% CO2. Following incubation, the cells were washed and resuspended in 
200µl FACS buffer. For the analysis of the migration assay, the cells migrated 
were counted using a Novocyte flow cytometer (Acea Biosciences) where the 
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2.4 Clonogenic assays 
 
2.4.1 Methylcellulose assay for murine lymphoid 
potential 
 
2000 cells were resuspended in 300µl of IMDM (Life Technologies). The cells 
were then transferred to 3ml of methylcellulose (M3630, Stem Cell 
Technologies) with cytokines (20ng/mL Scf, Il7 and Flt3L) and mixed 
vigorously by vortexing. The mixture was left to settle for at least 5 minutes 
and 1ml of the methylcellulose containing the cells was dispensed into a 35mm 
plate.  The three technical replicates (three plates) were placed in a 35mm 
petri dish along with an extra petri dish containing sterile water. The cells were 
incubated at 37°C with 5% CO2 for 10 days. After 10 days, the number of 
colonies was counted. For re-plating, 2000 cells were re-plated into a new CFU 
assay where the cells were incubated at 37°C with 5% CO2 for 10 days.  
 
2.4.2 Methylcellulose assay for human myeloid potential 
 
MethoCultÔ H4034 Optimum (Stem Cell Technologies) was used for the 
assessment of the myeloid potential of human stem and progenitor cells. 3ml 
of MethoCultÔ H4034 Optimum used for each sample where 2000 cells were 
resuspended into 300µl of IMDM (Life Technologies). The cells were then 
transferred to 3ml methylcellulose and mixed vigorously by vortexing. The 
mixture was left to settle for at least 5 minutes and 1ml of the methylcellulose 
containing the cells was dispensed into a 35mm plate.  The three technical 
replicates (three plates) were placed in a 35mm petri dish with an extra petri 
dish containing sterile water. The plates were incubated at 37°C, in 5% CO2 
for 14 days. After 14 days, the number of colonies was counted. 
 
   
  41 
2.4.3 Clonogenic assay for human lymphoid potential 
 
For the B cell differentiation assay, I used the MS5 stroma cell line which 
supports differentiation of stem cells towards the B cell lineage. MS5 cells were 
grown in alphaMEM (Life Technologies) supplemented with 10% FSC, 1% L-
Glutamine (Life Technologies), 1% HEPES (Life Technologies), 1% 2-
mercaptoethanol (Life Technologies) and 1% penicillin/streptomycin 
(pen/strep). MS5 were thawed 72 hours prior to passaging and re-plated 24 
hours prior to initiation of the differentiation.  
For the differentiation, 25000 MS5 cells were plated in a 24-well plate, 24 hours 
prior to the initiation of the differentiation. On the day of the experiment, the 
MS5 cells were confluent. For the differentiation assay, I used 1000 -10000 
haematopoietic stem and progenitor cells. The differentiation media contained 
the MS5 medium supplement with recombinant human cytokines including 
Flt3L (10ng/mL), SCF (20ng/ml), interleukin-2 (IL2) (10ng/ml), interleukin-7 
(IL7) (5ng/mL) (Miltenyi Biotec). During differentiation, half of the medium was 
replaced every 4 days and the plates were incubated at 37°C, in 5% CO2 for 
14. At the end of the differentiation period, the cells were analysing using flow 
cytometry for lymphoid and myeloid markers using the following antibodies 




CD19 PE HIB19 Biolegend 
CD33 APC Cy7 P67.6 Biolegend 
CD10 APC HI10a Biolegend 
Table 2.3 | List of antibodies for assessing lymphoid and myeloid potential. 
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2.5 RNA extraction 
2.5.1 RNA extraction from small cell numbers  
 
RNA extraction of small cell numbers (800 – 50000 cells) was performed using 
the NucleoSpin RNA XS kit (Macherey-Nagel). Cell pellets were lysed with 
100μl of RA1 containing 2μl TCEP (where TCEP is a reducing agent) and the 
samples were vigorously vortexed. 100μl of 70% EtOH were added to the 
homogenised lysate and the samples were vortexed again. The samples were 
transferred into NucleoSpinâ RNA XS columns and the tubes centrifuged for 
30 sec at 11000xg, which allowed binding of the RNA to the column. The next 
step was to desalt the silica membrane by the addition of 100μl of Membrane 
Desalting Buffer (MDB) followed by centrifugation for 30 sec at 11000xg. The 
next step was the digestion of DNA, which was achieved by addition of 25μl of 
rDNase reaction mixture (3μl of rDNase and 27μl Reaction buffer for rDNase) 
on top of the membrane, followed by incubation for 15 minutes at room 
temperature. The next step was inactivation of the rDNase with 100µl of RA2 
buffer, followed by a 2-minute incubation at room temperature and 
centrifugation for 30 sec at 11000xg. This was followed by two washing steps. 
For the first wash step, 400μl of RA3 buffer were added to the column, which 
was followed by spinning at 11000xg for 30 seconds. For the second wash, 
200μl RA3 buffer were added, followed by spinning at 11000xg for 2 minutes. 
One final spin was conducted in order to ensure that the column was 
completely dry. Finally, 12μl of RNase-free water was added to the centre of 
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2.5.2 RNA extraction from large cell numbers  
 
RNA extraction from large cell numbers (>50000 cells) was performed using 
the RNA mini kit (Qiagen). Cell pellets were disrupted by the addition of 600μl 
of RLT buffer and the lysates homogenised with vigorous vortexing and 
pipetting. 600μl of 70% EtOh was added to the cell lysates and the lysates 
were further vortexed and mixed well by pipetting. 700μl of the samples were 
transferred into an RNease spin column and the samples centrifuged for 15 
seconds at 8000xg. This step was repeated one more time to allow the entire 
lysate to be loaded onto the column, after which the flow through was 
discarded. 350μl of RW1 buffer were added to the spin columns and the 
samples were spun down at 8000xg for 15 seconds. It should be noted that a 
DNase (Qiagen) step was incorporated into the standard RNA extraction 
protocol. For each reaction, 10μl of DNase I (27.27 Kunitz units) solution were 
added to 70μl of buffer RDD (Qiagen) and the solution was added directly to 
the columns and incubated for 15 minutes at room temperature. 350μl of buffer 
RWI were added to the RNeasy spin column and the column was centrifuged 
for 15 sec at 10000rpm.  Two more washing steps followed with RPE buffer, 
one with 500μl and spinning at 8000xg for 15 seconds and the second with 
500μl RPE with spinning at 8000xg for 2 minutes. Another spinning step was 
incorporated in order to ensure that the column was dry. For the final step, 30μl 
of RNase-free water were added to the centre of the column and the RNA was 
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2.6 DNA extraction 
 
2.6.1 DNA extraction 
 
DNA extraction was performed with the DNeasy Blood and Tissue kit (Qiagen). 
1-2x106 cells were centrifuged at 300xg for 5 minutes and the pellet was 
resuspended in 200µl PBS to which 20µl of proteinase K were added. 200µl of 
buffer AL were further added to the mixture and the samples incubated for 10 
min at 56ºC. 200µl of ethanol were added and the samples mixed thoroughly. 
The mixture was transferred into a DNeasy Mini spin column and centrifuged 
at 6000xg for 1 min, after which the flow through was discarded. 500µl of AW1 
buffer were added to the columns and the columns centrifuged at 6000xg for 
1 minute, after which the flow through was discarded. 500µl of AW2 buffer 
were added to the columns, the columns centrifuged at 20000xg for 3 minutes 
and the flow through again discarded. The columns were further centrifuged 
for 1 minute at 6000xg. Finally, 200µl buffer AE were added directly onto the 
DNease membrane, the columns incubated for 1 minute at room temperature 
and then centrifuged at 6000xg for 1 minute.  
 
2.6.2 Gel extraction  
 
DNA was extracted using the QIAquick gel extraction kit (Qiagen). Initially, the 
DNA band containing the product of interest was excised from the agarose gel 
and the gel slice weighed. 3 volumes of buffer QG were added to 1 volume of 
gel and the mixture was incubated at 50ºC for 10 min or until the gel slice was 
completely dissolved. Once the gel slice was completely dissolved, 1 gel 
volume of isopropanol was added, and the mixture placed in a QIAquick spin 
column and centrifuged at 17900xg for 1 minute and the flow through 
discarded. 500µl of buffer QG were added and the column was centrifuged at 
   
  45 
17900x g for 1 minute and the flow through discarded. 750µl of buffer PE were 
added and the column was centrifuged at 17900x g for 1 minute and the flow 
through discarded. The column was further centrifuged at 17900x g for 1 
minute and the flow through discarded. 50µl of buffer EB were added and the 
column was incubated for 1 minute at room temperature before it was further 
centrifuged at 17900x g for 1 minute.  
 
2.6.3 PCR product purification 
 
PCR product purification was achieved using a PCR purification kit (Qiagen). 
5 volumes of buffer PB were added to 1 volume of PCR sample. The mixture 
was transferred into a QIAquick column which it was centrifuged at 17900xg 
for 1 minute and the flow through discarded. 750µl of buffer PE were added, 
the column centrifuged at 17900x g for 1 minute and the flow through 
discarded. The column was further centrifuged at 17900x g for 1 minute and 
the flow through discarded. 50µl of buffer EB was added and the column 
incubated for 1 minute at room temperature before it was further centrifuged 
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2.7 RNA and DNA quantification 
 
2.7.1 RNA quantification with Agilent High Sensitivity 
DNA Screen Tape 
 
The Agilent Tapestation system allows electrophoresis of RNA samples. 2μl of 
RNA samples or RNA ladder (Agilent) were mixed with 1μl of High Sensitivity 
RNA Screen Tape sample buffer (Agilent) and vortexed using IKA vortexer 
(Agilent) at 2000 rpm for 1 minute and spun down. To achieve denaturation of 
the samples, they were placed in a thermal cycler at 72°C for 3 minutes and 
then at 4 ºC for 2 minutes. Finally, the samples were loaded onto the 
Tapestation for analysis.  
 
2.7.2 DNA quantification with Agilent High Sensitivity 
DNA Screen Tape 
 
The Agilent Tapestation system allows electrophoresis of DNA samples. 2μl of 
DNA samples or DNA ladder were mixed with 2μl of High Sensitivity D1000 
sample buffer and vortexed for 1 minute. The mixed samples were spun down 
and loaded onto the Tapestation for analysis alongside a ladder.  
 
2.7.3 DNA quantification with Qubit 
 
Qubit RNA HS (Thermo Fisher Scientific) and Qubit dsDNA HS (Thermo Fisher 
Scientific) assays were also used for the quantification of RNA and DNA. For 
each assay, the appropriate standards were set up and the samples were 
prepared according to the manual. Briefly, the appropriate amount of sample 
(usually 2μl) was added to the working solution (1μl of Qubit RNA/DNA reagent 
in 200μl of Qubit RNA/DNA buffer), the samples were vortexed and incubated 
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for 2 minutes. After incubation, the samples were analysed using the Qubit 2.0 
Fluorometer. In order to determine the amount of RNA/DNA the following 
formula was used:  
Concentration of sample = QF value × ( 200 x X ),  
where: QF value = the value given by the Qubit® fluorometer 
 X = the number of microliters of sample added to the assay tube 
 
2.7.4 DNA and RNA quantification using Nanodrop 
 
Nanodrop 2000 (Thermo Fisher Scientific) was also utilised for the 
measurement of both RNA and DNA, specifically for larger samples. The 
Nanodrop was initially cleaned and the appropriate blank was utilised (water 
for RNA and elution buffer for DNA) and 1μl of sample was placed in the 
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2.8 Library preparation for RNA sequencing  
 
The SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian v1 and v2 
was used for the generation of indexed cDNA libraries from approximately 1ng 
of high-quality RNA that were compatible with next-generation sequencing 
(NSG) and in particular the Illumina platform Hiseq4000. The preparation of 
libraries using the SMARTer Stranded RNA seq pico input protocol can be 
divided into seven different steps: 1) first-strand cDNA synthesis, 2) addition 
of Illumina Adapters and barcodes, 3) library purification with AMPure beads, 
4) depletion of Ribosomal cDNA, 5) final PCR amplification and 6) library 
purification with AMPure beads and 7) library validation.  
1. First-strand cDNA synthesis 
Following RNA extraction, 1 ng of RNA was mixed with 1μl SMART Pico Oligos 
Mix, 4μl 5X first Strand buffer and nuclease-free water, and the reaction 
mixture was placed in a thermal cycler at 94°C for 4 minutes. Following 
incubation, the samples were placed immediately on ice for 2 minutes. The 
first step of first strand cDNA synthesis was fragmentation of RNA into 
fragments of the appropriate size for Illumina sequencing platforms.  
Following RNA fragmentation, the first strand master mix (4.5μl Template 
Switching Oligo Mix, 0.5μl RNase Inhibitor, 2μl SMARTScribe Reverse 
Transcriptase) was added to the mixture and the mixture was placed in a 
preheated hot-lid thermal cycler at 42°C for 90 minutes followed by 70°C for 
10 minutes, after which the samples were stored at 4°C until the next step.  
2. Addition of Illumina adapters and indexes 
The second step was the addition of Illumina adapters since each 
sample/library should have a different adapter in order to be distinguished 
during the analysis. After the first strand cDNA synthesis, 2μl Nuclease-free 
water, 25μl 2X SeqAmp PCR buffer, 1μl Seq Amp DNA polymerase, 1μl 
Forward PCR primer HT and 1μl Reverse PCR primer HT were added to the 
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tube. The samples were mixed and briefly spun down before being placed in 
a preheated hot-lid thermal cycler using the following program.  
94°C 1 minute 
98°C 15sec 
55°C 15sec  
68°C 30sec 
68°C 2 minutes 
4°C forever  
3.  Purification of the RNA-sequencing library using AMPure 
beads 
This step allowed for the purification of cDNA by binding of the cDNA to the 
AMPure beads, which are magnetic. During this step, fragments less than 
100bp were removed. 
45μl of AMPure beads were added to the 50μl sample mixture, the beads and 
the sample were incubated for 10 minutes in order for the DNA to bind to the 
beads. After the incubation, the tubes were placed on a magnetic stand for 
several minutes (until the solution was clear and the sample with beads sitting 
at one side of the tube). Once the supernatant was clean, it was removed and 
the beads were washed twice with 70% ethanol and then allowed to dry. Once 
the beads were dry, 18μl of nuclease-free water were added and the beads 
incubated with the water for rehydration. The tubes were again placed on the 
magnetic stand until the solution was completely clear. 16μl of the supernatant 
were transferred to a new tube, which is the sample.  
4.  Depletion of Ribosomal cDNA with ZapR and R-probes 
During this step, the library fragments that have been generated during the 
previous step are “cleaned” from fragments originating from rRNA. This was 
5 cycles 
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achieved by hybridisation of the rRNA with R-probes, which were then cut by 
ZapR.  
To the libraries, that have been previously generated, 2μl 10X ZapR Buffer, 
1μl R-probes (previously incubated in a thermal cycler at 72°C for 2 minutes) 
and 1.25μl ZapR were added. The tubes were incubated in a pre-heated hot-
lid thermal cycler at 37°C for 60 minutes, followed by 10 minutes at 72°C after 
which the samples were stored at 4°C until the next step.  
5. Final RNA-seq library amplification 
During the previous step, the library fragments derived from rRNA were 
cleaved thus leaving only the library fragments of interest. During this step, 
those library fragments were amplified, and since the barcodes have already 
been added, a single pair of primers was used to amplify all the libraries.  
In order for the library amplification to occur, 26μl Nuclease-free water, 50μl 
2X SeqAmp PCR buffer, 2μl Seq Amp DNA polymerase and 2μl PCR2 primer 
mix were added to the mixture and the samples placed in a thermal cycler 
using the following program: 
94°C  1 minute 
98°C 15sec 
55°C 15sec  
68°C 30sec 
4°C forever  
6. Purification of final RNA-seq library using AMPure beads 
The final step of this protocol is the purification of the final RNA-seq libraries 
using the AMPure beads as described in step 3. However, it should be noted 
that I used 100µl of beads. 
 
15 cycles 
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     7. Quantification of the libraries using Agilent Tapestation and Qubit.  
Following quantification, the libraries were pooled together into one sample of 
10nM. The libraries were sequenced on a HiSeq4000 Next-Generation-
Sequencing platform.  
It should be noted that for the human samples 100bp Paired-end RNA-
sequencing was performed with illumina NextSeq sequencing instrument 
(HiSeq 4000), while for the murine samples 75bp Paired-end RNA-seq was 
performed with illumina NextSeq sequencing instrument (HiSeq 4000).  
 
2.9 Cell lines and plasmids  
 
The following cell lines were used:  
1)  SEM K2 (SEM) cells were cultured in RPMI (Gibco), 1% pen/strep and 10% 
FCS. SEM cell line was established from a five-year old patient during relapse, 
this patient did present with MLL-AF4-driven leukaemia at infancy.  
2) HEK 293 (HEK) cells were cultured in GMEM (Gibco), 10% FCS, 200mM L-
Glutamine (Thermo Fisher Scientific), 1% Penicilin/Strepromyocin, 1% Non-
essential amino acids (Thermo Fisher Scientific). The human embryonic 
kidney 293 cells (HEK) were originally obtained from human embryonic kidney 
cells that were grown in tissue culture and were immortalised.  
3) MS5 cells were cultured in alphaMEM (Gibco), 1% pen/strep, 2mM L-
glutamine, 10mM HEPES (Thermo Fisher Scientific), 50µM 2-
mercaptoethanol (Thermo Fisher Scientific). The MS5 stromal cell line was 
derived from murine bone marrow stromal cells.  
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The following plasmids were used:  
Plasmid Notes for use 
pEF1a-MLL-AF4-PGK-eGFP Lentiviral MLL-AF4 expressing 
vector 
pEF1a-PGK-eGFP Empty vector for MLL-AF4 
experiments 
pEFS-NS-Cas9-P2A-eGFP Lentiviral Cas9 vector 
U6-gRNA-P2A-BFP Lentiviral gRNA vectror 
pCMV-DACH1-P2A-gGFP PiggyBac DACH1 expressing vector 
pCMV-rtTA-P2A-BFP PiggyBac control vectror for DACH1 
experiments 
pCMV-hyPBase Hyperactive piggyBac transposase 
used along with the DACH1 and 
control vector to allow integration into 
the genome 
psPAX2 2nd generation lentiviral packaging 
plasmid 
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2.10 Transfection 
 
2.10.1 Transection via nucleofection 
 
Transfection of SEM cells was achieved via nucleofection, using the SF kit 
(Lonza). 24 hours prior, the nucleofection cells were passaged in a 1:4 ratio. 
On the day of the nucleofection, cells were counted and 1x106 cells were 
placed in a 15ml falcon and centrifuged for 5 minutes at 2000rpm. While the 
samples were spinning, the nucleofection solution was prepared, which 
contained 100µl of SF solution and 4mg of the plasmid of interest. Following 
centrifugation, the supernatant was removed and the nucleofection solution 
(containing the plasmid) was added to the cells. The cells with the solution 
were transferred into a nucleofection cuvette and the samples were 
immediately transfected using the DJ100 pulse of a Lonza 4D nucleofector 
(Lonza). Following nucleofection, 500µl of medium were added to the cuvette 
and the entire content was transferred to a 6-well plate and 1.5ml of fresh 
medium (RPMI+10% FCS) were added, before the cells were incubated at 
37°C with 5%CO2. 
 
2.10.2 Transfection with PEI for lentiviral particle 
production 
 
This protocol was used for the preparation of the MLL-AF4 lentiviral particles 
and it was performed in the lab of Pablo Menendez.  
Prior to the transfection, 2x106 HEK cells were seeded in a 10cm dish with 
10ml of HEK cell culture media so that the confluency of the cells on the day 
of the experiments was around 40-50%. 
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On the day of the transfection, a plasmid master mix was prepared comprising 
the viral packaging plasmid pPax2 (8µg), the viral envelop pMD2.4 (4 µg) and 
the plasmid of interest, 2µg for MLL-AF4 or empty vector, if multiple plates 
were used then multiple master mixes were prepared. To each tube containing 
the plasmid mix, 500µl of DMEM (Thermo Fisher Scientific) and 35µl PEI 
(1µg/µl) (Sigma-Aldrich) were added and the mixture incubated for 20 minutes 
at room temperature. The DNA/PEI mixture was added to the cells and 4 hours 
later fresh media was added. The viral supernatant was harvested 48 post-
transfection; it was filtered using a 0.45-micron syringe filter (Millipore) and 
stored at -80ºC.  
 
2.10.3 Transfection with Fugene for lentiviral particle 
production 
 
Prior to the transfection, 135x105 HEK cells were seeded on a 6-well plate with 
2ml of HEK cell culture media. This achieved 40-50% confluence on the day 
of the transfection.  
On the day of the transfection, the following mix was prepared: for each 
reaction 570 µl of OPTI-MEM serum reduced media (Life Technologies) was 
mixed with 30µl of Fugene (Promega). The mixture was vortexed and 
incubated for 5 minutes at room temperature. To the same mixture, the 
plasmids of interest were added: 2.5µg of plasmid of interest was mixed with 
3.6µg psPAX2 and 1.4µg pMD.G. The mixture was vortexed and incubated at 
room temperature for 15 minutes. The DNA-Fugene mixture was added to the 
293T cells in a drop-wise manner and the plate was gently swirled in order to 
ensure homogenous distribution. The cells were incubated at 37°C and 5% 
CO2 for 16 hours and the medium was replaced with 2ml of fresh HEK cell 
media. The supernatant was collected 48 after the first media change and was 
filtered using a 0.45-micron syringe filter (Millipore) and either stored at -80ºC 
or further processed with LentiX concentrator.  
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2.11 Virus concentration 
 
The harvested supernatants containing lentiviral particles for MLL-AF4 and 
Cas9 were further concentrated. The former with ultracentrifugation and the 




For the ultracentrifugation, the samples were centrifuged at 26000rpm for 2 
hours at 4°C using the Beckton Dickinson UltraCentrifuge. This was done in 




The lentiviral particles for Cas9 were concentrated using the LentiX system, 
where, following filtering of the virus, 4.7ml of LentiX were used for 14ml of 
viral solution and the mixture was incubated for 24 hours at 4°C. Following the 
incubation, the samples were centrifuged for 2 hours at 1500rpm at 4°C. 
Following centrifugation, the supernatant was removed, and the pellet was 
resuspended in 140µl of GMEM and left overnight at 4°C. Finally, the 140µl 
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2.12 Bacteria transformation and inoculation 
 
Subcloning Efficiency DH5aTM competent cells (Life Technologies) were used 
for the purposes of this project. Competent cells, which were stored at -80°C, 
were thawed on ice. For the transformation, 10ng of plasmid were added in a 
50µl aliquot of competent cells. The competent cells with the plasmid were 
incubated for 30 minutes on ice. Following incubation, the cells were placed in 
a dry bath at 42°C for 30 seconds and then immediately placed on ice for 2 
minutes. 200ml of pre-warmed SOC (Life Technologies) were added to the 
tube and the tubes were incubated at 37°C for 1 hours at 225-220 rpm. 
Following incubation, 200µl of the mixture were spread on LB agar plates with 
ampicillin (50 mg/ml) and the plates were left to dry for 5 minutes before being 
placed overnight at 37°C. After 8 hours, a single colony was picked and placed 
in LB with appropriate antibiotics and incubated at 37ºC overnight. It should be 
noted that I used 100ml of LB for a maxi/midi prep, while for miniprep I used 
3ml of LB. 
 
2.13 Plasmid DNA purification 
 
2.13.1 HiSpeed plasmid Maxi/Midi kit 
 
For the isolation of large amounts of DNA from competent cell pellets, the 
HiSpeed Maxi/Midi Kit was used following the manufacturer’s instructions. 
Specifically, the LB culture containing the bacteria of interest was pelleted at 
6000xg for 15 minutes at 4°C. The pellet was resuspended in 10ml of P1 buffer 
and was homogenised. 10ml of P2 were added and the tubes inverted a few 
times before incubating the mixture for 5 minutes at room temperature. 10ml 
of pre-chilled buffer P3 were added and the tubes inverted a few times in order 
for the components to mix and the mixture then incubated at room temperature 
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for 10 minutes. The lysate was filtered through a pre-equilibrated QIAfilter 
cartridge and washed with 60ml of buffer QC. The DNA was eluted with 15ml 
of buffer QF. The DNA was precipitated with the addition of 10.5ml 
isopropanol, which was incubated for 5 minutes with the eluate. The eluate -
isopropanol mixture was placed in a QIAprecipitator and the mixture filtered. 
2ml of 70% ethanol were also added to the QIAprecipitator and the ethanol 
filtered. The membrane of the QIAprecipitator was dried before attaching it to 
a 1.5ml syringe containing 1ml of TE buffer, which was eluted into a 1ml 
Eppendorf tube.  
 
2.13.2 MiniPrep kit 
 
For the isolation of small quantities of DNA from competent cells, the Qiagen 
MiniPrep protocol was used. 3ml of the bacteria were cultured in LB overnight. 
The following morning, they were pelleted by centrifugation at 8000rpm for 3 
minutes at room temperature. The pellet was resuspended in 250µl buffer P1 
and transferred into a micro centrifuge tube. 250µl of buffer P2 were added 
and the contents mixed through by inverting a few times. 350µl of N3 buffer 
were added and the tube was immediately mixed thoroughly. The tube was 
centrifuged for 10 minutes at 13000 rpm in a table top micro centrifuge. 
Following centrifugation, 800µl of the supernatant were transferred to a 
QIAprep 2.0 spin column and the column centrifuged for 60 seconds at 13000 
rpm. The column was further washed with 500µl buffer PB and with 750µl 
buffer PE. The column was centrifuged for 1 minute in order to remove any 
residual wash buffer. Finally, the DNA was eluted by the addition of 50µl of 
buffer EB.  
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2.14 sgRNA design, cloning and validation 
 
The sgRNA sequences were designed using Chop Chop and were further 
validated against GeCKO (Labun et al., 2019, Labun et al., 2016, Montague et 
al., 2014). (https://chopchop.cbu.uib.no/) 
The sgRNA were 20 base sequences and to the top strand (+) was added the 
following sequence -caccG and to the bottom strand (-) was added the 
following sequence aaac C.  
Initially, the backbone was linearised by digesting it with BsbI (NEB) for 3 hours 
at 37ºC, using the following:  
Components 1x 
Backbone (1.8µg/µl) 







Total  50µl 
 
Following linearisation, the backbone was separated on a 1% w/v agarose gel. 
The linearised backbone was excised and column-purified using QIAquick gel 
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At the same time, the sgRNAs (Table 2.5) were annealed as follows: 
Components 1x 
Top strand oligo (100 µM) 
Bottom strand oligo (100 µM) 




Total  20µl 
 
The two oligos were annealed using a heat block starting at 95ºC and ramping 
down to 25ºC at 5 º/min. Following annealing, the ds-oligos were diluted with 
EB (Qiagen): 
1st dilution: 180µl EB were added to the original annealing mixture (A) 
2nd dilution: 137µl EB were mixed with 4 µl of A ds-oligo (B) 
3rd dilution: 57µl EB were mixed with 3 µl of B 
For the ligation of the backbone with the ds oligo the following were mixed on 
ice 
Components  
Linearised backbone   
ds-oligo                       
Ligase buffer (10x) 
T4 ligase 
H2O 
1µl (=3.7 fmol) 




Total 10µl  
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The ligation mixture was left for 1-2h at room temperature. 5µl of the ligation 
mixture was used for bacteria transformation. Following appropriate 
purification method, the plasmid DNA was sent for sequencing to ensure 
correct insertion of the sgRNA. The oligo used for sequencing was: 
TACGATACAAGGCTGTTAGAGAG 
In order to validate the “cutting efficiency” of the sgRNAs, I either had two 
sgRNAs for the same gene showing the same effect on the phenotype of the 
cells or I performed TIDE assay. (https://tide.deskgen.com/) 
TIDE assay was used to determine the frequency of insertion and deletion in 
a pool of SEM Cas9-sgRNA transduced cells (Brinkman et al., 2014). For the 
TIDE assay, SEM Cas9 cells were transduced with sgRNA lentiviral particles 
and after 30 – 48 hours, genomic DNA was extracted from the transduced cells 
and from control SEM Cas9 Cells. The following were used for one reaction:  
Components Amount 
Genomic DNA 50ng 
Forward primer (10µM) 
Reverse primer (10 µM) 
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The above were placed in a PCR tube and in a thermal cycler at 
95ºC  1 minute 
95ºC 15sec 
58ºC 15sec  
72ºC 30sec 
4ºC forever  
 
Following the PCR reaction, the PCR product was purified using the QIAquick 
PCR purification kit (Qiagen). The purified PCR product was sent for standard 
capillary (Sanger) sequencing using one of the TIDE sequencing primers 
(Table 2.4). The sequencing data were uploaded on the TIDE assay tool. It 
should be noted that I used a test sample and a control sample. The control 
sample was used as a template to estimate the frequency of insertions and 
deletions and therefore the efficiency of the sgRNA. 
   
Gene Primer F  Primer R  
BUB1B sg1 ACCATGAATAATCACCTTTCGG CTGCACCACAGTGAAATGAAAT 
ELOVL1 sg1 TCTCCTTTCCAGAGAGGTTCAG GTGCTTTTTCCACCAAAGGTAG 
SKIDA1 sg1 ACCTCATCATTAAAGGGAAGCA CGGGGTATTTGCTAAAAATCTG 
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Gene sgRNA sequence 
APEX1 g1 GTAACGGGAATGCCGAAGCG 
APEX1 g2 AATTGACCTTCGCAACCCCA 
ASPM g1 AGACCAATTCGAAGCCACAA 
ASPM g2 TTCGAAAAGATAGACACCTA 
BUB1B g1 GCGGATCATGTCCACGCTTC 
BUB1B g2 TCGTTGAGCTAAAACTCGTG 
CCNB1 g1 AGGCGCAAAGCGCGTTCCTA 
CCNF g1 CGGCCTTCATTGTAGAGGT 
CCNF g2 GTGTGGACCGGTACCTGCGG 
CENFP g1 AATGTCGCGGTGATTCATGG 
CENPF g2 GTTTCAGCTTGACAGTCTCG 
DLAT g1 TCTAGAAGCATACCTACCGG 
DLAT g2 CTGTTGCGACGAGCGGGAGC 
ELOVL1 g1 GTGGGGGGTAAAGATTGCCC 
ENC1 g1 ACGATCCAACATTAGACGTG 
ENC1 g2 CTGTTCCACACGTCTAATGT 
HMMR g1 CGTGTTCTTCTACAGGAACG 
HMMR g2 GGGTCATTGAATCGTTTCAA 
HSPD1 g1 GGCTTCGAGAAGATTAGCAA 
HSPD1 g2 GCTGAACGTCTTCAAGATTC 
HSPD1 g3 CGGCTTGCAAAACTTTCAGA 
TGA4 g1 AGTAGCCGAACAGCGTGTTG 
TGA4 g2 CTCACCATCGGTTCGCCCCG 
K F20A g1 AGAAACTACGACATCGTCAT 
K F20A g2 CCCCTGCCGTCATGTCGCAA 
LMNB1 g1 GCATGAAACGCGCTTGGTAG 
LMNB1 g2 CGTAGTGTACGTACAACTAG 
NUTF2 g1 TTACGTAAATTGCGCCTAGT 
NUTF2 g2 AGTGGGCTGATGGTCCTGCG 
RGL1 g1 CAGCCGAGAACTACTGATGA 
RGL1 g2 CTGCGAGTCGAACCACTCAG 
SK DA1 g1 TGAGCGTGCATTTGGCGGCG 
SUV39H2 g1 TTCGGGGAAGACGAGTATCG 
SUV39H3 g2 AATCACGTATCTCTTTGATC 
TPX2 g1 CATCAACTTACAGGAGATGA 
TPX2 g2 ACCGGTTCGTCCTCTTCCTA 
TTLL12 g1 CATCATACACGAACAACCGT 
TTLL12 g2 TCCCCAGCGTCGAAAACCTG 
RPS19 TACCCCCAGCTTCCACAGCG 
Negative control GTAGCGAACGTGTCCGGCGT 
Table 2.5 |sgRNA sequences used in this study 
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2.15 Transduction 
 
2.15.1 Transduction of SEM cells 
 
Transduction of SEM cells was achieved via spinoculation. Specifically, 2x 105 
SEM cells were placed in a 12-well plate and transduced with lentiviral particles 
in the presence of polybrene at 1µg/ml (Sigma-Aldrich). SEM cells were then 
centrifuged at 2000 rpm for 45 minutes and, following centrifugation, 1.5ml 
fresh media was added. 
 
2.15.2 Transduction of human primary cells 
 
Human foetal liver derived CD34+ cells, approximately 1-2x106 cells, were 
transferred into a 12-well fibronectin coated plate (Corning) and transduced 
with concentrated virus in the presence of polybrene at 1µg/ml. The cells were 
left overnight with the virus and the following day fresh media was added. 
 
2.16 Real-time quantitative PCR 
 
2.16.1 cDNA synthesis 
 
Following RNA extraction, cDNA synthesis was performed with iScriptTM 
Advanced (BioRad) cDNA synthesis kit for RT-qPCR following manufacturer’s 
instructions. For a single reaction, the following were added to a PCR tube: 4µl 
of 5x iScript Advanced reaction mix, 1µl of iScript Advanced Reverse 
transcriptase, the required amount of RNA template and the reaction mix was 
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topped up with water to 20µl. If multiple reactions were required, then a master 
mix for the 5x iScript Advanced reaction mix and iScript Advanced Reverse 
transcriptase would be prepared. The PCR tubes were placed in a thermal 
cycler for 20min at 46°C and the reverse transcription reaction terminated by 




RT-qPCR was performed either using the SYBR Green or TaqMan technology. 
For SYBR Green, all the primer pairs were validated to ensure 1.8-2.0 
efficiency. A master mix was generated for each primer pair as follows: 
Component Amount 
cDNA (4ng/ml) 
Forward primer (10nM) 
Reverse primer (10nM) 
LightCycler® 480 SYBR Green I Master (Roche) or TaqMan 








Note: for TaqMan, instead of forward and reverse primer, 1µl of TaqMan 
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2.17 Statistics and star system  
 
The statistical test used in each experiment is denoted in the caption with the 
exception of the RNA sequencing data. The normal distribution of the data was 
ensured using the Shapiro-Wilk normality test with the exception of the RNA 
sequencing data.  
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2.18 RNA sequencing analysis pipeline 
 
Raw reads were initially trimmed using Trimmomatic – this was done by the 
company that performed Next Generation Sequencing. For some of the 
sequenced libraries, further adaptor trimming was required and for this Trim 
Galore! (v0.4.5) was used.  
(https://www.bioinformatics.babraham.ac.uk/projects/trim galore/)  
The quality of the data was assessed with FASTQC (v.0.11.5). 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
The reads were aligned with Kallisto (v0.43.1) (human reads were aligned to 
GRCh38 and murine data were aligned to GRCm38) (Bray et al., 2016).  
Kallisto is a pseudoaligner that was developed by the Pachter lab and is a 
method for quantifying abundances of transcripts for RNA sequencing 
experiments.  
The Bioconductor package Tximport (v.3.5) was used to import transcript-level 
abundance, estimated counts and transcript lengths and also to summarise 
them into matrices that are compatible with DeSeq2 (Soneson et al., 2015). 
For the Tximport, the abundance.h5 was used, which is the output from 
Kallisto.  
The expression level of each gene and the differential expression analysis was 
performed using the DESeq2 (v.3.5) pipeline (Love et al., 2014). Genes were 
considered differentially expressed if they had an adjusted p-value of less than 
0.05. 
Gene Set Enrichment Analysis was performed using the GSEA Jana Desktop 
tool (Subramanian et al., 2005, Mootha et al., 2003).  
Gene Ontology analysis was performed using Panther (Mi et al., 2019) .  
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Heatmaps were generated using Pheatmap.                          
(https://CRAN.R-project.org/package=pheatmap).  
PCAs were generated using either DeSeq2 or pcaExplorer (v.3.6) 
(http://bioconductor.org/packages/pcaExplorer/).   
HISAT2 (v.2.1.0) was used for the genotyping of the Mll-AF4+ Vec-Cre+ and 
Mll-AF4-Vec-Cre+ RNA sequencing libraries. This was achieved be creating 
an index using the human AF4 cDNA sequence.  
 R version 3.4.3 was used (http://www.rstudio.org/) 
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2.19 Lipidome  
 
For the lipidome experiment SEM-Cas9 cells were transduced with sgRNAs 
for ELOVL1 and neg control. The transduced cells were sorted at day 2 and 4 
following transduction using flow cytometry for live, GFP (Cas9) and BFP 
(sgRNAs). The sorted cells were span down at 2000rpm for 5 min, the 
supernatant was removed, and the pellets were stored at -80ºC.  
Lipids were extracted in 100% isopropanol (MS grade) and extracts were 
cleared by centrifugation. 10 ul of lipid extract was loaded onto an Accucore 
C18 column (150 x 2.1 mm, Thermo Scientific) fitted with a guard column 
attached to a Thermo Ultimate 3000 BioRS HPLC. The column was 
equilibrated in 60% buffer A (50 % methanol, 50 % water, 10 mM ammonium 
acetate, 0.1 % v/v formic acid, 8 μM phosphoric acid) and 40% buffer B (100% 
isopropanol, 10 mM ammonium acetate, 0.1 % v/v formic acid, 8 μM 
phosphoric acid) and the following gradient at 500 μl/min was applied 
(time/%B): 0.3/40, 3.5/45, 7/75, 25/97. Lipids were eluted into a Q Exactive 
mass spectrometer (Thermo Scientific) in positive mode with a scan range of 
150-2000 in MS1 and data-dependent Top5 MS2 (normalised collision energy 
25, isolation window 0.8 Da). Other settings were as standard. 
Data were processed using Compound Discoverer (Thermo Scientific) with 
lipid annotations matching an in-house mass list and with MS2 verifications 




   
  70 
Chapter 3 Defining the transcriptional profile 
of LMPPs in wild-type and Mll-AF4 
expressing mouse models 
 
3.1 Defining the transcriptional profile of foetal liver 




Infant leukaemia is rare, however, in the majority of these few patients there is 
a common disease driver, the fusion between MLL and AF4. This t (4; 11) 
translocation results in the production of an aberrant fusion protein that is the 
only molecular abnormality identified in the majority of these patients. In 
addition to the fusion protein, it has long been speculated that the foetal origin 
of the disease is also a critical contributor to the aggressive disease 
phenotype.  
To answer this question, Barrett et al. performed an investigation on the effects 
of Mll-AF4 expression in the foetal and adult murine haematopoietic system. 
In this study, using an Mll-AF4-expressing mouse model, they showed that 
foetal-derived cells are more prone to transformation by Mll-AF4 compared to 
their adult counterparts. In particular, they observed that when Mll-AF4 was 
expressed in E14.5 foetal liver there was a dramatic increase in the B lymphoid 
output. However, there was little enhancement observed when Mll-AF4 was 
expressed in adult bone marrow cells. This emphasises the critical contribution 
of the leukaemia-initiating cell in the disease phenotype. Additionally, in the 
same study they observed that the greatest impact was observed when the 
fusion was expressed in the LMPPs, suggesting that they are key contributors 
to this enhancement and potential cells of origin of the disease (Barrett et al., 
2016, Malouf and Ottersbach, 2018). 
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Following from Barrett et al. it is clear that the foetal liver cells are more 
permissive to transformation by Mll-AF4 compared to adult bone marrow-
derived cells. However, we have limited understanding of what makes foetal 
cells vulnerable to Mll-AF4 while adult cells seem to be more resistant. It has 
already been established that foetal and adult cells possess fundamentally 
different characteristics, and one key example is that foetal cells are much 
more proliferative (Ivanovs et al., 2011, Catlin et al., 2011, Holyoake et al., 
1999, Jassinskaja et al., 2017). We can imagine that the difference in the 
proliferation potential of foetal and adult cells could be a key contributor to this 
disease. But is that all? Are there other key characteristics?  
To answer this question, I performed an RNA sequencing experiment 
comparing foetal liver and adult bone marrow-derived LMPPs. The aim of this 
experiment was to define the transcriptional profile of these cells. This 
experiment will aid in understanding why foetal LMPPs are more prone to 
transformation by Mll-AF4 compared to their adult counterparts. Additionally, 
we will get a general idea of how the foetal origin of the disease might influence 
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3.1.2 Experimental design used to define the 
transcriptional profile of foetal liver and bone 
marrow-derived LMPPs 
 
In order to define the transcriptional profile of the foetal liver and adult bone 
marrow-derived LMPPs an RNA sequencing experiment was performed (Fig. 
3.1). 
 
Figure 3.1| Experimental design used to define the transcriptional profile of foetal liver 
and adult bone marrow derived LMPPs.  (Simplified version).  
The steps used for this experiment were as follows: 1) dissection of E14.5 foetal liver 
and adult bone marrow, 2) sorting of LMPPs (Lin- B220- CD19- ckit+Sca1+CD45+ Flt3+),  
3) RNA extraction,  4) validation of RNA quality and quantity (only samples with RIN ≥ 8 
were used), 5) library preparation for RNA sequencing, 6) libraries/samples were 
sequenced with the HiSeq 4000 platform, 7) sequencing data quality control and 
analysis.   
 
For the purposes of this experiment E14.5 foetal liver and adult bone marrow 
(8-10 weeks) LMPPs were sorted and RNA sequencing libraries were 
prepared. RNA samples used in this experiment were of the highest quality 
(RNA integrity number (RIN) ≥ 8) (Fig. 3.2). Four libraries were prepared per 
condition and these libraries were pooled together and send for sequencing. 
The Illumina HiSeq 4000 platform was used, and 75bp-paired end sequencing 
was performed.  
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Figure 3.2| Quality control of RNA sequencing libraries - pre sequencing. 
a) Electropherogram of one of the RNA samples used to prepare one of the libraries. 
The abundance of 18S and 28S ribosomal RNA peaks is measured and used to 
determine the RIN value. b) Gel view of the same RNA sample (second lane) and the 
ladder (first lane), the RIN of this sample was 9.6. c) Electropherogram of the library 
prepared using 1ng of the RNA sample. d) Gel view of the same library (second lane) 
and ladder (first lane).  
 
3.1.3 Quality control of RNA sequencing data 
 
Following an RNA sequencing experiment, the first step is quality control of 
the data.  Initially, it is important to ensure that the raw reads of all the libraries 
are of good quality and this is a critical step for downstream application. In 
order to check the quality of the raw reads FASTQC was performed. Following 
success of FASTQC, the next step was to perform quality control of the 
libraries in order to ensure consistency between them.  
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Figure 3.3| Quality control of the RNA sequencing libraries - post sequencing.  
a) Boxplot of outliers, b) Dispersion plot, c) MA plot.  
 
Towards this end, Cook’s distance was computed for all the samples. Cook’s 
distance measures the influence exerted by each sample on the log fold 
change (LFC) and how LFC would change if that sample was to be removed. 
This showed that there were no outliers amongst the samples (Fig. 3.3a). Next, 
the dispersion was quantified and with this approach it was ensured that there 
was only a small number of gene outliers (Fig. 3.3b). It can be observed that 
for the majority of the genes, the final dispersion estimates (blue points) follow 
the mean dispersion (red line) and only a small number of genes are outliers 
(larger blue circles at the top of the graph). Finally, by plotting the LFC versus 
the mean of normalised counts, it can be observed that only a fraction of the 
genes (dots) are differentially expressed (dots in red) while the majority of them 
are distributed around 0 on the y-axis (Fig. 3.3c).   
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Figure 3.4| Principal component analysis of foetal liver and bone marrow-derived 
LMPPs.  
a) PCA plot of the foetal liver (FL) and bone marrow (BM)-derived libraries reveals a 
clear clustering of the two population. 
 
Another way to visualise the data is by performing principal component 
analysis (PCA). PCA revealed a consistency between the libraries of the same 
population. In particular, we can observe that the foetal liver (FL) and bone 
marrow (BM)-derived LMPPs form two different clusters, one cluster for each 
tissue of origin. There is a clear separation between the two clusters in PC1, 
with PC1 = 51% (Fig. 3.4). Differential expression analysis revealed 768 
differentially expressed (DE) genes between the two populations, with 333 
upregulated in the foetal liver and 435 in the bone marrow derived LMPPs 
(Appendix 1). It should be noted that genes were considered DE if the padj 
≤0.05.  
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3.1.4 Genes differentially expressed between foetal liver 
and bone marrow-derived LMPPs 
 
Figure 3.5| Heatmap of the top 50 differentially expressed genes between foetal liver 
(FL) and adult bone marrow (BM)-derived LMPPs. 
 
The top 50 DE genes are shown in Fig. 3.5. Lin28b was upregulated in the 
foetal-derived LMPPs, while Dntt was upregulated in their bone marrow-
derived counterparts. The expression pattern of these genes is a critical 
validation of this experiment as Lin28b is known to be uniquely expressed in 
foetal tissues, while Dntt has been to shown to be upregulated in adult tissues 
(Boiers et al., 2018, Copley et al., 2013).   
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upregulated in the foetal liver-derived LMPPs (Fig. 3.7a-b). Amongst those 
genes was Lin28b, which is an onco-foetal protein. Lin28b has been shown to 
be over-expressed in aggressive forms of Juvenile myelomonocytic leukaemia 
(JMML) and AML. Inhibition of this gene impaired leukaemia growth in AML 
suggesting that it is a potent oncogene (Helsmoortel et al., 2016, Zhou et al., 
2017). Other onco-foetal proteins included the Insulin-like growth factor 2 
mRNA-binding (IGF2BP) family. Igf2bp1 has been shown to play a critical role 
in ovarian cancer and ETV6/RUNX1-driven leukaemia. In both cases 
downregulation of this gene resulted in growth impairment of the 
cancer/leukaemia cells (Muller et al., 2018, Stoskus et al., 2016). The second 
family member, Igf2bp2 has been associated with colorectal cancer and AML 
(Ye et al., 2016, He et al., 2018). The last member of the family, Igf2bp3, has 
an established role in promoting lung tumourigenesis. (Zhao et al., 2017, 
Palanichamy et al., 2016). Intriguingly, IGF2BP3 has been shown to be 
overexpressed in MLL-R B ALL. (Zhao et al., 2017, Palanichamy et al., 2016). 
The High-mobility group AT-hook family of proteins 1 and 2 (Hmga1 and 2) 
were also upregulated in the foetal liver-derived LMPPs. High expression of 
both genes has been linked with poor clinical outcome in leukaemia, the former 
with childhood B-ALL and the latter with AML (Roy et al., 2013, Marquis et al., 
2018). Busch et al. studied the collective over-expression of HMGA2, LIN28B 
and IGF2BP1 in an ovarian cancer cell model. From this study, it was 
concluded that this “oncogenic triangle” is critical for cancer initiation and could 
be used as a promising target for therapeutic treatment (Busch et al., 2016).  
Boiers et al. showed that IL7R-expressing cells are more frequent in the 
haematopoietic progenitor compartment (CD34+CD45+) derived from human 
foetal liver as compared to cord blood and bone marrow (Boiers et al., 2018). 
This is also what has been observed in the present study. IL7R has been 
implicated in paediatric T-ALL and has recently been shown to be a promising 
therapeutic target for the same disease (Akkapeddi et al., 2019, Zenatti et al., 
2011). Cyclin D1 (Ccnd1), which is  a cell cycle regulator, has been found to 
be upregulated, amongst others, in hairy cell leukaemia (Bosch et al., 1995). 
ID1 overexpression has been established in AML patients. Intriguingly, 

   
  80 
Dnmt3a and b were also upregulated in foetal liver LMPPs (Fig. 3.7c). Dnmt3a 
mutations are frequent in patients with AML and the presence of these 
mutations has been associated with poor overall survival. These mutations can 
result in both loss or gain of function and in general affect translation. Mutations 
in DNMT3A do not cause dramatic alterations in the gene expression level or 
genomic instability and yet they play a critical role in the disease pathogenesis 
(Ley et al., 2010, Sandoval et al., 2019). DNMT3B over-expression has been 
recently linked with T-ALL and Burkitt’s lymphoma were it was shown to exert 
a tumour promoter function (Poole et al., 2017).  
Investigation of the top upregulated genes in the bone marrow-derived LMPPs 
revealed that some of them had an established tumour suppressor role (Fig. 
3.8). Padi4 and Aatk overexpression inhibited cancer cell growth in a number 
of cancer cell lines (Tanikawa et al., 2009, Haag et al., 2014). Klf9, LNC2 and 
TAP1 exerted a tumour suppressor role in colorectal cancer, whereas Per1 
played the same role in breast cancer (Brown et al., 2015, Kim et al., 2017, 
Ling et al., 2017, Yang et al., 2009). MYCT1 overexpression led to inhibition of 
cell proliferation and increased apoptosis in AML cell lines HL-60 and KG-1a 
(Fu et al., 2018). Dach1 was also upregulated in the bone marrow-derived 
LMPPs. Intriguingly, DACH1 has been shown to act as a tumour suppressor 
in a number of different cancers. These cancers include hepatocellular 
carcinoma, lung adenocarcinoma, glioma cells, laryngeal squamous cell 
carcinoma, colorectal cancer, breast cancer, pancreatic cancer and renal 
cancer (Cao et al., 2017, Zhang et al., 2018, Liu et al., 2015, Chen et al., 2013, 
Watanabe et al., 2011, Xu et al., 2017, Bu et al., 2016, Chu et al., 2014).  
Although a number of tumour suppressor genes were amongst the top 
upregulated in the bone marrow-derived LMPPs, some oncogenes were also 
part of the same list (Fig. 3.8). Muc13 has been shown to be overexpressed in 
many cancers and it has been shown to be a promising therapeutic target for 
colon cancer (Sheng et al., 2017). Additionally, Ltbp3 expression levels have 
been linked to the initiation of early metastatic events in a number of different 
cancers (Deryugina et al., 2018). Aff3, which is a member of the same family 
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as AF4, has been shown to be upregulated in breast cancer, and this resulted 
in resistance of the cancer cells to tamoxifen (Shi et al., 2018). Itgb5 has also 
been found to a play role in breast cancer by increasing the tumorigenic 
potential of breast cancer cells (Bianchi-Smiraglia et al., 2013).  
 
 
Figure 3.8 | Tumour suppressors and oncogenes upregulated in the bone marrow-
derived LMPPs. Heatmap of tumour suppressor genes and oncogenes upregulated in 
the bone marrow-derived LMPPs.  
 
Another gene that was upregulated in bone marrow LMPPs was Sell (Fig. 3.9). 
Sell (CD62L) is a cell adhesion molecule and has been recently described as 
a marker that can be used to identify human bone marrow-derived LMPPs (Lin-
CD34+CD10-CD62Lh ) (Kohn et al., 2012). Interestingly, in the same study 
they suggested that there is only a small number of Lin-CD34+CD10-CD62Lh  
in cord blood cells. A similar phenotype was observed in murine systems 
where it was suggested that CD62L could be used as an alternative to Flt3  to 
define murine LMPPs (Cho and Spangrude, 2011). However, we can observe 
in figure 3.9 that Sell is highly expressed in bone marrow derived LMPPs but 
there is very low expression in their foetal liver-derived counterparts. This 
expression pattern and in accordance with the previous publications suggests 
a different role for Sell in foetal and adult-derived cells.  
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GO revealed that in the foetal liver-derived LMPPs the top upregulated 
processes were involved in cell cycle/ division and regulation thereof (Fig. 
3.10a). Other processes included immune system development and 
haematopoietic or lymphoid organ development (Fig. 3.10a).  On the other 
hand, bone marrow-derived LMPPs predominantly upregulated processes 
involved with the immune system (Fig. 3.10b). Intriguingly, the adult cells also 
upregulated some developmental processes suggesting that those cells still 
undergo developmental changes.  
Surprisingly, the GO process related to haematopoietic and lymphoid organ 
development was present in both foetal and adult bone marrow-derived 
LMPPs (Fig. 3.10). In order to further investigate this, I identified the genes 
that make up this process in both populations (Fig. 3.11). There was no 
consistency in the genes as they were all members of different families of 
proteins, except for Anxa1 and Anxa2 that were upregulated in bone marrow 
LMPPs. To further validate this data, the expression of these genes was 
investigated in a previously published proteomics study where they compared 
E14.5 foetal liver and adult bone marrow Lin-Sca+c-kit+ cells (LSK) 
(Jassinskaja et al., 2017). It should be noted that I did not analyse this dataset 
but the data I show were obtained from an excel spreadsheet the authors 
provided/submitted with this paper.  A number of genes were in common 
between the two studies (underlined genes) (Fig. 3.11). It should be noted that 
the majority of the genes that were not in common, were not present in the 
proteomics study as opposed to having a different expression pattern. From 
this data, we can observe a different requirement of foetal and adult 
haematopoietic or lymphoid organ development, which is a reflection of 
haematopoiesis in general.  
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Figure 3.11| Genes that make up the GO process “Haematopoietic or lymphoid organ 
development” in foetal liver and bone marrow derived LMPPs.  
First box represents genes upregulated in foetal liver (FL) derived LMPPs while the 
second box represents genes upregulated in bone marrow (BM) derived LMPPs. 
Underlined genes had similar expression pattern between the present study and the 
one performed by Jassinskaja et al., 2017. It should be noted that I did not analyse this 
dataset but the data I show were obtained from an excel spreadsheet the authors 
provided/submitted with this paper. 
 
Another way to obtain a general idea about the differentially expressed genes 
between the two populations is to perform gene set enrichment analysis 
(GSEA). GSEA, similar to GO, groups functionally related genes and allows 
identification of biological pathways and processes that differ between two 
populations. The top upregulated pathways in the foetal liver-derived LMPPs 
were involved in cell cycle, proliferation and growth (Fig. 3.12). In particular, 
G2M checkpoint was the top upregulated pathway, and this reflects the 
proliferative nature of the cells. E2F targets were also enriched, and E2F 
transcription factors have been deemed crucial for regulation of cell cycle 
progression and tumourigenesis (Bracken et al., 2004). The MTORC1 
signalling pathway was also enriched in the same population, wish is a master 
growth regulator that promotes cellular growth and proliferation (Dowling et al., 
2010).  
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Figure 3.12| Gene set enrichment analysis of foetal liver derived LMPPs (FDR= false 
discovery rate, NES = normalised enrichment score).  
 
The bone marrow-derived LMPPs showed an enrichment for immune system-
related pathways. There was enrichment in interferon-gamma response, 
interferon-alpha response and TNFA signalling via NFKB. Jassinskaja et al. 
also identified multiple proteins of interferon-alpha signalling pathway to be 
upregulated in the bone marrow-derived LSK. All the pathways upregulated in 
the bone marrow-derived cells have established roles in the immune system. 
This suggests that bone marrow LMPPs have a more mature and immune cell-
like transcriptional profile.  
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Figure 3.13| Gene set enrichment analysis of genes upregulated in the bone marrow 
derived LMPPs.   
 
GO and GSEA results were consistent. Foetal liver LMPPs upregulated 
pathways involved in cell proliferation and growth, while bone marrow LMPPs 
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3.2 Molecular characterisation of the initial stages of 
transformation during the pre-leukaemic state 
 
3.2.1 Introduction  
 
It is well established that MLL-AF4-driven infant ALL arises in utero and 
multiple efforts have been made to capture the early disease stages. This will 
allow us to understand how MLL-AF4 co-operates with its environment in order 
to initiate and drive this aggressive infant leukaemia. Barrett et al., using a 
mouse model where Mll-AF4 expression was conditional to VE-Cadherin 
(VEC) expression, conducted an investigation into the early disease stages in 
the developing embryo. In this study, they observed that Mll-AF4 expression 
in foetal cells led to an increase in B lymphoid output and self-renewal 
potential. These features were present from as early as the E11.5 AGM but 
were more pronounced in the E14.5 foetal liver. They also observed that 
LMPPs were the main contributor to the enhanced B lymphoid output. It should 
be noted that the median survival of these mice were 437 days and the mice 
developed B and T cell lymphomas as exemplified by surface markers B220 
and CD3 respectively, therefore this mouse model in not representative of the 
aggressive infant disease. However, in this study, they were able to capture 
for the first time, a pre-leukaemia state, which was most prominent at E14.5 
and define the LMPP as the potential cell of origin of the disease (Barrett et 
al., 2016). 
Having captured a pre-leukaemic stage and identified a potential cell of origin, 
it would now be possible to examine the early stages of the disease initiation. 
In order to achieve this, an RNA sequencing experiment was performed where 
E14.5 Mll-AF4 expressing LMPPs were compared with control LMPPs. The 
aim of this was to identify early transcriptional changes that take place when 
Mll-AF4 is expressed. 
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3.2.2  Experimental design used to define the 
transcriptional changes induced by Mll-AF4 during 
the pre-leukaemic state 
 
In order to define the transcriptional profile of Mll-AF4 expressing LMPPs, an 
RNA sequencing experiment was performed (Fig. 3.14). 
 
Figure 3.14 | Experimental design used to define the transcriptional prolife of Mll-AF4 
expressing foetal liver LMPPs.  (Simplified version) 
The steps used for this experiment were as follows: 1) Crossing of Cre-conditional Mll-
AF4 invertor mouse line with VE-Cadherin Cre-mouse line, 2) Harvesting of E14.5 
embryos, 3) Embryo genotyping, 4) Sorting of LMPPs from Mll-AF4+Vec-Cre+ (Mll-
AF4+) and Mll-AF4-Vec-Cre+ (control), 5) RNA extraction,  6) validation of RNA quality 
and quantity (only samples with RIN ≥ 8 were used), 7) library preparation for RNA 
sequencing, 8) libraries/samples were sequenced with the HiSeq 4000 platform, 9) 
sequencing data quality control and analysis.   
 
For the purposes of this experiment, the Cre-conditional Mll-AF4 invertor 
mouse line was crossed with the VE-Cadherin (VEC)-Cre line (Metzler et al., 
2006, Chen et al., 2009, Barrett et al., 2016). E14.5 embryos were harvested 
and genotyped in order to identify embryos that would express the fusion (Mll-
AF4+VEC-Cre+) and controls (Mll-AF4-VEC-Cre+). The foetal livers were 
dissected from embryos with the desired genotype, LMPPs were sorted and 
RNA sequencing libraries were prepared (as described in the previous 
section). Four libraries were prepared per condition, pooled together and sent 
for sequencing. The Illumina HiSeq 4000 platform was used and 75bp-paired 
end sequencing was performed.  
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3.2.3 Quality control of the RNA sequencing data 
 
In order to ensure that the correct population was sorted, the first step was to 
perform a lymphoid colony assay comparing Mll-AF4 expressing HSC/MPPs 
(haematopoietic stem cells/ multipotent progenitors) with LMPPs. We can 
observe in Fig. 3.15 that there was a greater number of B lymphoid colonies 
when LMPPs were plated as compared to HSC/MPPs, thus confirming 
previous results (Barrett et al., 2016). This difference was persistent between 
first and second plating.  
 
Figure 3.15 | Lymphoid colony assay using Mll-AF4 expressing HSC/MPPs and 
LMPPs.  
a) Number of colonies obtained when 2000 Mll-AF4 expressing HSC/MPPs and LMPPs 
were plated on methylcellulose under lymphoid conditions, first plating. b) Number of 
colonies obtained when 2000 Mll-AF4 expressing HSC/MPPs and LMPPs were re-plated 
on methylcellulose under lymphoid conditions, second plating.   
 
In accordance with the previous RNA sequencing experiment, the first step 
was to perform FASTQC in order to ensure that the raw reads were of good 
quality. Following success of the first step, the next step was to perform quality 
control of the libraries. Initial analysis indicated that one of the libraries was an 
outlier. Cook’s distance was measured, which showed that for sample MA2 
Cook’s distance was larger compared to that of the other samples (3.16a). This 
suggests that inclusion of this sample in downstream analysis could lead to 
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distortion of any statistical tests. Further to this, PCA was performed where it 
was revealed that in PC1 there was a great difference between sample MA2 
and the remaining seven samples (Fig. 3.16b). This data also suggests that 
sample MA2 is an outlier and this sample was removed from further analysis. 
 
Figure 3.16 | Quality control reveals an outlier amongst the libraries.  
a)  Cook’s distance identified MA2 as an outlier. b) PCA identified MA2 as an outlier.  
 
Following removal of the outlier, quality control of the remaining libraries was 
performed were the consistency of the remaining libraries was ensured (Fig. 
3.17). Even though preliminary quality controlled ensured consistency 
amongst the libraries, PCA analysis revealed that there was no clear clustering 
amongst the two populations (Fig. 3.18a).  
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Figure 3.17| Quality control of the RNA sequencing libraries - post sequencing   
a) Boxplot of outliers, b) Dispersion plot, c) MA plot. 
 
In order to ensure that this was not due to a technical error during the library 
preparation and that the genotypes of the samples were correct, the RNA 
sequencing data were further genotyped using HISAT2. For the purposes of 
the transcriptional genotyping, the libraries were aligned to the human AF4 
cDNA. In theory, the samples with Mll-AF4+VEC-Cre+ genotype will have 
greater number of aligned reads to AF4 as compared to Mll-AF4-VEC-Cre+ 
samples. Indeed, following transcriptional genotyping, the results showed that 
samples with the Mll-AF4+VEC-Cre+ genotype exclusively expressed AF4 
(Fig. 318b), suggesting that there was no technical error. From this, it was 
concluded that there was a small difference between Mll-AF4 expressing and 
control LMPPs. Differential expression analysis revealed 53 genes DE 
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between the two populations (Appendix 2). As with the previous RNA 
sequencing experiment, genes were considered DE if padj≤0.05.  
 
Figure 3.18| PCA plot and genotyping of the Mll-AF4 and control LMPPs RNA 
sequencing libraries 
 a) PCA plot of the 7 libraries reveals no clear clustering amongst the libraries Mll-
AF4+VEC-Cre+ (MA4) and Mll-AF4-VEC-Cre+ (VEC) samples. b) Transcriptional 
genotyping of libraries using AF4, Mll-AF4-VEC-Cre+ (Control) and Mll-AF4+VEC-Cre+ 
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3.2.4 Genes differentially expressed between Mll-AF4 
expressing and control LMPPs 
 
The differential expression analysis revealed 53 genes differentially expressed 
between the Mll-AF4 expressing and control LMPPs. Interestingly, Hoxa9 
which has an established role in the disease was upregulated in the Mll-AF4 
expressing LMPPs (padj = 0.057) (Fig. 3.19a).  
 
Figure 3.19 | Genes differentially expressed between Mll-AF4 expressing and control 
LMPPs 
a) Hoxa9 expression in Mll-AF4 expressing (MA4+) and control LMPPs. RNA 
sequencing data are shown as mean ±SD, and each dot represents a sample library. b) 
Heatmap of top 10 DE genes between Mll-AF4 (MA4) expressing and control (VEC) 
LMPPs.  
 
In order to identify genes that are direct targets of the fusion, the genes 
differentially expressed were compared with data obtained from a previously 
published MLL-AF4 ChIP-Sequencing experiment. This MLL-AF4 ChIP-seq 
experiment was performed using the SEM cell line (Kerry et al., 2017). SEM is 
a cell line that was derived from the peripheral blood of a patient that was 
diagnosed with MLL-AF4-driven ALL at infancy, but the cell line was derived 
when the patient relapsed at the age of 5 years old. It should be noted that I 
did not analyse the ChIP-seq data and the data used were part of a 
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CD33-), myeloid progenitor cells (CD34+CD33+) and B-cell progenitors 
(CD34+CD19+). In order to compare the infant blasts with the healthy controls, 
the three healthy population were considered as one. Interestingly, SKIDA1 
was upregulated in the infant patients compared to the healthy controls, 
however, AGO3 was not (Fig. 3.21).  
 
Figure 3.21 | Expression of SKIDA1 and AGO3 in the blasts of infant patients with MLL-
AF4 driven ALL and healthy controls. (Microarray data)  (Data obtained from (Munoz-
Lopez et al., 2016).  
a) Expression of SKIDA1 in blasts of infant patients with MLL-AF4 driven ALL (iALL) 
and healthy controls (Control). b) Expression of AGO3 in blasts of infant patients with 
MLL-AF4 driven ALL (iALL) and healthy controls (Control). Microarray data are shown 
as mean ±SD, and each dot represents a sample. 
 
Following from this, I investigated expression of the two genes in a different 
dataset published by the same group (Agraz-Doblas et al., 2019). In this study, 
they performed RNA sequencing of the blasts of 27 infant patients with MLL-
AF4-driven ALL and 5 healthy controls. The healthy controls in this study were 
foetal liver derived CD34+CD19+ cells. Excitingly, SKIDA1 was differentially 
expressed between the infant blasts and the healthy controls (Fig. 3.22a). 
However, AGO3 was not differentially expressed. It should be noted that I did 
not analyse this dataset and the authors provided the data I present here. 
Additionally, I also investigated SKIDA1 expression in the Andersson et al. 
dataset (Andersson et al., 2015).  In this study they performed RNA 
sequencing of the blasts of 17 infant and 5 paediatric patients with MLL-AF4-
driven ALL. I performed differential expression analysis between the infant and 
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paediatric (> 2 years) patients, and SKIDA1 was one of the genes differentially 
expressed between the two populations (Fig. 3.22b). 
 
Figure 3.22| Expression of SKIDA1 in the blasts of infant, paediatric patients with MLL-
AF4 driven ALL and healthy controls.  
 a) SKIDA1 expression in blasts of infants with MLL-AF4-driven ALL (iALL) and foetal 
liver (FL control) derived CD34+CD19+ cells, data obtained from (Agraz-Doblas et al., 
2019); data are shown as mean ±SD. It should be noted that I did not analyse this dataset 
and the authors provided the data I present here.  b) SKIDA1 expression in blasts of 
infant (iALL) and paediatric (pALL) patients with MLL-AF4 driven ALL. Data obtained 
from Andersson et al., 2015. RNA sequencing data are shown as mean ±SD.  
 
SKIDA1 expression pattern is intriguing and suggests that it might play a role 
in the disease initiation and maintenance. Interestingly, SKIDA1 upregulation 
has previously been associated with cancer and leukaemia. In particular, 
SKIDA1 (also known as C10orf140) expression was positively correlated with 
HOXA9 expression in AML patients (Chen et al., 2019). Additionally, SKIDA1 
upregulation has been associated with ovarian cancer and colon 
adenocarcinoma (Pharoah et al., 2013, Cortes-Ciriano et al., 2017). SKIDA1 
(Ski/Dach domain-containing protein 1) is a member of the Dachshund 
(DACH) family of proteins. Interestingly, another member of this family, Dach1 
was upregulated in the bone marrow- derived LMPPs compared to the foetal 
liver derived ones (described in the previous section). While SKIDA1 
expression has been positively correlated with cancer and leukaemia, the 
opposite is true for DACH1, which has been shown to act as tumour 
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3.3 Discussion 
 
Infant MLL-AF4-driven ALL is a devastating disease with a unique underlying 
biology, which we do not completely understand. The uniqueness of this 
disease has been attributed to the foetal origin of the leukaemia-initiating cell. 
Although, it has long been established that foetal and adult cells are 
fundamentally different, it was Barrett et al. that first established how these 
differences influence MLL-AF4-driven ALL. In particular, in this study they 
showed that foetal derived cells are more prone to transformation by Mll-AF4 
compared to their adult counterparts. To investigate the underlying reasons for 
this, the transcriptional profile of foetal liver and adult bone marrow LMPPs 
was compared.  
The transcriptional landscape of foetal-derived LMPPs revealed the 
proliferative and oncogenic nature of these cells. On the other hand, bone 
marrow-derived cells upregulated both tumour suppressors and oncogenes, 
suggesting a more “balanced” nature. From this data, it is clear that the foetal 
nature of the leukaemia-initiating cell could be a critical factor in the initiation 
of this aggressive disease. We can imagine that the environment that supports 
rapid growth of the embryo if hijacked by MLL-AF4 could lead to an aggressive 
disease.   
Having identified the potential role of the cell of origin of this disease in wild 
type mice, I then investigated what happens when Mll-AF4 hijacks it. In order 
to investigate the early stages of transformation, I performed an RNA 
sequencing experiment comparing murine foetal liver Mll-AF4 expressing 
LMPPs with control LMPPs. Initially, it was observed that the two populations 
appear very similar and this would explain why the Mll-AF4 mouse model does 
not develop acute leukaemia. However, Hoxa9 was upregulated in the Mll-AF4 
expressing cells suggesting that in the mouse model some aspects of the 
disease are recapitulated. Of particular interest was the expression pattern of 
Skida1, which was upregulated in the Mll-AF4 expressing LMPPs. Further 
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investigation into its expression in a clinical setting revealed that this gene was 
upregulated in infant patients with MLL-AF4-driven ALL compared to paediatric 
patients with the same disease and compared to healthy controls. Intriguingly, 
DACH1, another gene of the same family of proteins was downregulated in the 
infant patients. These findings suggest that this family of proteins could play a 
role in the initiation and maintenance of the infant disease. 
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Chapter 4 Defining the transcriptional profile 
of human foetal and neonatal 
haematopoietic stem and progenitor 
cells. 
 
4.1 Defining the transcriptional profile of human 




It has long been speculated that the foetal origin of the leukaemia-initiating cell 
of infant MLL-AF4-driven ALL plays a critical role in the disease development. 
In the previous chapter, by defining the transcriptional profile of the cell of origin 
of the disease in mice, I showed that its over-proliferative and oncogenic nature 
could contribute to the disease initiation and exert an additive effect to the 
aggressiveness of this disease. Therefore, we now have a potential 
explanation of why murine foetal cells are more prone to transformation by Mll-
AF4 compared to their adult counterparts.  
Due to the fundamental differences that exist between humans and mice, great 
caution should be taken when projecting conclusions that are true in one 
species to the other. Following from this, it is important to further confirm and 
validate that the above findings hold true for human foetal liver-derived cells. 
Towards this end, an RNA sequencing experiment was performed comparing 
human foetal liver and cord blood-derived haematopoietic stem and progenitor 
cells (HSC/MPPs). Additionally, in order to identify the cell of origin of the 
disease, the transcriptional profile of foetal liver-derived HSC/MPPs was 
compared to that of LMPPs and the genes differentially expressed were further 
compared to the targets identified from an MLL-AF4 chromatin  
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immunoprecipitation sequencing (ChIP-seq) experiment recently published 
(Kerry et al., 2017)  
 
4.1.2 Experimental design  
 
In order to define the transcriptional profile of foetal liver and cord blood-
derived HSC/MPPs (CD34+CD38-CD45RA-), an RNA sequencing experiment 
was performed (Fig. 4.1). 
 
Figure 4.1| Experimental design used to define the transcriptional profile of foetal liver 
(FL) and cord blood (CB) derived HSC/MPPs (Simplified version)   
The steps for this experiment were as follows: 1) dissection of second trimester foetal 
liver, 2) CD34+ enrichment using magnetic-activated cell sorting (MACS), 3) sorting of 
HSC/MPPs , 4) RNA extraction, 5) validation of RNA quality and quantity (only samples 
with RIN≥8 were used), 6) library preparation for RNA sequencing, 7) libraries/samples 
were sequenced with the HiSeq 4000 platform, 8) sequencing data quality control and 
analysis.  
 
For the purposes of this experiment, second trimester foetal liver and cord 
blood-derived samples were used. The samples were initially enriched for 
CD34 using magnetic-activated cell sorting (MACS). Following from this, the 
samples were further sorted, using flow cytometry, for HSC/MPPs 
(CD34+CD38-CD45RA-) and LMPPs (CD34+CD38-CD45RA+). There was a 
consistency in the percentage of the two populations between foetal liver and 
cord blood-derived samples (Fig. 4.2).  
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groups (Fig. 4.3d). Post sort purity check was performed where the high purity 
of the two populations was ensured (Fig. 4.3e). It should be noted that due to 
the low number of cells and scarcity of samples, post sort purity check was 
performed twice, and I assumed that the high purity was maintained in the 
remaining of the sorted samples. I also ensured expression of cell surface 
markers used to sort the population where I observed high expression of CD34 
and low expression of CD38 (Fig. 4.3f). It should be noted that CD45RA 
expression could not be checked as due to the presence of multiple transcripts 
I could not specifically distinguish CD45RA from CD45. Additionally, the 
expression of CD31 was checked in this experiment where I observed that it 
was highly expressed in both FL and CB derived samples (Fig. 4.3f).  CD31 
expression could be indicative of endothelial contaminations in the sorted 
samples, however, as its expression was high in both foetal liver and cord 
blood it could be indicative of a different role in the HSPCs compartment. 
Further experimentation is required to confirm whether CD31 expression is 
due to contaminants or it is naturally expressed in these populations. 
Differential expression analysis revealed 2866 genes differentially expressed 
(DE) between the two populations, with 1418 upregulated in the foetal liver and 
1448 in the cord blood derived cells (Appendix 3). In accordance with the 
previous RNA sequencing experiments, genes were considered DE if padj ≤ 
0.05.   
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4.1.4 Genes differentially expressed between foetal liver 
and cord blood-derived HSC/MPPs 
 
The top 30 DE genes between the two populations are shown in Fig. 4.4. As 
expected, developmental gene LIN28B was amongst those genes, providing 
validation for this experiment.  
  
Figure 4.4| Heatmap of the top 30 differentially expressed genes between foetal liver 
(FL) and cord blood (CB)-derived HSC/MPPs.  
 
Interestingly, the top upregulated gene in the foetal liver-derived cells was 
MKI67, which is a known marker of proliferation. To further investigate the 
proliferative nature of these cells, I examined the expression of genes that are 
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Figure 4.8| Expression of TOP2A and PARP1 in foetal liver (FL) and cord blood (CB)-
derived HSC/MPPs. RNA sequencing data are shown as mean ± SD, each dot represents 
a sample.  
 
In the previous chapter it was shown that murine foetal liver LMPPs upregulate 
a large number of genes that have previously been linked with cancer or 
leukaemia. Interestingly, the same is true for the human foetal liver-derived 
HSC/MPPs; however, the presence of such genes is more prominent in this 
experiment. In particular, amongst the top 25 DE genes, 12 genes have 
previously been associated with cancer or leukaemia (Fig. 4.9). 
 
Figure 4.9| Heatmap of genes that have been previously linked with cancer or 
leukaemia. 
Genes upregulated in the foetal liver-derived cells included LIN28B which, as 
mentioned, was overexpressed in JMML and AML (Helsmoortel et al., 2016, 
Zhou et al., 2017). RRM2 has been shown to be frequently overexpressed in 
colorectal and prostate cancer and to confer drug resistance to cancer cells 
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(Grade et al., 2011, Mazzu et al., 2019). FOXM1 was upregulated in a number 
of cancers including liver, lung and paediatric pre-B ALL (Gusarova et al., 
2007, Kim et al., 2006, Buchner et al., 2015). Downstream targets of FOXM1, 
CCNB1 and CCNA2 were also upregulated in the foetal liver-derived cells and 
have been shown to be important for AML (Nakamura et al., 2010). STAB1 
plays a critical role in breast cancer, glioblastoma and AML (Riabov et al., 
2016, David et al., 2012, Chuang et al., 2015). HSPH1 expression was 
positively correlated with B cell non-Hodgkin lymphoma where it was shown to 
promote stabilization of Bcl-6 and c-Myc (Zappasodi et al., 2015). CHD7 
overexpression promoted glioblastoma, while CENP-F has been associated 
with poor prognosis in breast cancer (Machado et al., 2019,  O'Brien et al., 
2007). ASPM and BUB1B were shown to be upregulated in gliomas and 
relapsed paediatric B ALL (Bikeye et al., 2010, Xu et al., 2019, Chow et al., 
2017, Ma et al., 2017). KLN1 was upregulated in colorectal cancer (Bai et al., 
2019). CXCR4, a gene that has been shown to play a critical role in a number 
of cancers including head and neck, glioblastoma and AML, was upregulated 
in the cord blood- derived cells (De-Colle et al., 2018, Richardson, 2016, Zhang 
et al., 2017). CXCR4 expression in CD34+ cells derived umbilical cord blood 
has been well documented and it has been shown to be important for homing 
and engraftment of these cells (Ramirez et al., 2013).    
In addition to these genes, proto-oncogenes MYC and MYNC were also 
upregulated in the foetal liver-derived cells (Fig. 4.10a). Interestingly, GSEA 
revealed that there was an enrichment of MYC targets in the foetal liver-
derived cells (4.10b). It is well established that mis-regulation of proto-
oncogenes is a prominent feature of aggressive types of cancers and 
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GO and GSEA of the genes upregulated in the cord blood-derived cells were 
in line with the murine experiment (Fig. 4.13). In particular, GO and GSEA 
revealed an upregulation in processes and pathways related to the immune 
system including TNFA signalling via NFKB and interferon gamma response. 
In accordance with the murine data, there were also some developmental 
processes upregulated. Interestingly, GSEA revealed enrichment in KRAS 
signalling downregulation and p53 pathway upregulation. These two genes are 
frequently mutated in a number of cancers, and mis-regulation of their 
pathways are landmarks of cancer, with KRAS being a proto-oncogene and 
p53 a tumour suppressor (Shimizu et al., 1983, Tsuchida et al., 2016, Baker et 
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In a recent study, Agraz-Doblas et al. showed that blasts derived from infant 
patients share a similar transcriptional profile with HSPCs (Lin-CD34+CD38-) 
which include HSC/MPPs and LMPPs (Agraz-Doblas et al., 2019). To identify 
the cell of origin of the disease, the transcriptional profile of human foetal liver-
derived HSC/MPPs and LMPPs were defined and the genes differentially 
expressed were compared with MLL-AF4 targets, obtained from a previously 
published ChIP sequencing experiment from (Kerry et al., 2017), 
 
4.2.2 Experimental design  
 
In order to define the transcriptional profile of foetal liver HSC/MPPs and 
LMPPs, an RNA sequencing experiment was performed (Fig. 4.14). The 
sequencing experiment had the same design as the previous experiments. 8 
RNA sequencing libraries were prepared, 4 from each population. The libraries 
were pooled together and sequenced on the Illumina HiSeq4000 platform. It 
should be noted that 100bp-paired end sequencing was performed.  
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Figure 4.14| Experimental design used to define the transcriptional profile of foetal liver 
(FL) HSC/MPPs and LMPPs (Simplified version)   
The steps for this experiment were as follows: 1) dissection of second trimester foetal 
liver, 2) CD34+ enrichment using magnetic-activated cell sorting (MACS), 3) sorting of 
HSC/MPPs  and LMPPs, 4) RNA extraction, 5) validation of RNA quality and quantity 
(only samples with RIN≥8 were used), 6) library preparation for RNA sequencing, 7) 
libraries/samples were sequenced with the HiSeq 4000 platform, 8) sequencing data 
quality control and analysis.  
 
As with the previous RNA sequencing experiment, I initially ensured the good 
quality of the reads and libraries. Interestingly, PCA revealed that the two 
populations separated in PC2, whereas we can see that in PC1 the populations 
sorted from the same sample were clustering together (Fig. 4.15). This shows 
the importance of biological variation that exists between different human 
foetal liver-derived samples. Differential expression analysis revealed 738 
genes differentially expressed (DE) between the two populations, with 499 
upregulated in HSC/MPPs and 239 in LMPPs (Appendix 4). As before, genes 
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Initially I observed that a similar number of genes was common between those 
identified as SEM MLL-AF4 targets from the ChIP sequencing experiment and 
those upregulated in HSC/MPPs or LMPPs, with a slightly higher number of 
genes common with the LMPPs. (Fig 4.18a). Interestingly, in this paper, they 
describe a binding pattern unique to MLL-AF4, where binding of MLL-AF4 
spreads into the gene body, and they suggested that this leads to increased 
transcription (n=149). I compared the DE genes with the spreading targets of 
SEM MLL-AF4 and observed that there was a greater overlap of spreading 
targets and genes upregulated in the LMPP population (Fig.4.18b). From this 
data, it can be concluded that LMPPs appear to be a closer transcriptional 
match to infant blasts compared to the HSC/MPPs, suggesting that they could 
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4.3 Use of in vitro assays to establish early disease 
stages using foetal liver-derived cells 
 
4.3.1 Experimental design  
 
Being able to capture a pre-leukaemic stage is important for better 
understanding the disease initiation and progression. Having identified a 
similar stage in the Mll-AF4 mouse model, it would be interesting to investigate 
whether we can replicate this using human foetal liver-derived cells. To 
investigate the effect of MLL-AF4 expression in foetal liver cells, a B cell 
differentiation assay was performed (Fig. 4.19). In particular, foetal liver CD34+ 
cells were transduced with MLL-AF4 or empty vector lentiviral particles. It 
should be noted that due to the large size of the MLL-AF4 construct, there was 
a great difference in the number of transduced cells between the MLL-AF4 and 
EV transduced cells.  
 
Figure 4.19| Experimental design of in vitro assays used to establish an early disease 
stage. (Simplified version)  
The steps for this experiment were as follows: 1) dissection of second trimester foetal 
livers, 2) enrichment for CD34 using MACS, 3) transduction of CD34+ cells with MLL-
AF4-GFP expressing plasmid or empty vector (EV)-GFP, 4) sorting of GFP+ cells (48 
hours post transduction), 5) CD34+ MLL-AF4 expressing and EV expressing cells were 
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4.3.2 In vitro B cell differentiation assay  
 
Following transduction and B cell differentiation of the CD34+ cells, flow 
cytometric analysis was performed in order to identify lymphoid (CD19) and 
myeloid (CD33) cells. It can be observed in Fig. 4.20 there were no CD19+ 
cells in the MLL-AF4 (MA4)-expressing cells, whereas there was a clear 
CD19+ population in the empty vector transduced cells. As mentioned earlier 
there was a great difference in the percentage of transduced cells when MLL-
AF4 or EV lentiviral particles were used. In my opinion, the lack of CD19+ cells 
is an indication that the correct progenitor was not transduced. The correct 
progenitor would be in the CD34+CD38- compartment which comprises less 
than 1% of the CD34+ cells. Given the rarity of these cells and the low viral 
titers of MLL-AF4, it is unlikely that the correct progenitor was transduced. 
These findings are particularly interesting, as this would explain why it has 
been difficult to model this disease and it was only when constructs with better 
titers were used a disease model was established (Lin et al., 2016).  
 
Figure 4.20| Flow cytometric analysis of B cell differentiation assay using MLL-AF4-
expressing and control CD34+ foetal liver-derived cells.  
Flow cytometric analysis was performed 14 days after transduction of CD34+ cells with 
either empty vector (EV) or MLL-AF4 (MA4) (n=2; one representative shown).  
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4.4 Discussion 
 
The latest Interfant study revealed that the prognosis of infant patients with 
MLL-AF4-driven ALL has not improved in the last decade (Pieters et al., 2019). 
Pieters et al. suggested that there is an urgent need for innovative therapeutic 
strategies for these patients. However, in order to identify novel therapeutic 
targets, it is essential to better understand the unique biology of this disease. 
What makes this disease a unique entity amongst paediatric leukaemias is its 
in utero origin. Therefore, it would be insightful to investigate the foetal cell of 
origin of the disease.   
In order to investigate the in utero origin of the disease, I performed an RNA 
sequencing experiment comparing foetal liver with cord blood-derived 
HSC/MPPs. From the results it was observed that the human foetal liver-
derived cells were characterised by an over-proliferating and oncogenic 
nature. In contrast to the foetal liver-derived cells, cord blood cells exerted a 
more mature and immune-cell like transcriptional profile, with a number of 
tumour suppressor genes upregulated. In addition to this, I further compared 
the transcriptional profile of foetal liver-derived HSC/MPPs and LMPPs with 
SEM MLL-AF4 targets obtained from a previously published ChIP-seq 
experiment, where it was shown that LMPPs are a closer transcriptional match 
to the infant blasts as represented by the SEM cell line (Kerry et al., 2017).  
Transcriptional profiling of human and murine foetal cells revealed a common 
over-proliferating and oncogenic signature. Following from this, it is safe to 
assume that the unique nature of the leukaemia-initiating cell could be a key 
contributor to the disease initiation, maintenance and its aggressiveness.  
Having identified the unique features of the cell of origin of the disease, it would 
now be possible to investigate whether they are maintained in the blasts of 
infants with MLL-AF4-driven ALL.  With this approach, it would be possible to 
identify genes in the blasts expression of which is a residue of the cell of origin. 
It is reasonable to speculate that these genes could be of great importance to 
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the pathogenesis of the disease and could therefore serve as novel therapeutic 
targets, which is the subject of the next chapter. 
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Chapter 5 Exploiting the foetal origin of MLL-




Infant MLL-AF4-driven ALL is a devastating disease that renders the patients 
with an extremely poor prognosis. To better understand the unique biology of 
this disease, I investigated its foetal origin. In particular, I examined the 
transcriptional profile of foetal and neonatal/adult haematopoietic stem and 
progenitor cells in humans and mice (chapters 4 and 3, respectively). In both 
species, the foetal-derived cells were characterised by a proliferative and 
oncogenic nature, which could serve as the perfect “partner in crime” for the 
initiation of an aggressive disease. In contrast, neonatal and adult cells were 
characterised by a more “mature” and protective transcriptional profile. Based 
on this data, I believe that it is safe to speculate that the foetal origin of the 
disease could be a critical contributor for the initiation of this aggressive infant 
disease.  
The latest Interfant study revealed that there is an urgent need for innovative 
therapeutic strategies for the infant patients (Pieters et al., 2019). Following 
from this, it would be interesting to investigate whether we could 
therapeutically target aspects of the foetal origin of the disease that are 
maintained in the blasts of patients. In order to do this, I compared my data 
with a previously published dataset where they performed RNA sequencing of 
blasts of 17 infant patients with MLL-AF4-driven ALL (Andersson et al., 2015). 
With this approach, I identified genes the expression of which was at similar 
levels between the foetal cells and the blasts. I speculated that expression of 
these genes could be either a residue of the foetal origin of the disease or 
aberrantly activated by the fusion protein and therefore of great importance for 
its maintenance. To validate this, I performed functional assays and with this 
approach, a number of novel therapeutic targets were identified.  
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To investigate further the clustering pattern of the samples, I identified the top 
10 loadings that drive the clustering in PC1 (Fig. 5.2). It was fascinating to 
see that genes HOXA9 and IRX1 were amongst them.  
 
Figure 5.2| Top 10 loadings of PC1 that drive the clustering in Andersson et al. dataset. 
 
5.2.1 HOXA9 and IRX1 expression defines two 
subgroups of the disease 
 
It is well known that there are two distinct subgroups of infant MLL-AF4-driven 
ALL (Trentin et al., 2009, Stam et al., 2010). In most studies, these two groups 
are defined based on their HOXA9 expression (as HOXA9 high and low), with 
patients with high HOXA9 expression having a better prognosis (Stam et al., 
2010, Kang et al., 2012, Agraz-Doblas et al., 2019). Interestingly, Trentin et al. 
and Agraz-Doblas et al. identified a positive correlation between HOXA9 
expression and the presence of the reciprocal fusion transcript of MLL-AF4,  
AF4-MLL  (Agraz-Doblas et al., 2019, Trentin et al., 2009). Although in most 
studies the two subgroups are defined based on their HOXA9 expression, 
investigation of the data revealed a clear correlation between HOXA9 and 
IRX1 expression (Kuhn et al., 2016, Stam et al., 2010). In particular, in these 
studies they observed that one of the top DE genes between HOXA9h  and 
HOXA9 ow was IRX1, where IRX1 was upregulated in the blasts derived from 
patients with HOXA9 ow expression.  
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It should be noted that all paediatric patient samples expressed HOXA9. I then 
decided to focus only on the infant samples where I observed that samples 
that express HOXA9 also upregulate a number of other HOXA cluster genes, 
which was in accordance with previous publications (Fig. 5.3b) (Stam et al., 
2010, Trentin et al., 2009). In contrast, there was very low expression of HOXA 
cluster genes in the samples that upregulated IRX1 (Fig. 5.3b). Investigation 
of HOXA9 and IRX1 expression in patient samples revealed a negative 
correlation between the two (p = 0.00015) (Fig. 5.3c, d).  
Kuhn et al. ectopically overexpressed IRX1 in HEK293T and SEM cells. It 
should be noted that the SEM cell line expressed HOXA9 and there was very 
low expression of IRX1 (Fig. 5.3e). Following from the IRX1 overexpression 
Kuhn et al.  observed that this resulted in a decrease in the transcriptional 
activity of several HOXA genes including HOXA9, HOXA10 and HOXA5. In 
addition, they observed that IRX1 binds to HOXA9 and HOXA10 promoters 
only in the presence of MLL-AF4. From this data they concluded that IRX1 is 
likely to be responsible for the HOXA expression pattern (Kuhn et al., 2016).  
Interestingly, similar to HOXA9, IRX1 is a homeobox protein that is required 
for embryonic patterning (Cavodeassi et al., 2001, Leyns et al., 1996). 
Homozygous knockout prevents gastrulation, and it is embryonically lethal at 
E9.5 (Kuhn et al., 2016).  
The negative correlation that exists between IRX1 and HOXA9 expression in 
the blasts of patients with MLL-AF4-driven ALL is of clinical importance, as 
patients with HOXA9 expression have a better prognosis. It is interesting how 
two different homeobox genes seem to be critical for the infant disease. 
Although these data are of great interest, they should be treated with caution 
due to the low number of data points. It would be interesting to further 
investigate how expression of these two genes define the two subgroups of 
patients; however, more samples would be required to perform this analysis.  
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5.3 Identification of genes common between humans 
and mice  
 
Expression of genes that play critical functions is conserved across species. 
In order to identify genes the expression of which was conserved across 
humans and mice, I intersected the RNA sequencing datasets of the previous 
two chapters. With this approach, I identified genes that were commonly 
upregulated in the foetal liver derived populations (humans and mice) and 
neonatal and adult populations (humans and mice). Overall, I identified 70 
genes that were commonly upregulated in the foetal liver derived population 
and 55 that were upregulated in the neonatal and adult derived populations 
(Appendix 5). As expected, investigation of the genes upregulated in the foetal 
liver-derived populations revealed a number of genes involved in cell 
proliferation and development. Interestingly, amongst the foetal-upregulated 
genes, there was a number of genes that have been shown to be upregulated 
in relapse pALL including AURKA, HMAG1, PLK1, BUB1B, CENPF, CCNF 
and ASPM (Chow et al., 2017, Bhojwani et al., 2006).  
From the genes that were common between the human and murine data, I 
investigated their expression in the blasts of infants with MLL-AF4-driven ALL 
(Andersson et al., 2015). For the purpose of this comparison, I performed 
differential expression analysis of the two datasets. In particular, the dataset 
described in chapter 4, comparing human foetal liver and cord blood-derived 
HSC/MPPs and the dataset obtained from Andersson et al. (infants only) (Fig. 
5.4).  As expected, the data were clustering based on experiment and there 
was a great technical error in this comparison. This was taken under 
consideration and genes of interest were independently validated with qPCR.  
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Figure 5.4|PCA of foetal liver HSC/MPPs, cord blood HSC/MPPs and infant ALL 
samples.  
PCA of samples derived from the RNA sequencing experiment described in Chapter 4, 
foetal liver (FL) and cord blood (CB) derived HSC/MPPs compared with RNA sequencing 
data obtained from Andersson et al. where they sequenced the blasts of 17 infant 
patients with MLL-AF4-driven ALL (ALL).  
 
With this approach, I selected 21 genes the expression of which was at similar 
levels between the foetal-derived cells and the blasts (Fig. 5.5). I selected 20 
genes that were upregulated in the foetal liver-derived samples and 1 gene 
(DACH1) that was upregulated in the neonatal/adult-derived populations. It 
should be noted that DACH1 was not included in the heatmap in Fig. 5.5c, this 
was due to the fact that its very low expression in the blasts was very prominent 
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PLK1 (Polo-like kinase 1) is a member of the serine/threonine (Ser/Thr) protein 
kinases that has been shown to play a critical role in cell cycle progression. 
The importance of this kinase was initially identified in Drosophila 
melanogaster and was later confirmed in higher organisms including humans 
(Sunkel and Glover, 1988, Descombes and Nigg, 1998, Simizu and Osada, 
2000, Knecht et al., 1999, Golsteyn et al., 1994). PLK1 has been shown to 
control multiple steps during M-phase progression including mitotic entry, entry 
to prometaphase, centrosome maturation and separation, chromosome arm 
resolution, cytokinesis and establishment of the spindle assembly checkpoint 
(SAC) (Schmucker and Sumara, 2014, Sumara et al., 2004, Lenart et al., 2007, 
Hanisch et al., 2006, Gimenez-Abian et al., 2004, Petronczki et al., 2008, von 
Schubert et al., 2015). In addition to its multiple roles in mitosis, Plk1 has been 
shown to be an important target of the DNA damage checkpoint (Smits et al., 
2000). In particular, Smits et al. showed that Plk1 was inhibited by DNA 
damage in G2 and mitosis, leading to a DNA-damage induced arrest. The 
same group later showed that, following recovery from such arrest, Plk1 re-
expression was essential for the cells to enter mitosis (van Vugt et al., 2004).  
In homeostasis, PLK1 has been shown to be expressed during embryonic 
development and in the adult in proliferative tissues (Schmucker and Sumara, 
2014). However, PLK1 has also been implicated in a number of cancers 
including non-small-cell lung cancer, breast cancer, oropharyngeal carcinoma, 
head and neck cancer, melanomas and gliomas (Wolf et al., 1997, Wolf et al., 
2000, Knecht et al., 2000, Knecht et al., 1999, Strebhardt et al., 2000, 
Dietzmann et al., 2001). In addition to solid tumours, PLK1 has been shown to 
be overexpressed in AML and relapse p-ALL (Renner et al., 2009, Chow et al., 
2017, Bhojwani et al., 2006). 
Given the dominant presence of PLK1 in a number of cancers, it was not 
surprising that a number of inhibitors have been developed. One of the earliest 
PLK1 inhibitors developed was BI2536, which was shown to inhibit tumour 
growth both in vitro and in vivo (Steegmaier et al., 2007). BI2536 was replaced 
by BI6727 (Volasertib), which was developed by Boehringer Ingelheim, which 
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is the newest addition to this family of PLK1 inhibitors. BI6727, similar to 
BI2536, is an ATP-competitive kinase inhibitor of the dihydropterinone class of 
compounds, which inhibits proliferation by competitive binding to the ATP-
binding pocket of PLK1 (Rudolph et al., 2009). Volasertib was the first PLK1 
inhibitor to enter clinical trials and its efficiency has been demonstrated in AML 
(Brandwein, 2015). Phase I/II clinical trials showed that Volasertib exerted an 
anti-leukaemic activity and was clinically manageable as monotherapy and in 
combination with low-dose-cytarabine (LDAC) (Kobayashi et al., 2015, Dohner 
et al., 2014). Given the promising results, the drug entered phase III clinical 
trial for AML where it was used in combination with LDAC. However, in 2016 
Boehringer Ingelheim announced that the phase III results did not meet the 
primary endpoint of objective response; however, it should be noted that the 
trial is ongoing.  
As mentioned earlier, PLK1 was upregulated in the foetal liver-derived cells 
(human and murine), and it was also expressed at the same levels between 
foetal liver-derived HSC/MPPs and infant blasts (Fig. 5.5). Given the 
availability of a potent inhibitor, I decided to investigate whether PLK1 could 
be used as a therapeutic target for infant MLL-AF4-driven ALL. This was 
achieved by treating the SEM cell line with 50nM of BI6727. The concentration 
was selected based on a previous publication where it was shown that 
treatment of NK cells derived from healthy donors with 50nM of BI6727 did not 
exert any cytotoxic effects (Gopalakrishnan et al., 2018). In SEM cells, 
however, the use of 50nM of BI6727 resulted in dramatic changes of their cell 
cycle profile and viability (Fig. 5.7a-c). In particular, 24 hours after treatment 
there was a dramatic decrease in the number of cells present in the G0/1 and 
S phases of the cell cycle, whereas there was a dramatic increase in the 
number of cells present in G2/M (Fig. 5.7a-b). 48 hours after treatment, almost 
50% of the SEM cells were apoptotic and therefore it was difficult to capture 
an accurate cell cycle profile of these cells (Fig. 5.7a & c). 78 hours after 
treatment, less than 5% of the cells were viable (Fig. 5.7 c). The cell cycle 
profile of the cells treated with BI6727 was in accordance with a previous 
publication, where they observed that treatment of MV4;11 and Kasumi-1 cells 
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5.5 Use of CRISPR-Cas9 to identify novel therapeutic 
targets for MLL-AF4-driven ALL 
 
To investigate whether the foetal origin of the disease is critical for the disease 
maintenance, I used a CRISPR-Cas9 approach. In particular, I identified 19 
genes that were upregulated in the foetal liver-derived populations (human and 
murine) and expression of which was at similar levels between the foetal liver-
derived HSC/MPPs and the infant blasts (Fig. 5.5 a-c). I ensured that these 
genes were expressed in the SEM cell line; the data for this were obtained 
from Kerry et al. where they performed nascent RNA sequencing of the SEM 
(Fig. 5.9) (Kerry et al., 2017). It should be noted that I did not analyse the 
nascent RNA seq experiment, the values of reads per Kilobase of transcript 
(RPKM) I used were obtained from a table that the authors provided/submitted 
in Gene Expression Omnibus (GEO). Following from this I generated a SEM-
Cas9-GFP cell line and, using sgRNAs knockout studies, I investigated the 
importance of these genes in the disease maintenance.  
 
Figure 5.9| Expression of genes of interest in SEM cell line. Data obtained from (Kerry 
et al., 2017) where they performed nascent RNA sequencing of SEM cell line. It should 
be noted that I did not analyse the nascent RNA seq experiment, the values (Reads Per 
Kilobase of transcript = RPKM) I used were obtained from a table that the authors 
provided/submitted in Gene Expression Omnibus (GEO). 
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Having generated a SEM-Cas9 system, the next step was to establish an 
assay where the effect of the knockout could be tested. A competition assay 
was established where the SEM-Cas9-expressing cells were mixed with SEM 
wild-type cells (in 1:1 ratio) and the mixture was transduced with the sgRNAs. 
Following from this, the cells were cultured and the percentage of GFP+ cells 
was measured using flow cytometry at different time points (Fig. 5.10a,b).  
The competition assay allowed for the identification of sgRNAs that exerted a 
negative effect on the viability of the SEM-Cas9 cells. An example of the 
competition assay can be seen in Fig. 5.10b. We can observe that for the 
negative sgRNA (Neg sgRNA) the percentage of GFP+ cells remained 
consistent between days 2, 6 and 12, suggesting that the sgRNA did not affect 
survival of the SEM-Cas9 cells. In contrast, the positive sgRNA (Pos sgRNA) 
had a tremendous impact on the SEM-Cas9 cells, with the percentage of GFP+ 
(and therefore Cas9 expressing cells) dramatically decreasing starting at day 
6 and very few viable SEM-Cas9+ cells remaining by day 12. We can also 
observe that there were no significant changes in the SEM wild type cells, 
which suggested that the decrease in the SEM-Cas9 cells was due to the 
knockout effect.  
This suggests that when the percentage of GFP+ cells (and therefore Cas9 
expressing cells) decreased, the sgRNA used affected the survival of SEM 
cells; however, the contrary is true for sgRNAs that did not exert an effect. The 
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5.5.1 HSPD1  
 
Two genes were uniquely identified in my screen, HSPD1 (also known as 
HSP60) and ELOVL1. HSPD1 was upregulated in the foetal liver-derived 
tissues compared to their adult counterparts (in both humans and mice) (Fig. 
5.13 a,b). Additionally, expression of this gene was at similar levels between 
the foetal liver derived HSC/MPPs and the infant blasts in the RNA sequencing 
data; however, this could not be validated using qPCR (Fig. 5.13 c,d). HSPD1 
is a member of the Heat Shock family of proteins.  
HSPD1 together with HSP10 forms a chaperonin complex, which has been 
shown to be important for mitochondrial protein import and the correct folding 
of the imported proteins (Richardson et al., 2001, Bross and Fernandez-
Guerra, 2016). Knockout of HSPD1 in the SEM-Cas9 expressing cells induced 
cell death, and we can see that only a small number of cells were viable by 
day 12 (Fig. 11 and 13e). It should be noted that two sgRNAs were used and 
exerted the same effect in the SEM-Cas9 cell line, suggesting that the effect 
was due to the knockout of the gene as opposed to an off-target effect or other 
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5.5.2 ELOVL1 
 
The second gene identified with this approach was ELOVL1. Knockout of 
ELOVL1 in SEM-Cas9 cells resulted in a dramatic decrease in the viability of 
the cells (Fig. 5.11). The decrease was present at day 6 and continued to day 
12, where less than 7 per cent of the cells were viable. Interestingly, knockout 
of ELOVL1 in AML and other cancer cell lines did not have any effect on the 
viability of the cells, suggesting this effect could be unique to the infant MLL-
AF4-driven ALL (Erb et al., 2017, Hart et al., 2015).  
ELOVL1, which is a member of the elongation of very long chain fatty acids 
(ELOVL) family of proteins, was upregulated in the foetal liver-derived tissues 
(both human and murine) (Fig. 5.14a,b). Additionally, ELOVL1 expression was 
at similar levels between human foetal liver-derived HSC/MPPs and infant 
blasts (Fig. 5.14c,d). To validate the ELOVL1 knockout, TIDE assay was 
performed where the high efficiency of the sgRNA was confirmed (Fig. 5.14e).  
To further investigate the mechanisms of action of ELOVL1, a lipidomics 
experiment was performed. The aim of this experiment was to obtain a global 
profile of the lipids that were affected by knockout of this gene. For this 
experiment, SEM-Cas9 cells were transduced with sgRNA for ELOVL1 and 
compared to SEM-Cas9 cells transduced with sgRNA for neg control. The 
comparison was performed at two time points – day 2 (D2) and day 4 (D4). 
After this point, there was a large number of apoptotic cells, and it would be 
difficult to obtain an accurate representation of the lipids. The SEM cells used 
for the lipidomics study were sorted using flow cytometry for live, GFP (Cas9), 
BFP (sgRNA) prior to the lipidomics experiment.  It should be noted that the 
lipidomics experiment and the analysis of the accompanied data was 
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Table 5.1| List of lipids identified from the study of the lipidome of SEM-Cas9 ELOVL1 
knockout cells. Comparison of day 4 ELOVL1 knockout with day 4 negative control 
knockout. (triglyceride (TG), sphingomyelin (SM), phosphatidylcholines (PC), hexosyl 
ceramides (HexCer).  
The results obtained from the lipidomics experiments were in accordance with 
previous publications where it was shown that ELOVL1 is critical for the 
elongation of very long chain fatty acids (VLCFAs) (Tvrdik et al., 2000), in 
particular, the elongation of saturated and monounsaturated VLCFAs which 
are critical for cellular membranes as they contribute to the fluidity and physico-
chemical properties of the membranes (Kraft, 2016, Ohno et al., 2010, Asadi 
et al., 2002).  
Interestingly, elongation of very long chain fatty acids has been implicated in 
breast cancer and lung cancer (Marien et al., 2016, Feng et al., 2016, 
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Yamashita et al., 2017). In particular, it was shown that high levels of ELOVL1 
in breast cancer and ELOVL6 in lung cancer lead to aberrant increase of 
phospholipids with longer fatty acid chains (Yamashita et al., 2017, Marien et 
al., 2016). In both studies, they suggest that targeting of appropriate ELOVLs 
could serve as a novel therapeutic approach. Following from this I believe it 
would be interesting to investigate knockout of ELOVL1 in a clinical setting 
using patient-derived samples and examine the membrane lipid composition 
of blasts derived from infant patients.  
 
5.5.3 Migration assay 
 
In the previous section, using a CRISPR–Cas9 approach I investigated the 
knockout effect of 19 genes where I identified 6 genes that induced apoptosis 
of SEM-Cas9 cells. The remaining genes did not have any effect on the 
survival of the SEM-Cas9 expressing cells.  
It is well known that there is a high incidence of central nervous system (CNS) 
infiltration in infants with MLL-AF4-driven ALL (Silverman, 2007). Following 
from this it would be interesting to investigate whether any of the genes 
upregulated in the foetal liver-derived cells (and expressed at similar levels in 
the infant blasts) had an effect on the migration potential of the SEM-Cas9 
cells. In a fascinating study, Yao et al. identified the interaction between α6 
integrin and laminin to be critical for migration of ALL cells. Additionally, they 
showed that ALL cells hijack neural migratory pathways in order to invade the 
CNS in mice (Yao et al., 2018).   
Amongst the genes upregulated in the foetal liver-derived tissues (human and 
murine) I identified a number of genes that have previously been shown to 
affect cell migration (Fig. 5.5). Amongst those genes were Integrin-α4 (ITGA4), 
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monitored. Flow cytometric analysis revealed that overexpression of DACH1 
in the SEM cells decreased the ability of the cells to proliferate (Fig. 518b). In 
particular, we can observe that at day 0 (D0) the fluorescent intensity of the 
cell tracer dye is at similar levels between the DACH1 expressing cells and the 
controls (Fig. 5.18b). However, at day 4 (D4) the peaks representing the 
DACH1 expressing cells were brighter than the control cells, suggesting that 
the DACH1-expressing cells divided less than the controls. From this, it can be 
concluded that DACH1 expression does not affect the survival of the cells; 
however, it does appear to have an effect of the proliferation potential of the 
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5.7 Discussion 
 
It has long been speculated that the foetal origin of infant MLL-AF4-driven ALL 
is responsible for the unique biology of this disease. In the previous two 
chapters, I investigated the foetal origin of the disease by understanding the 
transcriptional landscape of foetal-derived cells in humans and mice. It was 
clear that in both species foetal-derived cells were characterised by a 
proliferative and oncogenic nature.  
Genes that are essential are usually conserved across species, therefore it 
was safe to speculate that this would hold true for genes that are critical for the 
foetal and neonatal/adult transcriptional signatures. Comparison of the human 
and murine datasets identified a number of genes that were common between 
the two species. As expected, the genes common in the foetal transcriptomes 
were predominantly developmental genes and genes involved in cell 
proliferation.  
To investigate whether the foetal origin of the disease is critical for the disease 
maintenance, I selected 20 genes that were upregulated in the foetal liver-
derived cells (both human and murine). Those genes were expressed at 
similar levels between the foetal liver-derived tissues and the blasts. From 
those genes, I identified seven genes including PLK1, ELOVL1, HSPD1, 
TPX2, NUTF2, BUB1B and CCNB1 that were acutely required for the viability 
of SEM cells. Although the majority of the genes were not unique to the infant 
disease, I think it would be interesting to further investigate whether they could 
be used to treat the infant disease. Of particular interest was PLK1 and its 
close “friend” AURKA as there are inhibitors available. One of the genes that 
seems to be unique to the infant leukaemia was ELOVL1. This gene, that has 
been shown to be important for the elongation of very long fatty acid chains, is 
very interesting as it is involved in the maintenance of cell membranes. Given 
the poor response of infants to chemotherapy for example prednisone, it will 
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not be surprising if the cell membrane of the blasts has a different composition 
which renders them more resistant to standard chemotherapy.  
A gene that was upregulated in the human neonatal and murine adult cells with 
very low expression in the blasts was DACH1. This gene was interesting, as it 
has been shown to be a tumour suppressor gene in a number of cancers. 
Overexpression of this gene in SEM did not exert a negative effect in the 
survival of the cells; however, it did decrease the proliferation potential of the 
cells.  
Infant MLL-AF4-driven ALL is a devastating disease and the patients have a 
very poor prognosis. This is mainly due to the fact that we do not completely 
understand the unique biology of the disease. By understanding which aspects 
of the disease could be a residue of its foetal origin, we could develop novel 
therapeutic targets. Using this approach, a number of such targets have been 
identified in this study, suggesting that the foetal origin of the disease could be 
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Chapter 6 Discussion  
 
Infant MLL-AF4-driven ALL is a rare but devastating disease with dismal 
prognosis. MLL-AF4 fusion occurs when the N terminal portion of MLL fuses 
with AF4 which results in the production of an aberrant fusion protein. 
Interestingly, the infant patients have a silent mutational landscape suggesting 
that the fusion is the main disease driver. It is well established that the disease 
arises in utero and that the foetal origin of the disease could be a critical 
contributor to the unique disease phenotype. It has been shown in many 
studies that foetal and adult blood cells possess a multitude of different 
characteristics. In fact, in one of the studies Barrett et al. using an Mll-AF4-
expressing mouse model showed that foetal liver-derived cells were more 
prone to transformation by Mll-AF4 compared to their adult counterparts 
(Barrett et al., 2016).  
Following from Barrett et al. it would be interesting to investigate how the foetal 
origin of the disease affects the disease phenotype. Towards this end, I initially 
defined the transcriptional profile of murine E14.5 foetal liver and adult bone 
marrow-derived LMPPs. From the data, it was clear that the two populations 
possessed distinct characteristics, which was a reflection of their different roles 
in haematopoiesis. Foetal liver-derived cells were characterised by a 
proliferative nature and upregulated a large number of genes that have 
previously been linked with cancer or leukaemia. These characteristics are a 
reflection of cells that are required to support the needs of a growing organism. 
On the contrary, the adult bone marrow-derived cells were defined by a mature 
and protective transcriptional profile as there was an upregulation in a number 
of tumour suppressor genes. To further validate this data and ensure that they 
hold true for humans, I defined the transcriptional profile of human foetal liver 
and cord blood-derived HSC/MPPs.  A similar picture emerged as that of the 
murine data; however, it appeared that the proliferative and oncogenic nature 
of the human foetal liver-derived population was more prominent. One key 
point is that it is difficult to ensure whether this was a true biological difference 
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or a technical artefact. I think the main limitation of this study was that different 
populations were sequenced for humans and mice and therefore the direct 
comparison came with this drawback. However, the RNA quality of human 
cord blood-derived LMPPs was consistently poor and inadequate for 
preparation of RNA sequencing libraries. It should also be mentioned that due 
to the rarity of human bone marrow samples no effort was made to obtain such 
samples.  
Regardless of the limitations, it was clear, from both the human and murine 
data, that the foetal-derived cells had a proliferative and oncogenic nature. 
Following from this, I believe that it is safe to speculate that the unique nature 
of the foetal cells could be a key contributor to the initiation of the aggressive 
infant disease. 
The next step was to corroborate these findings in the infant disease setting. 
To do this, I initially identified genes, which were common between the human 
and murine dataset. In my opinion, the presence of genes in both datasets 
showed their critical role, as they were conserved across species. Additionally, 
I used this approach to validate my RNA sequencing data, by validating one 
experiment with the other. Following from this, I identified genes the 
expression of which was at similar levels between the foetal liver-derived cells 
and the infant blasts. With this approach, I speculated that expression of those 
genes was a residue of the foetal origin of the leukaemia initiating cells. 
Expression of these genes could also be an aberration caused by the fusion 
protein; however, it should be mentioned that there were no activating/de-
activating mutations in the infant blasts. This point is critical, as in adult 
leukaemias or cancers the abnormal over-expression of genes is usually linked 
to a mutation(s); however, as mentioned earlier, infants are characterised by 
a silent mutational landscape. Therefore, I believe it is safe to assume that 
expression of the genes was due to its foetal origin and that their sustained 
expression indicates that they may be important for the disease phenotype.  
From the genes the expression of which was common between the foetal liver-
derived cells and the blasts, I selected 21 genes. The selection was based on 
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the role of the gene but also the expression levels of the gene in the SEM cell 
line. The selected genes were RGL1, HMMR, ITGA4, ASPM, ENC1, 
SUV39H2, ELOVL1, PLK1, TPX2, HSPD1, APEX1, DLAT, NUTF2, TTLL12, 
LMNB1, CCNB1, CCNF, KIF20A, BUB1B and DACH1. The majority of the 
genes selected were involved in different aspects of the cell cycle/proliferation. 
Amongst those genes were ASPM, PLK1, TPX2, APEX1, CCNB1, CCNF, 
KIF20A and BUB1B. Other genes have been shown to be important for cell 
migration including HMMR, ITGA4, ENC1 and LMNB1. The remaining genes 
have a number of different roles including chromatin binding for SUV39H2, 
pyruvate metabolism for DLAT and less defined roles for RGL1 and TTLL12. I 
have already discussed the roles of ELOVL1, NUTF2 and HSPD1.  
The first gene I investigated in this study was PLK1, as there was an inhibitor 
readily available (Volasertib). It was fascinating to see the tremendous effect 
that the inhibitor exerted in the SEM cell line. A key limitation here was that the 
SEM cells are not an accurate representation of clinical samples derived from 
infants with MLL-AF4-driven ALL. However, I believe the data obtained from 
this experiment were promising and it would be interesting to investigate the 
effect of Volasertib in a clinical setting. Similar to Volasertib, another inhibitor 
that in my opinion would be worth trying with infant blasts is Alisertib which 
inhibits AURKA, which was also highly expressed in the blasts.  
In order to investigate the role of RGL1, HMMR, ITGA4, ASPM, ENC1, 
SUV39H2, ELOVL1, TPX2, HSPD1, APEX1, DLAT, NUTF2, TTLL12, LMNB1, 
CCNB1, CCNF, KIF20A and BUB1B, I used a CRISPR-Cas9 approach. I 
generated a SEM-Cas9-expressing cell line and tested two sgRNAs for each 
gene and performed a knockout screen. The small number of sgRNAs used 
here is the major drawback, as we cannot be certain that for those genes that 
did not exerted an effect whether this was due to an inefficient knockout or 
because the genes are not important for the survival of the SEM cells.  
With the CRISPR-Cas9 approach, I identified ELOVL1, TPX2, HSPD1, 
NUTF2, CCNB1 and BUB1B that affected the viability of the SEM cells. 
Investigation into other, published CRISPR-Cas9 screens revealed that some 
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of the genes were not unique to the infant disease, but played similar roles in 
other leukaemia and cancer cell lines. Amongst those genes were TPX2, 
NUTF2, CCNB1 and BUB1B. Although they are not unique, I think it is still 
interesting to investigate the role of those genes and their potential use to treat 
the infant disease.  
HSPD1, was one of the genes that was unique to this screen; however, I was 
not able to validate the RNA sequencing data with qPCR. Additionally, I 
investigated expression of HSPD1 is normal bone marrow cells (using 
http://www.altanalyze.org/ICGS/HCA/splash.php) where I observed that this 
gene was highly expressed in the majority of the haematopoietic cells and 
therefore not the perfect target to inhibit.  
Of particular interest was ELOVL1 as it appears to be unique to the infant 
leukaemia and its expression in normal bone marrow blood cells is low (as 
shown in http://www.altanalyze.org/ICGS/HCA/splash.php). ELOVL1 
knockout had a dramatic impact on the SEM cell line and investigation into the 
mechanisms of action revealed that it only affects lipids with very long fatty 
acid chains, which are known to be important for cell membranes.  
From this data, I believe that it safe to say that the foetal origin of the leukaemia 
initiating cells is critical not only for the disease initiation but also for its 
maintenance. Identifying genes, the expression of which could be due to the 
foetal origin of the disease has proved to be a novel approach for identifying 
disease targets.  
Another aim of the study was to understand the molecular events that take 
place during the early stages of transformation by MLL-AF4. It is well 
established that MLL-AF4-driven infant ALL arises in utero, and multiple efforts 
have been made to capture the early disease stages. Towards this end, I 
investigated how MLL-AF4 co-operates with its environment in order to initiate 
and drive this aggressive infant leukaemia. For this, I used a mouse model 
where Mll-AF4 was expressed at the stage of the first definitive haematopoietic 
cells and defined the transcriptional profile of Mll-AF4-expressing LMPPs. With 
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this approach, I identified a number of genes that were aberrantly expressed 
due to the fusion protein. Of particular interest was Skida1 as it was 
upregulated in the murine Mll-AF4-expressing LMPPs but also in the blasts of 
infants with MLL-AF4-driven ALL compared to paediatric patients with the 
same disease and healthy controls. Interestingly, another gene of the same 
family came up in the previous screens as it was upregulated in human cord 
blood and murine adult bone marrow-derived cells. This gene was DACH1, 
which was shown to be a tumour suppressor gene in a number of solid 
cancers. Investigation of those two genes using the SEM cell line revealed that 
neither of the genes influenced the survival of the SEM cells; however, DACH1 
did decrease the proliferation potential of the cells. Although the data are not 
very encouraging, I think it is important to consider that the SEM cell line is a 
reflection of the paediatric disease as opposed to an infant one. Following from 
this, I believe that it would be interesting to investigate the effect of these genes 
in samples derived from infant patients.  
Given the fundamental differences between humans and mice, I tried to 
investigate the early disease stages in humans. In particular, I transduced 
human foetal liver-derived HSPCs with MLL-AF4 lentiviral particles and 
performed B cell differentiation. However, I was unable to obtain a positive 
result with this approach.  
I believe this has been a proof of concept study where by defining the cell of 
origin of the disease I was able to identify novel therapeutic targets for infant 
MLL-AF4-driven ALL. In this study, the cell of origin was identified to be the 
human foetal liver-derived LMPP; however, this was when compared to the 
SEM cell line. Given the recent advancement in single RNA sequencing it has 
been clear that there is tremendous heterogeneity in what was previously 
thought to be one population. Following from this, I believe that it could be 
possible that different patients have different cells of origin. Different cells of 
origin may even explain inter-patient differences in response to treatment and 
risk of relapse or lineage switching. However, one thing is certain that the 
disease arises in utero and that the foetal origin of the disease is critical. It was 
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also interesting to see that the infant blasts formed two different clusters and 
that these clusters could be defined by their HOXA9/IRX1 expression. There 
was a clear negative correlation between expression of these two genes and 
this was of clinical relevance as patients with IRX1 expression do not have the 
AF4-MLL reciprocal fusion and also suffer from a worse prognosis than the 
infants that express HOXA9. Although there were very few patients to perform 
further analysis, I think it is important to investigate these two clusters for 
further clues as to how to treat these patients.  
From this study it is clear that the foetal origin of the disease is critical for the 
disease initiation, maintenance and unique disease phenotype and, as a 
consequence, appears to be a promising therapeutic target. Another aspect of 
the foetal origin of the disease that is likely to further support the initiation of 
this aggressive disease, but was not investigated in this study, is the 
microenvironment. Indeed, Barrett et al using the Mll-AF4-Vec-Cre mouse 
model investigated expression of Mll-AF4 in endothelial cells, mesenchymal 
stromal cells and osteoblasts. They observed that the highest expression was 
in endothelial cells whereas there was very low expression in both 
mesenchymal stromal and osteoblasts. This data suggested the possibility that 
endothelial cells might be involved in the disease initiation by further 
supporting the Mll-AF4 expressing haematopoietic cells. This was in line with 
finding in the same study as comparison of Mll-AF4 activation using the mouse 
model described above, gave a slightly more severe phenotype when 
compared to a mouse model where Mll-AF4 expression was initiated at the 
definitive haematopoietic stage (using Vac-Cre). Although further evidence is 
required, it is very likely that the leukaemia-initiating cells works in synergy with 
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Chapter 7 Future work 
 
Following from this study, I think it is important to further investigate genes the 
expression of which was at similar levels between the foetal liver-derived cells 
and the blasts, with focus on the human dataset. I believe that with this 
approach, we could identify more therapeutic targets and the focus should be 
on genes that are not expressed in healthy tissues. For the targets that were 
identified in this study in particular PLK1, AURKA and ELOVL1, it would be 
interesting to test the effect of these genes in vivo using blasts derived from 
infant patients.  
In my opinion of particular interest is ELOVL1, as it appears to be unique to 
the infant leukaemia. Given the poor response of patients to chemotherapy, 
for example prednisone, it would be interesting to investigate whether the cell 
membrane of the blasts derived from infant patients with MLL-AF4-driven ALL 
differ from healthy ones. Additionally, it would be interesting to investigate 
differences in the lipid composition of foetal and adult cells and whether these 
differences allow the foetal cells to escape the effect of chemotherapy.  
It has been well established that infant patients with MLL-AF4-driven ALL could 
be divided into two subcategories based on their HOXA9 expression. This was 
further confirmed in this study, and I was able to show that there is an inverse 
correlation between HOXA9 and IRX1. Of course, given the low number of 
patients, these finding should be treated with caution. One key point here is 
that now there is another dataset publicly available from Agraz-Doblas et al., it 
would be possible to further investigate the two sub-clusters of the infant 
disease (Agraz-Doblas et al., 2019). It would be interesting to investigate the 
transcriptome of the two different sub-clusters, in order to find clues that would 
allow improving the prognosis of the patients that express IRX1.  
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Chapter 8 Concluding remarks 
 
Infant MLL-AF4-driven ALL is a devastating disease with a unique underlying 
biology, which we do not completely understand. The uniqueness of this 
disease has been attributed to the foetal origin of the leukaemia-initiating cell. 
We can speculate that the environment that supports rapid growth of the 
embryo when hijacked by MLL-AF4 could lead to the aggressive leukaemia 
that is observed in the infant patients.  
This has been a proof of concept study where it was shown that by defining 
the transcriptome of the cell of origin of the disease it was possible to identify 
novel disease targets. In my opinion, this approach could be valuable for 
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Chapter 10 Appendices 
 
10.1 Appendix 1  
List of genes differentially expressed between murine foetal liver and bone 
marrow derived LMPPs (positive log fold represents genes upregulated in the 
foetal liver derived LMPPs), described in chapter 3.  
Ensemb  ID og2 Fo d Change padj Gene Name 
ENSMUSG00000029814 5.092845825 1.16E 47 Igf2bp3 
ENSMUSG00000022824 5.336799901 4.08E 40 Muc13 
ENSMUSG00000055413 6.634453962 2.88E 38 H2 Q5 
ENSMUSG00000061232 3.12051343 2.22E 35 H2 K1 
ENSMUSG00000025330 4.430730244 1.41E 27 Pad 4 
ENSMUSG00000024940 4.60709422 2.93E 25 Ltbp3 
ENSMUSG00000013415 3.542743884 6.36E 23 Igf2bp1 
ENSMUSG00000056758 3.487073113 4.84E 21 Hmga2 
ENSMUSG00000064147 3.608096007 6.41E 19 Rab44 
ENSMUSG00000055639 4.262475575 9.87E 19 Dach1 
ENSMUSG00000074151 3.638787671 1.33E 18 N rc5 
ENSMUSG00000073411 2.727067828 2.97E 18 H2 D1 
ENSMUSG00000027073 5.952321216 8.92E 18 Prg2 
ENSMUSG00000004952 3.201717229 1.46E 16 Rasa4 
ENSMUSG00000021262 2.789650262 5.69E 16 Ev  
ENSMUSG00000024924 3.003836961 6.11E 16 V d r 
ENSMUSG00000032265 4.189100534 1.46E 15 Fam46a 
ENSMUSG00000037280 2.956430692 2.09E 15 Ga nt6 
ENSMUSG00000025877 4.492537264 1.04E 14 Hk3 
ENSMUSG00000029581 3.813553495 1.61E 14 Fscn1 
ENSMUSG00000078922 4.597168139 3.64E 14 Tgtp1 
ENSMUSG00000070348 2.846442494 4.83E 14 Ccnd1 
ENSMUSG00000061311 3.219218547 4.83E 14 Rag1 
ENSMUSG00000070348 2.172355157 2.02E 13 Dnmt3b 
ENSMUSG00000063804 3.182723333 2.62E 13 L n28b 
ENSMUSG00000024900 2.21786076 3.34E 13 Cpt1a 
ENSMUSG00000073409 3.209016995 9.06E 13 H2 Q8 
ENSMUSG00000034361 3.889494414 3.18E 12 Cpne2 
ENSMUSG00000039315 3.198390493 4.15E 12 C nk 
ENSMUSG00000070643 2.435760317 7.78E 12 Sox13 
ENSMUSG00000026581 2.67251405 8.63E 12 Se  
ENSMUSG00000004891 3.646496156 4.06E 11 Nes 
ENSMUSG00000038370 4.946659004 4.41E 11 Pcp4 1 
ENSMUSG00000022636 3.212690119 5.17E 11 A cam 
ENSMUSG00000007682 4.333140837 5.64E 11 D o2 
ENSMUSG00000034485 2.307494917 1.63E 10 Uaca 
ENSMUSG00000078921 3.507238528 2.44E 10 Tgtp2 
ENSMUSG00000033863 3.98339275 2.45E 10 K f9 
ENSMUSG00000025014 7.697730133 2.51E 10 Dntt 
ENSMUSG00000020893 2.599305767 3.31E 10 Per1 
ENSMUSG00000053931 2.350802597 4.57E 10 Cnn3 
ENSMUSG00000003882 3.222059829 6.73E 10 I 7r 
ENSMUSG00000015970 3.475637556 7.39E 10 Chdh 
ENSMUSG00000029716 3.340231599 9.10E 10 Tfr2 
ENSMUSG00000023972 2.218672622 1.56E 09 Ptk7 
ENSMUSG00000037169 2.192825496 2.20E 09 Mycn 
ENSMUSG00000026822 5.122360547 2.67E 09 Lcn2 
ENSMUSG00000037138 2.401265593 2.82E 09 Aff3 
ENSMUSG00000035929 2.671368888 3.43E 09 H2 Q4 
ENSMUSG00000034930 2.74218158 3.71E 09 Rtkn 
ENSMUSG00000025529 4.279764418 3.87E 09 Zfp711 
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ENSMUSG00000022534 4.774416057 4.12E 09 Mefv 
ENSMUSG00000054435 2.97057295 4.96E 09 G map4 
ENSMUSG00000071226 2.066225734 5.81E 09 Cecr2 
ENSMUSG00000005474 4.742905876 5.90E 09 My 10 
ENSMUSG00000022817 3.433792523 6.42E 09 Itgb5 
ENSMUSG00000024164 3.566174301 8.31E 09 C3 
ENSMUSG00000022755 2.966345358 9.08E 09 Adgrg7 
ENSMUSG00000026921 2.55650818 1.20E 08 Egf 7 
ENSMUSG00000022686 2.674718341 1.39E 08 B3gnt5 
ENSMUSG00000060550 2.994227037 1.42E 08 H2 Q7 
ENSMUSG00000029561 2.059571822 1.83E 08 Oas 2 
ENSMUSG00000048612 2.794064176 2.40E 08 Myof 
ENSMUSG00000037922 3.371133442 2.68E 08 Bank1 
ENSMUSG00000028528 3.899223799 3.40E 08 Dnajc6 
ENSMUSG00000026222 1.622990809 3.53E 08 Sp100 
ENSMUSG00000015053 1.926578339 4.97E 08 Gata2 
ENSMUSG00000000782 3.457572647 5.02E 08 Tcf7 
ENSMUSG00000051397 4.37224512 7.02E 08 Tacstd2 
ENSMUSG00000020715 2.267850687 7.68E 08 Ern1 
ENSMUSG00000036594 3.166403746 7.79E 08 H2 Aa 
ENSMUSG00000054072 3.931977848 8.10E 08 I gp1 
ENSMUSG00000039234 2.57344171 8.21E 08 Sec24d 
ENSMUSG00000040856 3.410733195 9.11E 08 D k1 
ENSMUSG00000098411 3.410733195 9.11E 08 D k1 
ENSMUSG00000048148 2.841850077 9.14E 08 Nwd1 
ENSMUSG00000034037 1.92280688 1.25E 07 Fgd5 
ENSMUSG00000043557 3.192754951 1.25E 07 Mdga1 
ENSMUSG00000033826 2.009191428 1.72E 07 Dnah8 
ENSMUSG00000014813 2.958982354 2.07E 07 Stc1 
ENSMUSG00000050105 3.424603487 2.54E 07 Grrp1 
ENSMUSG00000039497 2.830522244 2.77E 07 Dse 
ENSMUSG00000045679 2.159394815 2.77E 07 Pq c3 
ENSMUSG00000073599 2.873221168 3.04E 07 Ecscr 
ENSMUSG00000060802 1.714171003 3.61E 07 B2m 
ENSMUSG00000052234 2.741831376 4.14E 07 Epx 
ENSMUSG00000022240 2.736699814 5.67E 07 Ctnnd2 
ENSMUSG00000040957 2.500027634 6.53E 07 Cab es1 
ENSMUSG00000037321 1.576347758 6.53E 07 Tap1 
ENSMUSG00000030559 2.564362217 7.78E 07 Rab38 
ENSMUSG00000025375 2.775890341 9.05E 07 Aatk 
ENSMUSG00000056071 7.748328823 9.05E 07 S100a9 
ENSMUSG00000020644 3.063200317 9.41E 07 Id2 
ENSMUSG00000056749 2.375293813 1.12E 06 Nf 3 
ENSMUSG00000078606 1.485922908 1.17E 06 Gm4070 
ENSMUSG00000046916 2.433548116 1.23E 06 Myct1 
ENSMUSG00000042700 1.667431327 1.23E 06 S pa1 1 
ENSMUSG00000036155 1.904065229 1.25E 06 Mgat5 
ENSMUSG00000029530 2.41230358 1.73E 06 Ccr9 
ENSMUSG00000018819 1.819448753 2.59E 06 Lsp1 
ENSMUSG00000043336 1.958384845 2.59E 06 F p1  
ENSMUSG00000019564 2.186565146 2.61E 06 Ar d3a 
ENSMUSG00000072601 7.273712872 2.61E 06 Ear1 
ENSMUSG00000020077 1.817698451 2.68E 06 Srgn 
ENSMUSG00000038648 1.844706942 2.73E 06 Creb3 2 
ENSMUSG00000044220 2.279468529 3.09E 06 Nkx2 3 
ENSMUSG00000001173 1.565088511 3.66E 06 Ocr  
ENSMUSG00000032698 1.598124622 3.81E 06 Lmo2 
ENSMUSG00000027199 2.980045 4.98E 06 Gatm 
ENSMUSG00000031097 2.791267937 5.16E 06 Tnn 2 
ENSMUSG00000051934 3.223498416 5.96E 06 Spats2 
ENSMUSG00000046711 1.997024362 6.34E 06 Hmga1 
ENSMUSG00000019768 2.56656866 6.46E 06 Esr1 
ENSMUSG00000038357 5.245884741 7.02E 06 Camp 
ENSMUSG00000025094 2.079997232 7.02E 06 S c18a2 
ENSMUSG00000025887 4.002566039 7.03E 06 Casp12 
ENSMUSG00000024339 2.021948881 7.99E 06 Tap2 
ENSMUSG00000031822 1.328329844 8.98E 06 Gse1 
   
  199 
ENSMUSG00000027201 1.475151392 9.57E 06 Myef2 
ENSMUSG00000038894 3.026949792 9.64E 06 Irs2 
ENSMUSG00000018008 1.400120057 9.71E 06 Cyth4 
ENSMUSG00000047945 1.72610153 1.07E 05 Marcks 1 
ENSMUSG00000045868 1.872412311 1.24E 05 Gv n1 
ENSMUSG00000004612 2.753099919 1.41E 05 Nkg7 
ENSMUSG00000024533 2.072174348 1.41E 05 Sp re1 
ENSMUSG00000028859 1.471385955 1.53E 05 Csf3r 
ENSMUSG00000005125 1.841358782 1.59E 05 Ndrg1 
ENSMUSG00000023034 5.093595666 1.74E 05 Nr4a1 
ENSMUSG00000017144 2.382775945 1.76E 05 Rnd3 
ENSMUSG00000007872 3.212318054 1.99E 05 Id3 
ENSMUSG00000070576 2.313349444 2.06E 05 Mn1 
ENSMUSG00000023951 2.494488958 2.32E 05 Vegfa 
ENSMUSG00000030657 1.818612803 2.51E 05 Xy t1 
ENSMUSG00000026893 2.939122225 2.56E 05 Gca 
ENSMUSG00000061665 1.35814136 2.86E 05 Cd2ap 
ENSMUSG00000056116 2.115679771 2.96E 05 H2 T22 
ENSMUSG00000033581 2.160631467 3.44E 05 Igf2bp2 
ENSMUSG00000030847 2.449026596 3.88E 05 Bag3 
ENSMUSG00000016239 2.289542238 4.42E 05 Lonrf3 
ENSMUSG00000018474 1.407389794 4.44E 05 Chd3 
ENSMUSG00000034612 1.670983001 4.89E 05 Chst11 
ENSMUSG00000059336 1.939827424 4.96E 05 S c14a1 
ENSMUSG00000042042 1.820551116 4.97E 05 Csga nact2 
ENSMUSG00000044037 2.235068031 5.20E 05 A s2c  
ENSMUSG00000003206 1.872213701 5.38E 05 Eb 3 
ENSMUSG00000051124 1.536865753 5.38E 05 G map9 
ENSMUSG00000069662 1.720710547 5.38E 05 Marcks 
ENSMUSG00000047821 2.296187898 5.38E 05 Tr m16 
ENSMUSG00000038712 1.652169083 6.16E 05 M ndy1 
ENSMUSG00000031266 1.9870316 6.26E 05 G a 
ENSMUSG00000037966 1.792526287 6.36E 05 N nj1 
ENSMUSG00000042289 1.837147271 6.97E 05 Hsd3b7 
ENSMUSG00000049804 1.432957895 7.12E 05 Armcx4 
ENSMUSG00000059994 2.866055184 7.12E 05 Fcr 1 
ENSMUSG00000035356 2.012077491 7.13E 05 Nfkb z 
ENSMUSG00000020227 2.364271066 7.17E 05 Irak3 
ENSMUSG00000069045 3.89504276 7.72E 05 Ddx3y 
ENSMUSG00000028341 3.303781803 7.72E 05 Nr4a3 
ENSMUSG00000042745 2.941862538 8.06E 05 Id1 
ENSMUSG00000040809 3.810750221 8.55E 05 Ch 3 
ENSMUSG00000024610 2.35167414 9.41E 05 Cd74 
ENSMUSG00000063171 2.347573775 9.42E 05 Rps4  
ENSMUSG00000027381 2.209889372 0.00010504 Bc 2 11 
ENSMUSG00000019889 1.797665248 0.00010852 Ptprk 
ENSMUSG00000055053 1.513076017 0.00011104 Nf c 
ENSMUSG00000021215 1.335736882 0.00011618 Net1 
ENSMUSG00000050953 2.017475978 0.00014499 G a1 
ENSMUSG00000021846 1.669962373 0.00015755 Pe 2 
ENSMUSG00000024968 1.718146791 0.00015803 Rcor2 
ENSMUSG00000016024 1.479398732 0.00015989 Lbp 
ENSMUSG00000029093 2.419512751 0.00016478 Sorcs2 
ENSMUSG00000062148 4.771065821 0.00017261 Ear7 
ENSMUSG00000073421 2.362826313 0.00019112 H2 Ab1 
ENSMUSG00000043263 1.877871671 0.00019638 If 209 
ENSMUSG00000027514 2.792858839 0.00019937 Zbp1 
ENSMUSG00000025880 1.744811022 0.00020222 Smad7 
ENSMUSG00000030157 1.357537428 0.00020259 C ec2d 
ENSMUSG00000015312 3.985792296 0.00021487 Gadd45b 
ENSMUSG00000031431 1.499305735 0.00022366 Tsc22d3 
ENSMUSG00000052776 1.720932973 0.0002315 Oas1a 
ENSMUSG00000058624 2.863422725 0.00023592 Gda 
ENSMUSG00000033355 1.793835532 0.00023592 Rtp4 
ENSMUSG00000052914 3.298658863 0.00026463 Cyp2j6 
ENSMUSG00000003452 2.420498229 0.00027838 B cd1 
ENSMUSG00000026580 2.497795436 0.00029317 Se p 
   
  200 
ENSMUSG00000028037 2.582591691 0.00030663 If 44 
ENSMUSG00000032231 2.557025791 0.00031042 Anxa2 
ENSMUSG00000032496 2.904645894 0.00031042 Ltf 
ENSMUSG00000020120 1.831216732 0.00032099 P ek 
ENSMUSG00000047394 3.04279858 0.00032481 Odf3b 
ENSMUSG00000028551 2.55187503 0.00033567 Cdkn2c 
ENSMUSG00000029596 3.897307392 0.00037681 Sds  
ENSMUSG00000067235 2.106766129 0.00038858 H2 Q10 
ENSMUSG00000064023 1.486759906 0.00038858 K k8 
ENSMUSG00000020323 3.473731633 0.00038858 Prss57 
ENSMUSG00000061186 1.879355515 0.00038858 Sfmbt2 
ENSMUSG00000025203 1.458351689 0.00043303 Scd2 
ENSMUSG00000040681 1.887340657 0.00043712 Hmgn1 
ENSMUSG00000029798 1.38570757 0.00044766 Herc6 
ENSMUSG00000015224 2.245695997 0.00048279 Cyp2j9 
ENSMUSG00000036478 1.721740478 0.00049149 Btg1 
ENSMUSG00000036944 2.581288899 0.00052033 Tmem71 
ENSMUSG00000031239 2.535703023 0.00052663 Itm2a 
ENSMUSG00000032484 6.034200756 0.00053158 Ngp 
ENSMUSG00000047844 2.860251497 0.00053774 Bex4 
ENSMUSG00000041773 1.68307215 0.00054711 Enc1 
ENSMUSG00000028464 1.992282504 0.00058104 Tpm2 
ENSMUSG00000026482 1.327618682 0.00060803 Rg 1 
ENSMUSG00000053113 2.011089511 0.00067809 Socs3 
ENSMUSG00000024665 1.546483494 0.00070416 Fads2 
ENSMUSG00000020272 1.290851049 0.00070416 Stk10 
ENSMUSG00000087141 2.165361929 0.00071489 P cxd2 
ENSMUSG00000054404 1.689697874 0.00071612 S fn5 
ENSMUSG00000047959 1.36782188 0.00072342 Kcna3 
ENSMUSG00000055541 2.338926875 0.00073215 La r1 
ENSMUSG00000057596 1.733715738 0.00073872 Tr m30d 
ENSMUSG00000032803 1.486770658 0.00080726 Cdv3 
ENSMUSG00000041431 1.307993713 0.00081422 Ccnb1 
ENSMUSG00000063605 1.618691346 0.00081908 Ccdc102a 
ENSMUSG00000040548 1.149594722 0.00082801 Tex2 
ENSMUSG00000024424 2.571540832 0.00082801 Ttc39c 
ENSMUSG00000037012 1.029953161 0.00086417 Hk1 
ENSMUSG00000039055 1.553720702 0.00087604 Eme1 
ENSMUSG00000054641 1.654255904 0.00090291 Mmrn1 
ENSMUSG00000018362 1.560884989 0.00097839 Kpna2 
ENSMUSG00000069633 1.359775897 0.00098613 Pex11g 
ENSMUSG00000023495 1.798995297 0.00101928 Pcbp4 
ENSMUSG00000039304 1.739185444 0.0010207 Tnfsf10 
ENSMUSG00000005774 1.455721392 0.00102912 Rfx5 
ENSMUSG00000026737 1.405902554 0.0010355 P p4k2a 
ENSMUSG00000032690 2.022594445 0.00105944 Oas2 
ENSMUSG00000038058 2.63534993 0.0010802 Nod1 
ENSMUSG00000004328 2.031861134 0.00111998 H f3a 
ENSMUSG00000072082 1.319472747 0.00112655 Ccnf 
ENSMUSG00000005580 1.65494841 0.00113708 Adcy9 
ENSMUSG00000024867 2.072013751 0.001141 P p5k1b 
ENSMUSG00000002957 1.159950245 0.00120063 Ap2a2 
ENSMUSG00000030921 1.24974147 0.00121505 Tr m30a 
ENSMUSG00000032965 1.208382318 0.00122184 Ift57 
ENSMUSG00000006398 1.261086801 0.00122874 Cdc20 
ENSMUSG00000030671 1.382371318 0.00122874 Pde3b 
ENSMUSG00000020732 1.467874465 0.00123261 Rab37 
ENSMUSG00000030287 1.671301267 0.00123599 Itpr2 
ENSMUSG00000027082 1.471908495 0.00127653 Tfp  
ENSMUSG00000064215 1.696945669 0.00128317 If 27 
ENSMUSG00000025498 1.656013382 0.00129177 Irf7 
ENSMUSG00000040997 1.520972967 0.00132553 Abhd4 
ENSMUSG00000056888 1.277234623 0.00136385 G pr1 
ENSMUSG00000027009 1.079145777 0.00136822 Itga4 
ENSMUSG00000062991 4.399543565 0.00137929 Nrg1 
ENSMUSG00000031799 1.629387822 0.00140776 Tpm4 
ENSMUSG00000029705 1.292721634 0.00145818 Cux1 
   
  201 
ENSMUSG00000064262 1.646798566 0.00146213 G map8 
ENSMUSG00000000168 1.436401665 0.00151917 D at 
ENSMUSG00000032936 2.650856557 0.00154477 Camkv 
ENSMUSG00000074682 1.944235654 0.00155312 Zcchc3 
ENSMUSG00000036611 2.172770333 0.00157212 Eepd1 
ENSMUSG00000028159 1.248612147 0.00157407 Dapp1 
ENSMUSG00000021281 2.631741843 0.00158103 Tnfa p2 
ENSMUSG00000046223 1.805757507 0.00165697 P aur 
ENSMUSG00000037731 1.631539132 0.00165697 Them s2 
ENSMUSG00000004044 2.589659191 0.0016745 Cav n1 
ENSMUSG00000033107 2.084451312 0.0016745 Rnf125 
ENSMUSG00000025980 1.382242215 0.00168091 Hspd1 
ENSMUSG00000022607 1.685938129 0.00172893 Ptk2 
ENSMUSG00000026980 1.926400413 0.00176547 Ly75 
ENSMUSG00000034462 1.538551168 0.00176547 Pkd2 
ENSMUSG00000019699 1.077227189 0.00182159 Akt3 
ENSMUSG00000000290 1.27655598 0.00182159 Itgb2 
ENSMUSG00000071203 1.226582445 0.00188423 Na p5 
ENSMUSG00000034614 1.609031272 0.00193918 P k3 p1 
ENSMUSG00000026458 1.466091602 0.0020789 Ppf a4 
ENSMUSG00000028970 1.166738406 0.00209796 Abcb1b 
ENSMUSG00000008845 2.53305754 0.00222291 Cd163 
ENSMUSG00000060131 1.875027968 0.00222528 Atp8b4 
ENSMUSG00000079523 1.263132263 0.00229854 Tmsb10 
ENSMUSG00000036863 1.592884074 0.00233941 Syde2 
ENSMUSG00000021065 1.137577143 0.00234129 Fut8 
ENSMUSG00000000078 2.041534808 0.00235094 K f6 
ENSMUSG00000028035 1.707668637 0.00239201 Dna b4 
ENSMUSG00000003779 1.331379511 0.00239201 K f20a 
ENSMUSG00000046658 1.510146602 0.00246227 Zfp316 
ENSMUSG00000030867 1.564143959 0.00251245 P k1 
ENSMUSG00000042726 1.252268697 0.00252728 Trafd1 
ENSMUSG00000029925 1.698782393 0.00253568 Tbxas1 
ENSMUSG00000033952 1.06173199 0.00261634 Aspm 
ENSMUSG00000022309 1.476302248 0.00270613 Angpt1 
ENSMUSG00000024353 2.693615156 0.00271592 Mzb1 
ENSMUSG00000075010 3.095214585 0.00284507 AW112010 
ENSMUSG00000043991 1.113204784 0.00287692 Pura 
ENSMUSG00000026034 1.155800489 0.00288522 C k1 
ENSMUSG00000001270 2.063352142 0.00291514 Ckb 
ENSMUSG00000063564 3.336013879 0.00292947 Co 23a1 
ENSMUSG00000030045 1.658194325 0.00299051 Mrp 19 
ENSMUSG00000025195 1.329514541 0.00307466 Dnmbp 
ENSMUSG00000036526 1.6111188 0.00322416 Card11 
ENSMUSG00000039976 1.339793827 0.00330971 Tbc1d16 
ENSMUSG00000035513 1.92324159 0.00331278 Ntng2 
ENSMUSG00000038545 1.080728153 0.00337081 Cu 7 
ENSMUSG00000052534 1.395572391 0.00337081 Pbx1 
ENSMUSG00000038349 3.003205543 0.00339975 P c 1 
ENSMUSG00000042097 1.99345701 0.00349012 Zfp239 
ENSMUSG00000005609 1.086642439 0.00353328 Ctr9 
ENSMUSG00000056515 1.437187812 0.00353328 Rab31 
ENSMUSG00000036553 1.707425976 0.00353328 Sh3tc1 
ENSMUSG00000036402 1.673231659 0.00357528 Gng12 
ENSMUSG00000005057 1.457580041 0.00358563 Sh2b2 
ENSMUSG00000015702 2.061509049 0.00362056 Anxa9 
ENSMUSG00000040152 5.182027138 0.00362056 Thbs1 
ENSMUSG00000025932 1.538655191 0.00363528 Eya1 
ENSMUSG00000026104 1.14663502 0.00363528 Stat1 
ENSMUSG00000074480 1.11774641 0.00378819 Mex3a 
ENSMUSG00000037902 1.050182458 0.0038396 S rpa 
ENSMUSG00000029185 2.130264766 0.00386804 Fam114a1 
ENSMUSG00000070327 0.958498547 0.0038817 Rnf213 
ENSMUSG00000049916 1.472028969 0.00390185 2610318N02R k 
ENSMUSG00000060913 2.48777942 0.00404212 Tr m55 
ENSMUSG00000040907 1.53391124 0.00422983 Atp1a3 
ENSMUSG00000036334 1.749551922 0.00423112 Igsf10 
   
  202 
ENSMUSG00000030142 1.743583244 0.0042502 C ec4e 
ENSMUSG00000063458 2.416891778 0.00433606 Lrmda 
ENSMUSG00000014905 1.65315032 0.00436892 Dnajb9 
ENSMUSG00000001403 1.346657118 0.0044257 Ube2c 
ENSMUSG00000000915 1.170625905 0.00460623 H p1r 
ENSMUSG00000073079 1.802079557 0.00474661 Srp54a 
ENSMUSG00000003746 1.197888916 0.0049024 Man1a 
ENSMUSG00000028268 1.544487065 0.00492866 Gbp3 
ENSMUSG00000022564 1.544733229 0.00493549 Gr na 
ENSMUSG00000030283 1.231239852 0.00497335 St8s a1 
ENSMUSG00000022108 1.086359916 0.00506464 Itm2b 
ENSMUSG00000032577 1.3295776 0.00512772 Mapkapk3 
ENSMUSG00000022091 1.531620402 0.00523053 Sorbs3 
ENSMUSG00000023805 1.486707479 0.00523053 Synj2 
ENSMUSG00000024921 1.070597112 0.00534626 Smarca2 
ENSMUSG00000039286 1.487707013 0.0053991 Fndc3b 
ENSMUSG00000029298 2.320999129 0.0054004 Gbp9 
ENSMUSG00000034674 1.193329741 0.0054004 Tdg 
ENSMUSG00000079547 1.92547091 0.00544708 H2 DMb1 
ENSMUSG00000059921 1.528474639 0.00579907 Unc5c 
ENSMUSG00000044068 1.373285905 0.00579907 Zrsr1 
ENSMUSG00000051727 1.807595726 0.00582491 Kctd14 
ENSMUSG00000033880 1.381493747 0.00582988 Lga s3bp 
ENSMUSG00000027750 2.344942935 0.00582988 Postn 
ENSMUSG00000027219 1.479202488 0.00582988 S c28a2 
ENSMUSG00000017132 1.528127753 0.00590323 Cyth1 
ENSMUSG00000020798 1.120114829 0.00591006 Spns3 
ENSMUSG00000031997 2.661897677 0.00591006 Trpc6 
ENSMUSG00000041488 1.605341088 0.00595096 Stx3 
ENSMUSG00000045328 1.14436025 0.0061536 Cenpe 
ENSMUSG00000026833 2.275499952 0.0061536 O fm1 
ENSMUSG00000024975 1.527811878 0.0061536 Pdcd4 
ENSMUSG00000038375 1.956628213 0.0061536 Trp53 np2 
ENSMUSG00000020661 0.875587893 0.00626945 Dnmt3a 
ENSMUSG00000040128 1.171043295 0.0065542 Pnrc1 
ENSMUSG00000033470 3.638802475 0.00679252 Cys tr2 
ENSMUSG00000059708 1.526481125 0.0069338 Akap17b 
ENSMUSG00000031562 0.980929656 0.00696356 Dctd 
ENSMUSG00000040264 1.463707294 0.00713731 Gbp2b 
ENSMUSG00000040537 2.420962568 0.00715489 Adam22 
ENSMUSG00000090113 3.155299123 0.00727767 Nh rc4 
ENSMUSG00000035329 1.545436048 0.00743546 Fbxo33 
ENSMUSG00000038677 1.711542321 0.00745869 Scube3 
ENSMUSG00000020777 1.201985948 0.00746486 Acox1 
ENSMUSG00000028034 0.918910813 0.00746486 Fubp1 
ENSMUSG00000031613 2.428631463 0.00746486 Hpgd 
ENSMUSG00000062098 1.286256892 0.007479 Btbd3 
ENSMUSG00000022175 1.107121523 0.007479 Lrp10 
ENSMUSG00000051910 2.197065786 0.00757411 Sox6 
ENSMUSG00000028270 1.441280198 0.00764164 Gbp2 
ENSMUSG00000003541 1.800089821 0.00792235 Ier3 
ENSMUSG00000038507 1.607500512 0.00797413 Parp12 
ENSMUSG00000090015 2.925260707 0.00797847 Gm15446 
ENSMUSG00000075602 2.068741423 0.00798587 Ly6a 
ENSMUSG00000032661 1.588669023 0.00798587 Oas3 
ENSMUSG00000026509 1.221500247 0.00803936 Capn2 
ENSMUSG00000001156 1.35261648 0.00828686 Mxd1 
ENSMUSG00000019790 1.215683638 0.00835783 Stxbp5 
ENSMUSG00000024659 1.342438464 0.0083772 Anxa1 
ENSMUSG00000022102 1.293818211 0.00870416 Dok2 
ENSMUSG00000026478 1.304302932 0.00874835 Lamc1 
ENSMUSG00000022883 1.956113467 0.00875164 Robo1 
ENSMUSG00000026360 1.488846797 0.00875905 Rgs2 
ENSMUSG00000059326 1.239555685 0.00884117 Csf2ra 
ENSMUSG00000041912 1.517334402 0.00884117 Tdrkh 
ENSMUSG00000020592 1.438507652 0.00888881 Sdc1 
ENSMUSG00000040549 1.068942953 0.00899791 Ckap5 
   
  203 
ENSMUSG00000020492 1.417525862 0.00930732 Ska2 
ENSMUSG00000060586 2.4555391 0.00950215 H2 Eb1 
ENSMUSG00000024007 1.112019861 0.00950215 Pp 1 
ENSMUSG00000046402 1.513921999 0.00950215 Rbp1 
ENSMUSG00000019856 1.430218325 0.0095076 Fam184a 
ENSMUSG00000041632 1.280321301 0.00953506 Mrps27 
ENSMUSG00000036330 1.814401064 0.00955818 S c18a1 
ENSMUSG00000024462 1.872219433 0.00958243 Gabbr1 
ENSMUSG00000051457 1.119538257 0.00958243 Spn 
ENSMUSG00000038070 1.106510518 0.00963191 Cnt n 
ENSMUSG00000084883 2.484052865 0.00966062 Ccdc85c 
ENSMUSG00000029387 1.19465835 0.00966062 Gtf2h3 
ENSMUSG00000021360 1.39320221 0.00989824 Gcnt2 
ENSMUSG00000022748 1.605988563 0.00996208 Cmss1 
ENSMUSG00000034926 1.322115433 0.00996208 Dhcr24 
ENSMUSG00000041538 1.725969461 0.01022165 H2 Ob 
ENSMUSG00000020189 1.071094072 0.01022165 Osbp 8 
ENSMUSG00000054619 1.239612712 0.01037428 Mett 7a1 
ENSMUSG00000032177 1.202014204 0.01039076 Pde4a 
ENSMUSG00000032733 1.458179754 0.01045154 Snx33 
ENSMUSG00000018427 2.184139353 0.01051476 Ype 2 
ENSMUSG00000035365 1.158525125 0.01070883 Parpbp 
ENSMUSG00000044456 1.182422057 0.01070883 R n3 
ENSMUSG00000036622 0.982206871 0.01075287 Atp13a2 
ENSMUSG00000028525 1.207710226 0.01095425 Pde4b 
ENSMUSG00000005417 0.841316353 0.01099048 Mpr p 
ENSMUSG00000027405 1.034401549 0.01112348 Nop56 
ENSMUSG00000027298 2.29307377 0.01112348 Tyro3 
ENSMUSG00000025876 1.919731511 0.01112348 Unc5a 
ENSMUSG00000048497 1.274804164 0.01125544 Mmgt2 
ENSMUSG00000026605 0.882782563 0.01150905 Cenpf 
ENSMUSG00000029708 1.293028931 0.01163928 Gcc1 
ENSMUSG00000026473 1.327549025 0.01163928 G u  
ENSMUSG00000030677 1.064256081 0.01163928 K f22 
ENSMUSG00000021823 1.020434589 0.01163928 Vc  
ENSMUSG00000028040 2.527177607 0.01165177 Efna4 
ENSMUSG00000034171 1.299862935 0.01165177 Faah 
ENSMUSG00000040945 1.136706007 0.01165177 Rcc2 
ENSMUSG00000063884 1.093258365 0.01186433 Ptcd3 
ENSMUSG00000053007 2.27702297 0.0122337 Creb5 
ENSMUSG00000067206 3.594635401 0.0122337 Lrrc66 
ENSMUSG00000066258 1.138535511 0.0122337 Tr m12a 
ENSMUSG00000030707 1.014769939 0.01246385 Coro1a 
ENSMUSG00000041268 1.213916943 0.01273294 Dmx 2 
ENSMUSG00000026014 1.435389864 0.01273294 Raph1 
ENSMUSG00000026986 2.366784193 0.01274676 Hnmt 
ENSMUSG00000026003 1.138909407 0.01290196 Acad  
ENSMUSG00000031441 1.659272099 0.01292951 Atp11a 
ENSMUSG00000005667 1.465342883 0.01292951 Mthfd2 
ENSMUSG00000005803 1.838299715 0.01292951 Sqor 
ENSMUSG00000001482 0.994008405 0.01311631 Def8 
ENSMUSG00000016552 1.10088401 0.01316463 Foxred2 
ENSMUSG00000020737 1.161287825 0.01316463 Jpt1 
ENSMUSG00000066456 1.541263828 0.0133492 Hmgn3 
ENSMUSG00000040183 1.229739727 0.01339881 Ankrd6 
ENSMUSG00000020454 0.976896303 0.01340277 E f4en f1 
ENSMUSG00000044162 2.550371419 0.01351643 Tn p3 
ENSMUSG00000031984 1.057963089 0.01356482 2810004N23R k 
ENSMUSG00000020647 1.13322137 0.01357768 Ncoa1 
ENSMUSG00000024109 1.51724315 0.01374528 Nrxn1 
ENSMUSG00000036067 2.057915505 0.01399404 S c2a6 
ENSMUSG00000020935 1.12428131 0.0140674 Dcakd 
ENSMUSG00000014980 1.213833902 0.01429499 Tsen15 
ENSMUSG00000038587 1.808367821 0.01457385 Akap12 
ENSMUSG00000021213 2.02983537 0.01461761 Akr1c13 
ENSMUSG00000044258 1.275180645 0.01461761 Ct a2a 
ENSMUSG00000056091 1.347417043 0.01461761 St3ga 5 
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ENSMUSG00000011148 1.492266566 0.01463547 Adss 1 
ENSMUSG00000023927 1.011806248 0.0148257 Satb1 
ENSMUSG00000007659 1.252433103 0.01495668 Bc 2 1 
ENSMUSG00000022265 1.321521527 0.01526976 Ank 
ENSMUSG00000026582 2.871825761 0.01539362 Se e 
ENSMUSG00000022237 2.938153396 0.01551794 Ankrd33b 
ENSMUSG00000036356 1.974731751 0.01551794 Csga nact1 
ENSMUSG00000052040 1.112918361 0.01551794 K f13 
ENSMUSG00000036432 1.519467573 0.01551794 S ah2 
ENSMUSG00000037921 1.562650514 0.01552688 Ddx60 
ENSMUSG00000020921 1.467422852 0.01556506 Tmem101 
ENSMUSG00000027496 1.322492527 0.0155742 Aurka 
ENSMUSG00000069516 1.507005659 0.01570657 Lyz2 
ENSMUSG00000052160 1.844456605 0.01581657 P d4 
ENSMUSG00000028678 0.947333956 0.0162211 K f2c 
ENSMUSG00000042249 1.054014256 0.01626963 Grk3 
ENSMUSG00000033900 1.810021453 0.01626963 Map9 
ENSMUSG00000057113 1.180717897 0.01626963 Npm1 
ENSMUSG00000052212 2.64255297 0.0165181 Cd177 
ENSMUSG00000024664 1.462131224 0.0166298 Fads3 
ENSMUSG00000030612 1.408006028 0.0166298 Mrp 46 
ENSMUSG00000063229 1.278607353 0.01667308 Ldha 
ENSMUSG00000090394 1.473242267 0.01680359 4930523C07R k 
ENSMUSG00000035208 1.055015211 0.01680949 S fn8 
ENSMUSG00000051329 1.313725948 0.01681259 Nup160 
ENSMUSG00000056666 1.396246762 0.01681259 Retsat 
ENSMUSG00000018654 0.967714378 0.01698564 Ikzf1 
ENSMUSG00000012519 1.191187403 0.01712543 M k  
ENSMUSG00000038510 1.340849845 0.01712543 Rpf2 
ENSMUSG00000076441 1.264290371 0.01727991 Ass1 
ENSMUSG00000014226 1.291021298 0.01734601 Cacybp 
ENSMUSG00000026826 2.127380299 0.01742873 Nr4a2 
ENSMUSG00000028173 1.247397118 0.01742873 W s 
ENSMUSG00000055782 1.865726661 0.01764328 Abcd2 
ENSMUSG00000021318 2.106084699 0.01778896 G 3 
ENSMUSG00000022899 2.029223777 0.01778896 S c15a2 
ENSMUSG00000058755 2.25466646 0.01800401 Osm 
ENSMUSG00000059900 1.654510704 0.01801158 Tmem40 
ENSMUSG00000053080 1.475763823 0.01813196 2700081O15R k 
ENSMUSG00000034903 1.161680468 0.01813196 Cob 1 
ENSMUSG00000026923 1.264333493 0.01813196 Notch1 
ENSMUSG00000017639 1.335867135 0.01821369 Rab11f p4 
ENSMUSG00000051223 1.075400631 0.01824251 Bzw1 
ENSMUSG00000022575 0.964972726 0.01827143 Gsdmd 
ENSMUSG00000076437 1.393146387 0.01827143 Se enoh 
ENSMUSG00000029014 1.154978873 0.01837463 Dnajc2 
ENSMUSG00000020307 1.385822906 0.01844855 Cdc34 
ENSMUSG00000003031 1.219817689 0.01877851 Cdkn1b 
ENSMUSG00000023456 1.118546651 0.01877851 Tp 1 
ENSMUSG00000023032 1.83356162 0.01896685 S c4a8 
ENSMUSG00000032549 2.145034035 0.01927961 Rab6b 
ENSMUSG00000041707 2.108715779 0.01930413 1810011H11R k 
ENSMUSG00000029859 1.820663277 0.01941162 Epha1 
ENSMUSG00000038612 1.133923219 0.01941162 Mc 1 
ENSMUSG00000025986 1.049282319 0.01941162 S c39a10 
ENSMUSG00000042524 0.940098221 0.01941162 Sun2 
ENSMUSG00000024359 1.036117551 0.01948531 Hspa9 
ENSMUSG00000032254 0.886126151 0.01948531 K f23 
ENSMUSG00000067212 1.046833577 0.0195938 H2 T23 
ENSMUSG00000040274 1.008690896 0.02017328 Cdk6 
ENSMUSG00000079057 1.68508627 0.02017328 Cyp4v3 
ENSMUSG00000026127 1.308835031 0.02017328 Imp4 
ENSMUSG00000027227 1.00536357 0.02045816 Sord 
ENSMUSG00000042351 1.509269979 0.02118792 Grap2 
ENSMUSG00000037111 0.844233021 0.02129605 Setd7 
ENSMUSG00000056054 5.400902529 0.02137179 S100a8 
ENSMUSG00000030930 0.872067885 0.02176343 Chst15 
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ENSMUSG00000026672 1.668171075 0.02176343 Optn 
ENSMUSG00000060860 1.166329665 0.02176343 Ube2s 
ENSMUSG00000002984 1.036540404 0.02240772 Tomm40 
ENSMUSG00000056018 1.031329556 0.02257923 Ccdc7b 
ENSMUSG00000031129 1.196750127 0.02268272 S c9a9 
ENSMUSG00000030400 0.897455043 0.02269993 Ercc2 
ENSMUSG00000026121 1.531866313 0.02271419 Sema4c 
ENSMUSG00000038331 1.593128462 0.02323979 Satb2 
ENSMUSG00000009378 3.041443691 0.02327297 S c16a12 
ENSMUSG00000042675 1.2006022 0.02327297 Ype 3 
ENSMUSG00000023259 1.795023045 0.02329699 S c26a6 
ENSMUSG00000051343 1.624334132 0.02360375 Rab11f p5 
ENSMUSG00000034330 0.887350068 0.02360831 P cg2 
ENSMUSG00000001435 1.391333925 0.02400427 Co 18a1 
ENSMUSG00000004263 1.187289364 0.02420181 Atn1 
ENSMUSG00000031502 1.349269083 0.0242738 Co 4a1 
ENSMUSG00000062209 2.989215667 0.0242738 Erbb4 
ENSMUSG00000052749 1.487435628 0.0242738 Tr m30b 
ENSMUSG00000034427 1.433854501 0.02446798 Myo15b 
ENSMUSG00000024208 1.086140722 0.0244719 Uqcc2 
ENSMUSG00000028803 1.015640493 0.02510263 N pa 3 
ENSMUSG00000060477 1.538044551 0.02522905 Irak2 
ENSMUSG00000008450 1.23280065 0.02522905 Nutf2 
ENSMUSG00000041390 1.860917002 0.02523114 Mdf c 
ENSMUSG00000059248 0.923569507 0.02554656 Sept9 
ENSMUSG00000025920 1.408737515 0.02554656 Stau2 
ENSMUSG00000026832 1.258864728 0.02581408 Cyt p 
ENSMUSG00000024308 1.048267299 0.02592775 Tapbp 
ENSMUSG00000003134 1.139028218 0.02597101 Tbc1d8 
ENSMUSG00000042082 1.129974817 0.02608116 Arsb 
ENSMUSG00000060962 2.896188416 0.02618869 Dmkn 
ENSMUSG00000037822 1.20858869 0.02622511 Sm m14 
ENSMUSG00000068184 1.293588843 0.0266613 Ndufaf2 
ENSMUSG00000030413 3.206970455 0.0266613 Pg yrp1 
ENSMUSG00000048285 1.191684057 0.02667108 Frmd6 
ENSMUSG00000020894 1.115550621 0.02684065 Vamp2 
ENSMUSG00000040938 1.672971566 0.02703375 S c16a11 
ENSMUSG00000060227 1.091732884 0.02713017 Casc4 
ENSMUSG00000004609 1.309246725 0.02713017 Cd33 
ENSMUSG00000026646 1.51897804 0.02713017 Suv39h2 
ENSMUSG00000036533 1.330063573 0.02730923 Cdc42ep3 
ENSMUSG00000068587 2.278256337 0.02730923 Mgam 
ENSMUSG00000055717 1.337008383 0.02744897 S a n1 
ENSMUSG00000016206 2.12836278 0.02748361 H2 M3 
ENSMUSG00000020361 1.054593837 0.02748361 Hspa4 
ENSMUSG00000011257 1.017751438 0.02748361 Pabpc4 
ENSMUSG00000029623 1.197728841 0.02748361 Pdap1 
ENSMUSG00000022391 1.036340948 0.02748361 Rangap1 
ENSMUSG00000042677 1.594825247 0.02748361 Zc3h12a 
ENSMUSG00000018666 0.967486864 0.02769886 Cbx1 
ENSMUSG00000067586 1.8028337 0.02769886 S1pr3 
ENSMUSG00000019850 1.901691271 0.02827087 Tnfa p3 
ENSMUSG00000032849 1.251481485 0.02827934 Abcc4 
ENSMUSG00000036504 1.187547006 0.02835075 Phpt1 
ENSMUSG00000032624 0.994746349 0.02867123 Em 4 
ENSMUSG00000009863 1.10778962 0.02887984 Sdhb 
ENSMUSG00000038059 1.406193849 0.02887984 Sm m3 
ENSMUSG00000035203 0.96564928 0.02927828 Epn1 
ENSMUSG00000090019 1.084038187 0.02932674 G map1 
ENSMUSG00000049047 1.031378088 0.02950346 Armcx3 
ENSMUSG00000028292 1.260205311 0.02950346 Rars2 
ENSMUSG00000020638 1.520775922 0.02966763 Cmpk2 
ENSMUSG00000025665 2.129483969 0.02966763 Rps6ka6 
ENSMUSG00000031827 1.034276887 0.02998579 Cot 1 
ENSMUSG00000006390 1.103810968 0.02998579 E ov 1 
ENSMUSG00000004698 1.362110109 0.02998579 Hdac9 
ENSMUSG00000001240 1.909749503 0.02998579 Ramp2 
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ENSMUSG00000035960 1.216175915 0.03001012 Apex1 
ENSMUSG00000057329 0.817710221 0.03006094 Bc 2 
ENSMUSG00000063953 1.510985221 0.03032116 Amd2 
ENSMUSG00000034957 1.468708565 0.03046894 Cebpa 
ENSMUSG00000002265 1.52765487 0.03093598 Peg3 
ENSMUSG00000013629 0.974580506 0.03132463 Cad 
ENSMUSG00000025869 1.269546713 0.03140311 Nop16 
ENSMUSG00000014932 2.164084537 0.03169311 Yes1 
ENSMUSG00000072663 1.86674038 0.03188727 Spef2 
ENSMUSG00000039167 0.877084697 0.03216441 Adgr 4 
ENSMUSG00000029822 1.088978223 0.03222658 Osbp 3 
ENSMUSG00000031821 1.187846685 0.03227299 G ns2 
ENSMUSG00000020330 0.75347698 0.03243509 Hmmr 
ENSMUSG00000042331 0.877861209 0.03247862 Specc1 
ENSMUSG00000031337 1.185638312 0.03253296 Mtm1 
ENSMUSG00000024588 1.09210122 0.03271192 Fech 
ENSMUSG00000019194 3.03831198 0.03271192 Scn1b 
ENSMUSG00000071653 1.221571502 0.03311998 1810009A15R k 
ENSMUSG00000022508 1.607071545 0.03311998 Bc 6 
ENSMUSG00000009575 1.032823074 0.03311998 Cbx5 
ENSMUSG00000003545 4.179192216 0.03311998 Fosb 
ENSMUSG00000029777 1.057247513 0.03311998 Gars 
ENSMUSG00000006014 2.531320305 0.03311998 Prg4 
ENSMUSG00000035000 1.569532593 0.03323275 Dpp4 
ENSMUSG00000009013 1.226049376 0.03323275 Dyn 1 
ENSMUSG00000053398 1.0273859 0.03323275 Phgdh 
ENSMUSG00000071076 1.40984111 0.03325422 Jund 
ENSMUSG00000034055 1.873380348 0.03325422 Phka1 
ENSMUSG00000052751 0.944226244 0.03325422 Rep n1 
ENSMUSG00000025962 1.374882856 0.03363945 Fastkd2 
ENSMUSG00000074896 2.674327264 0.03363945 If t3 
ENSMUSG00000039410 1.335093609 0.03363945 Prdm16 
ENSMUSG00000052926 0.959073221 0.03381724 Rnaseh2a 
ENSMUSG00000039081 2.174630267 0.03384209 Zfp503 
ENSMUSG00000079363 2.15489895 0.03386271 Gbp4 
ENSMUSG00000025776 3.732056727 0.03406521 Cr sp d1 
ENSMUSG00000056612 1.131789915 0.03432166 Ppp1r14b 
ENSMUSG00000031954 0.920295485 0.03458616 Cfdp1 
ENSMUSG00000094626 2.015147798 0.03458616 Tmem121b 
ENSMUSG00000031870 4.384534897 0.03476133 Pgr 
ENSMUSG00000068742 0.977477666 0.03479395 Cry2 
ENSMUSG00000057193 0.865983926 0.03479395 S c44a2 
ENSMUSG00000052539 0.960851381 0.03493629 Mag 3 
ENSMUSG00000061086 1.536228939 0.03502296 My 4 
ENSMUSG00000006931 3.016245758 0.03502296 P3h4 
ENSMUSG00000021217 1.897685769 0.03502296 Tshz3 
ENSMUSG00000033585 2.84256567 0.0351192 Ndn 
ENSMUSG00000034664 1.847824942 0.03518945 Itga2b 
ENSMUSG00000009418 1.283942431 0.03528285 Nav1 
ENSMUSG00000033257 0.868277471 0.03533169 Tt 4 
ENSMUSG00000028849 1.086289105 0.03550935 Map7d1 
ENSMUSG00000034438 2.047483228 0.03573667 Gbp8 
ENSMUSG00000072596 2.446097822 0.03600904 Ear2 
ENSMUSG00000000204 2.466961302 0.03623511 S fn4 
ENSMUSG00000079017 1.939328187 0.03646321 If 27 2a 
ENSMUSG00000025888 1.573258547 0.03653549 Casp1 
ENSMUSG00000013089 1.481387853 0.03653549 Etv5 
ENSMUSG00000040010 1.165256461 0.03653549 S c7a5 
ENSMUSG00000046572 1.208077042 0.03653549 Zfp518b 
ENSMUSG00000023089 1.198194305 0.03660884 Ndufa5 
ENSMUSG00000018381 1.289084641 0.03666364 Ab 3 
ENSMUSG00000003812 0.999082217 0.03684301 Dnase2a 
ENSMUSG00000021009 1.188697685 0.03695233 Ptpn21 
ENSMUSG00000056592 1.553482547 0.03695233 Zfp658 
ENSMUSG00000016757 1.031606226 0.03723725 Tt 12 
ENSMUSG00000028651 1.10552606 0.03758815 Pp e 
ENSMUSG00000040463 1.00585743 0.03765097 Mybbp1a 
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ENSMUSG00000005583 0.971246795 0.0377308 Mef2c 
ENSMUSG00000032216 0.757059093 0.0377308 Nedd4 
ENSMUSG00000024480 1.747579447 0.0379734 Ap3s1 
ENSMUSG00000028664 1.121870583 0.03830312 Ephb2 
ENSMUSG00000027589 1.107335663 0.03830312 Pcmtd2 
ENSMUSG00000048764 3.461885316 0.03830312 Tmprss11f 
ENSMUSG00000011263 1.655138609 0.03859247 Exoc3 2 
ENSMUSG00000021069 1.321024975 0.03859247 Pyg  
ENSMUSG00000021256 1.491492195 0.03859247 Vash1 
ENSMUSG00000029570 1.138213567 0.03908024 Lfng 
ENSMUSG00000090100 1.488371877 0.03976087 Ttbk2 
ENSMUSG00000009687 0.857965319 0.03982134 Fxyd5 
ENSMUSG00000007617 1.106704863 0.03982134 Homer1 
ENSMUSG00000060601 0.921859985 0.03982134 Nr1h2 
ENSMUSG00000048546 1.01002164 0.03982134 Tob2 
ENSMUSG00000027469 1.173116165 0.03982134 Tpx2 
ENSMUSG00000040592 1.281237309 0.03984786 Cd79b 
ENSMUSG00000035711 2.044344875 0.04001088 Dok3 
ENSMUSG00000063904 0.989754065 0.04001088 Dpp3 
ENSMUSG00000027364 1.580295362 0.04001088 Usp50 
ENSMUSG00000033287 1.492444352 0.04007924 Kctd17 
ENSMUSG00000028459 1.431511411 0.04010577 Cd72 
ENSMUSG00000030830 0.84203817 0.04019769 Itga  
ENSMUSG00000028455 1.096594653 0.04020303 Stom 2 
ENSMUSG00000030319 0.931515148 0.04025189 Cand2 
ENSMUSG00000015966 2.397286752 0.04025189 I 17rb 
ENSMUSG00000021356 1.964610618 0.04025189 Irf4 
ENSMUSG00000036768 0.886634595 0.04048463 K f15 
ENSMUSG00000022436 0.894146409 0.04048463 Sh3bp1 
ENSMUSG00000020167 0.74349892 0.04048463 Tcf3 
ENSMUSG00000022015 2.169054846 0.04048463 Tnfsf11 
ENSMUSG00000036902 1.229559736 0.04066079 Neto2 
ENSMUSG00000032556 1.64859875 0.04085837 Bfsp2 
ENSMUSG00000020261 1.210947169 0.04085837 S c36a1 
ENSMUSG00000043279 0.818133485 0.04085837 Tr m56 
ENSMUSG00000040084 1.038957697 0.04095059 Bub1b 
ENSMUSG00000064037 0.908667376 0.0409813 Gpn1 
ENSMUSG00000006378 1.489217605 0.04158195 Gcat 
ENSMUSG00000038943 0.749630835 0.04158195 Prc1 
ENSMUSG00000024235 1.604370441 0.04167402 Map3k8 
ENSMUSG00000037795 0.828149086 0.04167402 N4bp2 
ENSMUSG00000037490 3.12655474 0.04181952 S c2a12 
ENSMUSG00000004661 1.119788497 0.04216028 Ar d3b 
ENSMUSG00000028518 2.909333601 0.0423783 Prkaa2 
ENSMUSG00000041115 1.280450108 0.04261412 Iqsec2 
ENSMUSG00000029594 1.028847797 0.04262387 Rbm19 
ENSMUSG00000026979 0.918055964 0.04271092 Psd4 
ENSMUSG00000000184 0.959235352 0.04294505 Ccnd2 
ENSMUSG00000061479 1.031511249 0.04298061 Snrpa 
ENSMUSG00000024590 0.88598343 0.04300089 Lmnb1 
ENSMUSG00000024217 1.004165892 0.04309871 Snrpc 
ENSMUSG00000049191 1.480912268 0.04322465 Rt 5 
ENSMUSG00000027843 1.002328205 0.04346908 Ptpn22 
ENSMUSG00000063787 1.313015856 0.04354111 Chchd1 
ENSMUSG00000006392 1.098663326 0.04356063 Med8 
ENSMUSG00000070871 1.334048312 0.0447849 Ccny 1 
ENSMUSG00000034413 1.421221557 0.04492309 Neur 1b 
ENSMUSG00000000552 1.139020342 0.04511928 Zfp385a 
ENSMUSG00000038085 0.857850007 0.04531323 Cnbd2 
ENSMUSG00000079173 1.476471067 0.0453782 Zan 
ENSMUSG00000024887 1.062188916 0.04586163 Asah2 
ENSMUSG00000062007 1.656342796 0.04586163 Hsh2d 
ENSMUSG00000017713 1.665629288 0.04586163 Tha1 
ENSMUSG00000023832 1.311128544 0.04590485 Acat2 
ENSMUSG00000037432 1.164373824 0.0459699 Fer1 5 
ENSMUSG00000027712 1.080427125 0.04603132 Anxa5 
ENSMUSG00000029790 1.455535861 0.04603132 Cep41 
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ENSMUSG00000031633 1.132611599 0.04618589 S c25a4 
ENSMUSG00000040061 0.9188053 0.04629189 P cb2 
ENSMUSG00000050914 2.483438947 0.04645238 Ankrd37 
ENSMUSG00000024063 1.150705654 0.04645238 Lbh 
ENSMUSG00000060427 1.255446493 0.04645238 Zfp868 
ENSMUSG00000020290 1.031812055 0.04656379 Xpo1 
ENSMUSG00000039217 2.172467654 0.04658134 I 18 
ENSMUSG00000028124 1.175877543 0.0466752 Gc m 
ENSMUSG00000023960 2.260639734 0.04706203 Enpp5 
ENSMUSG00000030031 1.558519378 0.04711052 Kbtbd8 
ENSMUSG00000028693 0.999665315 0.04733094 Nasp 
ENSMUSG00000089669 2.915653023 0.04747579 Tnfsf13 
ENSMUSG00000037940 1.451809538 0.04782985 Inpp4b 
ENSMUSG00000047592 1.692740753 0.04789106 Nxpe5 
ENSMUSG00000019139 1.034246269 0.04823667 Isyna1 
ENSMUSG00000020160 0.969009473 0.04830186 Me s1 
ENSMUSG00000022270 0.975199613 0.04830241 Retreg1 
ENSMUSG00000067071 1.102346786 0.0485858 Hes6 
ENSMUSG00000028882 0.922408637 0.04860666 Ppp1r8 
ENSMUSG00000036106 0.995056666 0.04886507 Prr5 
ENSMUSG00000038535 1.177216906 0.04895286 Zfp280d 
ENSMUSG00000046598 1.256594041 0.04940525 Bdh1 
ENSMUSG00000040236 0.853920286 0.04940525 Trappc5 
ENSMUSG00000039693 1.563411116 0.04981489 Msantd3 
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10.2 Appendix 2 
List of genes differentially expressed between murine foetal liver Mll-AF4 
expressing and control LMPPs (positive log fold represents genes upregulated 
in control LMPPs), described in chapter 3.  
Ensemb  ID og2 Fo d Change padj Gene Name 
ENSMUSG00000026185 3.738711553 3.39E 05 Igfbp5 
ENSMUSG00000028842 2.454889876 8.27E 05 Ago3 
ENSMUSG00000029108 1.778396401 0.00053864 Pcdh7 
ENSMUSG00000054074 2.929767218 0.00075377 Sk da1 
ENSMUSG00000040434 4.718079818 0.00099866 Large2 
ENSMUSG00000029640 1.610432546 0.00099866 Usp12 
ENSMUSG00000042129 1.746862471 0.00099866 Rassf4 
ENSMUSG00000026826 4.287646289 0.00099866 Nr4a2 
ENSMUSG00000026009 4.830723256 0.00175573 Icos 
ENSMUSG00000044768 2.056149289 0.00177908 D1Ertd622e 
ENSMUSG00000071516 1.404147396 0.00203439 H st1h2a  
ENSMUSG00000020303 4.641900197 0.0023237 Stc2 
ENSMUSG00000044645 8.647851666 0.00396915 Gm7334 
ENSMUSG00000026921 1.293103057 0.00415524 Egf 7 
ENSMUSG00000049539 1.317109491 0.00432333 H st1h1a 
ENSMUSG00000026792 2.414244101 0.00525646 Lrsam1 
ENSMUSG00000068855 1.444836166 0.00525646 H st2h2ac 
ENSMUSG00000078249 8.249162763 0.005775 Hmga1b 
ENSMUSG00000021911 1.28203562 0.00638099 Parg 
ENSMUSG00000004837 2.763341622 0.00845366 Grap 
ENSMUSG00000017950 1.885020047 0.00845366 Hnf4a 
ENSMUSG00000024501 7.541278071 0.01134386 Dpys 3 
ENSMUSG00000028339 5.733546995 0.01333867 Co 15a1 
ENSMUSG00000008682 1.115329378 0.01333867 Rp 10 
ENSMUSG00000049624 2.567986944 0.01614021 S c17a5 
ENSMUSG00000043986 7.346866141 0.01710793 Spata31d1d 
ENSMUSG00000020053 2.347073059 0.0204358 Igf1 
ENSMUSG00000042770 3.338144188 0.02118367 Hebp1 
ENSMUSG00000036040 4.430949292 0.02168957 Adamts 2 
ENSMUSG00000079157 4.66347091 0.02481842 Fam155a 
ENSMUSG00000032702 7.382998029 0.02702348 Kank1 
ENSMUSG00000027750 2.104274853 0.02702348 Postn 
ENSMUSG00000022623 1.375368005 0.02702348 Shank3 
ENSMUSG00000005611 1.652032709 0.02905611 Mrv 1 
ENSMUSG00000045636 2.283523963 0.02905611 Mtus1 
ENSMUSG00000027447 1.244535804 0.03214762 Cst3 
ENSMUSG00000023341 3.029450771 0.03817316 Mx2 
ENSMUSG00000068263 1.89122449 0.03817316 Efcc1 
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10.3 Appendix 3  
List of genes differentially expressed between human foetal liver and cord 
blood derived HSC/MPPs (positive log fold represents genes upregulated in 
the foetal liver derived HSC/MPPs), described in chapter 4.  
Ensemb  ID og2 Fo d Change padj Gene Name 
ENSG00000148773 3.678028191 1.74E 34 MKI67 
ENSG00000171848 4.311828438 9.16E 30 RRM2 
ENSG00000112414 3.790156785 1.00E 25 ADGRG6 
ENSG00000175164 4.033047393 2.43E 24 ABO 
ENSG00000153707 3.107578312 1.78E 23 PTPRD 
ENSG00000010327 3.248204484 6.17E 22 STAB1 
ENSG00000066279 3.284183021 3.09E 21 ASPM 
ENSG00000171316 3.03584906 6.80E 19 CHD7 
ENSG00000173080 4.780011177 8.44E 17 RXFP4 
ENSG00000145386 4.314420415 2.64E 16 CCNA2 
ENSG00000156970 3.001664859 4.16E 16 BUB1B 
ENSG00000168453 5.007578435 7.24E 16 HR 
ENSG00000114805 3.40910624 2.30E 15 PLCH1 
ENSG00000111206 2.66323754 2.33E 15 FOXM1 
ENSG00000205777 4.39169507 7.05E 15 GAGE1 
ENSG00000137812 2.824350342 1.22E 14 KNL1 
ENSG00000117724 2.439880328 1.24E 14 CENPF 
ENSG00000121966 5.109975459 3.28E 14 CXCR4 
ENSG00000134690 3.215432043 3.81E 14 CDCA8 
ENSG00000187772 3.672812154 3.81E 14 LIN28B 
ENSG00000138315 5.507958886 1.53E 13 OIT3 
ENSG00000120694 2.795970354 2.33E 13 HSPH1 
ENSG00000212866 3.820837936 3.15E 13 HSPA1B 
ENSG00000134057 3.592345623 3.36E 13 CCNB1 
ENSG00000144655 3.577252444 4.62E 13 CSRNP1 
ENSG00000154479 3.230283937 7.36E 13 CCDC173 
ENSG00000198826 2.695242437 1.16E 12 ARHGAP11A 
ENSG00000131747 4.236273811 1.33E 12 TOP2A 
ENSG00000180354 2.275924052 1.38E 12 MTURN 
ENSG00000117983 3.709117685 1.62E 12 MUC5B 
ENSG00000169679 2.709893887 3.14E 12 BUB1 
ENSG00000260314 4.67428378 3.14E 12 MRC1 
ENSG00000171522 3.829893469 3.14E 12 PTGER4 
ENSG00000115541 2.591148192 3.49E 12 HSPE1 
ENSG00000137804 2.197596996 6.94E 12 NUSAP1 
ENSG00000131016 4.50566973 9.97E 12 AKAP12 
ENSG00000277059 3.504811127 1.47E 11 FAM30A 
ENSG00000080824 2.176348567 2.02E 11 HSP90AA1 
ENSG00000164045 3.061976513 2.08E 11 CDC25A 
ENSG00000204197 2.760025652 4.56E 11 KIFC1 
ENSG00000092853 2.618356649 4.93E 11 CLSPN 
ENSG00000109805 2.875769913 4.93E 11 NCAPG 
ENSG00000170312 3.032725202 5.50E 11 CDK1 
ENSG00000186185 2.437599602 9.77E 11 KIF18B 
ENSG00000124610 4.733351533 1.13E 10 HIST1H1A 
ENSG00000169607 2.950568764 1.23E 10 CKAP2L 
ENSG00000162645 3.767641418 1.24E 10 GBP2 
ENSG00000037280 3.02117776 1.71E 10 FLT4 
ENSG00000126787 3.453630116 1.81E 10 DLGAP5 
ENSG00000088325 2.397139965 2.51E 10 TPX2 
ENSG00000122952 3.215215433 2.92E 10 ZWINT 
ENSG00000142731 2.493708873 4.03E 10 PLK4 
ENSG00000116962 3.985069982 5.37E 10 NID1 
ENSG00000159217 2.191312834 1.59E 09 IGF2BP1 
ENSG00000188305 4.317215152 1.90E 09 PEAK3 
ENSG00000066056 1.770635797 2.20E 09 TIE1 
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ENSG00000163687 4.149292392 2.32E 09 DNASE1L3 
ENSG00000138160 2.260134921 2.63E 09 KIF11 
ENSG00000100100 2.778957864 2.78E 09 PIK3IP1 
ENSG00000115194 2.828211607 2.88E 09 SLC30A3 
ENSG00000132313 2.619268264 3.72E 09 MRPL35 
ENSG00000122966 1.768491682 4.81E 09 CIT 
ENSG00000144381 1.666396606 5.11E 09 HSPD1 
ENSG00000133800 4.194376982 6.09E 09 LYVE1 
ENSG00000157456 2.720254709 6.12E 09 CCNB2 
ENSG00000213085 4.322328223 6.25E 09 CFAP45 
ENSG00000101057 2.833733994 7.53E 09 MYBL2 
ENSG00000121211 3.771077326 9.39E 09 MND1 
ENSG00000136011 6.411810943 9.39E 09 STAB2 
ENSG00000126583 4.21121871 1.06E 08 PRKCG 
ENSG00000159674 3.021304691 1.20E 08 SPON2 
ENSG00000139318 2.501196493 1.25E 08 DUSP6 
ENSG00000177084 1.722874804 1.25E 08 POLE 
ENSG00000173276 2.470638086 1.25E 08 ZBTB21 
ENSG00000186777 4.510613658 1.31E 08 ZNF732 
ENSG00000111602 2.208751665 1.81E 08 TIMELESS 
ENSG00000166851 2.637904852 1.91E 08 PLK1 
ENSG00000164087 3.890120907 2.19E 08 POC1A 
ENSG00000079819 1.882262294 2.23E 08 EPB41L2 
ENSG00000196565 4.142130553 2.81E 08 HBG2 
ENSG00000244242 3.444307647 2.81E 08 IFITM10 
ENSG00000213799 2.718843121 2.81E 08 ZNF845 
ENSG00000175514 3.691465979 2.82E 08 GPR152 
ENSG00000179094 2.954637638 3.41E 08 PER1 
ENSG00000104738 2.462050529 3.43E 08 MCM4 
ENSG00000164104 2.245148964 3.61E 08 HMGB2 
ENSG00000180044 5.768476395 3.81E 08 C3orf80 
ENSG00000118193 2.046801648 3.89E 08 KIF14 
ENSG00000188389 6.01885514 4.12E 08 PDCD1 
ENSG00000163808 3.063521641 4.60E 08 KIF15 
ENSG00000011426 2.927133328 5.31E 08 ANLN 
ENSG00000155090 2.912969385 5.37E 08 KLF10 
ENSG00000119408 2.052363233 6.82E 08 NEK6 
ENSG00000179399 6.198741435 9.39E 08 GPC5 
ENSG00000112312 2.615080444 1.02E 07 GMNN 
ENSG00000101200 4.190595714 1.11E 07 AVP 
ENSG00000130787 2.48086093 1.29E 07 HIP1R 
ENSG00000228716 2.559623836 1.56E 07 DHFR 
ENSG00000126259 5.278848763 1.83E 07 KIRREL2 
ENSG00000140534 2.202033106 1.83E 07 TICRR 
ENSG00000163874 4.111434916 1.93E 07 ZC3H12A 
ENSG00000276043 2.663658876 2.19E 07 UHRF1 
ENSG00000184661 2.747448349 2.27E 07 CDCA2 
ENSG00000004139 2.095171115 2.27E 07 SARM1 
ENSG00000185022 2.85141979 2.62E 07 MAFF 
ENSG00000100968 2.619095494 2.80E 07 NFATC4 
ENSG00000176890 2.163518393 3.19E 07 TYMS 
ENSG00000013573 1.631455223 3.30E 07 DDX11 
ENSG00000112984 3.170611109 4.04E 07 KIF20A 
ENSG00000160339 6.040827751 4.19E 07 FCN2 
ENSG00000175063 2.495566021 4.31E 07 UBE2C 
ENSG00000206560 1.668917604 4.53E 07 ANKRD28 
ENSG00000165682 3.829901803 4.92E 07 CLEC1B 
ENSG00000136982 2.728153057 5.60E 07 DSCC1 
ENSG00000173218 2.120180651 5.74E 07 VANGL1 
ENSG00000105711 3.858145578 6.20E 07 SCN1B 
ENSG00000107968 2.290786425 6.23E 07 MAP3K8 
ENSG00000086827 2.297253251 7.52E 07 ZW10 
ENSG00000119969 1.975153105 7.53E 07 HELLS 
ENSG00000108669 1.823083917 7.75E 07 CYTH1 
ENSG00000139364 3.306860202 7.75E 07 TMEM132B 
ENSG00000127564 2.621064416 7.85E 07 PKMYT1 
ENSG00000146278 1.574981566 7.86E 07 PNRC1 
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ENSG00000093217 2.018971742 7.88E 07 XYLB 
ENSG00000152760 1.939184398 9.95E 07 TCTEX1D1 
ENSG00000119138 4.57386661 1.00E 06 KLF9 
ENSG00000100767 2.03815236 1.06E 06 PAPLN 
ENSG00000093009 2.734699435 1.17E 06 CDC45 
ENSG00000113368 2.821541111 1.18E 06 LMNB1 
ENSG00000105383 2.533462049 1.25E 06 CD33 
ENSG00000138778 2.638944578 1.40E 06 CENPE 
ENSG00000014138 2.066412036 1.51E 06 POLA2 
ENSG00000140525 1.73173758 1.58E 06 FANCI 
ENSG00000103187 1.730949493 1.68E 06 COTL1 
ENSG00000185559 2.94248447 1.68E 06 DLK1 
ENSG00000121152 2.088734773 1.68E 06 NCAPH 
ENSG00000143369 3.592890419 1.74E 06 ECM1 
ENSG00000156427 4.772482475 1.83E 06 FGF18 
ENSG00000277236 8.258214562 1.86E 06 CCL14 
ENSG00000130518 3.485805792 2.36E 06 IQCN 
ENSG00000059915 3.216530248 2.48E 06 PSD 
ENSG00000161103 2.300908602 2.57E 06 LOC102725072 
ENSG00000072571 2.299525922 2.81E 06 HMMR 
ENSG00000132646 2.729766002 3.19E 06 PCNA 
ENSG00000129173 2.288253434 3.33E 06 E2F8 
ENSG00000161270 4.202159113 3.70E 06 NPHS1 
ENSG00000119508 3.348680834 3.88E 06 NR4A3 
ENSG00000138829 2.478685509 3.89E 06 FBN2 
ENSG00000139722 1.983818943 4.15E 06 VPS37B 
ENSG00000138080 2.082114019 4.35E 06 EMILIN1 
ENSG00000146670 2.067184803 4.57E 06 CDCA5 
ENSG00000188549 2.383260509 4.77E 06 CCDC9B 
ENSG00000105486 1.508038317 4.85E 06 LIG1 
ENSG00000132002 2.571714695 4.99E 06 DNAJB1 
ENSG00000213672 2.366009657 4.99E 06 NCKIPSD 
ENSG00000121753 3.521627688 5.02E 06 ADGRB2 
ENSG00000220008 2.740457986 5.02E 06 LINGO3 
ENSG00000182759 3.912320295 5.48E 06 MAFA 
ENSG00000116161 1.813984258 5.78E 06 CACYBP 
ENSG00000112182 1.790255643 5.90E 06 BACH2 
ENSG00000076003 2.074445456 5.99E 06 MCM6 
ENSG00000118898 3.212720421 6.53E 06 PPL 
ENSG00000104369 2.188378567 6.75E 06 JPH1 
ENSG00000058804 2.052486031 6.75E 06 NDC1 
ENSG00000121104 1.434645523 7.00E 06 FAM117A 
ENSG00000143228 2.468071564 7.44E 06 NUF2 
ENSG00000175745 4.336779873 7.47E 06 NR2F1 
ENSG00000128655 2.425425972 8.37E 06 PDE11A 
ENSG00000135047 3.739579731 8.64E 06 CTSL 
ENSG00000120885 2.950305584 9.43E 06 CLU 
ENSG00000197536 2.595954778 9.97E 06 C5orf56 
ENSG00000153291 2.601709841 1.03E 05 SLC25A27 
ENSG00000117748 2.36337171 1.11E 05 RPA2 
ENSG00000179869 2.617569116 1.15E 05 ABCA13 
ENSG00000161011 2.262170573 1.15E 05 SQSTM1 
ENSG00000167604 2.411176201 1.21E 05 NFKBID 
ENSG00000091483 1.932255447 1.22E 05 FH 
ENSG00000112029 2.148166228 1.26E 05 FBXO5 
ENSG00000161981 2.04057804 1.27E 05 SNRNP25 
ENSG00000151136 1.794433591 1.28E 05 BTBD11 
ENSG00000178999 2.035272688 1.29E 05 AURKB 
ENSG00000069399 2.430700182 1.29E 05 BCL3 
ENSG00000260220 3.226960523 1.29E 05 CCDC187 
ENSG00000117650 2.457967759 1.34E 05 NEK2 
ENSG00000109321 6.934445028 1.36E 05 AREG 
ENSG00000118298 2.935447407 1.46E 05 CA14 
ENSG00000138669 2.54697573 1.46E 05 PRKG2 
ENSG00000101407 2.06925318 1.46E 05 TTI1 
ENSG00000075426 2.450056522 1.54E 05 FOSL2 
ENSG00000169302 4.100633897 1.54E 05 STK32A 
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ENSG00000089692 3.891795749 1.62E 05 LAG3 
ENSG00000156103 2.592761015 1.62E 05 MMP16 
ENSG00000274750 3.21998286 1.68E 05 HIST1H3E 
ENSG00000175768 2.072372663 1.68E 05 TOMM5 
ENSG00000158987 1.671432328 1.72E 05 RAPGEF6 
ENSG00000040275 2.441387165 1.77E 05 SPDL1 
ENSG00000185112 1.980122042 1.84E 05 FAM43A 
ENSG00000058335 3.136432227 1.84E 05 RASGRF1 
ENSG00000126803 2.052889106 1.85E 05 HSPA2 
ENSG00000109971 1.674372144 2.25E 05 HSPA8 
ENSG00000141753 2.640279128 2.27E 05 IGFBP4 
ENSG00000177103 3.282742997 2.43E 05 DSCAML1 
ENSG00000149927 2.435130834 2.46E 05 DOC2A 
ENSG00000122490 2.304415029 2.46E 05 PQLC1 
ENSG00000111247 2.708271058 2.46E 05 RAD51AP1 
ENSG00000081320 1.574260999 2.46E 05 STK17B 
ENSG00000147852 2.101017992 2.46E 05 VLDLR 
ENSG00000164362 2.98380964 2.49E 05 TERT 
ENSG00000065328 2.766426879 2.52E 05 MCM10 
ENSG00000124942 2.357102761 2.58E 05 AHNAK 
ENSG00000077782 1.904425624 2.58E 05 FGFR1 
ENSG00000132819 3.235608326 2.62E 05 RBM38 
ENSG00000149554 1.674995917 2.77E 05 CHEK1 
ENSG00000152455 1.938390917 2.79E 05 SUV39H2 
ENSG00000178809 2.428601791 2.85E 05 TRIM73 
ENSG00000125810 1.483619853 2.86E 05 CD93 
ENSG00000172889 1.362755016 2.86E 05 EGFL7 
ENSG00000076248 2.697677529 3.21E 05 UNG 
ENSG00000160949 1.788186352 3.22E 05 TONSL 
ENSG00000051180 2.055187534 3.42E 05 RAD51 
ENSG00000258947 3.435218523 3.42E 05 TUBB3 
ENSG00000013364 1.539236617 3.51E 05 MVP 
ENSG00000109674 2.8346941 3.70E 05 NEIL3 
ENSG00000120802 1.889420419 3.81E 05 TMPO 
ENSG00000088305 1.611251825 3.85E 05 DNMT3B 
ENSG00000116830 1.593376261 4.00E 05 TTF2 
ENSG00000196227 2.258781419 4.19E 05 FAM217B 
ENSG00000087586 2.639376551 4.25E 05 AURKA 
ENSG00000143751 2.416857195 4.27E 05 SDE2 
ENSG00000134291 1.894671786 4.39E 05 TMEM106C 
ENSG00000138180 2.539437038 4.59E 05 CEP55 
ENSG00000227231 4.701372186 4.59E 05 IER3 
ENSG00000181991 1.63514659 4.59E 05 MRPS11 
ENSG00000023041 1.914202988 4.60E 05 ZDHHC6 
ENSG00000165655 2.26974934 4.60E 05 ZNF503 
ENSG00000232804 5.040571546 4.74E 05 HSPA1B 
ENSG00000091127 2.163220019 4.76E 05 PUS7 
ENSG00000275019 4.88825365 4.77E 05 LILRB3 
ENSG00000022267 1.848065292 4.79E 05 FHL1 
ENSG00000073111 2.101371896 4.91E 05 MCM2 
ENSG00000092020 1.622211788 4.91E 05 PPP2R3C 
ENSG00000081059 2.638280991 4.91E 05 TCF7 
ENSG00000128513 1.962444985 5.05E 05 POT1 
ENSG00000204420 4.11429157 5.21E 05 MPIG6B 
ENSG00000144354 1.854901469 5.36E 05 CDCA7 
ENSG00000176208 1.773125177 5.39E 05 ATAD5 
ENSG00000198056 1.911672139 5.49E 05 PRIM1 
ENSG00000149257 1.481285 5.56E 05 SERPINH1 
ENSG00000156876 1.817906012 6.04E 05 SASS6 
ENSG00000151090 2.971466713 6.17E 05 THRB 
ENSG00000078804 2.388841949 6.25E 05 TP53INP2 
ENSG00000114796 1.721001831 6.31E 05 KLHL24 
ENSG00000138346 1.574465111 6.84E 05 DNA2 
ENSG00000130164 2.158985597 7.10E 05 LDLR 
ENSG00000115758 1.993852055 7.11E 05 ODC1 
ENSG00000117632 1.809488234 7.11E 05 STMN1 
ENSG00000156049 4.223622216 7.19E 05 GNA14 
   
  214 
ENSG00000138658 1.748384259 7.37E 05 ZGRF1 
ENSG00000215045 2.994763684 7.41E 05 GRID2IP 
ENSG00000090273 1.62566833 7.43E 05 NUDC 
ENSG00000159335 1.76350335 7.56E 05 PTMS 
ENSG00000154188 2.048257385 8.03E 05 ANGPT1 
ENSG00000166856 3.226403066 8.21E 05 GPR182 
ENSG00000107819 1.917157504 8.60E 05 SFXN3 
ENSG00000105808 1.614928166 8.91E 05 RASA4 
ENSG00000118257 2.235127898 8.94E 05 NRP2 
ENSG00000004478 1.525680211 9.02E 05 FKBP4 
ENSG00000163602 2.088644956 9.11E 05 RYBP 
ENSG00000115648 2.617451389 9.13E 05 MLPH 
ENSG00000223609 5.370505173 9.44E 05 HBD 
ENSG00000128944 1.824501254 9.51E 05 KNSTRN 
ENSG00000214688 2.951162435 9.53E 05 C10orf105 
ENSG00000149577 2.044734266 9.73E 05 SIDT2 
ENSG00000099797 1.963907688 9.96E 05 TECR 
ENSG00000123240 1.929978325 0.000102472 OPTN 
ENSG00000085840 1.795406109 0.000105489 ORC1 
ENSG00000178342 3.199112227 0.00011082 KCNG2 
ENSG00000011485 1.651852861 0.000111131 PPP5C 
ENSG00000118785 3.273537046 0.000111131 SPP1 
ENSG00000100234 1.690453118 0.000111131 TIMP3 
ENSG00000070985 3.496975337 0.000111131 TRPM5 
ENSG00000139734 1.937897092 0.000111772 DIAPH3 
ENSG00000171206 1.436443375 0.000116065 TRIM8 
ENSG00000067533 2.088348299 0.000118607 RRP15 
ENSG00000145604 1.915258186 0.000120183 SKP2 
ENSG00000124164 1.551401806 0.000120183 VAPB 
ENSG00000132780 1.637915812 0.000120454 NASP 
ENSG00000123416 1.892334681 0.000127723 TUBA1B 
ENSG00000131002 7.737254381 0.000130066 TXLNGY 
ENSG00000204165 2.854254492 0.000130326 CXorf65 
ENSG00000027644 4.100428913 0.000131645 INSRR 
ENSG00000155657 1.680842957 0.000131645 TTN 
ENSG00000184227 4.5875217 0.000132262 ACOT1 
ENSG00000178966 2.215332241 0.000132262 RMI1 
ENSG00000156675 1.676048866 0.000132498 RAB11FIP1 
ENSG00000005381 2.423678224 0.000141651 MPO 
ENSG00000143622 2.029895164 0.000151471 RIT1 
ENSG00000175592 3.029215068 0.000152276 FOSL1 
ENSG00000099860 2.351929949 0.000156183 GADD45B 
ENSG00000174099 1.413119458 0.000156636 MSRB3 
ENSG00000224393 3.261761482 0.000163048 MPIG6B 
ENSG00000230060 3.261761482 0.000163048 MPIG6B 
ENSG00000231003 3.261761482 0.000163048 MPIG6B 
ENSG00000237459 3.261761482 0.000163048 MPIG6B 
ENSG00000246922 1.979899029 0.000172216 UBAP1L 
ENSG00000145075 2.446017675 0.000172265 CCDC39 
ENSG00000101003 1.886836032 0.000173432 GINS1 
ENSG00000175197 2.764007142 0.000179134 DDIT3 
ENSG00000130222 4.323665978 0.000179134 GADD45G 
ENSG00000169914 1.855338437 0.000179414 OTUD3 
ENSG00000186868 3.248100381 0.000180663 MAPT 
ENSG00000133063 2.815578407 0.000182659 CHIT1 
ENSG00000198355 2.255727794 0.000183992 PIM3 
ENSG00000198825 1.269229563 0.000192267 INPP5F 
ENSG00000112246 3.764862903 0.000194219 SIM1 
ENSG00000128595 1.647227998 0.000195461 CALU 
ENSG00000117054 1.661669643 0.000195883 ACADM 
ENSG00000167900 1.845937796 0.000200618 TK1 
ENSG00000166004 1.229528906 0.000203085 CEP295 
ENSG00000166086 1.744816684 0.000203085 JAM3 
ENSG00000205089 3.898036606 0.000203157 CCNI2 
ENSG00000176624 1.576211687 0.000203157 MEX3C 
ENSG00000088986 1.818002162 0.000203686 DYNLL1 
ENSG00000108840 1.430539301 0.000203699 HDAC5 
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ENSG00000159388 2.310875908 0.000204045 BTG2 
ENSG00000101213 2.065557183 0.000204306 PTK6 
ENSG00000170558 2.122630718 0.000206475 CDH2 
ENSG00000105650 3.441268519 0.000206475 PDE4C 
ENSG00000143870 1.614907108 0.000206475 PDIA6 
ENSG00000008513 1.698014684 0.000206475 ST3GAL1 
ENSG00000115750 1.74450864 0.000209133 TAF1B 
ENSG00000169926 2.172746073 0.000211825 KLF13 
ENSG00000198155 1.956258295 0.000212204 ZNF876P 
ENSG00000151849 1.852663019 0.000214387 CENPJ 
ENSG00000103067 2.550608085 0.000216772 ESRP2 
ENSG00000162913 2.712968629 0.000216772 OBSCN AS1 
ENSG00000172840 1.992452098 0.000217131 PDP2 
ENSG00000221968 1.718940493 0.000220452 FADS3 
ENSG00000197261 2.505350619 0.000220766 C6orf141 
ENSG00000114395 2.274517446 0.000220766 CYB561D2 
ENSG00000115457 2.057192053 0.000220766 IGFBP2 
ENSG00000205978 1.241718272 0.000220766 NYNRIN 
ENSG00000113761 1.54535801 0.000220766 ZNF346 
ENSG00000132681 2.256103061 0.000234192 ATP1A4 
ENSG00000170075 2.213376897 0.000234192 GPR37L1 
ENSG00000182628 2.072737238 0.000234192 SKA2 
ENSG00000013016 2.090452998 0.000236253 EHD3 
ENSG00000128165 3.49544319 0.00023659 ADM2 
ENSG00000112118 2.170991148 0.00023659 MCM3 
ENSG00000064309 2.573916192 0.00024447 CDON 
ENSG00000110172 1.483015279 0.00024447 CHORDC1 
ENSG00000159131 1.606511487 0.00024447 GART 
ENSG00000175643 2.179289003 0.000250228 RMI2 
ENSG00000170482 2.123999508 0.000258795 SLC23A1 
ENSG00000066294 1.68213496 0.000266239 CD84 
ENSG00000165757 1.424070207 0.000266239 JCAD 
ENSG00000148468 3.454158796 0.000267501 FAM171A1 
ENSG00000053747 2.662454282 0.000267501 LAMA3 
ENSG00000197557 2.374059991 0.000267501 TTC30A 
ENSG00000170893 1.858363211 0.000270726 TRH 
ENSG00000142748 3.337269913 0.000279025 FCN3 
ENSG00000074266 1.591917476 0.000280695 EED 
ENSG00000124207 1.54745116 0.000281843 CSE1L 
ENSG00000165929 2.529538955 0.000282629 TC2N 
ENSG00000262418 1.632212585 0.000282639 PTPRC 
ENSG00000152193 2.019519777 0.000283595 RNF219 
ENSG00000167088 1.893078215 0.000284059 SNRPD1 
ENSG00000115875 1.581999771 0.000291503 SRSF7 
ENSG00000129355 3.549483244 0.000291842 CDKN2D 
ENSG00000071539 2.116752305 0.000292795 TRIP13 
ENSG00000178718 2.432927961 0.000293696 RPP25 
ENSG00000119616 1.532241878 0.000297874 FCF1 
ENSG00000184205 1.887596779 0.000297874 TSPYL2 
ENSG00000225824 3.764754591 0.000300724 HLA DQB1 
ENSG00000174197 1.246375707 0.000300724 MGA 
ENSG00000083093 1.73703741 0.000300724 PALB2 
ENSG00000110328 2.302238528 0.000300922 GALNT18 
ENSG00000117480 2.299148659 0.000303834 FAAH 
ENSG00000167670 1.507517612 0.0003069 CHAF1A 
ENSG00000155561 1.81762521 0.0003069 NUP205 
ENSG00000121764 2.966104323 0.000319071 HCRTR1 
ENSG00000168264 1.430967788 0.000319071 IRF2BP2 
ENSG00000154473 1.925173508 0.000320543 BUB3 
ENSG00000094804 1.887636346 0.000332351 CDC6 
ENSG00000111906 1.459446871 0.000344585 HDDC2 
ENSG00000169744 2.547199752 0.000346553 LDB2 
ENSG00000164938 1.769068031 0.000346553 TP53INP1 
ENSG00000106328 4.91988237 0.000365254 FSCN3 
ENSG00000206557 1.675594948 0.000367505 TRIM71 
ENSG00000134571 2.793276523 0.00036783 MYBPC3 
ENSG00000132341 1.695826381 0.00036783 RAN 
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ENSG00000102096 2.185805328 0.000373442 PIM2 
ENSG00000240505 2.460674557 0.000373442 TNFRSF13B 
ENSG00000182175 1.904806235 0.000373755 RGMA 
ENSG00000128050 1.622343783 0.000376891 PAICS 
ENSG00000165934 1.662953539 0.000382124 CPSF2 
ENSG00000133401 1.201808771 0.000382288 PDZD2 
ENSG00000239305 1.593891796 0.000382288 RNF103 
ENSG00000205710 3.023959336 0.000387257 C17orf107 
ENSG00000165480 2.587072535 0.000388769 SKA3 
ENSG00000140564 1.94297013 0.000395862 FURIN 
ENSG00000100906 2.548401392 0.00039668 NFKBIA 
ENSG00000198785 3.189500992 0.000400452 GRIN3A 
ENSG00000065534 2.10271767 0.000411739 MYLK 
ENSG00000107807 4.947769063 0.000421514 TLX1 
ENSG00000130520 1.889048666 0.000427412 LSM4 
ENSG00000145911 2.539655224 0.000443899 N4BP3 
ENSG00000105875 1.939177703 0.000445169 WDR91 
ENSG00000105856 1.466373386 0.000446942 HBP1 
ENSG00000144893 1.67595341 0.000450636 MED12L 
ENSG00000122547 1.560490809 0.000452877 EEPD1 
ENSG00000115461 3.828162101 0.000459718 IGFBP5 
ENSG00000148925 1.479637951 0.000470897 BTBD10 
ENSG00000213066 1.438211671 0.000470897 FGFR1OP 
ENSG00000070808 3.142482688 0.00047393 CAMK2A 
ENSG00000185650 2.008781417 0.00049371 ZFP36L1 
ENSG00000177511 3.448482697 0.00051496 ST8SIA3 
ENSG00000109586 1.315013619 0.000515553 GALNT7 
ENSG00000152256 1.57770903 0.000516579 PDK1 
ENSG00000012048 1.573454935 0.00051868 BRCA1 
ENSG00000148908 1.594636492 0.00052793 RGS10 
ENSG00000100297 1.592786186 0.000530253 MCM5 
ENSG00000008441 1.794401525 0.000530253 NFIX 
ENSG00000216775 2.677541316 0.000538371 LOC730101 
ENSG00000089195 2.077681388 0.000538371 TRMT6 
ENSG00000242114 2.357575651 0.00054493 MTFP1 
ENSG00000111674 2.28556978 0.000546372 ENO2 
ENSG00000188612 1.426905982 0.000550646 SUMO2 
ENSG00000106366 2.808441328 0.000561621 SERPINE1 
ENSG00000170448 1.558446459 0.000561911 NFXL1 
ENSG00000135838 2.479660045 0.000562256 NPL 
ENSG00000008226 2.417869264 0.000583854 DLEC1 
ENSG00000091262 1.479094729 0.000585952 ABCC6 
ENSG00000189067 1.57109079 0.000595504 LITAF 
ENSG00000153044 1.878479113 0.000601056 CENPH 
ENSG00000183484 2.478495065 0.000607816 GPR132 
ENSG00000171223 2.703184765 0.000607816 JUNB 
ENSG00000138587 2.120171166 0.000607816 MNS1 
ENSG00000079313 1.560996882 0.000607816 REXO1 
ENSG00000168907 2.718078646 0.00061354 PLA2G4F 
ENSG00000069812 2.587466868 0.000620537 HES2 
ENSG00000108561 1.786227026 0.00062831 C1QBP 
ENSG00000183853 1.712092726 0.000636148 KIRREL1 
ENSG00000278318 1.624470278 0.000659094 ZNF229 
ENSG00000141756 1.553117648 0.000659152 FKBP10 
ENSG00000169291 1.936246526 0.000666752 SHE 
ENSG00000163082 2.057797669 0.000676554 SGPP2 
ENSG00000068323 1.784061496 0.000679863 TFE3 
ENSG00000067048 11.74398947 0.000689547 DDX3Y 
ENSG00000127418 2.219353069 0.000690573 FGFRL1 
ENSG00000089723 2.443012546 0.000695427 OTUB2 
ENSG00000026751 2.606738348 0.000695427 SLAMF7 
ENSG00000140403 1.479265889 0.000696568 DNAJA4 
ENSG00000198932 1.37238421 0.000696568 GPRASP1 
ENSG00000158042 1.818415628 0.000696568 MRPL17 
ENSG00000108679 1.946836308 0.000719971 LGALS3BP 
ENSG00000198858 2.170988102 0.000725522 R3HDM4 
ENSG00000125414 3.309414334 0.000728304 MYH2 
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ENSG00000079616 1.254545278 0.000728875 KIF22 
ENSG00000141030 1.290551938 0.000735416 COPS3 
ENSG00000034152 2.300282843 0.000735422 MAP2K3 
ENSG00000064933 1.476887064 0.000735474 PMS1 
ENSG00000127423 2.063196421 0.000740507 AUNIP 
ENSG00000167325 1.490454962 0.000740507 RRM1 
ENSG00000167565 2.078918123 0.00074212 SERTAD3 
ENSG00000137494 2.179430295 0.00076431 ANKRD42 
ENSG00000123219 1.47106549 0.000765133 CENPK 
ENSG00000138735 2.064897192 0.000765133 PDE5A 
ENSG00000100399 2.758087904 0.000765925 CHADL 
ENSG00000134755 1.81189364 0.000777379 DSC2 
ENSG00000050344 2.223731457 0.000780032 NFE2L3 
ENSG00000163520 1.786045397 0.000780302 FBLN2 
ENSG00000131470 1.646877484 0.000785752 PSMC3IP 
ENSG00000155428 2.967508126 0.000786859 TRIM74 
ENSG00000151576 1.213338701 0.000806562 QTRT2 
ENSG00000177169 2.350050204 0.000840821 ULK1 
ENSG00000129007 2.239016657 0.000848243 CALML4 
ENSG00000164332 1.579375147 0.0008647 UBLCP1 
ENSG00000100030 1.168938967 0.000894836 MAPK1 
ENSG00000162073 1.663948086 0.000898434 PAQR4 
ENSG00000159618 2.109977675 0.000901248 ADGRG5 
ENSG00000173588 1.295837255 0.00093216 CEP83 
ENSG00000161800 1.91022084 0.00093216 RACGAP1 
ENSG00000203760 2.506895744 0.00093238 CENPW 
ENSG00000183196 1.78739151 0.00093238 CHST6 
ENSG00000198517 2.111732169 0.00093238 MAFK 
ENSG00000188786 2.052906458 0.00093238 MTF1 
ENSG00000275430 2.855207742 0.00093238 MUC20 
ENSG00000076242 1.451357246 0.000939349 MLH1 
ENSG00000125347 2.118108798 0.000945735 IRF1 
ENSG00000109756 1.415963768 0.000945735 RAPGEF2 
ENSG00000138095 1.506097566 0.000981145 LRPPRC 
ENSG00000099901 1.711313947 0.000981145 RANBP1 
ENSG00000120833 1.333954606 0.000982167 SOCS2 
ENSG00000127329 2.307053199 0.000985956 PTPRB 
ENSG00000163154 2.259672989 0.000995777 TNFAIP8L2 
ENSG00000108953 1.483312163 0.001000533 YWHAE 
ENSG00000213988 1.505997925 0.001038768 ZNF90 
ENSG00000273703 2.503743454 0.001041719 HIST1H2BM 
ENSG00000137309 1.501081788 0.00104362 HMGA1 
ENSG00000276600 2.972331503 0.001054693 RAB7B 
ENSG00000135218 2.797934171 0.001073222 CD36 
ENSG00000165355 2.133576575 0.001073222 FBXO33 
ENSG00000114850 1.569592676 0.001082697 SSR3 
ENSG00000125885 1.493517344 0.001100754 MCM8 
ENSG00000281500 6.268392199 0.00110489 SLC37A4 
ENSG00000146463 1.231572176 0.001107281 ZMYM4 
ENSG00000188312 1.808855787 0.001113884 CENPP 
ENSG00000186480 2.152686076 0.001120881 INSIG1 
ENSG00000185298 1.508369898 0.001130385 CCDC137 
ENSG00000136205 1.295908894 0.001135431 TNS3 
ENSG00000230989 1.709442387 0.00114843 HSBP1 
ENSG00000153140 1.732897764 0.001163673 CETN3 
ENSG00000101444 1.468280129 0.001214346 AHCY 
ENSG00000092470 1.605229607 0.00122982 WDR76 
ENSG00000241697 2.28374043 0.001240649 TMEFF1 
ENSG00000150753 1.773194084 0.001249738 CCT5 
ENSG00000165476 1.566435563 0.001263717 REEP3 
ENSG00000081237 1.464938571 0.001275767 PTPRC 
ENSG00000149636 1.758147856 0.001280231 DSN1 
ENSG00000088899 2.457052411 0.001280231 LZTS3 
ENSG00000187510 5.596679534 0.001294527 PLEKHG7 
ENSG00000133636 4.77622093 0.001315527 NTS 
ENSG00000143819 1.494421488 0.001326619 EPHX1 
ENSG00000110777 1.960192886 0.001326619 POU2AF1 
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ENSG00000165490 2.569963011 0.001331102 DDIAS 
ENSG00000151465 1.44466487 0.001344518 CDC123 
ENSG00000179115 1.377519924 0.001348417 FARSA 
ENSG00000111665 1.489429911 0.001353352 CDCA3 
ENSG00000105722 2.125771651 0.001374811 ERF 
ENSG00000169519 1.712127257 0.001376628 METTL15 
ENSG00000100241 1.391753937 0.001387257 SBF1 
ENSG00000089685 1.983689144 0.001403356 BIRC5 
ENSG00000164136 1.925891702 0.001403645 IL15 
ENSG00000167378 1.666512153 0.001403645 IRGQ 
ENSG00000133119 2.099108891 0.001403645 RFC3 
ENSG00000054793 1.19396221 0.001403878 ATP9A 
ENSG00000173039 1.708013298 0.001424185 RELA 
ENSG00000143498 1.639661074 0.001434566 TAF1A 
ENSG00000239672 2.046725809 0.001458804 NME1 
ENSG00000113790 1.806026646 0.001460225 EHHADH 
ENSG00000164167 1.811780392 0.001460225 LSM6 
ENSG00000144043 1.705282089 0.001460225 TEX261 
ENSG00000115355 1.000855567 0.001467025 CCDC88A 
ENSG00000185338 2.0677506 0.001487631 SOCS1 
ENSG00000240370 2.825745384 0.001487833 RPL13P5 
ENSG00000051596 2.00648147 0.001487833 THOC3 
ENSG00000047617 3.44553311 0.001521622 ANO2 
ENSG00000114115 2.553911654 0.001551062 RBP1 
ENSG00000014824 1.513118493 0.001551062 SLC30A9 
ENSG00000198554 2.555124258 0.001566077 WDHD1 
ENSG00000099365 1.999209022 0.001568927 STX1B 
ENSG00000167470 2.030319915 0.001573213 MIDN 
ENSG00000253882 2.288683764 0.001582022 LOC154761 
ENSG00000164403 2.663835877 0.001597469 SHROOM1 
ENSG00000145687 1.029843637 0.001618664 SSBP2 
ENSG00000137807 1.591927072 0.001618839 KIF23 
ENSG00000168676 1.947841141 0.001623574 KCTD19 
ENSG00000113916 4.420015498 0.001634234 BCL6 
ENSG00000012171 4.555070855 0.001675755 SEMA3B 
ENSG00000142230 1.67551427 0.001680942 SAE1 
ENSG00000146386 2.159053645 0.001682797 ABRACL 
ENSG00000080839 2.129535132 0.001689743 RBL1 
ENSG00000100307 1.656026995 0.00169353 CBX7 
ENSG00000178904 1.291427029 0.00169353 DPY19L3 
ENSG00000178295 1.680905931 0.00169353 GEN1 
ENSG00000092054 2.740043229 0.00169353 MYH7 
ENSG00000131196 1.728485442 0.00169353 NFATC1 
ENSG00000129824 11.2041093 0.001697621 RPS4Y1 
ENSG00000115085 1.764483053 0.00170995 ZAP70 
ENSG00000109814 1.672409385 0.001751556 UGDH 
ENSG00000186193 1.930219292 0.001752767 SAPCD2 
ENSG00000124813 1.789218964 0.001762555 RUNX2 
ENSG00000256870 6.497336374 0.001772717 SLC5A8 
ENSG00000156136 1.710631284 0.001775576 DCK 
ENSG00000168309 3.071456634 0.001775649 FAM107A 
ENSG00000164855 2.554309277 0.001775649 TMEM184A 
ENSG00000121410 1.407216704 0.001788428 A1BG 
ENSG00000182050 2.506890721 0.001798198 MGAT4C 
ENSG00000163918 2.122219586 0.001819339 RFC4 
ENSG00000156299 1.462684946 0.001819339 TIAM1 
ENSG00000187595 1.836682552 0.001819339 ZNF385C 
ENSG00000008323 2.307250935 0.001824368 PLEKHG6 
ENSG00000221886 2.658653521 0.001843875 ZBED8 
ENSG00000146232 2.23863827 0.001846249 NFKBIE 
ENSG00000127311 1.244965859 0.001851955 HELB 
ENSG00000118961 1.585310834 0.001851955 LDAH 
ENSG00000006453 2.485770633 0.00185665 BAIAP2L1 
ENSG00000180917 1.547422698 0.00186143 CMTR2 
ENSG00000276256 1.656980664 0.00186271 LOC389831 
ENSG00000130775 2.020437705 0.00186271 THEMIS2 
ENSG00000137441 5.761698275 0.001873393 FGFBP2 
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ENSG00000128408 2.970438622 0.001880961 RIBC2 
ENSG00000266028 1.129569573 0.001880961 SRGAP2 
ENSG00000073910 1.588829844 0.001886695 FRY 
ENSG00000111276 1.751207484 0.001894686 CDKN1B 
ENSG00000100196 2.263878341 0.00190231 KDELR3 
ENSG00000140307 1.755745702 0.001903414 GTF2A2 
ENSG00000125505 1.716820203 0.001903414 MBOAT7 
ENSG00000168566 1.238409525 0.001903414 SNRNP48 
ENSG00000182885 1.917533148 0.001904529 ADGRG3 
ENSG00000100350 1.685549402 0.001936028 FOXRED2 
ENSG00000163492 1.664174007 0.001939352 CCDC141 
ENSG00000163629 1.564979676 0.001939352 PTPN13 
ENSG00000122862 2.036594592 0.001939352 SRGN 
ENSG00000165816 3.047043697 0.001939352 VWA2 
ENSG00000170891 1.865257412 0.001942307 CYTL1 
ENSG00000162063 1.517205524 0.001958153 CCNF 
ENSG00000172828 1.645601028 0.001958153 CES3 
ENSG00000169813 1.357318762 0.001958153 HNRNPF 
ENSG00000160460 2.965599234 0.001958153 SPTBN4 
ENSG00000127124 1.097372382 0.001968579 HIVEP3 
ENSG00000150977 1.323874801 0.001977941 RILPL2 
ENSG00000146731 1.177019632 0.001977967 CCT6A 
ENSG00000176845 2.145253577 0.001989723 METRNL 
ENSG00000162924 1.439657244 0.001989723 REL 
ENSG00000046889 1.117349324 0.002037067 PREX2 
ENSG00000277518 2.297240558 0.002043972 MUC6 
ENSG00000166473 1.687472867 0.002072237 PKD1L2 
ENSG00000186638 1.560569618 0.002093991 KIF24 
ENSG00000111581 1.296787483 0.002093991 NUP107 
ENSG00000118473 2.481419949 0.00209789 SGIP1 
ENSG00000149503 1.755267533 0.002104291 INCENP 
ENSG00000104938 2.95563559 0.002160829 CLEC4M 
ENSG00000088881 2.521540438 0.002160829 EBF4 
ENSG00000145990 1.511137428 0.002160829 GFOD1 
ENSG00000073060 1.36415227 0.002160829 SCARB1 
ENSG00000167780 4.743256994 0.002160829 SOAT2 
ENSG00000171617 2.53639364 0.002173501 ENC1 
ENSG00000102172 1.404432353 0.002176083 SMS 
ENSG00000276409 3.251555649 0.00217795 CCL14 
ENSG00000100442 1.432354778 0.00219076 FKBP3 
ENSG00000111639 1.644554028 0.002204002 MRPL51 
ENSG00000255346 1.911140198 0.002204002 NOX5 
ENSG00000130309 1.469823961 0.00223909 COLGALT1 
ENSG00000241394 2.616153272 0.00223909 HLA DMA 
ENSG00000163346 1.244990476 0.00223909 PBXIP1 
ENSG00000186834 1.599253254 0.002240054 HEXIM1 
ENSG00000136628 1.259655535 0.002245147 EPRS 
ENSG00000166111 2.576606688 0.00225383 SVOP 
ENSG00000100522 2.171475349 0.002303381 GNPNAT1 
ENSG00000134575 1.402187785 0.0023267 ACP2 
ENSG00000138092 1.393211129 0.0023267 CENPO 
ENSG00000136824 1.614508399 0.0023267 SMC2 
ENSG00000137720 1.963510077 0.002359469 C11orf1 
ENSG00000174177 1.717086735 0.002359469 CTU2 
ENSG00000167315 1.51761786 0.002364082 ACAA2 
ENSG00000023287 1.901094645 0.002427241 RB1CC1 
ENSG00000143862 1.553660669 0.002430814 ARL8A 
ENSG00000134438 3.865550539 0.002432443 RAX 
ENSG00000175697 3.651588559 0.002440058 GPR156 
ENSG00000109861 1.219041702 0.0024477 CTSC 
ENSG00000151725 1.692238676 0.002448906 CENPU 
ENSG00000077152 2.288642335 0.002448906 UBE2T 
ENSG00000163655 1.355706852 0.002469009 GMPS 
ENSG00000235162 1.581261378 0.002470767 C12orf75 
ENSG00000176532 2.588298098 0.002470767 PRR15 
ENSG00000068976 4.474982084 0.002477156 PYGM 
ENSG00000124532 1.947714818 0.002478416 MRS2 
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ENSG00000162510 2.340483513 0.002482985 MATN1 
ENSG00000164163 1.234655062 0.002492979 ABCE1 
ENSG00000128284 1.336595286 0.002519695 APOL3 
ENSG00000006625 1.547956967 0.002556727 GGCT 
ENSG00000170255 4.263621738 0.002589007 MRGPRX1 
ENSG00000088682 1.57018761 0.002611139 COQ9 
ENSG00000196305 1.093053477 0.002637068 IARS 
ENSG00000162600 1.594663058 0.002637068 OMA1 
ENSG00000163406 1.365835678 0.002637068 SLC15A2 
ENSG00000107443 1.744877018 0.002637777 CCNJ 
ENSG00000165810 2.315354745 0.002637779 BTNL9 
ENSG00000131759 1.650864796 0.002645148 RARA 
ENSG00000263528 1.721721152 0.002650426 IKBKE 
ENSG00000253729 1.129230541 0.002680183 PRKDC 
ENSG00000164109 2.381559832 0.002684315 MAD2L1 
ENSG00000154099 1.997252592 0.002687186 DNAAF1 
ENSG00000160741 1.632720186 0.00270715 CRTC2 
ENSG00000128052 3.70692521 0.00270715 KDR 
ENSG00000112640 1.232948353 0.002743403 PPP2R5D 
ENSG00000168026 2.528997409 0.002743403 TTC21A 
ENSG00000274768 6.894511354 0.002759137 CISD3 
ENSG00000145736 2.134282844 0.002767984 GTF2H2 
ENSG00000172000 1.846166013 0.002767984 ZNF556 
ENSG00000168496 1.543840834 0.002815467 FEN1 
ENSG00000148481 1.450757781 0.002815467 MINDY3 
ENSG00000048540 3.002076434 0.002816581 LMO3 
ENSG00000175262 2.702367823 0.002828835 C1orf127 
ENSG00000205403 2.95581385 0.002833726 CFI 
ENSG00000197444 2.784694886 0.002869158 OGDHL 
ENSG00000134874 1.859929503 0.002875384 DZIP1 
ENSG00000135698 1.604526825 0.002883853 MPHOSPH6 
ENSG00000235925 8.553770048 0.002896656 LY6G6C 
ENSG00000241484 2.4597669 0.002905274 ARHGAP8 
ENSG00000146038 2.628393385 0.00293051 DCDC2 
ENSG00000205339 1.415001356 0.002957338 IPO7 
ENSG00000163938 1.367662296 0.002957804 GNL3 
ENSG00000175928 2.063287054 0.002957804 LRRN1 
ENSG00000143217 2.298081783 0.002985931 NECTIN4 
ENSG00000254996 1.247511131 0.002989619 ANKHD1 EIF4EBP3 
ENSG00000109881 1.381397677 0.002989619 CCDC34 
ENSG00000011028 1.334323454 0.002989619 MRC2 
ENSG00000148459 1.898624134 0.002989619 PDSS1 
ENSG00000160584 1.265290951 0.002989619 SIK3 
ENSG00000104447 2.085131956 0.002989619 TRPS1 
ENSG00000010292 1.358007529 0.003011169 NCAPD2 
ENSG00000120318 2.145930429 0.003141328 ARAP3 
ENSG00000132510 1.671002426 0.003141328 KDM6B 
ENSG00000003509 1.406426915 0.003141328 NDUFAF7 
ENSG00000099985 2.59011196 0.003153252 OSM 
ENSG00000083535 1.226463796 0.003153252 PIBF1 
ENSG00000006071 2.533731035 0.003179744 ABCC8 
ENSG00000177602 2.019568075 0.00318472 HASPIN 
ENSG00000092621 1.321731124 0.003194296 PHGDH 
ENSG00000151135 1.164826378 0.003198216 TMEM263 
ENSG00000107485 2.014131897 0.0032009 GATA3 
ENSG00000142149 2.040004806 0.003207851 HUNK 
ENSG00000146281 1.341258486 0.003233364 PM20D2 
ENSG00000156711 1.942874846 0.003248324 MAPK13 
ENSG00000165672 1.826047902 0.003274293 PRDX3 
ENSG00000166405 1.972683392 0.003329147 RIC3 
ENSG00000166147 1.290377957 0.003359498 FBN1 
ENSG00000024526 2.269674339 0.003373812 DEPDC1 
ENSG00000114988 1.801253482 0.003373812 LMAN2L 
ENSG00000145794 3.073882541 0.003394904 MEGF10 
ENSG00000261210 4.902288856 0.003413275 CLEC19A 
ENSG00000123360 1.467608573 0.003414724 PDE1B 
ENSG00000184357 1.771828019 0.00345652 HIST1H1B 
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ENSG00000172586 1.843377858 0.003474407 CHCHD1 
ENSG00000110074 1.12681087 0.003482206 FOXRED1 
ENSG00000130816 1.224813336 0.003486002 DNMT1 
ENSG00000068724 1.325489487 0.003495659 TTC7A 
ENSG00000183304 2.071969388 0.003509398 FAM9A 
ENSG00000182255 3.218112369 0.003510872 KCNA4 
ENSG00000109046 0.990460791 0.003510872 WSB1 
ENSG00000257242 3.945579594 0.00352187 LINC01619 
ENSG00000100226 1.289204464 0.003548733 GTPBP1 
ENSG00000183856 1.506937319 0.00355678 IQGAP3 
ENSG00000214114 2.232500633 0.00355678 MYCBP 
ENSG00000163584 1.425338367 0.003557278 RPL22L1 
ENSG00000148019 1.313043662 0.003572968 CEP78 
ENSG00000153234 2.061821944 0.003604694 NR4A2 
ENSG00000101138 1.413698957 0.003624736 CSTF1 
ENSG00000068971 1.753207083 0.003630545 PPP2R5B 
ENSG00000157303 1.695074243 0.003630545 SUSD3 
ENSG00000250722 1.967393421 0.003641028 SELENOP 
ENSG00000139133 1.496938192 0.003675594 ALG10 
ENSG00000115295 1.623844435 0.003675594 CLIP4 
ENSG00000131435 3.713628634 0.003752498 PDLIM4 
ENSG00000072501 1.1846659 0.003754716 SMC1A 
ENSG00000145391 1.345912373 0.003782505 SETD7 
ENSG00000116237 1.711663145 0.003787753 ICMT 
ENSG00000060558 1.533737998 0.003802027 GNA15 
ENSG00000100441 1.159888498 0.003802027 KHNYN 
ENSG00000105617 3.973610164 0.003802027 LENG1 
ENSG00000132334 1.625259462 0.003802027 PTPRE 
ENSG00000076382 1.370110053 0.003802027 SPAG5 
ENSG00000144118 1.150051478 0.003802845 RALB 
ENSG00000174038 2.080069816 0.003833525 C9orf131 
ENSG00000274542 6.800931876 0.003837902 CHRNA7 
ENSG00000171310 1.421342827 0.003837902 CHST11 
ENSG00000106078 2.139064976 0.003837902 COBL 
ENSG00000173145 1.435015287 0.003837902 NOC3L 
ENSG00000274474 1.436086245 0.003838426 YWHAE 
ENSG00000137841 1.178515169 0.003884964 PLCB2 
ENSG00000172382 1.933973887 0.003914159 PRSS27 
ENSG00000170903 1.570783312 0.00392244 MSANTD4 
ENSG00000085662 1.403844012 0.003932542 AKR1B1 
ENSG00000136731 1.34354136 0.003943477 UGGT1 
ENSG00000188818 2.13847284 0.003947757 ZDHHC11 
ENSG00000198042 1.590129704 0.003962659 MAK16 
ENSG00000165669 1.107449949 0.003991068 FAM204A 
ENSG00000166257 1.931245781 0.004006933 SCN3B 
ENSG00000276234 1.227723938 0.004006933 TADA2A 
ENSG00000156860 1.24042391 0.004033307 FBRS 
ENSG00000204301 3.052503472 0.004044145 NOTCH4 
ENSG00000186767 1.269002733 0.004044145 SPIN4 
ENSG00000109919 1.604201541 0.004122489 MTCH2 
ENSG00000111452 1.638124036 0.004135751 ADGRD1 
ENSG00000127586 1.598272293 0.004135751 CHTF18 
ENSG00000134901 1.724706096 0.004135751 KDELC1 
ENSG00000110077 2.76129034 0.004135751 MS4A6A 
ENSG00000140538 2.463559703 0.004135751 NTRK3 
ENSG00000117450 1.508970946 0.004135751 PRDX1 
ENSG00000113369 1.590311241 0.004174305 ARRDC3 
ENSG00000185090 2.583957541 0.004174305 MANEAL 
ENSG00000101856 1.519610537 0.004174305 PGRMC1 
ENSG00000125870 1.377028107 0.004174305 SNRPB2 
ENSG00000149591 2.152511028 0.004174305 TAGLN 
ENSG00000275246 1.600127648 0.004174305 TLCD2 
ENSG00000159958 1.740170721 0.004174305 TNFRSF13C 
ENSG00000179041 1.846240062 0.004191504 RRS1 
ENSG00000060069 1.850808054 0.004196676 CTDP1 
ENSG00000119771 2.29043958 0.004239081 KLHL29 
ENSG00000196139 1.985947166 0.004261761 AKR1C3 
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ENSG00000114904 1.657377468 0.004261761 NEK4 
ENSG00000138411 2.437320875 0.004263498 HECW2 
ENSG00000115421 1.057749519 0.004267511 PAPOLG 
ENSG00000145675 1.205235347 0.004270674 PIK3R1 
ENSG00000115364 1.274159208 0.004276279 MRPL19 
ENSG00000100028 1.453803867 0.004279312 SNRPD3 
ENSG00000077150 1.914359804 0.004289238 NFKB2 
ENSG00000198743 1.162303579 0.004307179 SLC5A3 
ENSG00000099219 1.482793917 0.004347985 ERMP1 
ENSG00000152404 1.230327123 0.004352101 CWF19L2 
ENSG00000274290 1.889090382 0.004365438 HIST1H2BE 
ENSG00000161013 1.378168787 0.004367279 MGAT4B 
ENSG00000164674 2.952855958 0.004383581 SYTL3 
ENSG00000187790 1.199594114 0.00441009 FANCM 
ENSG00000135604 2.697465366 0.00445858 STX11 
ENSG00000105011 1.727248117 0.004507041 ASF1B 
ENSG00000166912 1.555462786 0.004535745 MTMR10 
ENSG00000041357 1.50139695 0.004535745 PSMA4 
ENSG00000089335 1.060531122 0.004561402 ZNF302 
ENSG00000164867 2.355829024 0.004604126 NOS3 
ENSG00000143344 2.379598616 0.004604265 RGL1 
ENSG00000160883 4.344588629 0.00461622 HK3 
ENSG00000075643 2.076716934 0.004621867 MOCOS 
ENSG00000121101 2.582817522 0.004628825 TEX14 
ENSG00000205022 2.96953884 0.004647282 PABPN1L 
ENSG00000077800 2.375695571 0.00467593 FKBP6 
ENSG00000165304 1.929098084 0.00467593 MELK 
ENSG00000006530 1.334709695 0.004677506 AGK 
ENSG00000175189 4.423049789 0.004679509 INHBC 
ENSG00000118412 1.318299691 0.004680777 CASP8AP2 
ENSG00000087263 1.296072664 0.004693757 OGFOD1 
ENSG00000203852 1.387033323 0.004705661 HIST2H3A 
ENSG00000203811 1.387033323 0.004705661 HIST2H3C 
ENSG00000065621 1.291490876 0.004707621 GSTO2 
ENSG00000020181 1.016893452 0.004710753 ADGRA2 
ENSG00000183530 1.347349392 0.004721805 PRR14L 
ENSG00000130300 1.949218013 0.004776598 PLVAP 
ENSG00000133477 1.529867972 0.004804233 FAM83F 
ENSG00000204138 1.384996934 0.004818751 PHACTR4 
ENSG00000157542 1.667602324 0.004833287 KCNJ6 
ENSG00000120903 1.967583523 0.004837919 CHRNA2 
ENSG00000197943 1.037169367 0.00484358 PLCG2 
ENSG00000022567 2.080491716 0.004875528 SLC45A4 
ENSG00000275118 1.779644177 0.004876204 MBOAT7 
ENSG00000119318 1.243991972 0.004896393 RAD23B 
ENSG00000225697 1.226183694 0.004896393 SLC26A6 
ENSG00000100242 1.299280659 0.004896393 SUN2 
ENSG00000011332 2.216660725 0.004902927 DPF1 
ENSG00000020577 1.600484781 0.004907643 SAMD4A 
ENSG00000206505 2.354922455 0.004964171 HLA A 
ENSG00000254685 2.066381145 0.004964264 FPGT 
ENSG00000150768 1.694973305 0.004985465 DLAT 
ENSG00000076344 2.35911036 0.004985465 RGS11 
ENSG00000123737 1.452612374 0.004991111 EXOSC9 
ENSG00000188263 5.613817821 0.004991111 IL17REL 
ENSG00000169288 1.568774758 0.004991111 MRPL1 
ENSG00000113924 5.2548152 0.005004004 HGD 
ENSG00000100312 2.293344022 0.005088777 ACR 
ENSG00000277775 2.061454692 0.005118465 HIST1H3F 
ENSG00000139269 2.742812148 0.005123189 INHBE 
ENSG00000099338 1.630377899 0.005127858 CATSPERG 
ENSG00000108590 1.971717677 0.005188715 MED31 
ENSG00000164877 1.40769639 0.005189118 MICALL2 
ENSG00000158747 2.158942936 0.005205478 NBL1 
ENSG00000169255 1.579135546 0.005226335 B3GALNT1 
ENSG00000067064 1.45300286 0.005226335 IDI1 
ENSG00000179564 3.60842845 0.005226335 LSMEM2 
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ENSG00000165030 1.531286246 0.005226335 NFIL3 
ENSG00000124568 4.538180501 0.005226335 SLC17A1 
ENSG00000163898 2.282742557 0.005230764 LIPH 
ENSG00000198176 1.34300919 0.005230764 TFDP1 
ENSG00000112742 1.772781511 0.005230764 TTK 
ENSG00000119403 1.031535959 0.00524087 PHF19 
ENSG00000172590 1.31732053 0.005261987 MRPL52 
ENSG00000147168 1.60519647 0.005269338 IL2RG 
ENSG00000100528 1.444825155 0.005274848 CNIH1 
ENSG00000186716 1.244859377 0.005284784 BCR 
ENSG00000182004 1.594157384 0.005284784 SNRPE 
ENSG00000160908 1.407973683 0.005286631 ZNF394 
ENSG00000170779 1.847622865 0.005289418 CDCA4 
ENSG00000138442 1.656889778 0.005314091 WDR12 
ENSG00000153303 3.087505155 0.005338491 FRMD1 
ENSG00000177426 1.443983072 0.005378771 TGIF1 
ENSG00000169762 1.302709844 0.005400686 TAPT1 
ENSG00000009694 2.958079499 0.00542515 TENM1 
ENSG00000075131 1.853002588 0.005435492 TIPIN 
ENSG00000172172 1.755101249 0.00544211 MRPL13 
ENSG00000196091 2.828647962 0.00544211 MYBPC1 
ENSG00000006432 1.683508818 0.005449361 MAP3K9 
ENSG00000114204 3.800697535 0.005481399 SERPINI2 
ENSG00000116661 4.951713282 0.005482806 FBXO2 
ENSG00000129744 4.012694701 0.005510112 ART1 
ENSG00000187260 2.463099637 0.005510112 WDR86 
ENSG00000177383 1.661099718 0.005548604 MAGEF1 
ENSG00000167641 1.798068558 0.005555839 PPP1R14A 
ENSG00000099290 1.303843498 0.005568552 WASHC2A 
ENSG00000128596 1.163588084 0.005587459 CCDC136 
ENSG00000165194 2.638496787 0.005592199 PCDH19 
ENSG00000176974 1.255701242 0.005622127 SHMT1 
ENSG00000134996 1.473775576 0.005648586 OSTF1 
ENSG00000130699 1.231584361 0.005648586 TAF4 
ENSG00000132436 1.765347013 0.005651932 FIGNL1 
ENSG00000075336 1.832148553 0.005665081 TIMM21 
ENSG00000144827 1.605484613 0.005703983 ABHD10 
ENSG00000173915 1.430423264 0.005703983 USMG5 
ENSG00000100714 1.180745253 0.005731962 MTHFD1 
ENSG00000132911 4.57496194 0.005866998 NMUR2 
ENSG00000281742 1.584999052 0.005880388 MCCC2 
ENSG00000008311 1.3354697 0.005881621 AASS 
ENSG00000091428 2.078241136 0.005915837 RAPGEF4 
ENSG00000197063 1.734035787 0.005925205 MAFG 
ENSG00000197771 1.597031623 0.005925205 MCMBP 
ENSG00000166181 1.231174849 0.005930347 API5 
ENSG00000155962 1.805298948 0.005931678 CLIC2 
ENSG00000120675 1.563360168 0.005931678 DNAJC15 
ENSG00000134532 2.154419176 0.005931678 SOX5 
ENSG00000184445 0.926616708 0.005957028 KNTC1 
ENSG00000116478 0.902874114 0.005971153 HDAC1 
ENSG00000145375 1.228331201 0.006093504 SPATA5 
ENSG00000124208 6.524228768 0.006093504 TMEM189 UBE2V1 
ENSG00000169857 1.490954832 0.006140643 AVEN 
ENSG00000121005 1.909255585 0.006163634 CRISPLD1 
ENSG00000156858 1.415354545 0.006190284 PRR14 
ENSG00000137834 1.839690182 0.006190284 SMAD6 
ENSG00000089048 1.419603885 0.006190808 ESF1 
ENSG00000233345 2.732230837 0.006190808 MSH5 
ENSG00000115687 1.266380202 0.006190808 PASK 
ENSG00000112759 1.690828838 0.006190808 SLC29A1 
ENSG00000082014 1.825754446 0.006190808 SMARCD3 
ENSG00000215397 3.714885026 0.006191009 SCRT2 
ENSG00000129757 1.550206615 0.006206668 CDKN1C 
ENSG00000133561 1.766030593 0.006206668 GIMAP6 
ENSG00000178297 1.659438593 0.006206668 TMPRSS9 
ENSG00000105447 1.868560866 0.0062643 GRWD1 
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ENSG00000166133 1.878750302 0.00627195 RPUSD2 
ENSG00000177853 1.220720287 0.006276821 ZNF518A 
ENSG00000160957 1.386185603 0.006288879 RECQL4 
ENSG00000101000 2.429573899 0.006317571 PROCR 
ENSG00000135045 2.324329287 0.006322274 C9orf40 
ENSG00000121579 1.269090384 0.006354939 NAA50 
ENSG00000085265 1.357709428 0.006405768 FCN1 
ENSG00000130589 1.325271939 0.00640994 HELZ2 
ENSG00000120696 1.346960046 0.006452496 KBTBD7 
ENSG00000013523 1.181751871 0.006459656 ANGEL1 
ENSG00000166881 1.180717219 0.006465492 NEMP1 
ENSG00000156030 1.820242547 0.006503531 ELMSAN1 
ENSG00000185950 1.587171316 0.006540221 IRS2 
ENSG00000228836 5.888539538 0.006590705 CT45A5 
ENSG00000277161 3.717940659 0.006590705 PIGW 
ENSG00000275464 1.449894779 0.006657048 LOC102724159 
ENSG00000120526 1.827339505 0.006657048 NUDCD1 
ENSG00000206455 2.84509105 0.006657048 TCF19 
ENSG00000234674 2.84509105 0.006657048 TCF19 
ENSG00000156261 1.039891991 0.006661966 CCT8 
ENSG00000115241 1.367275662 0.006665684 PPM1G 
ENSG00000081721 1.305823284 0.00669276 DUSP12 
ENSG00000162607 1.291842907 0.00669276 USP1 
ENSG00000143149 1.392532847 0.00671762 ALDH9A1 
ENSG00000183023 2.319306922 0.006736217 SLC8A1 
ENSG00000228278 3.337340991 0.00679515 ORM2 
ENSG00000142528 1.545355932 0.00679515 ZNF473 
ENSG00000139687 1.071994374 0.006900193 RB1 
ENSG00000241685 1.411033589 0.006905008 ARPC1A 
ENSG00000085117 1.563165126 0.006940712 CD82 
ENSG00000088992 1.630874402 0.006989064 TESC 
ENSG00000198830 1.326460819 0.007042544 HMGN2 
ENSG00000085831 2.131424456 0.007047918 TTC39A 
ENSG00000154678 1.484978059 0.007118906 PDE1C 
ENSG00000153015 1.248238802 0.007147102 CWC27 
ENSG00000127081 1.372631194 0.007159168 ZNF484 
ENSG00000157978 1.754164579 0.00717457 LDLRAP1 
ENSG00000177108 2.900731981 0.00723997 ZDHHC22 
ENSG00000233136 2.207746321 0.007255237 USP17L11 
ENSG00000162521 1.094817603 0.007257143 RBBP4 
ENSG00000236334 1.663902729 0.007263406 PPIAL4G 
ENSG00000179958 1.815652658 0.007269237 DCTPP1 
ENSG00000243492 2.5099197 0.007279303 HLA L 
ENSG00000165792 1.132580932 0.007282271 METTL17 
ENSG00000101773 1.387019061 0.007345156 RBBP8 
ENSG00000136518 1.213389347 0.007366268 ACTL6A 
ENSG00000015592 2.489606519 0.007378432 STMN4 
ENSG00000173110 4.250479301 0.007392048 HSPA6 
ENSG00000179387 1.663776696 0.007400901 ELMOD2 
ENSG00000156475 1.347643425 0.007400901 PPP2R2B 
ENSG00000168209 1.806991353 0.007448699 DDIT4 
ENSG00000118702 6.238651866 0.007448699 GHRH 
ENSG00000143434 1.228387651 0.007448699 SEMA6C 
ENSG00000189091 1.275437036 0.007448699 SF3B3 
ENSG00000243667 2.118727654 0.007464273 WDR92 
ENSG00000089006 0.94840949 0.007583617 SNX5 
ENSG00000109572 1.138647879 0.007620316 CLCN3 
ENSG00000184752 1.600470972 0.007620316 NDUFA12 
ENSG00000073169 1.746409034 0.007620316 SELENOO 
ENSG00000127526 1.251823488 0.007620316 SLC35E1 
ENSG00000175216 1.04032636 0.007640703 CKAP5 
ENSG00000181722 1.172752927 0.007641009 ZBTB20 
ENSG00000260596 1.880290205 0.007652671 DUX4 
ENSG00000188428 1.470866395 0.007659064 BLOC1S5 
ENSG00000101695 1.241746231 0.007696777 RNF125 
ENSG00000092201 1.119348264 0.007699895 SUPT16H 
ENSG00000161958 1.72000388 0.007754877 FGF11 
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ENSG00000146648 2.334651527 0.007759749 EGFR 
ENSG00000187902 2.994538833 0.007765083 SHISA7 
ENSG00000214787 1.806146147 0.00779157 MS4A4E 
ENSG00000149136 1.29340815 0.007836899 SSRP1 
ENSG00000136141 1.075636097 0.007912552 LRCH1 
ENSG00000197870 3.61919038 0.007912552 PRB3 
ENSG00000120156 1.619944292 0.007912552 TEK 
ENSG00000111196 1.323275815 0.007913646 MAGOHB 
ENSG00000129951 1.686624618 0.007927534 PLPPR3 
ENSG00000005379 3.5184503 0.007952909 TSPOAP1 
ENSG00000141437 6.164792674 0.007954421 SLC25A52 
ENSG00000233622 1.901732506 0.007994476 CYP2T1P 
ENSG00000086991 2.148194481 0.007994476 NOX4 
ENSG00000171793 1.408450156 0.008011135 CTPS1 
ENSG00000107331 0.989842434 0.008031138 ABCA2 
ENSG00000090382 1.681499678 0.008031138 LYZ 
ENSG00000229859 2.060645068 0.008031138 PGA3 
ENSG00000180043 2.852921115 0.008032832 FAM71E2 
ENSG00000004779 1.75746862 0.008032832 NDUFAB1 
ENSG00000085760 1.502333649 0.008177372 MTIF2 
ENSG00000164175 5.675959312 0.008180502 SLC45A2 
ENSG00000166183 3.674486409 0.008204043 ASPG 
ENSG00000135535 1.280326143 0.008204043 CD164 
ENSG00000185182 4.79848925 0.008204043 GOLGA8EP 
ENSG00000142945 2.252817217 0.008204043 KIF2C 
ENSG00000092345 4.103247154 0.008250239 DAZL 
ENSG00000108474 1.038268418 0.008252721 PIGL 
ENSG00000124193 1.161612424 0.008266582 SRSF6 
ENSG00000023516 1.04579089 0.008298683 AKAP11 
ENSG00000166263 1.380061726 0.008303633 STXBP4 
ENSG00000125775 2.281638064 0.008304978 SDCBP2 
ENSG00000099625 2.280151145 0.008306227 CBARP 
ENSG00000206306 9.005249644 0.008307595 HLA DRB1 
ENSG00000147166 2.016626965 0.008307595 ITGB1BP2 
ENSG00000067842 2.614563081 0.008316296 ATP2B3 
ENSG00000162889 1.327362297 0.008316296 MAPKAPK2 
ENSG00000223760 2.954296448 0.008316296 MED15P9 
ENSG00000277104 6.142769206 0.008316296 TADA2A 
ENSG00000184465 1.418328262 0.008316296 WDR27 
ENSG00000097046 1.616065701 0.008321598 CDC7 
ENSG00000009954 1.04306041 0.008327288 BAZ1B 
ENSG00000152518 1.607547713 0.008327288 ZFP36L2 
ENSG00000111481 1.175085 0.008338187 COPZ1 
ENSG00000157933 4.296215543 0.008338187 SKI 
ENSG00000129244 1.934849384 0.008340718 ATP1B2 
ENSG00000197299 1.407219434 0.008340718 BLM 
ENSG00000140718 1.172420737 0.008340718 FTO 
ENSG00000089818 1.493490174 0.008340718 NECAP1 
ENSG00000121578 1.077480797 0.008371516 B4GALT4 
ENSG00000231021 7.068140137 0.008371516 HLA DRB4 
ENSG00000033178 1.089814059 0.008371516 UBA6 
ENSG00000111087 2.304997488 0.008389961 GLI1 
ENSG00000276286 6.111018953 0.008418003 ADAM2 
ENSG00000104312 1.112459019 0.008511427 RIPK2 
ENSG00000069188 1.558291816 0.008546881 SDK2 
ENSG00000179921 2.634637239 0.008563101 GPBAR1 
ENSG00000095319 0.949233194 0.008565592 NUP188 
ENSG00000124635 1.636937455 0.008598755 HIST1H2BJ 
ENSG00000136826 2.16340185 0.008598755 KLF4 
ENSG00000277140 3.382064225 0.008598755 MARF1 
ENSG00000154358 0.958131282 0.008598755 OBSCN 
ENSG00000100979 1.411308448 0.008598755 PLTP 
ENSG00000171928 1.39821857 0.008598755 TVP23B 
ENSG00000155367 3.162479927 0.008613634 PPM1J 
ENSG00000166839 1.473254047 0.008621777 ANKDD1A 
ENSG00000168952 2.131824488 0.008704823 STXBP6 
ENSG00000164638 1.67557183 0.008732156 SLC29A4 
   
  226 
ENSG00000127184 1.135052963 0.008755544 COX7C 
ENSG00000159433 0.940280159 0.008779389 STARD9 
ENSG00000100749 1.181378414 0.008779389 VRK1 
ENSG00000112110 2.240788245 0.008829296 MRPL18 
ENSG00000164056 1.239648555 0.008832215 SPRY1 
ENSG00000166477 1.212099389 0.008833082 LEO1 
ENSG00000121931 1.333716426 0.008901767 LRIF1 
ENSG00000154415 4.811505495 0.008926401 PPP1R3A 
ENSG00000055732 1.665678451 0.009097709 MCOLN3 
ENSG00000214491 1.52062648 0.009116974 SEC14L6 
ENSG00000162069 2.369918846 0.009177889 BICDL2 
ENSG00000006210 2.232110207 0.009177889 CX3CL1 
ENSG00000175606 1.644037875 0.009177889 TMEM70 
ENSG00000178171 2.85928264 0.00918804 AMER3 
ENSG00000164303 2.638736299 0.009245414 ENPP6 
ENSG00000177697 1.790789641 0.009246775 CD151 
ENSG00000143179 1.533978548 0.009246775 UCK2 
ENSG00000131732 1.43269714 0.009278577 ZCCHC9 
ENSG00000229676 1.629662178 0.009278577 ZNF492 
ENSG00000118194 1.911603492 0.009403973 TNNT2 
ENSG00000153071 1.867344793 0.009434318 DAB2 
ENSG00000204583 4.876567012 0.009450609 LRCOL1 
ENSG00000166069 2.743874741 0.009450609 TMCO5A 
ENSG00000101493 1.56496551 0.009450609 ZNF516 
ENSG00000109452 1.022148862 0.009488976 INPP4B 
ENSG00000125462 1.934747739 0.009515069 C1orf61 
ENSG00000196937 1.764406914 0.009515069 FAM3C 
ENSG00000144136 1.164716661 0.009515069 SLC20A1 
ENSG00000106484 1.253075235 0.0095563 MEST 
ENSG00000277422 2.004112657 0.009586491 REXO1L2P 
ENSG00000198865 1.365008084 0.009597372 CCDC152 
ENSG00000116032 2.033630719 0.009597372 GRIN3B 
ENSG00000163531 1.733879251 0.009598193 NFASC 
ENSG00000115392 1.391499424 0.009632763 FANCL 
ENSG00000106591 1.200198651 0.009632763 MRPL32 
ENSG00000188536 3.555761554 0.009720975 HBA2 
ENSG00000206240 8.040330788 0.009772039 HLA DRB1 
ENSG00000119013 2.155060519 0.009772039 NDUFB3 
ENSG00000276293 1.094557619 0.009772039 PIP4K2B 
ENSG00000234511 1.759265801 0.009788868 C5orf58 
ENSG00000126001 1.313174235 0.009794365 CEP250 
ENSG00000093134 1.542812507 0.009794365 VNN3 
ENSG00000164687 1.449219677 0.009804865 FABP5 
ENSG00000167874 2.325152383 0.009804865 TMEM88 
ENSG00000125901 1.58448351 0.009927009 MRPS26 
ENSG00000196843 1.920663911 0.009945247 ARID5A 
ENSG00000129235 2.147786392 0.009989615 TXNDC17 
ENSG00000184905 3.25599323 0.010004445 TCEAL2 
ENSG00000183508 2.145990332 0.010008926 FAM46C 
ENSG00000166948 5.329378002 0.010008926 TGM6 
ENSG00000116604 1.301336009 0.010011 MEF2D 
ENSG00000183605 1.72059035 0.010011 SFXN4 
ENSG00000273983 1.845376818 0.010031635 HIST1H3G 
ENSG00000185436 2.956139129 0.010031635 IFNLR1 
ENSG00000141622 2.002959736 0.010031635 RNF165 
ENSG00000143933 1.145597093 0.010170029 CALM2 
ENSG00000144283 1.182783317 0.010184834 PKP4 
ENSG00000187268 3.098728128 0.010198731 FAM9C 
ENSG00000057608 1.197634546 0.010198731 GDI2 
ENSG00000144554 0.999814426 0.010247307 FANCD2 
ENSG00000131153 1.673490294 0.010304245 GINS2 
ENSG00000186417 2.293787396 0.010355766 GLDN 
ENSG00000185262 1.611943878 0.010355766 UBALD2 
ENSG00000128951 1.169687264 0.010360011 DUT 
ENSG00000174013 1.313735047 0.010416912 FBXO45 
ENSG00000110852 1.897735555 0.010425128 CLEC2B 
ENSG00000126524 1.278096527 0.010457887 SBDS 
   
  227 
ENSG00000009844 1.553822084 0.010468488 VTA1 
ENSG00000112149 1.896193317 0.010495225 CD83 
ENSG00000159086 1.045269478 0.010496985 PAXBP1 
ENSG00000182831 1.050178522 0.010531385 C16orf72 
ENSG00000101203 2.511189401 0.010532017 COL20A1 
ENSG00000144736 1.316081044 0.010532991 SHQ1 
ENSG00000074964 2.811845447 0.010571213 ARHGEF10L 
ENSG00000086061 1.181327856 0.010571213 DNAJA1 
ENSG00000145934 3.256106878 0.010571213 TENM2 
ENSG00000162772 1.779424532 0.010648467 ATF3 
ENSG00000140374 1.238907082 0.010648467 ETFA 
ENSG00000169403 1.393936814 0.010648467 PTAFR 
ENSG00000106069 1.523400438 0.01066329 CHN2 
ENSG00000180776 1.299676512 0.01066329 ZDHHC20 
ENSG00000163029 1.049899088 0.010664634 SMC6 
ENSG00000111049 5.471830714 0.010687324 MYF5 
ENSG00000118655 1.708757035 0.010722365 DCLRE1B 
ENSG00000181610 1.636752601 0.010858038 MRPS23 
ENSG00000141682 1.938384531 0.010858038 PMAIP1 
ENSG00000178217 2.697362275 0.010858038 SH2D4B 
ENSG00000178996 1.483943644 0.010936765 SNX18 
ENSG00000149256 2.274528577 0.010948242 TENM4 
ENSG00000203618 2.133539908 0.010951354 GP1BB 
ENSG00000065485 1.305825494 0.010951354 PDIA5 
ENSG00000134109 1.02446809 0.011084023 EDEM1 
ENSG00000171115 1.588688092 0.011084023 GIMAP8 
ENSG00000155438 1.67077537 0.011084023 NIFK 
ENSG00000274843 3.119499799 0.011108476 MUC20 
ENSG00000277753 3.119499799 0.011108476 MUC20 
ENSG00000133321 1.82469965 0.011108476 RARRES3 
ENSG00000009724 1.429464755 0.011138854 MASP2 
ENSG00000198842 1.652548725 0.011164478 DUSP27 
ENSG00000177947 2.137643036 0.011183871 ODF3 
ENSG00000100678 1.15934889 0.011183871 SLC8A3 
ENSG00000172508 1.558906403 0.011184708 CARNS1 
ENSG00000163026 2.02373559 0.011198161 WDCP 
ENSG00000172340 1.448205074 0.011222767 SUCLG2 
ENSG00000100815 1.317265094 0.011225658 TRIP11 
ENSG00000162552 2.862005771 0.011225658 WNT4 
ENSG00000137747 1.62946044 0.011290852 TMPRSS13 
ENSG00000206395 2.011476084 0.011292664 DDAH2 
ENSG00000095951 1.198982131 0.011292664 HIVEP1 
ENSG00000136750 3.005315959 0.011293579 GAD2 
ENSG00000146856 1.738222468 0.011300851 AGBL3 
ENSG00000184730 1.589745953 0.01134038 APOBR 
ENSG00000142227 1.233949579 0.011374257 EMP3 
ENSG00000142207 1.059737953 0.011381315 URB1 
ENSG00000105854 1.059633782 0.01140247 PON2 
ENSG00000164649 1.165832621 0.01140537 CDCA7L 
ENSG00000198015 1.064883349 0.011574024 MRPL42 
ENSG00000121067 0.981667468 0.011574024 SPOP 
ENSG00000254535 1.499715387 0.011642254 PABPC4L 
ENSG00000160360 0.989333903 0.011662143 GPSM1 
ENSG00000178053 1.690071606 0.011732342 MLF1 
ENSG00000112902 1.888876115 0.011732342 SEMA5A 
ENSG00000123243 1.517918185 0.011736647 ITIH5 
ENSG00000157570 1.663939203 0.011736647 TSPAN18 
ENSG00000103365 1.043673622 0.011737259 GGA2 
ENSG00000146233 5.986634337 0.011757842 CYP39A1 
ENSG00000064989 1.030033672 0.011761704 CALCRL 
ENSG00000166816 1.719532759 0.011798559 LDHD 
ENSG00000116299 1.889776276 0.011805565 KIAA1324 
ENSG00000171385 2.543004244 0.011860827 KCND3 
ENSG00000151304 1.094635656 0.011954344 SRFBP1 
ENSG00000196352 1.426195412 0.011956255 CD55 
ENSG00000012232 1.14957136 0.011961876 EXTL3 
ENSG00000107518 2.725641779 0.012096215 ATRNL1 
   
  228 
ENSG00000114767 1.987930354 0.012118463 RRP9 
ENSG00000133028 1.151762829 0.012118463 SCO1 
ENSG00000214517 1.149143156 0.012145794 PPME1 
ENSG00000145362 2.081034668 0.012155257 ANK2 
ENSG00000157240 1.999579345 0.012155257 FZD1 
ENSG00000109158 2.60899858 0.012155257 GABRA4 
ENSG00000166206 1.93493118 0.012155257 GABRB3 
ENSG00000133706 1.239637291 0.012155257 LARS 
ENSG00000174175 1.782271168 0.012216789 SELP 
ENSG00000197312 1.116908113 0.012222464 DDI2 
ENSG00000273706 3.356153472 0.012222464 LHX1 
ENSG00000135624 1.126328749 0.01224373 CCT7 
ENSG00000172339 1.759163982 0.012253807 ALG14 
ENSG00000006695 1.652124904 0.012266508 COX10 
ENSG00000134222 2.094490247 0.012266508 PSRC1 
ENSG00000163104 1.19721371 0.012266508 SMARCAD1 
ENSG00000128973 1.162020327 0.012330939 CLN6 
ENSG00000166508 1.11643075 0.012330939 MCM7 
ENSG00000197483 1.241486075 0.012343905 ZNF628 
ENSG00000122483 0.975382912 0.012364151 CCDC18 
ENSG00000198756 2.352469638 0.012368271 COLGALT2 
ENSG00000135451 1.440361973 0.012368271 TROAP 
ENSG00000122783 1.431063704 0.012368551 C7orf49 
ENSG00000066322 1.272064854 0.012372745 ELOVL1 
ENSG00000164611 1.878578951 0.012405305 PTTG1 
ENSG00000100867 1.377440985 0.012414417 DHRS2 
ENSG00000156110 1.121818717 0.012416588 ADK 
ENSG00000131462 1.280619178 0.012431214 TUBG1 
ENSG00000132432 1.418533168 0.012494069 SEC61G 
ENSG00000161835 3.90493084 0.012498601 GRASP 
ENSG00000184588 1.710277229 0.012498601 PDE4B 
ENSG00000068354 1.373835001 0.012498601 TBC1D25 
ENSG00000075223 1.71348329 0.012500863 SEMA3C 
ENSG00000188760 2.999649409 0.012500863 TMEM198 
ENSG00000149243 1.923815701 0.012540745 KLHL35 
ENSG00000196793 2.290523958 0.012540745 ZNF239 
ENSG00000147174 2.521808672 0.012630388 GCNA 
ENSG00000138182 1.509674795 0.012630388 KIF20B 
ENSG00000204099 3.890285299 0.012630388 NEU4 
ENSG00000277926 3.890285299 0.012630388 NEU4 
ENSG00000241119 6.252839957 0.012630388 UGT1A9 
ENSG00000163637 2.696779619 0.012646782 PRICKLE2 
ENSG00000107736 1.781873681 0.012761981 CDH23 
ENSG00000115165 1.234191926 0.012761981 CYTIP 
ENSG00000176358 1.305496658 0.012768022 TAC4 
ENSG00000239732 2.935065234 0.012804222 TLR9 
ENSG00000123933 1.318937612 0.012822953 MXD4 
ENSG00000149782 1.307705558 0.01288557 PLCB3 
ENSG00000004455 1.113491084 0.012942701 AK2 
ENSG00000179833 1.300115316 0.012983005 SERTAD2 
ENSG00000163166 1.088948026 0.013031684 IWS1 
ENSG00000117174 1.055428083 0.013066264 ZNHIT6 
ENSG00000198633 4.241659247 0.013068694 ZNF534 
ENSG00000130595 1.489542403 0.013100099 TNNT3 
ENSG00000080573 3.018460451 0.013105539 COL5A3 
ENSG00000106541 3.759717821 0.013107763 AGR2 
ENSG00000152076 3.157434053 0.013107763 CCDC74B 
ENSG00000102230 1.434357536 0.013186151 PCYT1B 
ENSG00000099994 2.80059349 0.013268624 SUSD2 
ENSG00000116721 2.86605118 0.013269015 PRAMEF1 
ENSG00000174282 1.413170666 0.013272228 ZBTB4 
ENSG00000280688 5.792468997 0.013285548 CEP72 
ENSG00000154380 1.559485482 0.013285548 ENAH 
ENSG00000080608 1.284449098 0.013285548 PUM3 
ENSG00000188089 2.351076928 0.013307938 PLA2G4E 
ENSG00000129810 1.699138433 0.013332895 SGO1 
ENSG00000256235 1.651894432 0.013372483 SMIM3 
   
  229 
ENSG00000206013 3.885157298 0.013391628 IFITM5 
ENSG00000126261 1.122453907 0.013391628 UBA2 
ENSG00000112033 2.071100079 0.013449503 PPARD 
ENSG00000126950 2.411430097 0.013451882 TMEM35A 
ENSG00000172543 1.39582987 0.01348848 CTSW 
ENSG00000204439 6.469622382 0.013526604 C6orf47 
ENSG00000242950 1.253719162 0.013618809 ERVW 1 
ENSG00000172602 1.922308194 0.013630928 RND1 
ENSG00000171241 1.620274762 0.013630928 SHCBP1 
ENSG00000115053 1.207353832 0.013641201 NCL 
ENSG00000153406 1.566703016 0.013645345 NMRAL1 
ENSG00000134070 1.736604334 0.013725654 IRAK2 
ENSG00000090889 2.194244771 0.013725654 KIF4A 
ENSG00000072657 1.836118007 0.013725654 TRHDE 
ENSG00000181444 1.243474095 0.013725654 ZNF467 
ENSG00000183978 1.88961546 0.013729279 COA3 
ENSG00000188981 2.014227875 0.013729279 MSANTD1 
ENSG00000129317 1.135999514 0.013729279 PUS7L 
ENSG00000127129 2.983228638 0.013826931 EDN2 
ENSG00000135052 1.127570733 0.013826931 GOLM1 
ENSG00000111237 1.300895855 0.013886686 VPS29 
ENSG00000143028 2.628809154 0.013923664 SYPL2 
ENSG00000022840 1.400894972 0.013972471 RNF10 
ENSG00000222009 1.676146338 0.014051646 BTBD19 
ENSG00000159079 1.267723297 0.014051646 C21orf59 
ENSG00000158669 1.097342155 0.014051646 GPAT4 
ENSG00000119285 1.167060106 0.014051646 HEATR1 
ENSG00000171246 2.201661441 0.014051646 NPTX1 
ENSG00000184226 1.555058494 0.014051646 PCDH9 
ENSG00000154146 1.391564686 0.01413147 NRGN 
ENSG00000110700 1.026712179 0.01413147 RPS13 
ENSG00000176490 2.555033605 0.014176727 DIRAS1 
ENSG00000166845 1.356821728 0.014192649 C18orf54 
ENSG00000153936 1.797217965 0.014280088 HS2ST1 
ENSG00000146722 1.92361612 0.014290809 LOC541473 
ENSG00000239900 1.205218784 0.014337904 ADSL 
ENSG00000155115 1.8405654 0.014337904 GTF3C6 
ENSG00000189410 2.830231747 0.01436801 SH2D5 
ENSG00000196922 1.414791855 0.01443529 ZNF252P 
ENSG00000144406 1.196705948 0.014461263 UNC80 
ENSG00000146555 1.76700559 0.014466061 SDK1 
ENSG00000138071 1.234519137 0.014469658 ACTR2 
ENSG00000125630 0.991733876 0.014470139 POLR1B 
ENSG00000109738 2.448263079 0.014471274 GLRB 
ENSG00000280789 1.472714162 0.014484699 PAGR1 
ENSG00000113845 1.611753801 0.014484699 TIMMDC1 
ENSG00000181126 1.876362339 0.014498009 HLA V 
ENSG00000093144 1.301411889 0.014543152 ECHDC1 
ENSG00000153395 1.528299018 0.014548585 LPCAT1 
ENSG00000127125 1.480874399 0.01456366 PPCS 
ENSG00000135749 1.117557762 0.014591581 PCNX2 
ENSG00000169169 2.168023155 0.014615372 CPT1C 
ENSG00000198734 2.268867393 0.014615372 F5 
ENSG00000161888 1.096440735 0.014621706 SPC24 
ENSG00000167721 1.141992554 0.014621706 TSR1 
ENSG00000105219 2.398129872 0.014635901 CNTD2 
ENSG00000162852 1.083358996 0.014715147 CNST 
ENSG00000092607 3.136467817 0.014715147 TBX15 
ENSG00000162438 2.057019825 0.014719059 CTRC 
ENSG00000184305 1.472339357 0.014740538 CCSER1 
ENSG00000175538 1.628494801 0.014745777 KCNE3 
ENSG00000066557 1.133472585 0.014745777 LRRC40 
ENSG00000187144 1.635965599 0.014745777 SPATA21 
ENSG00000160803 1.004057296 0.014745777 UBQLN4 
ENSG00000167553 1.311099002 0.014787632 TUBA1C 
ENSG00000180210 3.488908638 0.014849393 F2 
ENSG00000165983 1.407787785 0.014920897 PTER 
   
  230 
ENSG00000180900 1.16843965 0.014931209 SCRIB 
ENSG00000166428 1.267661237 0.015032209 PLD4 
ENSG00000241127 2.053573178 0.015072053 YAE1D1 
ENSG00000140057 2.176004239 0.015137955 AK7 
ENSG00000157445 3.237332598 0.015137955 CACNA2D3 
ENSG00000150776 1.104360987 0.015137955 NKAPD1 
ENSG00000197728 1.779039204 0.015139566 RPS26 
ENSG00000172650 1.718532286 0.015211979 AGAP5 
ENSG00000113552 2.044217127 0.015335664 GNPDA1 
ENSG00000124831 1.081079785 0.015358133 LRRFIP1 
ENSG00000167106 1.609512089 0.015374997 FAM102A 
ENSG00000011143 1.411268037 0.015378644 MKS1 
ENSG00000170476 1.296340071 0.015424479 MZB1 
ENSG00000038427 2.51731346 0.015482246 VCAN 
ENSG00000116133 1.648962572 0.015508016 DHCR24 
ENSG00000198952 1.08785005 0.01553584 SMG5 
ENSG00000136213 1.403024375 0.015544711 CHST12 
ENSG00000166197 1.339684476 0.015548154 NOLC1 
ENSG00000184014 1.30046723 0.015561967 DENND5A 
ENSG00000131187 2.544255016 0.015573601 F12 
ENSG00000081791 1.113960503 0.015573601 KIAA0141 
ENSG00000277564 1.835423453 0.015573601 RBFOX2 
ENSG00000151500 1.383239645 0.01572288 THYN1 
ENSG00000155980 2.486722174 0.015730585 KIF5A 
ENSG00000154174 1.065978106 0.015775575 TOMM70 
ENSG00000181773 2.477514915 0.015779533 GPR3 
ENSG00000179270 2.99174857 0.015819919 C2orf71 
ENSG00000164741 1.811355659 0.015819919 DLC1 
ENSG00000179097 1.193518127 0.015819919 HTR1F 
ENSG00000078668 1.226948904 0.015819919 VDAC3 
ENSG00000140030 1.747372178 0.015838901 GPR65 
ENSG00000073849 0.965695492 0.01585293 ST6GAL1 
ENSG00000102057 1.679168132 0.01585391 KCND1 
ENSG00000158864 0.977791619 0.016037364 NDUFS2 
ENSG00000196262 1.136698996 0.016066699 PPIA 
ENSG00000213390 1.500703997 0.016121185 ARHGAP19 
ENSG00000136541 2.040582519 0.016121185 ERMN 
ENSG00000196277 1.955008864 0.016121185 GRM7 
ENSG00000196878 2.225563362 0.016121185 LAMB3 
ENSG00000108055 1.325853316 0.016121185 SMC3 
ENSG00000100304 1.360910792 0.016121185 TTLL12 
ENSG00000166444 1.344666312 0.016125804 ST5 
ENSG00000189350 1.199875549 0.016161292 TOGARAM2 
ENSG00000217801 1.285853418 0.01621374 LOC100288175 
ENSG00000276644 1.038512791 0.016223299 DACH1 
ENSG00000169016 1.340663379 0.016223299 E2F6 
ENSG00000188163 2.261529577 0.016223299 FAM166A 
ENSG00000174718 1.185788888 0.016223299 KIAA1551 
ENSG00000244482 3.231456515 0.016223299 LILRA6 
ENSG00000198754 5.385493041 0.016223299 OXCT2 
ENSG00000233954 1.505926129 0.016223299 UQCRHL 
ENSG00000164902 1.515376828 0.01625069 PHAX 
ENSG00000134001 1.154832385 0.016313259 EIF2S1 
ENSG00000141551 1.534713898 0.01635364 CSNK1D 
ENSG00000172830 1.577960092 0.01635364 SSH3 
ENSG00000197279 1.772098199 0.01635364 ZNF165 
ENSG00000121486 1.537919016 0.016357621 TRMT1L 
ENSG00000139719 1.171489587 0.016357621 VPS33A 
ENSG00000080345 0.875105089 0.016380381 RIF1 
ENSG00000119185 1.218707589 0.016465709 ITGB1BP1 
ENSG00000104549 1.312665473 0.016471705 SQLE 
ENSG00000213397 1.327764794 0.016480043 HAUS7 
ENSG00000177946 1.416101684 0.016522483 CENPBD1 
ENSG00000136108 1.115365341 0.016645876 CKAP2 
ENSG00000145833 0.845181311 0.016710916 DDX46 
ENSG00000142102 1.481696253 0.016741137 PGGHG 
ENSG00000188486 1.085680644 0.016743597 H2AFX 
   
  231 
ENSG00000183638 1.424840518 0.016774252 RP1L1 
ENSG00000189007 1.041045425 0.016777818 ADAT2 
ENSG00000106771 0.967038819 0.016822368 TMEM245 
ENSG00000116001 1.27801757 0.016823572 TIA1 
ENSG00000155755 1.288040491 0.016827815 TMEM237 
ENSG00000122705 1.132405738 0.016837731 CLTA 
ENSG00000102100 2.024246054 0.016888132 SLC35A2 
ENSG00000177238 1.401791538 0.016989323 TRIM72 
ENSG00000173662 2.493804998 0.017002593 TAS1R1 
ENSG00000105176 0.971112605 0.017078777 URI1 
ENSG00000142864 1.083257067 0.017104096 SERBP1 
ENSG00000146674 2.254499508 0.017118343 IGFBP3 
ENSG00000115738 1.844476173 0.017127675 ID2 
ENSG00000101311 3.15244413 0.017166984 FERMT1 
ENSG00000141582 1.324578809 0.017181427 CBX4 
ENSG00000127337 1.878839648 0.017181427 YEATS4 
ENSG00000116120 1.159540047 0.017185457 FARSB 
ENSG00000115484 1.104221732 0.017197404 CCT4 
ENSG00000164946 1.452370944 0.017206254 FREM1 
ENSG00000109762 2.269643281 0.017226534 SNX25 
ENSG00000086730 1.029773816 0.017246808 LAT2 
ENSG00000101150 0.971433929 0.017308289 TPD52L2 
ENSG00000124562 1.203964478 0.017373651 SNRPC 
ENSG00000232423 5.90504843 0.017427805 PRAMEF6 
ENSG00000119421 1.658578247 0.017439205 NDUFA8 
ENSG00000276910 1.577927179 0.017454915 GTF2H2 
ENSG00000055957 2.225861034 0.017478279 ITIH1 
ENSG00000105143 1.25271651 0.017494482 SLC1A6 
ENSG00000225828 2.311799541 0.017513725 FAM229A 
ENSG00000163170 1.506177837 0.01752019 BOLA3 
ENSG00000154642 1.188499164 0.01752019 C21orf91 
ENSG00000141404 1.9135735 0.01752019 GNAL 
ENSG00000150477 1.343043669 0.01752019 KIAA1328 
ENSG00000029725 1.10244446 0.01752019 RABEP1 
ENSG00000139890 2.254120816 0.01752019 REM2 
ENSG00000116171 1.084675777 0.01752019 SCP2 
ENSG00000120800 1.051274765 0.01752019 UTP20 
ENSG00000100722 1.219599346 0.01752019 ZC3H14 
ENSG00000251247 1.238399515 0.017532317 ZNF345 
ENSG00000150764 1.744940417 0.017680999 DIXDC1 
ENSG00000142347 0.94152046 0.017772488 MYO1F 
ENSG00000129675 0.932068435 0.017849755 ARHGEF6 
ENSG00000100162 1.188521243 0.017849755 CENPM 
ENSG00000164418 2.218504502 0.017849755 GRIK2 
ENSG00000136802 0.967380178 0.017849755 LRRC8A 
ENSG00000021645 1.976283168 0.017849755 NRXN3 
ENSG00000178279 3.610917538 0.017849755 TNP2 
ENSG00000118640 1.16610322 0.017849755 VAMP8 
ENSG00000165061 2.867580351 0.017849755 ZMAT4 
ENSG00000111845 2.083708452 0.017862779 PAK1IP1 
ENSG00000270392 1.111157181 0.017867428 PFN1P2 
ENSG00000230445 2.817277451 0.017872798 LRRC37A6P 
ENSG00000177646 0.980736455 0.017897548 ACAD9 
ENSG00000111058 2.373032267 0.017957602 ACSS3 
ENSG00000198924 1.48796458 0.017973241 DCLRE1A 
ENSG00000116584 0.990329855 0.018003952 ARHGEF2 
ENSG00000196834 1.485765999 0.018003952 POTEI 
ENSG00000139287 1.149920662 0.018003952 TPH2 
ENSG00000170959 1.824781924 0.018016301 DCDC1 
ENSG00000248496 5.627704482 0.018016301 ZBED9 
ENSG00000128654 1.632966824 0.01812035 MTX2 
ENSG00000198805 1.699475424 0.018153574 PNP 
ENSG00000136045 1.278162748 0.018153574 PWP1 
ENSG00000160796 0.738742254 0.018230581 NBEAL2 
ENSG00000143851 0.944457426 0.018274278 PTPN7 
ENSG00000277224 1.164695916 0.018287797 HIST1H2BF 
ENSG00000167476 2.215353751 0.018287797 JSRP1 
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ENSG00000156564 3.758748085 0.018287797 LRFN2 
ENSG00000116044 0.970136856 0.018287797 NFE2L2 
ENSG00000204909 1.114193823 0.018383329 SPINK9 
ENSG00000179335 0.940913428 0.018459136 CLK3 
ENSG00000118246 1.154744536 0.018499673 FASTKD2 
ENSG00000234651 1.035913131 0.018507351 BAG6 
ENSG00000165995 1.58648958 0.018507351 CACNB2 
ENSG00000175595 1.115478313 0.018507351 ERCC4 
ENSG00000151876 1.397522298 0.018516183 FBXO4 
ENSG00000168291 1.327142263 0.018516183 PDHB 
ENSG00000084733 1.363220851 0.018516183 RAB10 
ENSG00000139636 1.202514442 0.01859327 LMBR1L 
ENSG00000257501 1.844949832 0.018654444 LOC643711 
ENSG00000188368 2.050275234 0.018654466 PRR19 
ENSG00000198793 0.925678624 0.018683234 MTOR 
ENSG00000123473 1.138003224 0.018693692 STIL 
ENSG00000163618 1.735014594 0.01871141 CADPS 
ENSG00000180957 0.881263689 0.01871141 PITPNB 
ENSG00000205176 1.462798856 0.01871141 REXO1L1P 
ENSG00000088448 0.770207679 0.018910453 ANKRD10 
ENSG00000116396 1.043174813 0.0189158 KCNC4 
ENSG00000206481 2.619011634 0.018961199 MDC1 
ENSG00000088876 1.533898746 0.019005755 ZNF343 
ENSG00000078018 2.081149326 0.019041501 MAP2 
ENSG00000106443 0.897686934 0.019041501 PHF14 
ENSG00000137760 1.293178466 0.019062914 ALKBH8 
ENSG00000137547 1.563670751 0.019091849 MRPL15 
ENSG00000103811 1.857250705 0.019141407 CTSH 
ENSG00000050767 2.700345797 0.019171293 COL23A1 
ENSG00000274811 1.26840308 0.019176578 CLPTM1L 
ENSG00000100591 1.340908777 0.01920611 AHSA1 
ENSG00000140986 1.398755687 0.019292303 RPL3L 
ENSG00000155052 2.787540822 0.019432339 CNTNAP5 
ENSG00000133835 1.114756963 0.019432339 HSD17B4 
ENSG00000070444 1.406977731 0.019432339 MNT 
ENSG00000120458 1.315470688 0.019432339 MSANTD2 
ENSG00000085063 1.017680197 0.019435101 CD59 
ENSG00000150457 1.618576886 0.019440022 LATS2 
ENSG00000105643 1.516349774 0.019462874 ARRDC2 
ENSG00000198000 1.084978302 0.019462874 NOL8 
ENSG00000138078 1.173286745 0.019462874 PREPL 
ENSG00000167635 1.228341035 0.019462874 ZNF146 
ENSG00000157766 2.102824125 0.019518893 ACAN 
ENSG00000165233 1.389533082 0.019518893 CARD19 
ENSG00000100439 1.726459287 0.019537571 ABHD4 
ENSG00000167747 0.948846424 0.019537571 C19orf48 
ENSG00000049656 1.293857735 0.019537571 CLPTM1L 
ENSG00000100632 1.435052266 0.019537571 ERH 
ENSG00000172216 1.46967762 0.019624101 CEBPB 
ENSG00000137288 1.217127574 0.019624101 UQCC2 
ENSG00000169604 2.57850417 0.019659085 ANTXR1 
ENSG00000175581 0.957370932 0.019659085 MRPL48 
ENSG00000066248 2.719583474 0.019672471 NGEF 
ENSG00000162366 2.361147345 0.019672471 PDZK1IP1 
ENSG00000120594 1.036406157 0.019672471 PLXDC2 
ENSG00000130844 1.692938372 0.019672471 ZNF331 
ENSG00000147614 1.74683545 0.019695966 ATP6V0D2 
ENSG00000112406 1.2910073 0.019723073 HECA 
ENSG00000272395 2.448637459 0.019723073 IFNL4 
ENSG00000163607 1.071123913 0.019746349 GTPBP8 
ENSG00000173898 1.665097546 0.019858588 SPTBN2 
ENSG00000164404 2.467531279 0.01987584 GDF9 
ENSG00000181333 3.10067663 0.01987584 HEPHL1 
ENSG00000122566 0.83476133 0.01987584 HNRNPA2B1 
ENSG00000089693 0.978783757 0.01987584 MLF2 
ENSG00000126822 1.769968977 0.01987584 PLEKHG3 
ENSG00000183963 1.450402974 0.01987584 SMTN 
   
  233 
ENSG00000107679 0.966965734 0.019921032 PLEKHA1 
ENSG00000124659 1.618554026 0.019968727 TBCC 
ENSG00000082996 1.369198052 0.020029481 RNF13 
ENSG00000112333 2.853592724 0.020058825 NR2E1 
ENSG00000277443 0.993011377 0.020180172 MARCKS 
ENSG00000050030 2.222621224 0.020180172 NEXMIF 
ENSG00000235376 5.33590607 0.020252127 RPEL1 
ENSG00000102898 1.397388092 0.020280629 NUTF2 
ENSG00000145708 1.750558784 0.02031315 CRHBP 
ENSG00000144596 2.108283944 0.020330129 GRIP2 
ENSG00000137819 1.755773645 0.020334685 PAQR5 
ENSG00000270647 0.99366068 0.020417467 TAF15 
ENSG00000131044 2.040369195 0.020427122 TTLL9 
ENSG00000065183 1.450680614 0.020427122 WDR3 
ENSG00000003147 0.912249827 0.020463334 ICA1 
ENSG00000154832 1.01624784 0.020477671 CXXC1 
ENSG00000181544 1.713656115 0.020477671 FANCB 
ENSG00000181904 0.999536819 0.020552057 C5orf24 
ENSG00000110887 3.105438175 0.020552057 DAO 
ENSG00000204103 2.646448465 0.02055848 MAFB 
ENSG00000065357 0.919870383 0.020566835 DGKA 
ENSG00000277157 1.522823531 0.020618346 HIST1H4D 
ENSG00000136997 1.684850095 0.020817452 MYC 
ENSG00000027075 1.020791178 0.020830444 PRKCH 
ENSG00000139117 1.20873035 0.020854061 CPNE8 
ENSG00000007866 2.464509828 0.020905315 TEAD3 
ENSG00000105290 4.559578393 0.020920707 APLP1 
ENSG00000178772 1.219371041 0.020925834 CPN2 
ENSG00000206053 1.596925153 0.020931813 JPT2 
ENSG00000186871 1.459462777 0.020960221 ERCC6L 
ENSG00000133612 1.539332124 0.020981332 AGAP3 
ENSG00000111716 1.15305858 0.020981332 LDHB 
ENSG00000156925 2.253679615 0.021037251 ZIC3 
ENSG00000170802 1.357184569 0.02109636 FOXN2 
ENSG00000162971 1.002983068 0.02109636 TYW5 
ENSG00000078295 1.350287499 0.021096899 ADCY2 
ENSG00000122188 1.225300689 0.021108892 LAX1 
ENSG00000135913 1.016988689 0.021108892 USP37 
ENSG00000168066 0.928968159 0.021116508 SF1 
ENSG00000183629 2.9906715 0.021237525 GOLGA8G 
ENSG00000054690 1.990793577 0.021237525 PLEKHH1 
ENSG00000134318 1.351487294 0.021268281 ROCK2 
ENSG00000178163 1.025482378 0.021285902 ZNF518B 
ENSG00000079785 1.09525637 0.021332897 DDX1 
ENSG00000092036 1.252319211 0.021357348 HAUS4 
ENSG00000168246 1.498187015 0.021357348 UBTD2 
ENSG00000257950 1.277834911 0.021412465 P2RX5 TAX1BP3 
ENSG00000104856 1.490055575 0.02144633 RELB 
ENSG00000175334 1.72656243 0.021520205 BANF1 
ENSG00000205363 1.44215108 0.021538031 C15orf59 
ENSG00000177000 1.430532271 0.021538031 MTHFR 
ENSG00000049245 1.233959582 0.021538031 VAMP3 
ENSG00000121335 3.178910972 0.021543501 PRB2 
ENSG00000110958 0.906247848 0.021543501 PTGES3 
ENSG00000120008 0.977011911 0.021543501 WDR11 
ENSG00000164935 3.474485116 0.021544725 DCSTAMP 
ENSG00000124882 1.716855743 0.021544725 EREG 
ENSG00000109576 1.46823606 0.021563871 AADAT 
ENSG00000132591 1.133144488 0.021587346 ERAL1 
ENSG00000163833 1.999144401 0.021587346 FBXO40 
ENSG00000103056 1.162913747 0.021587346 SMPD3 
ENSG00000139343 1.193162616 0.021587346 SNRPF 
ENSG00000155660 1.156213691 0.021593401 PDIA4 
ENSG00000149100 1.044285226 0.021597719 EIF3M 
ENSG00000111254 2.361532477 0.021747643 AKAP3 
ENSG00000118503 1.417704625 0.021747643 TNFAIP3 
ENSG00000101298 2.961237736 0.021843319 SNPH 
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ENSG00000163286 4.357038101 0.021907066 ALPPL2 
ENSG00000162396 2.033624591 0.021975024 PARS2 
ENSG00000160679 1.159239733 0.021988622 CHTOP 
ENSG00000101052 1.468706818 0.022009193 IFT52 
ENSG00000137860 1.73767077 0.022009193 SLC28A2 
ENSG00000100285 1.176771889 0.022012437 NEFH 
ENSG00000127074 1.922516172 0.022032084 RGS13 
ENSG00000171314 1.307318289 0.022054736 PGAM1 
ENSG00000139405 1.852106733 0.022054736 RITA1 
ENSG00000143977 1.378151199 0.022054736 SNRPG 
ENSG00000275885 1.126010884 0.022096307 PRPF31 
ENSG00000159166 3.216219152 0.022267043 LAD1 
ENSG00000073969 1.521719159 0.022289405 NSF 
ENSG00000163810 2.910962542 0.02229763 TGM4 
ENSG00000281886 2.910962542 0.02229763 TGM4 
ENSG00000171791 1.103891904 0.022304253 BCL2 
ENSG00000156411 1.255991144 0.022304253 C14orf2 
ENSG00000262814 1.407352032 0.022304253 MRPL12 
ENSG00000138166 2.220753103 0.022323464 DUSP5 
ENSG00000242028 1.692117307 0.022378828 HYPK 
ENSG00000072163 2.215531749 0.022390125 LIMS2 
ENSG00000196547 0.81159322 0.022390125 MAN2A2 
ENSG00000198650 2.372317736 0.022390125 TAT 
ENSG00000178988 1.261888948 0.022417846 MRFAP1L1 
ENSG00000188176 3.074650277 0.022422782 SMTNL2 
ENSG00000160014 1.183718676 0.022479625 CALM2 
ENSG00000176046 1.468413909 0.022479625 NUPR1 
ENSG00000150433 1.568034615 0.022479625 TMEM218 
ENSG00000144908 1.62407611 0.022549276 ALDH1L1 
ENSG00000198692 2.643066093 0.022561047 EIF1AY 
ENSG00000172244 1.676699348 0.022570061 C5orf34 
ENSG00000157119 4.000829355 0.022570061 KLHL40 
ENSG00000271605 1.785952584 0.022570061 MILR1 
ENSG00000187098 1.31774454 0.022570061 MITF 
ENSG00000168081 3.370598249 0.022570061 PNOC 
ENSG00000100823 1.064780388 0.022586411 APEX1 
ENSG00000131188 1.426938251 0.022586411 PRR7 
ENSG00000147654 1.211522937 0.022702609 EBAG9 
ENSG00000197345 1.169558585 0.022702609 MRPL21 
ENSG00000122176 2.29071764 0.022806686 FMOD 
ENSG00000109118 1.33081625 0.022820238 PHF12 
ENSG00000147408 1.184268427 0.022961331 CSGALNACT1 
ENSG00000131148 1.304687649 0.022961331 EMC8 
ENSG00000120699 1.063487784 0.022997057 EXOSC8 
ENSG00000126218 3.327831654 0.02300058 F10 
ENSG00000198856 1.273568194 0.02300058 OSTC 
ENSG00000165105 1.096510964 0.02300058 RASEF 
ENSG00000118363 1.272976744 0.02300058 SPCS2 
ENSG00000165409 2.042208683 0.02300058 TSHR 
ENSG00000198873 1.161307292 0.023015664 GRK5 
ENSG00000023445 1.33492502 0.023062393 BIRC3 
ENSG00000068878 1.22288122 0.023064168 PSME4 
ENSG00000197162 1.043762326 0.023080815 ZNF785 
ENSG00000181751 1.603462806 0.023163132 C5orf30 
ENSG00000198648 1.24188633 0.023169717 STK39 
ENSG00000135241 1.387044749 0.023253296 PNPLA8 
ENSG00000088826 2.043441565 0.023253296 SMOX 
ENSG00000121898 1.903482743 0.023273683 CPXM2 
ENSG00000179698 1.400933233 0.023279617 WDR97 
ENSG00000173578 3.07135102 0.023279617 XCR1 
ENSG00000269343 1.132343108 0.023279617 ZNF587B 
ENSG00000151806 1.083704472 0.023293568 GUF1 
ENSG00000129682 1.164942514 0.023340347 FGF13 
ENSG00000274026 1.709510691 0.023453172 FAM27E3 
ENSG00000080031 2.885077336 0.023453172 PTPRH 
ENSG00000115112 2.293705961 0.02347112 TFCP2L1 
ENSG00000010322 0.792772029 0.023481103 NISCH 
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ENSG00000186130 1.699881004 0.023522551 ZBTB6 
ENSG00000104413 3.561900501 0.02354407 ESRP1 
ENSG00000235715 2.235053329 0.02354407 PSMB8 
ENSG00000189120 3.317506045 0.02354407 SP6 
ENSG00000131467 1.041949083 0.023547701 PSME3 
ENSG00000132541 1.66314797 0.023574127 RIDA 
ENSG00000079950 1.195812581 0.023605675 STX7 
ENSG00000274734 8.611605629 0.023647355 ARHGAP11B 
ENSG00000118369 1.817762369 0.023647355 USP35 
ENSG00000172939 0.918967403 0.023655208 OXSR1 
ENSG00000125844 1.304515129 0.023688576 RRBP1 
ENSG00000204653 1.674824528 0.023820573 ASPDH 
ENSG00000166801 1.018253307 0.023820573 FAM111A 
ENSG00000161031 2.674717661 0.023820573 PGLYRP2 
ENSG00000189056 1.81131678 0.023820573 RELN 
ENSG00000065057 1.413411651 0.023821883 NTHL1 
ENSG00000136371 1.32768135 0.023833192 MTHFS 
ENSG00000055483 1.449483932 0.023924016 USP36 
ENSG00000123146 1.132395164 0.023970585 ADGRE5 
ENSG00000110104 1.464176438 0.023970585 CCDC86 
ENSG00000179091 1.167208447 0.023970585 CYC1 
ENSG00000178084 3.27688701 0.023970585 HTR3C 
ENSG00000155636 1.909850786 0.023970585 RBM45 
ENSG00000196600 1.545591397 0.023970585 SLC22A25 
ENSG00000018699 1.101401856 0.023979495 TTC27 
ENSG00000141446 0.829810222 0.024024219 ESCO1 
ENSG00000147894 1.033342387 0.024071663 C9orf72 
ENSG00000188107 1.249462332 0.024071663 EYS 
ENSG00000110169 2.909278827 0.024071663 HPX 
ENSG00000130294 2.443034743 0.024071663 KIF1A 
ENSG00000180764 1.73345513 0.024071663 PIPSL 
ENSG00000103472 1.118988757 0.024071663 RRN3P2 
ENSG00000162923 1.048624824 0.024071663 WDR26 
ENSG00000186529 1.836272528 0.024094898 CYP4F3 
ENSG00000112039 1.152964293 0.024094898 FANCE 
ENSG00000177272 4.124268562 0.024094898 KCNA3 
ENSG00000182253 2.064149818 0.024156902 SYNM 
ENSG00000143401 1.239938353 0.024248485 ANP32E 
ENSG00000151718 1.074221844 0.024248485 WWC2 
ENSG00000104081 1.637472513 0.024293189 BMF 
ENSG00000164032 1.194820615 0.024293189 H2AFZ 
ENSG00000116649 1.330830655 0.024308842 SRM 
ENSG00000109079 1.11389564 0.024308842 TNFAIP1 
ENSG00000122574 2.021074141 0.024308842 WIPF3 
ENSG00000148408 2.507291845 0.024386624 CACNA1B 
ENSG00000228284 1.006489292 0.024386624 HLA DQA1 
ENSG00000166126 2.473081452 0.024419405 AMN 
ENSG00000189233 1.339038514 0.024419405 NUGGC 
ENSG00000174990 1.310418807 0.024438043 CA5A 
ENSG00000124313 1.768464575 0.024531794 IQSEC2 
ENSG00000007062 0.930186718 0.024531794 PROM1 
ENSG00000187862 1.662140312 0.024557763 TTC24 
ENSG00000100726 1.074281782 0.02460044 TELO2 
ENSG00000168275 2.095560601 0.024806299 COA6 
ENSG00000135912 1.07148502 0.02482324 TTLL4 
ENSG00000108342 3.062754768 0.024873674 CSF3 
ENSG00000027869 1.554519753 0.024873674 SH2D2A 
ENSG00000065923 1.059951481 0.024873674 SLC9A7 
ENSG00000143476 1.328904054 0.024908853 DTL 
ENSG00000077684 0.977169057 0.024908853 JADE1 
ENSG00000263006 1.563110216 0.024908853 ROCK1P1 
ENSG00000129946 2.18078659 0.024908853 SHC2 
ENSG00000274803 1.567278084 0.024911913 BDP1 
ENSG00000101220 1.588766562 0.024911913 C20orf27 
ENSG00000145293 1.287747188 0.024962265 ENOPH1 
ENSG00000197406 3.770935802 0.025012946 DIO3 
ENSG00000188343 1.186991755 0.025048388 FAM92A 
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ENSG00000101076 1.70843872 0.025055765 HNF4A 
ENSG00000166897 2.299503327 0.025182589 ELFN2 
ENSG00000145332 1.103038453 0.02518835 KLHL8 
ENSG00000165283 1.255296037 0.025205143 STOML2 
ENSG00000105609 2.061606024 0.025208823 LILRB5 
ENSG00000056050 1.796865656 0.02524732 HPF1 
ENSG00000054967 1.381629968 0.02524732 RELT 
ENSG00000139437 0.968900737 0.02524732 TCHP 
ENSG00000148154 1.59204825 0.025397838 UGCG 
ENSG00000105472 1.499695285 0.025414834 CLEC11A 
ENSG00000020129 1.170698108 0.025414834 NCDN 
ENSG00000164168 1.187074906 0.025414834 TMEM184C 
ENSG00000164393 1.711305021 0.025451128 ADGRF2 
ENSG00000125485 1.261206191 0.025451128 DDX31 
ENSG00000175054 1.005120508 0.025468043 ATR 
ENSG00000105549 2.380771125 0.025469604 THEG 
ENSG00000158786 2.553424744 0.025522551 PLA2G2F 
ENSG00000122025 1.167689434 0.025572332 FLT3 
ENSG00000275342 1.314139166 0.025572332 PRAG1 
ENSG00000134987 1.327091017 0.025613988 WDR36 
ENSG00000205642 3.112164886 0.025638964 VCX3B 
ENSG00000221914 0.920547524 0.025641696 PPP2R2A 
ENSG00000105388 2.628653893 0.025660843 CEACAM5 
ENSG00000185664 1.944698014 0.025660843 PMEL 
ENSG00000163751 2.252078031 0.025661559 CPA3 
ENSG00000179348 1.328428811 0.025661559 GATA2 
ENSG00000153767 1.454529871 0.025661559 GTF2E1 
ENSG00000173113 1.199811361 0.025661559 TRMT112 
ENSG00000044459 0.917852979 0.025692037 CNTLN 
ENSG00000142459 1.022957289 0.025712456 EVI5L 
ENSG00000206579 1.466197301 0.025712456 XKR4 
ENSG00000172478 1.85692088 0.025722853 C2orf54 
ENSG00000185483 2.288580819 0.025806428 ROR1 
ENSG00000124733 1.263259261 0.025913607 MEA1 
ENSG00000116353 1.287302551 0.025947583 MECR 
ENSG00000100068 1.313639415 0.025966965 LRP5L 
ENSG00000168906 1.082211698 0.025966965 MAT2A 
ENSG00000152359 1.476531195 0.025966965 POC5 
ENSG00000124092 1.151010884 0.026020563 CTCFL 
ENSG00000173227 1.999259098 0.026020563 SYT12 
ENSG00000181458 1.206852839 0.026021284 TMEM45A 
ENSG00000007384 1.309419733 0.026026915 RHBDF1 
ENSG00000128342 2.465680912 0.02602734 LIF 
ENSG00000148308 0.835229323 0.026034134 GTF3C5 
ENSG00000168758 1.099923997 0.026076708 SEMA4C 
ENSG00000130305 1.230678661 0.026088324 NSUN5 
ENSG00000078237 2.064721432 0.026093995 TIGAR 
ENSG00000146926 5.238271556 0.026157091 ASB10 
ENSG00000189182 3.342910376 0.026157091 KRT77 
ENSG00000095303 1.239641575 0.02618663 PTGS1 
ENSG00000151967 1.400418684 0.02618663 SCHIP1 
ENSG00000177830 0.883562495 0.026218043 CHID1 
ENSG00000139344 1.594513313 0.0263227 AMDHD1 
ENSG00000113749 2.061448815 0.0263227 HRH2 
ENSG00000129194 2.653494254 0.0263227 SOX15 
ENSG00000152936 1.645263045 0.026420686 LMNTD1 
ENSG00000123485 1.606679977 0.026450663 HJURP 
ENSG00000115232 0.926184096 0.026454423 ITGA4 
ENSG00000186564 2.688529135 0.026542862 FOXD2 
ENSG00000130762 1.434213695 0.026559069 ARHGEF16 
ENSG00000086696 1.110045075 0.026559069 HSD17B2 
ENSG00000231824 5.273694306 0.026559608 AKAIN1 
ENSG00000186665 1.928610465 0.026559608 C17orf58 
ENSG00000065618 1.611810775 0.026583462 COL17A1 
ENSG00000158486 1.675789632 0.026583462 DNAH3 
ENSG00000137094 2.277445766 0.026583462 DNAJB5 
ENSG00000197102 1.0899515 0.026583462 DYNC1H1 
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ENSG00000152580 1.253321764 0.026584857 IGSF10 
ENSG00000162407 2.015840518 0.026584857 PLPP3 
ENSG00000185507 1.072000561 0.02664246 IRF7 
ENSG00000134830 1.203886068 0.026660206 C5AR2 
ENSG00000198286 0.992183399 0.026660206 CARD11 
ENSG00000130202 1.135945403 0.026660206 NECTIN2 
ENSG00000134815 1.015792175 0.026728612 DHX34 
ENSG00000146263 0.927165558 0.0267635 MMS22L 
ENSG00000172403 1.505090332 0.026774024 SYNPO2 
ENSG00000119547 2.704010016 0.026844462 ONECUT2 
ENSG00000184281 1.495421592 0.026844462 TSSC4 
ENSG00000076108 1.213921861 0.026951862 BAZ2A 
ENSG00000074071 1.518082068 0.026951862 MRPS34 
ENSG00000269437 2.232868294 0.026951862 NXF2B 
ENSG00000119392 1.210703788 0.027013196 GLE1 
ENSG00000151834 1.649567639 0.027038372 GABRA2 
ENSG00000176945 3.784364205 0.02705488 MUC20 
ENSG00000279761 6.150585875 0.02705488 OR5D13 
ENSG00000117868 0.953007988 0.027066969 ESYT2 
ENSG00000185958 1.382623215 0.027098399 FAM186A 
ENSG00000116062 1.125805983 0.027098399 MSH6 
ENSG00000161714 1.442710024 0.027098399 PLCD3 
ENSG00000085377 1.161609337 0.027098399 PREP 
ENSG00000165186 1.798343609 0.027098399 PTCHD1 
ENSG00000100647 1.281690441 0.027098399 SUSD6 
ENSG00000187066 1.653201087 0.027098399 TMEM262 
ENSG00000149150 1.01497603 0.027099433 SLC43A1 
ENSG00000198298 1.581998368 0.027116333 ZNF485 
ENSG00000102796 1.000400252 0.02712817 DHRS12 
ENSG00000099139 1.634909232 0.02712817 PCSK5 
ENSG00000146070 1.693701463 0.02712817 PLA2G7 
ENSG00000176170 1.80401585 0.02712817 SPHK1 
ENSG00000120438 0.842935501 0.027254654 TCP1 
ENSG00000197601 0.826313403 0.027284955 FAR1 
ENSG00000148834 0.990504863 0.027300003 GSTO1 
ENSG00000226763 1.578647917 0.027300003 SRRM5 
ENSG00000148700 0.98568878 0.027316786 ADD3 
ENSG00000138759 1.906462218 0.027316786 FRAS1 
ENSG00000197713 1.193232949 0.027316786 RPE 
ENSG00000185238 1.169447423 0.027363466 PRMT3 
ENSG00000155868 1.348022853 0.027403563 MED7 
ENSG00000170458 2.361336292 0.027416571 CD14 
ENSG00000116127 0.989941141 0.027435093 ALMS1 
ENSG00000141526 1.659019875 0.027435093 SLC16A3 
ENSG00000163041 1.077542078 0.027473502 H3F3A 
ENSG00000143106 1.177817979 0.027662131 PSMA5 
ENSG00000251380 6.227523852 0.0276826 DCANP1 
ENSG00000189299 5.254445566 0.027758789 FOXR2 
ENSG00000147883 3.056916967 0.027817597 CDKN2B 
ENSG00000117036 1.290154892 0.027852338 ETV3 
ENSG00000184454 1.476440364 0.027929854 NCMAP 
ENSG00000040341 1.219508263 0.027954667 STAU2 
ENSG00000116785 2.052773748 0.027989949 CFHR3 
ENSG00000005175 1.359437191 0.027989949 RPAP3 
ENSG00000058085 2.614816603 0.028041892 LAMC2 
ENSG00000185164 1.128545699 0.028041892 NOMO2 
ENSG00000204444 2.001544577 0.028131753 APOM 
ENSG00000167447 1.140008982 0.028194109 SMG8 
ENSG00000074201 0.939002232 0.02826198 CLNS1A 
ENSG00000009765 1.517879626 0.028297968 IYD 
ENSG00000173465 1.926669137 0.028297968 SSSCA1 
ENSG00000173334 1.675048445 0.028301992 TRIB1 
ENSG00000185055 1.608273509 0.028351642 EFCAB10 
ENSG00000170370 1.641400007 0.028351642 EMX2 
ENSG00000139974 1.480071353 0.028351642 SLC38A6 
ENSG00000094916 1.145484948 0.028357762 CBX5 
ENSG00000229185 4.246798974 0.028380617 OR2H2 
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ENSG00000168118 1.186741108 0.028380617 RAB4A 
ENSG00000107295 3.453050435 0.028380617 SH3GL2 
ENSG00000156009 4.040645776 0.028408426 MAGEA8 
ENSG00000125977 1.128901496 0.028528421 EIF2S2 
ENSG00000100629 0.941973285 0.028547189 CEP128 
ENSG00000119203 1.106635634 0.02857179 CPSF3 
ENSG00000167723 1.863555962 0.028574376 TRPV3 
ENSG00000269404 1.311730765 0.028605216 SPIB 
ENSG00000143183 1.252791206 0.028692429 TMCO1 
ENSG00000121766 1.174913443 0.028721495 ZCCHC17 
ENSG00000198700 1.225525398 0.028733588 IPO9 
ENSG00000197768 2.6512992 0.028733588 STPG3 
ENSG00000178209 1.108860086 0.028743995 PLEC 
ENSG00000112667 1.53404538 0.028778199 DNPH1 
ENSG00000154813 1.273171941 0.028778199 DPH3 
ENSG00000105939 1.042183623 0.028778199 ZC3HAV1 
ENSG00000103496 0.972714156 0.028829689 STX4 
ENSG00000135046 2.26812839 0.028831931 ANXA1 
ENSG00000139684 1.209815586 0.028831931 ESD 
ENSG00000174776 1.989412169 0.028831931 WDR49 
ENSG00000154359 1.139398464 0.02886942 LONRF1 
ENSG00000114270 1.688025924 0.028873827 COL7A1 
ENSG00000176124 1.087411146 0.028896525 DLEU1 
ENSG00000171657 2.247671656 0.028899232 GPR82 
ENSG00000099725 1.744692073 0.028953214 PRKY 
ENSG00000152253 1.311869978 0.028953214 SPC25 
ENSG00000263247 1.367210427 0.028987456 PRR4 
ENSG00000152495 2.153245107 0.029003074 CAMK4 
ENSG00000196188 2.327234943 0.029003074 CTSE 
ENSG00000114491 1.672265085 0.029003074 UMPS 
ENSG00000007516 1.444005893 0.029025967 BAIAP3 
ENSG00000132823 1.282268624 0.029082569 OSER1 
ENSG00000086189 1.066310381 0.029140593 DIMT1 
ENSG00000106348 1.310351525 0.029140593 IMPDH1 
ENSG00000146918 1.416918709 0.029140593 NCAPG2 
ENSG00000100567 0.984080218 0.029140593 PSMA3 
ENSG00000108064 1.321228164 0.029140593 TFAM 
ENSG00000147124 1.462307948 0.029159718 ZNF41 
ENSG00000197965 1.20695602 0.029179812 MPZL1 
ENSG00000230873 1.691472828 0.029179812 STMND1 
ENSG00000169627 1.445227317 0.029317761 BOLA2 
ENSG00000188483 1.277414011 0.02935328 IER5L 
ENSG00000072840 1.197084356 0.029385412 EVC 
ENSG00000096006 5.234552448 0.029386611 CRISP3 
ENSG00000216490 1.727630602 0.029396596 IFI30 
ENSG00000135002 1.09289308 0.029514814 RFK 
ENSG00000164430 1.160910554 0.02954794 CGAS 
ENSG00000111358 1.284993298 0.02954794 GTF2H3 
ENSG00000099284 1.294911247 0.02954794 H2AFY2 
ENSG00000206052 2.466484676 0.02955195 DOK6 
ENSG00000150637 1.663723115 0.029574914 CD226 
ENSG00000205085 1.146024935 0.029647519 FAM71F2 
ENSG00000139645 0.975637173 0.029663443 ANKRD52 
ENSG00000123191 1.788969816 0.029663443 ATP7B 
ENSG00000156162 1.202362533 0.029663443 DPY19L4 
ENSG00000011600 1.84667464 0.029663443 TYROBP 
ENSG00000144366 2.252391201 0.029675184 GULP1 
ENSG00000278637 1.471990755 0.029705834 HIST1H4A 
ENSG00000135925 3.802955916 0.029705834 WNT10A 
ENSG00000157087 2.083358801 0.029737871 ATP2B2 
ENSG00000145451 2.055151962 0.029840791 GLRA3 
ENSG00000237071 2.851085605 0.029971447 TRIM27 
ENSG00000236279 3.950958091 0.029980333 CLEC2L 
ENSG00000148824 0.951447049 0.029980333 MTG1 
ENSG00000187583 4.038142523 0.029980333 PLEKHN1 
ENSG00000100462 1.023032791 0.030014121 PRMT5 
ENSG00000183878 5.721143664 0.030014121 UTY 
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ENSG00000197405 1.513130498 0.030140185 C5AR1 
ENSG00000128510 1.89706843 0.030224692 CPA4 
ENSG00000180881 1.136889694 0.030252855 CAPS2 
ENSG00000175311 1.398956721 0.030261303 ANKS4B 
ENSG00000106211 1.121085773 0.030261303 HSPB1 
ENSG00000112096 1.067690741 0.030282527 SOD2 
ENSG00000258839 1.260938686 0.030287292 MC1R 
ENSG00000188959 1.794620325 0.030288333 C9orf152 
ENSG00000008256 1.570193358 0.030312331 CYTH3 
ENSG00000161638 1.58937639 0.030312331 ITGA5 
ENSG00000188011 5.123188524 0.030312331 RTP5 
ENSG00000277949 5.123188524 0.030312331 RTP5 
ENSG00000211450 1.202360655 0.030312331 SELENOH 
ENSG00000032219 1.082543387 0.030347871 ARID4A 
ENSG00000140598 0.856274082 0.030347871 EFL1 
ENSG00000133216 1.611105294 0.030347871 EPHB2 
ENSG00000198885 1.562581399 0.030347871 ITPRIPL1 
ENSG00000182450 4.735617295 0.030347871 KCNK4 
ENSG00000163935 1.969584291 0.030347871 SFMBT1 
ENSG00000052749 1.098007834 0.030402054 RRP12 
ENSG00000251595 2.070904212 0.030402438 ABCA11P 
ENSG00000162383 2.860878326 0.030402438 SLC1A7 
ENSG00000182583 2.30487779 0.030402438 VCX 
ENSG00000173715 1.466614366 0.030419141 C11orf80 
ENSG00000240972 1.311223432 0.030419141 MIF 
ENSG00000276701 1.311223432 0.030419141 MIF 
ENSG00000174607 1.367212173 0.030419141 UGT8 
ENSG00000124557 3.042153645 0.030443937 BTN1A1 
ENSG00000136274 2.440939911 0.030470938 NACAD 
ENSG00000135845 1.702029121 0.030470938 PIGC 
ENSG00000156218 1.165842102 0.030495375 ADAMTSL3 
ENSG00000272916 1.124468998 0.030553523 NDST2 
ENSG00000181788 1.579614078 0.030553523 SIAH2 
ENSG00000188710 3.28570236 0.030569325 QRFP 
ENSG00000076864 2.257006588 0.030569325 RAP1GAP 
ENSG00000126768 1.233847626 0.030569325 TIMM17B 
ENSG00000130598 1.930828356 0.030569325 TNNI2 
ENSG00000130204 1.356703141 0.030569325 TOMM40 
ENSG00000147394 1.606548672 0.030606947 ZNF185 
ENSG00000141664 1.229077681 0.030614307 ZCCHC2 
ENSG00000105771 0.830207165 0.030677631 SMG9 
ENSG00000196391 1.272593313 0.030677631 ZNF774 
ENSG00000007174 1.994037955 0.03068621 DNAH9 
ENSG00000203734 2.266279744 0.030744049 ECT2L 
ENSG00000153391 1.090365772 0.030744049 INO80C 
ENSG00000213024 1.112708847 0.030744049 NUP62 
ENSG00000197417 1.056226519 0.030744049 SHPK 
ENSG00000164543 1.325697954 0.030744049 STK17A 
ENSG00000023902 1.288904215 0.030867182 PLEKHO1 
ENSG00000145220 1.50319018 0.03092628 LYAR 
ENSG00000213619 0.949066505 0.03092628 NDUFS3 
ENSG00000198723 1.955853149 0.031050631 TEX45 
ENSG00000173214 1.099485977 0.031062662 MFSD4B 
ENSG00000125741 1.503252479 0.031062662 OPA3 
ENSG00000175785 4.346786898 0.031062662 PRIMA1 
ENSG00000274089 4.346786898 0.031062662 PRIMA1 
ENSG00000183576 0.861606159 0.031099253 SETD3 
ENSG00000077348 1.21308395 0.031115716 EXOSC5 
ENSG00000134317 1.796524863 0.031115716 GRHL1 
ENSG00000144224 1.257075034 0.031115716 UBXN4 
ENSG00000236446 5.841529816 0.031133857 CT47B1 
ENSG00000196924 1.464064177 0.031133857 FLNA 
ENSG00000163395 2.329340098 0.031133857 IGFN1 
ENSG00000170807 2.828494744 0.031133857 LMOD2 
ENSG00000111341 1.6193564 0.031133857 MGP 
ENSG00000143799 1.139138 0.031133857 PARP1 
ENSG00000106344 1.241959976 0.031133857 RBM28 
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ENSG00000171729 1.48530256 0.031133857 TMEM51 
ENSG00000160953 0.752379143 0.031195323 MUM1 
ENSG00000100813 1.005315406 0.03128579 ACIN1 
ENSG00000115526 1.801153805 0.03128579 CHST10 
ENSG00000110492 1.328098203 0.03128579 MDK 
ENSG00000189308 0.933254412 0.03131918 LIN54 
ENSG00000033867 1.103985946 0.031445805 SLC4A7 
ENSG00000048707 0.785396733 0.031456474 VPS13D 
ENSG00000186642 1.811347716 0.03147138 PDE2A 
ENSG00000198346 1.115232579 0.03147138 ZNF813 
ENSG00000146540 1.135976778 0.031510116 C7orf50 
ENSG00000183765 1.132744077 0.031510116 CHEK2 
ENSG00000111364 1.026522647 0.031510116 DDX55 
ENSG00000111834 1.867564564 0.031510116 RSPH4A 
ENSG00000106355 1.040615486 0.031566058 LSM5 
ENSG00000113905 1.569168332 0.031705751 HRG 
ENSG00000170153 0.990654783 0.031717712 RNF150 
ENSG00000122367 2.49371028 0.031727977 LDB3 
ENSG00000137801 2.037892311 0.031754826 THBS1 
ENSG00000104327 1.460878198 0.031755709 CALB1 
ENSG00000275045 2.08531608 0.031814977 GTF2H2 
ENSG00000162616 1.327258934 0.031830244 DNAJB4 
ENSG00000222047 1.952193911 0.031932336 C10orf55 
ENSG00000124701 2.912826216 0.031955408 APOBEC2 
ENSG00000261236 1.032705006 0.031991099 BOP1 
ENSG00000075790 1.417846995 0.031995585 BCAP29 
ENSG00000183311 1.638117493 0.032083936 TUBB 
ENSG00000164011 1.61051789 0.032117581 ZNF691 
ENSG00000169019 2.423009235 0.032126924 COMMD8 
ENSG00000140044 1.325672043 0.032126924 JDP2 
ENSG00000173212 1.170242036 0.032126924 MAB21L3 
ENSG00000111731 0.969867015 0.032195686 C2CD5 
ENSG00000119729 1.128035054 0.032202986 RHOQ 
ENSG00000126432 1.261939323 0.032250342 PRDX5 
ENSG00000166557 1.032997845 0.032250342 TMED3 
ENSG00000141655 1.54573351 0.032250342 TNFRSF11A 
ENSG00000119801 0.93709271 0.032250342 YPEL5 
ENSG00000165891 1.835793901 0.032253537 E2F7 
ENSG00000143554 1.122046029 0.032295385 SLC27A3 
ENSG00000197540 3.244512731 0.032310962 GZMM 
ENSG00000100644 0.880214462 0.032310962 HIF1A 
ENSG00000221826 2.437115556 0.032310962 PSG3 
ENSG00000157782 1.617545622 0.032326733 CABP1 
ENSG00000166265 1.62546006 0.032422142 CYYR1 
ENSG00000081277 3.046596095 0.032422142 PKP1 
ENSG00000165731 2.580072095 0.03242599 RET 
ENSG00000159450 1.707445289 0.032431428 TCHH 
ENSG00000112782 2.78455657 0.032484815 CLIC5 
ENSG00000065150 0.931625199 0.032484815 IPO5 
ENSG00000148362 1.404158744 0.032484815 PAXX 
ENSG00000182054 1.046575682 0.032503809 IDH2 
ENSG00000213801 1.6180132 0.032544522 ZNF321P 
ENSG00000008517 1.406722374 0.032555257 IL32 
ENSG00000104320 0.939528921 0.032555257 NBN 
ENSG00000112365 1.139803449 0.032555257 ZBTB24 
ENSG00000075340 1.932692953 0.032561327 ADD2 
ENSG00000162757 1.470234515 0.032561327 C1orf74 
ENSG00000188313 0.954555375 0.032575571 PLSCR1 
ENSG00000109819 1.40278595 0.032598668 PPARGC1A 
ENSG00000168404 0.814784094 0.032631697 MLKL 
ENSG00000034677 0.80391202 0.03263874 RNF19A 
ENSG00000141543 0.950440581 0.032687527 EIF4A3 
ENSG00000162728 3.019248388 0.032687527 KCNJ9 
ENSG00000138050 0.884010059 0.032688673 THUMPD2 
ENSG00000006747 1.186913668 0.032754919 SCIN 
ENSG00000146267 1.998320047 0.032770194 FAXC 
ENSG00000162813 1.291619928 0.032772757 BPNT1 
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ENSG00000275397 5.835359138 0.032772757 DHRS11 
ENSG00000186453 3.307000816 0.032772757 FAM228A 
ENSG00000123104 0.872499029 0.032772757 ITPR2 
ENSG00000147955 1.413700513 0.032772757 SIGMAR1 
ENSG00000197106 1.55626937 0.032772757 SLC6A17 
ENSG00000213551 1.109566259 0.032795035 DNAJC9 
ENSG00000135778 1.135063339 0.03286672 NTPCR 
ENSG00000050438 0.975750936 0.03287528 SLC4A8 
ENSG00000159055 1.942121407 0.033129422 MIS18A 
ENSG00000168658 1.863773274 0.033197519 VWA3B 
ENSG00000115590 3.776753652 0.033234249 IL1R2 
ENSG00000184270 0.957586285 0.033277715 HIST2H2AB 
ENSG00000114378 1.954040193 0.033277715 HYAL1 
ENSG00000163161 0.856294013 0.033304751 ERCC3 
ENSG00000158691 0.93261064 0.033305368 ZSCAN12 
ENSG00000278272 1.604698089 0.03336114 HIST1H3C 
ENSG00000170442 3.981545234 0.03336114 KRT86 
ENSG00000160193 1.2196639 0.03336114 WDR4 
ENSG00000123131 1.314183725 0.033481952 PRDX4 
ENSG00000169174 2.840828604 0.033566434 PCSK9 
ENSG00000171621 2.723614518 0.033641006 SPSB1 
ENSG00000169894 1.415479327 0.033689104 MUC3A 
ENSG00000107758 1.175359503 0.033777769 PPP3CB 
ENSG00000189292 3.275089937 0.033791917 ALKAL2 
ENSG00000278437 3.791087278 0.033791917 LILRB5 
ENSG00000137727 1.252068928 0.033841693 ARHGAP20 
ENSG00000164776 1.448531668 0.033933351 PHKG1 
ENSG00000258130 1.46867673 0.033950161 LOC613038 
ENSG00000136143 1.418269219 0.034264154 SUCLA2 
ENSG00000188130 0.960879708 0.034288289 MAPK12 
ENSG00000206073 5.89385689 0.034317073 SERPINB4 
ENSG00000166797 1.33400616 0.034375464 FAM96A 
ENSG00000196767 2.924720063 0.034474962 POU3F4 
ENSG00000166073 2.583515753 0.034488314 GPR176 
ENSG00000132383 0.912406063 0.034488314 RPA1 
ENSG00000165724 1.277235613 0.034488314 ZMYND19 
ENSG00000177034 1.194660546 0.034491754 MTX3 
ENSG00000135540 0.882853704 0.034523873 NHSL1 
ENSG00000117592 0.976178336 0.034551702 PRDX6 
ENSG00000108370 1.752563567 0.034551702 RGS9 
ENSG00000186448 1.25762046 0.034560874 ZNF197 
ENSG00000281709 1.25762046 0.034560874 ZNF197 
ENSG00000174353 0.956969203 0.034737257 TRIM74 
ENSG00000188816 4.135406437 0.03484838 HMX2 
ENSG00000173085 1.290157902 0.034888087 COQ2 
ENSG00000144488 2.662637804 0.034940398 ESPNL 
ENSG00000134533 1.580479892 0.03495407 RERG 
ENSG00000175110 1.095574623 0.034969846 MRPS22 
ENSG00000218336 2.335206751 0.034982666 TENM3 
ENSG00000166167 0.908476706 0.035002744 BTRC 
ENSG00000119333 1.235711268 0.03504354 WDR34 
ENSG00000274821 3.778331191 0.035092997 SERPINA2 
ENSG00000101868 1.034379954 0.03524419 POLA1 
ENSG00000134323 1.520752435 0.035284099 MYCN 
ENSG00000141574 3.378398466 0.035284099 SECTM1 
ENSG00000163159 1.128575177 0.035307456 VPS72 
ENSG00000168610 1.137033257 0.035425934 STAT3 
ENSG00000125962 1.230638948 0.035475181 ARMCX5 
ENSG00000140379 2.203747192 0.035494143 BCL2A1 
ENSG00000103550 1.414263603 0.035513094 KNOP1 
ENSG00000148400 0.89627652 0.035535377 NOTCH1 
ENSG00000149527 1.985652415 0.035537674 PLCH2 
ENSG00000176472 1.50014108 0.035537674 ZNF575 
ENSG00000170498 5.642600654 0.035554612 KISS1 
ENSG00000148143 1.03137453 0.035575426 ZNF462 
ENSG00000109787 1.19161398 0.035688369 KLF3 
ENSG00000052850 2.162425892 0.035751455 ALX4 
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ENSG00000216937 1.182621449 0.035751455 CCDC7 
ENSG00000082516 1.159223972 0.035751455 GEMIN5 
ENSG00000175287 1.497304301 0.035751455 PHYHD1 
ENSG00000156171 1.298021138 0.035772867 DRAM2 
ENSG00000131142 5.555967141 0.035860421 CCL25 
ENSG00000138663 1.219547978 0.035889998 COPS4 
ENSG00000038295 2.868196474 0.035889998 TLL1 
ENSG00000119777 1.034351957 0.035889998 TMEM214 
ENSG00000188290 2.450537313 0.035938488 HES4 
ENSG00000135824 2.70369277 0.036019106 RGS8 
ENSG00000181789 0.905608042 0.036021614 COPG1 
ENSG00000174326 2.265557475 0.036033946 SLC16A11 
ENSG00000167612 3.041270699 0.036073385 ANKRD33 
ENSG00000123843 1.15201882 0.036078395 C4BPB 
ENSG00000183317 1.788024759 0.036133675 EPHA10 
ENSG00000276907 2.48293276 0.036177417 ARHGAP27 
ENSG00000119977 1.185708741 0.036272277 TCTN3 
ENSG00000119714 2.152273152 0.036387843 GPR68 
ENSG00000155827 1.045071357 0.036387843 RNF20 
ENSG00000149742 1.712627571 0.036387843 SLC22A9 
ENSG00000128915 0.907485118 0.036398639 ICE2 
ENSG00000179477 2.500397383 0.036554065 ALOX12B 
ENSG00000172260 1.087699165 0.036554065 NEGR1 
ENSG00000164463 0.958753223 0.036584561 CREBRF 
ENSG00000184647 2.606417061 0.036584561 PRSS55 
ENSG00000104941 2.035131103 0.036584561 RSPH6A 
ENSG00000139921 1.36838089 0.036584561 TMX1 
ENSG00000260103 1.024480495 0.036589846 LOC101929333 
ENSG00000214290 4.927154162 0.036596373 COLCA2 
ENSG00000235942 5.046393035 0.036622766 LCE6A 
ENSG00000171530 0.987089687 0.036622766 TBCA 
ENSG00000163518 2.530336395 0.03665078 FCRL4 
ENSG00000204183 1.987560474 0.036682908 GDF5OS 
ENSG00000182333 4.863870367 0.036682908 LIPF 
ENSG00000183648 1.148788736 0.036682908 NDUFB1 
ENSG00000143869 1.619252374 0.036682995 GDF7 
ENSG00000137501 1.294730828 0.036694278 SYTL2 
ENSG00000095397 1.904562276 0.036766881 WHRN 
ENSG00000102401 1.05400663 0.036945209 ARMCX3 
ENSG00000181013 3.67172236 0.036949515 C17orf47 
ENSG00000197006 0.879956492 0.036949515 METTL9 
ENSG00000134339 1.801396643 0.036949515 SAA2 
ENSG00000163755 1.246644829 0.036983192 HPS3 
ENSG00000177191 1.649357135 0.036997243 B3GNT8 
ENSG00000168418 1.337078355 0.037085237 KCNG4 
ENSG00000088812 0.919314644 0.037127463 ATRN 
ENSG00000180992 1.485632174 0.037193154 MRPL14 
ENSG00000151176 1.188139166 0.037322133 PLBD2 
ENSG00000115762 1.105317736 0.037322133 PLEKHB2 
ENSG00000167487 1.213171677 0.037370469 KLHL26 
ENSG00000106554 1.074995988 0.037373522 CHCHD3 
ENSG00000182326 1.214697026 0.037435474 C1S 
ENSG00000162604 0.963706871 0.037440201 TM2D1 
ENSG00000183779 1.946243746 0.037448794 ZNF703 
ENSG00000235173 1.647211622 0.037458402 HGH1 
ENSG00000107187 2.470356639 0.037519514 LHX3 
ENSG00000148702 3.228549776 0.037639362 HABP2 
ENSG00000007908 2.911320149 0.037744939 SELE 
ENSG00000204655 4.5355328 0.03776758 MOG 
ENSG00000056972 0.967526752 0.037773888 TRAF3IP2 
ENSG00000175793 2.450229958 0.037781112 SFN 
ENSG00000138769 3.330366326 0.037828105 CDKL2 
ENSG00000134255 0.925964646 0.037919719 CEPT1 
ENSG00000100422 1.116386756 0.037919719 CERK 
ENSG00000135747 1.161524454 0.037919719 ZNF670 ZNF695 
ENSG00000102554 1.992466671 0.037921293 KLF5 
ENSG00000159199 1.445275685 0.037921625 ATP5G1 
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ENSG00000167103 2.115365579 0.037921625 PIP5KL1 
ENSG00000174945 1.48782619 0.03793898 AMZ1 
ENSG00000106829 0.829791494 0.037964254 TLE4 
ENSG00000103326 0.814294853 0.038003468 CAPN15 
ENSG00000078967 1.00516806 0.038073272 UBE2D4 
ENSG00000138675 1.811274525 0.038076619 FGF5 
ENSG00000232062 5.470338737 0.038076619 HLA DQA1 
ENSG00000263163 1.210857842 0.038076619 SLC27A3 
ENSG00000138162 1.312088012 0.038089178 TACC2 
ENSG00000179915 1.547638786 0.038119143 NRXN1 
ENSG00000070367 1.011295669 0.038122173 EXOC5 
ENSG00000172771 1.276604427 0.038231753 EFCAB12 
ENSG00000143107 3.03009921 0.038231753 FNDC7 
ENSG00000142798 1.271806654 0.038231753 HSPG2 
ENSG00000163599 3.272455762 0.038445006 CTLA4 
ENSG00000198837 0.724317378 0.038445006 DENND4B 
ENSG00000135835 1.60015162 0.038445006 KIAA1614 
ENSG00000099250 1.451481829 0.038445006 NRP1 
ENSG00000128271 1.794042331 0.038547984 ADORA2A 
ENSG00000152234 1.057768355 0.038668932 ATP5A1 
ENSG00000224531 1.43576971 0.038673161 SMIM13 
ENSG00000112367 1.4212673 0.038679306 FIG4 
ENSG00000165125 1.640956644 0.038734343 TRPV6 
ENSG00000099814 2.059674348 0.038806181 CEP170B 
ENSG00000154237 1.029630244 0.038806181 LRRK1 
ENSG00000157064 1.907889252 0.038806181 NMNAT2 
ENSG00000233917 6.173738341 0.038806181 POTEB 
ENSG00000081870 1.10281087 0.03888565 HSPB11 
ENSG00000162643 4.093058081 0.03888565 WDR63 
ENSG00000183018 0.970697316 0.038912299 SPNS2 
ENSG00000174358 2.914571012 0.038917892 SLC6A19 
ENSG00000126088 0.95443833 0.039072656 UROD 
ENSG00000198576 2.00168387 0.039091125 ARC 
ENSG00000106331 2.304031456 0.039091125 PAX4 
ENSG00000112511 1.719004372 0.039213829 PHF1 
ENSG00000139973 1.46685091 0.039216824 SYT16 
ENSG00000243649 2.127187182 0.03928032 CFB 
ENSG00000228253 1.030835825 0.039310753 ATP8 
ENSG00000146376 1.472396961 0.039330893 ARHGAP18 
ENSG00000170248 0.955552046 0.039350208 PDCD6IP 
ENSG00000166803 1.097937698 0.039457697 PCLAF 
ENSG00000151320 1.53626998 0.039540497 AKAP6 
ENSG00000132199 0.952255316 0.039540497 ENOSF1 
ENSG00000268869 2.441903673 0.039540497 ESPNP 
ENSG00000102383 1.099431707 0.039540497 ZDHHC15 
ENSG00000102962 1.320278399 0.039583555 CCL22 
ENSG00000095139 0.981336038 0.039648174 ARCN1 
ENSG00000175455 0.938726038 0.039648174 CCDC14 
ENSG00000275395 2.757472483 0.039648174 FCGBP 
ENSG00000134324 1.243706991 0.039648174 LPIN1 
ENSG00000146007 1.120023588 0.039648174 ZMAT2 
ENSG00000152082 1.074744965 0.039684472 MZT2B 
ENSG00000114446 0.920355308 0.039685977 IFT57 
ENSG00000140478 2.072544111 0.039710526 GOLGA6D 
ENSG00000141371 3.421972636 0.039713397 C17orf64 
ENSG00000189337 1.265769081 0.039757266 KAZN 
ENSG00000166292 3.334551732 0.039757266 TMEM100 
ENSG00000166682 2.002699118 0.039768919 TMPRSS5 
ENSG00000185347 1.420680978 0.039779781 TEDC1 
ENSG00000150779 1.828946567 0.039978482 TIMM8B 
ENSG00000163872 0.738619142 0.039995771 YEATS2 
ENSG00000135446 1.132483846 0.04004944 CDK4 
ENSG00000146221 2.402738502 0.040066101 TCTE1 
ENSG00000151148 1.142705327 0.040066101 UBE3B 
ENSG00000163468 1.086926685 0.040144465 CCT3 
ENSG00000160888 1.457903241 0.040176237 IER2 
ENSG00000145912 1.03072328 0.040176237 NHP2 
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ENSG00000146757 1.435055049 0.040176237 ZNF92 
ENSG00000105366 1.223308855 0.040180732 SIGLEC8 
ENSG00000160058 1.352476149 0.040232361 BSDC1 
ENSG00000180376 0.816091977 0.040232361 CCDC66 
ENSG00000234487 1.184098146 0.040249495 HLA F 
ENSG00000225691 5.931218442 0.04025259 HLA C 
ENSG00000276155 2.389483489 0.040269355 MAPT 
ENSG00000138892 2.89618309 0.040269355 TTLL8 
ENSG00000258429 1.803049683 0.040286188 PDF 
ENSG00000178741 1.192539057 0.040420599 COX5A 
ENSG00000123143 0.794003771 0.040420599 PKN1 
ENSG00000132953 0.786646817 0.040425119 XPO4 
ENSG00000055163 0.983378092 0.040425134 CYFIP2 
ENSG00000205629 1.169293169 0.040425134 LCMT1 
ENSG00000131236 0.982944555 0.040425594 CAP1 
ENSG00000189108 3.304714383 0.040425594 IL1RAPL2 
ENSG00000176946 1.104978391 0.040425594 THAP4 
ENSG00000126814 1.312215349 0.040532131 TRMT5 
ENSG00000100024 1.745767775 0.040580535 UPB1 
ENSG00000088205 0.916099694 0.040583122 DDX18 
ENSG00000116132 2.161769807 0.040583122 PRRX1 
ENSG00000100504 0.819193479 0.040600626 PYGL 
ENSG00000136099 3.301165988 0.040636941 PCDH8 
ENSG00000095752 1.963128156 0.040669548 IL11 
ENSG00000075975 0.93950992 0.040669548 MKRN2 
ENSG00000143036 4.600821704 0.04067249 SLC44A3 
ENSG00000172247 1.163620837 0.040684507 C1QTNF4 
ENSG00000198909 0.972207892 0.040684507 MAP3K3 
ENSG00000257150 2.656735078 0.040883688 PGAM1P5 
ENSG00000145777 4.426256838 0.040883688 TSLP 
ENSG00000130054 2.171316838 0.040914884 FAM155B 
ENSG00000172209 2.243762534 0.040914884 GPR22 
ENSG00000102935 1.222428761 0.040914884 ZNF423 
ENSG00000084652 0.887650583 0.040966735 TXLNA 
ENSG00000106258 0.951544934 0.040971282 CYP3A5 
ENSG00000156453 2.502785776 0.04101911 PCDH1 
ENSG00000140612 0.92109645 0.041043175 SEC11A 
ENSG00000135763 1.644187646 0.041068501 URB2 
ENSG00000110871 1.026705806 0.041111414 COQ5 
ENSG00000165271 0.883867188 0.041157147 NOL6 
ENSG00000149262 0.757952935 0.041182629 INTS4 
ENSG00000163431 2.421339874 0.041182629 LMOD1 
ENSG00000087269 1.016857677 0.041182629 NOP14 
ENSG00000091651 0.882485356 0.041182629 ORC6 
ENSG00000175274 1.004998509 0.041182629 TP53I11 
ENSG00000102901 0.768178934 0.041249707 CENPT 
ENSG00000124767 1.356180563 0.041249707 GLO1 
ENSG00000108946 0.734880395 0.041249707 PRKAR1A 
ENSG00000160208 0.855890304 0.041249707 RRP1B 
ENSG00000112983 1.026642227 0.041393655 BRD8 
ENSG00000169062 0.87430424 0.041446522 UPF3A 
ENSG00000077498 2.966378037 0.041542168 TYR 
ENSG00000169035 2.457947329 0.041543208 KLK7 
ENSG00000174738 0.983997688 0.041554763 NR1D2 
ENSG00000088451 1.795992009 0.041554763 TGDS 
ENSG00000164983 0.804780315 0.041613801 TMEM65 
ENSG00000105185 1.13569801 0.041658657 PDCD5 
ENSG00000007264 0.980163062 0.041704588 MATK 
ENSG00000139914 3.208978319 0.041716072 FITM1 
ENSG00000197982 1.659331266 0.041882292 C1orf122 
ENSG00000072803 0.97123175 0.041882292 FBXW11 
ENSG00000132109 1.251506765 0.041895107 TRIM21 
ENSG00000137699 2.230544254 0.041895107 TRIM29 
ENSG00000112576 1.014071319 0.042035262 CCND3 
ENSG00000278224 2.569856059 0.042050717 PRICKLE4 
ENSG00000105392 1.623194857 0.042106408 CRX 
ENSG00000140259 1.002571307 0.042152321 MFAP1 
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ENSG00000112697 0.901256136 0.042152321 TMEM30A 
ENSG00000198053 0.913535025 0.042191569 SIRPA 
ENSG00000100336 0.909594582 0.04223799 APOL4 
ENSG00000174059 0.99109874 0.04223799 CD34 
ENSG00000176809 1.051299563 0.04223799 LRRC37A3 
ENSG00000131242 1.362446834 0.04223799 RAB11FIP4 
ENSG00000226858 4.268413393 0.04223799 ZFP57 
ENSG00000187951 0.948386565 0.042355328 ARHGAP11B 
ENSG00000149557 1.864292931 0.042371142 FEZ1 
ENSG00000128191 1.066281157 0.042536178 DGCR8 
ENSG00000138678 1.703641613 0.042536178 GPAT3 
ENSG00000160593 1.223955932 0.042536178 JAML 
ENSG00000116288 1.145449525 0.042536178 PARK7 
ENSG00000183632 4.501980644 0.042536178 TP53TG3 
ENSG00000166793 1.434149709 0.042536178 YPEL4 
ENSG00000146858 1.380027186 0.042536178 ZC3HAV1L 
ENSG00000155714 1.409921694 0.042569856 PDZD9 
ENSG00000064886 1.693156971 0.042611323 CHI3L2 
ENSG00000138780 1.008690202 0.042634077 GSTCD 
ENSG00000184381 0.997335313 0.042634077 PLA2G6 
ENSG00000101307 1.246088534 0.042666218 SIRPB1 
ENSG00000237763 2.2090687 0.042668394 AMY1A 
ENSG00000205835 3.811582076 0.042736615 GMNC 
ENSG00000149451 1.787351344 0.042757631 ADAM33 
ENSG00000100890 0.993484805 0.042817411 KIAA0391 
ENSG00000100416 0.747467604 0.042817411 TRMU 
ENSG00000146909 0.887458522 0.042907697 NOM1 
ENSG00000164975 1.274121966 0.042907697 SNAPC3 
ENSG00000148200 1.2792292 0.042914045 NR6A1 
ENSG00000001497 0.807226774 0.042968075 LAS1L 
ENSG00000110200 1.023991372 0.043004879 ANAPC15 
ENSG00000276068 1.516442213 0.043005345 NAIP 
ENSG00000160613 0.897518385 0.043005345 PCSK7 
ENSG00000162430 0.840329755 0.043005345 SELENON 
ENSG00000197275 1.585618543 0.043036063 RAD54B 
ENSG00000100014 0.75796346 0.043162154 SPECC1L 
ENSG00000108509 0.906402098 0.043183816 CAMTA2 
ENSG00000171916 2.401370762 0.043183816 LGALS9C 
ENSG00000140992 1.037284314 0.043183816 PDPK1 
ENSG00000221878 2.63089403 0.043183816 PSG7 
ENSG00000048028 1.727887345 0.043183816 USP28 
ENSG00000130713 1.033695811 0.043237151 EXOSC2 
ENSG00000185332 2.404988668 0.043237151 TMEM105 
ENSG00000166558 3.651973399 0.04333001 SLC38A8 
ENSG00000184497 1.822974907 0.04335022 TMEM255B 
ENSG00000124541 1.108286002 0.043511259 RRP36 
ENSG00000007001 1.457226483 0.043540198 UPP2 
ENSG00000100216 1.031382415 0.043565911 TOMM22 
ENSG00000172927 1.976775677 0.043597847 MYEOV 
ENSG00000179846 1.541189622 0.043679868 NKPD1 
ENSG00000143942 1.761290813 0.043759936 CHAC2 
ENSG00000169239 1.049572188 0.043763915 CA5B 
ENSG00000128262 1.686270731 0.043763915 POM121L9P 
ENSG00000157224 1.180389884 0.043785519 CLDN12 
ENSG00000177082 0.794904155 0.04385949 WDR73 
ENSG00000101935 1.7821161 0.043946829 AMMECR1 
ENSG00000213923 0.794497731 0.043946829 CSNK1E 
ENSG00000186526 1.427748051 0.043946829 CYP4F8 
ENSG00000197653 1.704470168 0.043946829 DNAH10 
ENSG00000070785 1.016476201 0.043985066 EIF2B3 
ENSG00000116191 0.877247172 0.04400198 RALGPS2 
ENSG00000114374 3.890337233 0.044010765 USP9Y 
ENSG00000184206 1.52799376 0.044219114 GOLGA6L4 
ENSG00000108433 0.855367581 0.044221567 GOSR2 
ENSG00000138378 1.488912057 0.044233269 STAT4 
ENSG00000180998 1.193426026 0.044391163 GPR137C 
ENSG00000100883 0.778785219 0.044407459 SRP54 
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ENSG00000144749 0.903526926 0.04441918 LRIG1 
ENSG00000106003 1.483544361 0.044501689 LFNG 
ENSG00000112290 1.047790361 0.044505912 WASF1 
ENSG00000182795 2.601351485 0.044550761 C1orf116 
ENSG00000090686 0.731689477 0.044566871 USP48 
ENSG00000152669 3.745074136 0.044668121 CCNO 
ENSG00000145626 2.353881628 0.044717299 UGT3A1 
ENSG00000099875 1.324970256 0.044730864 MKNK2 
ENSG00000150676 1.727218692 0.044766599 CCDC83 
ENSG00000115919 1.111482644 0.044766599 KYNU 
ENSG00000177879 0.993660922 0.044827184 AP3S1 
ENSG00000222011 1.425489166 0.045022648 FAM185A 
ENSG00000163291 0.967832779 0.045117998 PAQR3 
ENSG00000169220 0.960721298 0.045117998 RGS14 
ENSG00000072756 0.83798732 0.045117998 TRNT1 
ENSG00000123836 1.289740063 0.045130231 PFKFB2 
ENSG00000138100 2.395389164 0.045154648 TRIM54 
ENSG00000162105 1.310888415 0.04515517 SHANK2 
ENSG00000171992 1.070535449 0.04515517 SYNPO 
ENSG00000213937 1.493508399 0.045175834 CLDN9 
ENSG00000053372 1.13505346 0.045175834 MRTO4 
ENSG00000174669 1.106627793 0.045175834 SLC29A2 
ENSG00000273274 0.958003015 0.045175834 ZBTB8B 
ENSG00000106688 3.143209566 0.045184342 SLC1A1 
ENSG00000234616 0.865165222 0.045206147 JRK 
ENSG00000149115 0.946124448 0.045206147 TNKS1BP1 
ENSG00000150938 1.072608786 0.045249605 CRIM1 
ENSG00000158769 0.944984749 0.045249605 F11R 
ENSG00000164347 0.938837524 0.045249605 GFM2 
ENSG00000109320 1.158140494 0.045249605 NFKB1 
ENSG00000143653 1.06536146 0.045249605 SCCPDH 
ENSG00000117153 1.352524427 0.045349699 KLHL12 
ENSG00000162437 0.809314089 0.045349699 RAVER2 
ENSG00000111728 1.149159976 0.045349699 ST8SIA1 
ENSG00000104219 1.303370336 0.045349699 ZDHHC2 
ENSG00000180616 1.062788046 0.045372352 SSTR2 
ENSG00000131848 1.324400967 0.045372352 ZSCAN5A 
ENSG00000151748 1.049620374 0.045392413 SAV1 
ENSG00000162599 1.312704571 0.045429524 NFIA 
ENSG00000110237 1.177333769 0.045563249 ARHGEF17 
ENSG00000158717 1.437267802 0.045597581 RNF166 
ENSG00000188613 1.870140595 0.045627298 NANOS1 
ENSG00000116685 1.069767788 0.04568842 KIAA2013 
ENSG00000186951 0.961908849 0.04568842 PPARA 
ENSG00000177398 1.730156191 0.04568842 UMODL1 
ENSG00000164465 1.608223159 0.045718511 DCBLD1 
ENSG00000105676 1.043761645 0.045729808 ARMC6 
ENSG00000125633 0.899612563 0.045816833 CCDC93 
ENSG00000019169 2.759151942 0.045816833 MARCO 
ENSG00000135074 1.200173159 0.04585921 ADAM19 
ENSG00000180259 4.131787766 0.04585921 PRNT 
ENSG00000143195 1.836159049 0.04590415 ILDR2 
ENSG00000243927 1.615587622 0.045954634 MRPS6 
ENSG00000145331 2.064733286 0.045954634 TRMT10A 
ENSG00000116039 2.988037076 0.046003216 ATP6V1B1 
ENSG00000265190 2.318869428 0.046188816 ANXA8 
ENSG00000099795 1.201594681 0.046239629 NDUFB7 
ENSG00000221955 1.166952045 0.046239629 SLC12A8 
ENSG00000179542 1.420095758 0.046271638 SLITRK4 
ENSG00000124279 1.883932139 0.046283078 FASTKD3 
ENSG00000125731 1.184335003 0.046283078 SH2D3A 
ENSG00000067646 8.493173659 0.046310515 ZFY 
ENSG00000172530 1.124437073 0.046311185 BANP 
ENSG00000240230 0.890126273 0.046422012 COX19 
ENSG00000062822 1.133123499 0.046458162 POLD1 
ENSG00000150907 1.096006525 0.046472196 FOXO1 
ENSG00000073712 1.780718409 0.046475811 FERMT2 
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ENSG00000196172 1.19274966 0.046475811 ZNF681 
ENSG00000277322 1.534060923 0.046480345 GOLGA6L6 
ENSG00000153237 1.231959284 0.046486122 CCDC148 
ENSG00000105855 1.277410606 0.046576256 ITGB8 
ENSG00000185888 3.54101345 0.046583363 PRSS38 
ENSG00000066735 2.027011832 0.04662363 KIF26A 
ENSG00000172772 3.03040407 0.04662363 OR10W1 
ENSG00000099960 4.324051414 0.04662363 SLC7A4 
ENSG00000117408 1.489749685 0.046685691 IPO13 
ENSG00000013297 1.204247738 0.046716864 CLDN11 
ENSG00000185101 1.221074049 0.046777958 ANO9 
ENSG00000180720 2.73156167 0.046777958 CHRM4 
ENSG00000146857 3.22535644 0.046818662 STRA8 
ENSG00000151572 2.550636287 0.04683329 ANO4 
ENSG00000069275 1.008405748 0.04683329 NUCKS1 
ENSG00000117448 1.056925757 0.046896744 AKR1A1 
ENSG00000166415 1.68720554 0.046944757 WDR72 
ENSG00000106714 1.948213634 0.046951958 CNTNAP3 
ENSG00000110344 0.785465118 0.046966832 UBE4A 
ENSG00000162704 1.205042241 0.046973115 ARPC5 
ENSG00000153574 1.283488154 0.046992881 RPIA 
ENSG00000139438 2.002638704 0.047005096 FAM222A 
ENSG00000060982 0.84339132 0.047022136 BCAT1 
ENSG00000104093 0.912934167 0.047022136 DMXL2 
ENSG00000278463 1.608307253 0.047095342 HIST1H2AB 
ENSG00000125995 1.303628275 0.047095342 ROMO1 
ENSG00000166546 1.496054121 0.047100044 BEAN1 
ENSG00000196338 1.666693098 0.047133092 NLGN3 
ENSG00000120094 2.970917969 0.047156413 HOXB1 
ENSG00000127774 1.377133915 0.047203049 EMC6 
ENSG00000128016 1.637821925 0.047263648 ZFP36 
ENSG00000198798 2.947891821 0.047273329 MAGEB3 
ENSG00000198899 1.001114261 0.047277617 ATP6 
ENSG00000168702 2.577547346 0.047277617 LRP1B 
ENSG00000125863 1.751518239 0.047277617 MKKS 
ENSG00000108179 1.295542934 0.047378449 PPIF 
ENSG00000197894 1.306293736 0.047387542 ADH5 
ENSG00000127445 1.250906071 0.047387542 PIN1 
ENSG00000262406 4.403885164 0.047459983 MMP12 
ENSG00000070778 1.876181639 0.047523738 PTPN21 
ENSG00000154719 1.192241214 0.047542578 MRPL39 
ENSG00000163376 1.302606788 0.047595766 KBTBD8 
ENSG00000212907 0.914587608 0.047620115 ND4L 
ENSG00000114956 1.241823725 0.04788175 DGUOK 
ENSG00000140395 1.064285817 0.048002855 WDR61 
ENSG00000140522 2.704259618 0.048006185 RLBP1 
ENSG00000132300 0.806864384 0.048015041 PTCD3 
ENSG00000169826 1.102590556 0.048031897 CSGALNACT2 
ENSG00000128891 0.982154797 0.048094633 CCDC32 
ENSG00000180329 1.152348386 0.048094633 CCDC43 
ENSG00000213218 3.940399569 0.048094633 CSH2 
ENSG00000170345 1.683373177 0.048094633 FOS 
ENSG00000090674 1.345222977 0.048094633 MCOLN1 
ENSG00000185960 1.175678045 0.048094633 SHOX 
ENSG00000164051 1.349706885 0.048276591 CCDC51 
ENSG00000145113 4.898061385 0.048276591 MUC4 
ENSG00000196290 1.263794303 0.048296379 NIF3L1 
ENSG00000176623 0.820577838 0.048319176 RMDN1 
ENSG00000117597 1.154562449 0.048431485 DIEXF 
ENSG00000129353 0.9562368 0.048431485 SLC44A2 
ENSG00000204983 2.240567858 0.048477584 PRSS1 
ENSG00000159905 1.21178015 0.048477584 ZNF221 
ENSG00000101412 1.141434467 0.048518178 E2F1 
ENSG00000151322 1.412671172 0.048518178 NPAS3 
ENSG00000154065 2.234521998 0.048625093 ANKRD29 
ENSG00000173846 1.236706277 0.048661647 PLK3 
ENSG00000125520 1.30419339 0.048690483 SLC2A4RG 
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ENSG00000258644 1.751007019 0.048775315 SYNJ2BP COX16 
ENSG00000183092 1.339182195 0.048793018 BEGAIN 
ENSG00000188641 0.803061747 0.048794344 DPYD 
ENSG00000005022 0.996698927 0.048813554 SLC25A5 
ENSG00000130559 0.816941503 0.048864708 CAMSAP1 
ENSG00000163006 1.296211376 0.048973369 CCDC138 
ENSG00000164484 1.414541988 0.049033794 TMEM200A 
ENSG00000121236 1.246434149 0.049033794 TRIM6 
ENSG00000130638 0.862619089 0.049093057 ATXN10 
ENSG00000181804 1.663327322 0.04912198 SLC9A9 
ENSG00000083168 0.941737544 0.049147909 KAT6A 
ENSG00000132475 0.846088316 0.049225916 H3F3B 
ENSG00000154262 1.735476758 0.049298105 ABCA6 
ENSG00000151338 0.950485503 0.049306676 MIPOL1 
ENSG00000163785 0.938539459 0.049336803 RYK 
ENSG00000278570 2.583703193 0.049418948 NR2E3 
ENSG00000055130 0.812187633 0.049455096 CUL1 
ENSG00000144824 0.949257717 0.049569554 PHLDB2 
ENSG00000152583 2.562813361 0.049569554 SPARCL1 
ENSG00000198965 4.686111907 0.049571566 OR10R2 
ENSG00000131620 2.265181292 0.049657774 ANO1 
ENSG00000129562 1.117042192 0.049657774 DAD1 
ENSG00000184207 1.466020626 0.049657774 PGP 
ENSG00000197901 2.285067329 0.04967704 SLC22A6 
ENSG00000011083 2.204729015 0.049681986 SLC6A7 
ENSG00000136840 1.030992813 0.049681986 ST6GALNAC4 
ENSG00000185905 0.920184847 0.049714471 C16orf54 
ENSG00000198937 1.510709787 0.049714471 CCDC167 
ENSG00000164933 0.916816159 0.049884179 SLC25A32 
ENSG00000197841 1.429385205 0.049884179 ZNF181 
ENSG00000106477 1.14388551 0.049897365 CEP41 
ENSG00000158623 1.065205895 0.049924384 COPG2 
ENSG00000125703 1.883209719 0.049980073 ATG4C 
ENSG00000106346 1.050257746 0.049980073 USP42 
ENSG00000177628 1.146802051 0.049996334 GBA 
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10.4 Appendix 4 
List of genes differentially expressed between human foetal liver HSC/MPPs 
and LMPPs (positive log fold represents genes upregulated in the foetal liver 
derived LMPPs), described in chapter 4.  
Ensemb  ID og2 Fo d Change padj Gene Name 
ENSG00000132744 4.020106581 2.76E 36 ACY3 
ENSG00000042062 3.019266039 5.37E 27 RIPOR3 
ENSG00000108924 2.664283841 2.41E 23 HLF 
ENSG00000261150 3.377185123 5.80E 22 EPPK1 
ENSG00000165168 5.24237647 1.10E 21 CYBB 
ENSG00000182557 2.217434516 7.94E 21 SPNS3 
ENSG00000128322 3.268381421 4.85E 20 IGLL1 
ENSG00000142185 3.218521912 1.04E 19 TRPM2 
ENSG00000164946 3.848039262 1.52E 19 FREM1 
ENSG00000109684 2.514816778 6.94E 18 CLNK 
ENSG00000005381 3.476677198 8.81E 17 MPO 
ENSG00000196159 2.980044081 2.63E 16 FAT4 
ENSG00000076641 2.742002584 4.20E 16 PAG1 
ENSG00000037280 2.85987931 6.55E 16 FLT4 
ENSG00000198752 3.148331961 9.53E 16 CDC42BPB 
ENSG00000000971 2.448074128 1.44E 15 CFH 
ENSG00000130396 2.783856733 1.63E 15 AFDN 
ENSG00000005844 1.887775641 5.18E 15 ITGAL 
ENSG00000142173 2.733756749 5.51E 15 COL6A2 
ENSG00000049323 2.759982987 3.48E 14 LTBP1 
ENSG00000134755 3.112116776 4.43E 14 DSC2 
ENSG00000154783 1.897973373 1.77E 13 FGD5 
ENSG00000186469 2.378779793 1.77E 13 GNG2 
ENSG00000140968 3.494688823 3.93E 13 IRF8 
ENSG00000120093 1.562145338 7.88E 13 HOXB3 
ENSG00000171791 1.866847601 1.03E 12 BCL2 
ENSG00000120156 3.153135366 1.20E 12 TEK 
ENSG00000005379 2.361585043 2.53E 12 TSPOAP1 
ENSG00000133026 1.83377913 4.94E 12 MYH10 
ENSG00000165092 2.174486874 1.39E 11 ALDH1A1 
ENSG00000141756 2.012888007 6.74E 11 FKBP10 
ENSG00000010327 2.02174646 7.05E 11 STAB1 
ENSG00000164125 1.958470525 8.08E 11 FAM198B 
ENSG00000171843 2.247920751 1.05E 10 MLLT3 
ENSG00000086730 1.685989284 2.32E 10 LAT2 
ENSG00000164330 2.921033266 3.17E 10 EBF1 
ENSG00000134871 3.364446401 5.12E 10 COL4A2 
ENSG00000133800 3.772481826 6.08E 10 LYVE1 
ENSG00000198879 1.658989128 6.82E 10 SFMBT2 
ENSG00000249751 8.242045336 3.43E 09 ECSCR 
ENSG00000131477 2.909727366 4.32E 09 RAMP2 
ENSG00000079337 1.177387984 4.32E 09 RAPGEF3 
ENSG00000177469 2.055525648 5.07E 09 CAVIN1 
ENSG00000130635 1.53925645 5.07E 09 COL5A1 
ENSG00000113389 1.302010418 7.56E 09 NPR3 
ENSG00000127507 1.571422648 8.04E 09 ADGRE2 
ENSG00000143995 1.323646128 8.83E 09 MEIS1 
ENSG00000162367 1.170090071 1.46E 08 TAL1 
ENSG00000132669 2.601975985 1.62E 08 RIN2 
ENSG00000068724 1.599004666 1.62E 08 TTC7A 
ENSG00000120278 3.35958562 1.80E 08 PLEKHG1 
ENSG00000105374 2.947615417 1.95E 08 NKG7 
ENSG00000182578 1.836969726 2.67E 08 CSF1R 
ENSG00000120279 3.928282531 3.25E 08 MYCT1 
ENSG00000135048 2.494366543 4.08E 08 TMEM2 
ENSG00000117480 2.074920135 6.70E 08 FAAH 
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ENSG00000106236 3.501264372 8.52E 08 NPTX2 
ENSG00000179776 2.861119168 8.73E 08 CDH5 
ENSG00000170476 1.650341174 9.25E 08 MZB1 
ENSG00000117069 4.665256604 1.27E 07 ST6GALNAC5 
ENSG00000266074 1.265778674 1.36E 07 BAHCC1 
ENSG00000167483 1.554200429 1.38E 07 FAM129C 
ENSG00000066056 1.095431615 1.38E 07 TIE1 
ENSG00000031081 1.409213605 1.39E 07 ARHGAP31 
ENSG00000154133 1.924207339 1.39E 07 ROBO4 
ENSG00000142611 1.90334699 1.61E 07 PRDM16 
ENSG00000147862 2.985501308 2.10E 07 NFIB 
ENSG00000124507 3.942054354 2.10E 07 PACSIN1 
ENSG00000157510 2.193428809 2.29E 07 AFAP1L1 
ENSG00000196684 1.299332088 2.80E 07 HSH2D 
ENSG00000102755 2.973628212 2.88E 07 FLT1 
ENSG00000109452 1.317338754 2.91E 07 INPP4B 
ENSG00000154479 1.740821856 2.98E 07 CCDC173 
ENSG00000132465 5.739898503 3.05E 07 JCHAIN 
ENSG00000125733 2.176721561 3.26E 07 TRIP10 
ENSG00000135709 2.548914741 3.86E 07 KIAA0513 
ENSG00000169398 1.296349706 4.91E 07 PTK2 
ENSG00000161544 3.291261866 4.94E 07 CYGB 
ENSG00000100968 1.879757475 5.82E 07 NFATC4 
ENSG00000003147 1.663159731 5.97E 07 ICA1 
ENSG00000274267 1.159163286 7.68E 07 HIST1H3B 
ENSG00000119919 3.28005373 7.68E 07 NKX2 3 
ENSG00000121966 2.412780229 8.93E 07 CXCR4 
ENSG00000160339 3.922635274 9.29E 07 FCN2 
ENSG00000181444 1.713384675 9.67E 07 ZNF467 
ENSG00000172889 0.932089324 9.94E 07 EGFL7 
ENSG00000184557 2.585209102 1.30E 06 SOCS3 
ENSG00000205978 1.414093145 1.33E 06 NYNRIN 
ENSG00000168497 1.507052417 1.53E 06 CAVIN2 
ENSG00000115085 1.858483191 1.92E 06 ZAP70 
ENSG00000197879 2.860577855 2.04E 06 MYO1C 
ENSG00000214193 1.331401518 2.28E 06 SH3D21 
ENSG00000143507 1.098339716 2.59E 06 DUSP10 
ENSG00000169291 2.210986951 2.65E 06 SHE 
ENSG00000102302 1.778409747 2.72E 06 FGD1 
ENSG00000107807 4.714337071 2.87E 06 TLX1 
ENSG00000169992 1.296343999 3.47E 06 NLGN2 
ENSG00000107281 2.602033096 3.49E 06 NPDC1 
ENSG00000011454 1.417217113 3.50E 06 GPR21 
ENSG00000120594 1.572137413 3.55E 06 PLXDC2 
ENSG00000181409 2.144582505 4.33E 06 AATK 
ENSG00000117519 1.579909554 4.44E 06 CNN3 
ENSG00000066735 2.858413861 4.44E 06 KIF26A 
ENSG00000260314 2.435246205 4.61E 06 MRC1 
ENSG00000169184 1.641018858 4.69E 06 MN1 
ENSG00000196839 1.506458553 5.46E 06 ADA 
ENSG00000144218 1.317287338 6.43E 06 AFF3 
ENSG00000179348 1.258392317 6.77E 06 GATA2 
ENSG00000151718 1.371626306 7.32E 06 WWC2 
ENSG00000148400 0.899377551 7.46E 06 NOTCH1 
ENSG00000203883 1.984147261 7.58E 06 SOX18 
ENSG00000130592 1.523994018 7.62E 06 LSP1 
ENSG00000101000 1.945729747 7.77E 06 PROCR 
ENSG00000170873 1.474510329 7.79E 06 MTSS1 
ENSG00000120280 1.218486308 7.88E 06 CXorf21 
ENSG00000162909 1.448295196 8.85E 06 CAPN2 
ENSG00000090097 2.815880704 1.07E 05 PCBP4 
ENSG00000169575 3.954741928 1.08E 05 VPREB1 
ENSG00000130300 2.051293373 1.16E 05 PLVAP 
ENSG00000186642 2.78505211 1.28E 05 PDE2A 
ENSG00000137834 2.490268506 1.30E 05 SMAD6 
ENSG00000128052 4.823405869 1.31E 05 KDR 
ENSG00000166349 2.241817612 1.37E 05 RAG1 
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ENSG00000177398 2.403109299 1.45E 05 UMODL1 
ENSG00000245848 1.475690597 1.52E 05 CEBPA 
ENSG00000118257 2.066976187 1.63E 05 NRP2 
ENSG00000126217 1.607573208 1.66E 05 MCF2L 
ENSG00000135047 3.423678435 1.73E 05 CTSL 
ENSG00000134709 1.816268527 1.80E 05 HOOK1 
ENSG00000215252 1.204185365 2.00E 05 GOLGA8B 
ENSG00000046889 1.270900046 2.26E 05 PREX2 
ENSG00000138449 1.960584002 2.36E 05 SLC40A1 
ENSG00000143889 1.770566975 2.42E 05 HNRNPLL 
ENSG00000171115 1.846122182 2.50E 05 GIMAP8 
ENSG00000100368 1.316829148 3.00E 05 CSF2RB 
ENSG00000135838 2.440465521 3.00E 05 NPL 
ENSG00000137726 1.516773696 3.21E 05 FXYD6 
ENSG00000122642 1.524137206 3.45E 05 FKBP9 
ENSG00000198851 2.466208709 3.57E 05 CD3E 
ENSG00000109756 1.097519297 3.74E 05 RAPGEF2 
ENSG00000065054 1.586129198 3.79E 05 SLC9A3R2 
ENSG00000187837 1.041296605 3.94E 05 HIST1H1C 
ENSG00000137198 1.997149199 4.48E 05 GMPR 
ENSG00000100068 1.096878958 5.01E 05 LRP5L 
ENSG00000108511 2.391090222 5.20E 05 HOXB6 
ENSG00000169418 3.035178331 5.22E 05 NPR1 
ENSG00000198729 4.459955583 5.22E 05 PPP1R14C 
ENSG00000165810 2.575753178 5.46E 05 BTNL9 
ENSG00000121858 1.788417033 5.59E 05 TNFSF10 
ENSG00000125968 2.546160431 5.64E 05 ID1 
ENSG00000131067 1.629349269 5.70E 05 GGT7 
ENSG00000122224 1.771399583 6.98E 05 LY9 
ENSG00000197409 1.050862458 7.07E 05 HIST1H3D 
ENSG00000116016 2.79405711 7.21E 05 EPAS1 
ENSG00000276053 1.100561488 7.30E 05 LAIR1 
ENSG00000135318 3.31043106 7.33E 05 NT5E 
ENSG00000151838 1.994641421 7.53E 05 CCDC175 
ENSG00000167780 4.579325415 7.96E 05 SOAT2 
ENSG00000136011 4.487830526 8.03E 05 STAB2 
ENSG00000163513 0.8763236 8.03E 05 TGFBR2 
ENSG00000134278 1.229813739 8.27E 05 SPIRE1 
ENSG00000183166 1.388932765 8.84E 05 CALN1 
ENSG00000184357 1.12666166 8.84E 05 HIST1H1B 
ENSG00000244242 2.69872112 8.84E 05 IFITM10 
ENSG00000141293 1.712900709 9.06E 05 SKAP1 
ENSG00000050820 3.435805675 9.72E 05 BCAR1 
ENSG00000174944 2.113552736 9.82E 05 P2RY14 
ENSG00000176105 1.421772497 9.82E 05 YES1 
ENSG00000149564 1.091935349 9.83E 05 ESAM 
ENSG00000138795 1.354336052 0.00010083 LEF1 
ENSG00000133636 4.918016934 0.00010101 NTS 
ENSG00000134817 2.826288483 0.00010171 APLNR 
ENSG00000095637 1.916610284 0.00010221 SORBS1 
ENSG00000138411 3.684423354 0.00011293 HECW2 
ENSG00000185010 2.729386424 0.00011378 F8 
ENSG00000153253 2.240067727 0.00012363 SCN3A 
ENSG00000181804 2.334304079 0.00012752 SLC9A9 
ENSG00000147168 1.418216699 0.00013234 IL2RG 
ENSG00000008311 1.662928875 0.00013284 AASS 
ENSG00000074660 1.099596572 0.00015409 SCARF1 
ENSG00000159640 1.50621142 0.00017102 ACE 
ENSG00000185499 2.329362505 0.00019402 MUC1 
ENSG00000149557 3.090357856 0.00019758 FEZ1 
ENSG00000085733 2.76382851 0.00020582 CTTN 
ENSG00000100234 1.103595751 0.00020582 TIMP3 
ENSG00000173269 1.546870929 0.00021103 MMRN2 
ENSG00000074047 2.496089882 0.00021271 GLI2 
ENSG00000130940 1.428802104 0.00022311 CASZ1 
ENSG00000111261 1.92429303 0.00022937 MANSC1 
ENSG00000281818 1.92429303 0.00022937 MANSC1 
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ENSG00000125266 3.057531769 0.0002345 EFNB2 
ENSG00000075240 1.286397588 0.00023541 GRAMD4 
ENSG00000152128 1.480257497 0.00023541 TMEM163 
ENSG00000215788 1.362680674 0.00023541 TNFRSF25 
ENSG00000064042 2.064655769 0.00023653 LIMCH1 
ENSG00000070882 1.277782674 0.00024321 OSBPL3 
ENSG00000091409 1.288418125 0.00025874 ITGA6 
ENSG00000130158 1.974124008 0.0002641 DOCK6 
ENSG00000184867 1.848108551 0.00027048 ARMCX2 
ENSG00000042493 1.314898081 0.00027048 CAPG 
ENSG00000105974 2.739047029 0.00027663 CAV1 
ENSG00000204186 1.128391983 0.00029537 ZDBF2 
ENSG00000105810 1.062031752 0.00030437 CDK6 
ENSG00000030419 1.300435137 0.00031092 IKZF2 
ENSG00000169744 1.877935724 0.00031092 LDB2 
ENSG00000161647 2.122174485 0.00031092 MPP3 
ENSG00000073712 2.735773818 0.00032737 FERMT2 
ENSG00000250722 1.902730924 0.0003455 SELENOP 
ENSG00000157873 1.545604558 0.00035197 TNFRSF14 
ENSG00000196628 1.02234501 0.00036427 TCF4 
ENSG00000173166 2.373905526 0.00038242 RAPH1 
ENSG00000129946 3.1040011 0.00038242 SHC2 
ENSG00000136114 1.852932528 0.00039414 THSD1 
ENSG00000159674 1.632341306 0.00040213 SPON2 
ENSG00000158528 1.394058635 0.00040281 PPP1R9A 
ENSG00000101439 1.514138545 0.00040962 CST3 
ENSG00000100242 0.841739024 0.00040962 SUN2 
ENSG00000073849 0.854028944 0.00043966 ST6GAL1 
ENSG00000068078 2.21075181 0.00044028 FGFR3 
ENSG00000147206 3.121395872 0.00044207 NXF3 
ENSG00000182568 1.256244433 0.00046421 SATB1 
ENSG00000198825 0.782709885 0.00047186 INPP5F 
ENSG00000198873 1.037491356 0.00049295 GRK5 
ENSG00000276043 1.367410465 0.00049295 UHRF1 
ENSG00000273936 1.504812546 0.0004951 TNFRSF14 
ENSG00000163519 4.73395632 0.00049646 TRAT1 
ENSG00000074219 2.680458179 0.00050089 TEAD2 
ENSG00000111057 1.657837434 0.00050658 KRT18 
ENSG00000198842 1.39841366 0.00052812 DUSP27 
ENSG00000117983 3.06606667 0.00053214 MUC5B 
ENSG00000144476 1.496628218 0.00053763 ACKR3 
ENSG00000204681 2.507183001 0.00053886 GABBR1 
ENSG00000107186 1.242614995 0.00054492 MPDZ 
ENSG00000114115 2.501356503 0.00054492 RBP1 
ENSG00000131016 3.296314586 0.00054794 AKAP12 
ENSG00000185386 1.091178258 0.00057504 MAPK11 
ENSG00000166856 2.313977843 0.00059201 GPR182 
ENSG00000143369 2.715424217 0.00061829 ECM1 
ENSG00000151176 1.446904089 0.0006308 PLBD2 
ENSG00000102362 1.020170903 0.00067584 SYTL4 
ENSG00000178498 1.072144832 0.00068124 DTX3 
ENSG00000198585 0.835853509 0.0007135 NUDT16 
ENSG00000197822 2.365280729 0.00073019 OCLN 
ENSG00000103489 1.185508319 0.00074386 XYLT1 
ENSG00000177685 2.820438435 0.00077182 CRACR2B 
ENSG00000163687 3.63548447 0.00079381 DNASE1L3 
ENSG00000143153 1.418346525 0.00081803 ATP1B1 
ENSG00000183735 0.85059981 0.00088714 TBK1 
ENSG00000118946 2.48493249 0.00090058 PCDH17 
ENSG00000157570 2.132397819 0.00090437 TSPAN18 
ENSG00000111961 2.216276349 0.0009123 SASH1 
ENSG00000175899 1.542207812 0.00095199 A2M 
ENSG00000250510 1.932393789 0.00096802 GPR162 
ENSG00000163069 2.477955265 0.00096802 SGCB 
ENSG00000172037 1.417130501 0.00097136 LAMB2 
ENSG00000111676 0.76463735 0.00099901 ATN1 
ENSG00000137804 0.791202735 0.00099901 NUSAP1 
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ENSG00000168056 1.081610416 0.00102939 LTBP3 
ENSG00000069702 2.509713405 0.00102939 TGFBR3 
ENSG00000153113 0.990377587 0.00106935 CAST 
ENSG00000278463 0.870671713 0.00109281 HIST1H2AB 
ENSG00000159216 0.85055811 0.00109379 RUNX1 
ENSG00000165030 1.452538147 0.00116044 NFIL3 
ENSG00000171680 2.2946288 0.00116044 PLEKHG5 
ENSG00000172493 1.049653148 0.00116588 AFF1 
ENSG00000196460 2.027472492 0.00116588 RFX8 
ENSG00000153162 2.09988576 0.00122732 BMP6 
ENSG00000036448 1.646406664 0.00122732 MYOM2 
ENSG00000137831 1.453662595 0.00122732 UACA 
ENSG00000069188 1.328029547 0.00123523 SDK2 
ENSG00000102575 2.268142104 0.00124019 ACP5 
ENSG00000140678 1.350902587 0.00131365 ITGAX 
ENSG00000005249 1.564904803 0.00141872 PRKAR2B 
ENSG00000026508 0.952635138 0.00143138 CD44 
ENSG00000049089 1.526629619 0.00143138 COL9A2 
ENSG00000174804 2.393912982 0.00143138 FZD4 
ENSG00000134107 3.167021532 0.00145786 BHLHE40 
ENSG00000153904 1.54745227 0.00146429 DDAH1 
ENSG00000188580 1.664286259 0.00146429 NKAIN2 
ENSG00000003393 0.789420189 0.00149435 ALS2 
ENSG00000138678 2.246229739 0.00149435 GPAT3 
ENSG00000117643 1.963856891 0.00156318 MAN1C1 
ENSG00000198589 0.895673112 0.00158164 LRBA 
ENSG00000152952 1.285043806 0.00163188 PLOD2 
ENSG00000274618 0.866833272 0.00163214 HIST1H4F 
ENSG00000174482 4.156368369 0.00174868 LINGO2 
ENSG00000112799 2.871349176 0.00175237 LY86 
ENSG00000227507 1.77875787 0.00181666 LTB 
ENSG00000157933 1.154218748 0.00185691 SKI 
ENSG00000180530 1.01737319 0.00186101 NRIP1 
ENSG00000124440 1.0664472 0.00190612 HIF3A 
ENSG00000120318 2.321100904 0.0019319 ARAP3 
ENSG00000134202 1.336586109 0.00198466 GSTM3 
ENSG00000160145 2.038879714 0.00201355 KALRN 
ENSG00000165682 3.641485881 0.00204777 CLEC1B 
ENSG00000142798 1.750129929 0.00204777 HSPG2 
ENSG00000141503 0.727790729 0.00208556 MINK1 
ENSG00000132321 1.554087388 0.00210975 IQCA1 
ENSG00000185101 1.650800916 0.00211932 ANO9 
ENSG00000205755 1.571911054 0.00211932 CRLF2 
ENSG00000148468 2.26170929 0.00218221 FAM171A1 
ENSG00000276368 0.960221747 0.00218221 HIST1H2AJ 
ENSG00000187800 1.184329313 0.00219641 PEAR1 
ENSG00000197992 2.514342471 0.0022425 CLEC9A 
ENSG00000041353 1.635704955 0.00231568 RAB27B 
ENSG00000130598 1.264235493 0.00231568 TNNI2 
ENSG00000106789 1.09108688 0.00235363 CORO2A 
ENSG00000165125 2.009690114 0.00240539 TRPV6 
ENSG00000096433 2.282310286 0.00241792 ITPR3 
ENSG00000007968 0.898461139 0.00242058 E2F2 
ENSG00000143469 1.457597587 0.00242338 SYT14 
ENSG00000076706 2.030899831 0.0024338 MCAM 
ENSG00000163637 3.873793049 0.0024338 PRICKLE2 
ENSG00000196632 1.511691532 0.0024338 WNK3 
ENSG00000278828 0.848996551 0.00247333 HIST1H3H 
ENSG00000132359 0.978685099 0.00247333 RAP1GAP2 
ENSG00000182866 1.517217527 0.00258769 LCK 
ENSG00000167703 1.138195703 0.00267273 SLC43A2 
ENSG00000072163 2.772333678 0.00269329 LIMS2 
ENSG00000134986 0.756000537 0.0027058 NREP 
ENSG00000101871 2.352623591 0.00276431 MID1 
ENSG00000092929 0.74260802 0.00276431 UNC13D 
ENSG00000177303 1.391855138 0.00281019 CASKIN2 
ENSG00000135540 1.062893243 0.00290796 NHSL1 
   
  254 
ENSG00000277401 3.281383535 0.00297056 TJP1 
ENSG00000185630 1.004253685 0.0029744 PBX1 
ENSG00000203852 0.815067631 0.00299006 HIST2H3A 
ENSG00000203811 0.815067631 0.00299006 HIST2H3C 
ENSG00000177374 1.556108546 0.00301525 HIC1 
ENSG00000148773 0.761912288 0.00301525 MKI67 
ENSG00000117586 0.923970013 0.00306916 TNFSF4 
ENSG00000163661 1.65810892 0.00315191 PTX3 
ENSG00000116962 2.877716701 0.00318629 NID1 
ENSG00000176083 2.068465556 0.00337635 ZNF683 
ENSG00000162430 0.817487422 0.0034414 SELENON 
ENSG00000168421 0.928183342 0.00349696 RHOH 
ENSG00000101333 1.182625763 0.00356031 PLCB4 
ENSG00000091592 0.872215474 0.00359557 NLRP1 
ENSG00000274750 1.314435953 0.00371685 HIST1H3E 
ENSG00000186583 1.737537225 0.00371685 SPATC1 
ENSG00000135476 0.935346642 0.00395106 ESPL1 
ENSG00000169403 1.507488243 0.00395106 PTAFR 
ENSG00000120693 1.662070874 0.00395106 SMAD9 
ENSG00000181631 1.740613691 0.00401134 P2RY13 
ENSG00000274137 2.773655599 0.00407083 MYOM2 
ENSG00000215126 1.485121333 0.00422623 CBWD2 
ENSG00000082438 1.354800846 0.00430114 COBLL1 
ENSG00000170482 1.441583989 0.00430114 SLC23A1 
ENSG00000138722 1.080940834 0.00431164 MMRN1 
ENSG00000100055 1.324142935 0.00434538 CYTH4 
ENSG00000064393 0.81492074 0.00434538 HIPK2 
ENSG00000138315 3.977965604 0.00434538 OIT3 
ENSG00000167994 2.207617674 0.00434538 RAB3IL1 
ENSG00000146674 2.846913899 0.00439704 IGFBP3 
ENSG00000170542 1.07916359 0.00439904 SERPINB9 
ENSG00000204197 0.838015864 0.00441044 KIFC1 
ENSG00000101200 2.76810155 0.00441383 AVP 
ENSG00000171703 0.798547752 0.0044334 TCEA2 
ENSG00000198467 0.915411802 0.0044334 TPM2 
ENSG00000070778 2.027628931 0.00443837 PTPN21 
ENSG00000010610 1.788650489 0.0047221 CD4 
ENSG00000198844 2.363042899 0.00492595 ARHGEF15 
ENSG00000164741 1.855899543 0.00492595 DLC1 
ENSG00000136286 0.79587199 0.00509648 MYO1G 
ENSG00000173548 1.297425432 0.00509674 SNX33 
ENSG00000124019 1.055307006 0.00513736 FAM124B 
ENSG00000197536 0.796970571 0.00522435 C5orf56 
ENSG00000104081 1.229399238 0.00524816 BMF 
ENSG00000165591 2.083680268 0.00524816 FAAH2 
ENSG00000082074 0.944112961 0.00524816 FYB1 
ENSG00000197061 0.852748499 0.00524816 HIST1H4C 
ENSG00000198053 0.903927721 0.00544013 SIRPA 
ENSG00000141753 1.998511789 0.00545646 IGFBP4 
ENSG00000110811 1.176174802 0.00555177 P3H3 
ENSG00000132613 0.669901891 0.00563437 MTSS1L 
ENSG00000142627 3.192884249 0.00563573 EPHA2 
ENSG00000196923 0.766442815 0.0056527 PDLIM7 
ENSG00000164877 0.917923689 0.00572897 MICALL2 
ENSG00000105472 1.222745906 0.00577277 CLEC11A 
ENSG00000133574 1.5129269 0.00582916 GIMAP4 
ENSG00000066382 1.143615174 0.00585647 MPPED2 
ENSG00000116833 2.03283586 0.00592996 NR5A2 
ENSG00000099250 1.776031517 0.00605101 NRP1 
ENSG00000176907 4.575879013 0.00612859 TCIM 
ENSG00000135218 3.098017829 0.00630926 CD36 
ENSG00000142089 1.092476529 0.0065896 IFITM3 
ENSG00000197355 1.157574142 0.00666022 UAP1L1 
ENSG00000198835 1.701583945 0.0066859 GJC2 
ENSG00000130783 1.341039766 0.00686218 CCDC62 
ENSG00000145708 2.799203461 0.00686218 CRHBP 
ENSG00000134874 1.472297621 0.00686218 DZIP1 
   
  255 
ENSG00000112715 1.234290358 0.00686218 VEGFA 
ENSG00000080200 0.996072182 0.00688273 CRYBG3 
ENSG00000142552 2.217940418 0.00688273 RCN3 
ENSG00000110841 0.805407456 0.00698431 PPFIBP1 
ENSG00000277157 1.13404813 0.00703419 HIST1H4D 
ENSG00000203814 0.616421003 0.00703419 HIST2H2BF 
ENSG00000188130 0.898978738 0.00735305 MAPK12 
ENSG00000271605 1.59325899 0.00745284 MILR1 
ENSG00000105251 2.602201109 0.00747592 SHD 
ENSG00000166963 1.228314448 0.00754852 MAP1A 
ENSG00000258102 2.782460807 0.00757357 MAP1LC3B2 
ENSG00000189007 0.745941789 0.00758038 ADAT2 
ENSG00000008277 1.28940099 0.00769947 ADAM22 
ENSG00000100596 0.848549389 0.00788316 SPTLC2 
ENSG00000090530 1.698877759 0.00799595 P3H2 
ENSG00000133246 0.808880251 0.00799595 PRAM1 
ENSG00000173762 1.542304179 0.00810547 CD7 
ENSG00000276966 0.845996018 0.00814811 HIST1H4E 
ENSG00000168067 0.739483259 0.00830828 MAP4K2 
ENSG00000153246 1.870811827 0.00845422 PLA2R1 
ENSG00000198722 1.073831039 0.0085074 UNC13B 
ENSG00000135655 0.682280556 0.00855699 USP15 
ENSG00000082458 1.405741 0.00860811 DLG3 
ENSG00000182247 0.877822424 0.00861175 UBE2E2 
ENSG00000155629 0.95600993 0.00863687 PIK3AP1 
ENSG00000167460 0.808028383 0.00869448 TPM4 
ENSG00000157978 1.033390748 0.00871964 LDLRAP1 
ENSG00000111077 2.006194362 0.00888739 TNS2 
ENSG00000166165 1.603132511 0.00918807 CKB 
ENSG00000277075 0.758540472 0.00918807 HIST1H2AE 
ENSG00000124575 0.788431954 0.00919852 HIST1H1D 
ENSG00000149212 0.923203725 0.00919852 SESN3 
ENSG00000126787 0.806655368 0.00923119 DLGAP5 
ENSG00000142748 4.008318466 0.00925999 FCN3 
ENSG00000163492 1.394539124 0.00931436 CCDC141 
ENSG00000139289 3.177309845 0.0095025 PHLDA1 
ENSG00000111879 1.179529604 0.0095089 FAM184A 
ENSG00000181218 1.375623197 0.0095089 HIST3H2A 
ENSG00000127124 0.945300029 0.0095089 HIVEP3 
ENSG00000056998 1.46439594 0.00960115 GYG2 
ENSG00000076555 0.93076214 0.00962699 ACACB 
ENSG00000277564 1.60140258 0.00965853 RBFOX2 
ENSG00000168758 1.174765552 0.00965853 SEMA4C 
ENSG00000115252 1.211225507 0.00975376 PDE1A 
ENSG00000107742 0.974399289 0.00975376 SPOCK2 
ENSG00000278550 3.976103006 0.00977482 SLC43A2 
ENSG00000101255 1.686735999 0.00977482 TRIB3 
ENSG00000273703 0.935084003 0.00977964 HIST1H2BM 
ENSG00000151917 1.217860041 0.00980151 BEND6 
ENSG00000182255 2.744114597 0.00997658 KCNA4 
ENSG00000125347 0.737308876 0.010056 IRF1 
ENSG00000234876 2.170588739 0.010056 NOTCH4 
ENSG00000124788 0.96795496 0.01016429 ATXN1 
ENSG00000107518 2.296610749 0.01034405 ATRNL1 
ENSG00000117724 0.684383506 0.01046694 CENPF 
ENSG00000100503 0.598684147 0.0105954 NIN 
ENSG00000185737 2.439374011 0.01061855 NRG3 
ENSG00000242732 1.136803489 0.01072517 RTL5 
ENSG00000002586 1.012496936 0.01080788 CD99 
ENSG00000104870 0.929643106 0.01080788 FCGRT 
ENSG00000172340 1.564131305 0.01080788 SUCLG2 
ENSG00000187498 3.255851954 0.01132641 COL4A1 
ENSG00000167286 2.171307525 0.0114575 CD3D 
ENSG00000122122 1.038065713 0.01155414 SASH3 
ENSG00000118200 1.529351172 0.01158139 CAMSAP2 
ENSG00000196422 0.82845191 0.01178152 PPP1R26 
ENSG00000174233 0.89969839 0.01204009 ADCY6 
   
  256 
ENSG00000182742 0.988398487 0.01235191 HOXB4 
ENSG00000163462 1.028135005 0.01235997 TRIM46 
ENSG00000141542 1.234048515 0.0125977 RAB40B 
ENSG00000078596 0.978243676 0.01264111 ITM2A 
ENSG00000127329 2.521092969 0.01273162 PTPRB 
ENSG00000137801 2.77530638 0.01273162 THBS1 
ENSG00000123094 1.119277467 0.0128626 RASSF8 
ENSG00000099864 1.331647036 0.01287122 PALM 
ENSG00000142583 0.837567825 0.01289638 SLC2A5 
ENSG00000146021 0.837076604 0.01300542 KLHL3 
ENSG00000026652 0.945737188 0.01306965 AGPAT4 
ENSG00000164035 1.470558422 0.01306965 EMCN 
ENSG00000179862 3.466424818 0.01368675 CITED4 
ENSG00000184270 0.789114047 0.01374522 HIST2H2AB 
ENSG00000141622 1.452821994 0.01374522 RNF165 
ENSG00000177663 1.104996807 0.01387989 IL17RA 
ENSG00000149948 0.631257261 0.01394561 HMGA2 
ENSG00000092421 1.148202829 0.01412102 SEMA6A 
ENSG00000143344 1.857549119 0.01474199 RGL1 
ENSG00000278677 0.803993535 0.01485477 HIST1H2AM 
ENSG00000198155 1.137051225 0.01489893 ZNF876P 
ENSG00000157456 0.764398168 0.01510585 CCNB2 
ENSG00000230143 1.228900068 0.01510585 FLOT1 
ENSG00000119411 1.121762129 0.01510744 BSPRY 
ENSG00000112419 0.761238566 0.01518796 PHACTR2 
ENSG00000198796 1.820970805 0.01537228 ALPK2 
ENSG00000173917 1.1126937 0.01537228 HOXB2 
ENSG00000156049 2.984184052 0.01575409 GNA14 
ENSG00000162415 1.359639267 0.01593229 ZSWIM5 
ENSG00000198908 1.094992266 0.01593891 BHLHB9 
ENSG00000142733 1.37138841 0.01593891 MAP3K6 
ENSG00000101017 1.574708965 0.01604283 CD40 
ENSG00000134352 1.114380306 0.01604283 IL6ST 
ENSG00000137509 0.829621545 0.01631121 PRCP 
ENSG00000183963 1.271691998 0.0163198 SMTN 
ENSG00000137507 2.296987854 0.01635228 LRRC32 
ENSG00000156738 2.80239281 0.01675353 MS4A1 
ENSG00000139679 1.134627118 0.01687196 LPAR6 
ENSG00000214140 2.200621325 0.01687196 PRCD 
ENSG00000174032 0.838175116 0.01687196 SLC25A30 
ENSG00000211584 0.80658172 0.01687196 SLC48A1 
ENSG00000232632 2.935651406 0.01697946 GABBR1 
ENSG00000172824 1.121865283 0.01698962 CES4A 
ENSG00000165475 1.058032782 0.01730444 CRYL1 
ENSG00000182195 1.283741139 0.01730444 LDOC1 
ENSG00000153933 0.926425361 0.01740892 DGKE 
ENSG00000104833 1.364361508 0.01745286 TUBB4A 
ENSG00000179588 1.209209951 0.01745286 ZFPM1 
ENSG00000184992 0.683911301 0.01749903 BRI3BP 
ENSG00000172568 1.826472292 0.01754062 FNDC9 
ENSG00000237112 2.854928397 0.017625 GABBR1 
ENSG00000198865 0.812354995 0.01776273 CCDC152 
ENSG00000206466 2.85260006 0.01776273 GABBR1 
ENSG00000174099 0.97052275 0.01795164 MSRB3 
ENSG00000131069 0.945877889 0.01813248 ACSS2 
ENSG00000145555 1.620672839 0.0183811 MYO10 
ENSG00000143382 1.073441852 0.01845393 ADAMTSL4 
ENSG00000133106 1.083920204 0.01868143 EPSTI1 
ENSG00000166147 0.989152905 0.01882868 FBN1 
ENSG00000196935 1.459434972 0.01912895 SRGAP1 
ENSG00000158406 0.98794617 0.01964309 HIST1H4H 
ENSG00000151651 0.922346937 0.0199834 ADAM8 
ENSG00000163751 1.789664594 0.0199834 CPA3 
ENSG00000106123 0.970725312 0.0199834 EPHB6 
ENSG00000130508 0.731653239 0.02001998 PXDN 
ENSG00000259207 2.451484301 0.02004146 ITGB3 
ENSG00000110092 1.441920381 0.02041688 CCND1 
   
  257 
ENSG00000185551 3.383726191 0.02041688 NR2F2 
ENSG00000067606 1.261573212 0.02051084 PRKCZ 
ENSG00000178573 1.752526701 0.02052871 MAF 
ENSG00000183918 3.319336552 0.02055578 SH2D1A 
ENSG00000107331 0.84403877 0.02065111 ABCA2 
ENSG00000080503 0.701211142 0.0209492 SMARCA2 
ENSG00000148841 1.362162987 0.02126323 ITPRIP 
ENSG00000167487 0.976074641 0.02126323 KLHL26 
ENSG00000129007 0.799603672 0.02131388 CALML4 
ENSG00000160883 3.670263793 0.02131388 HK3 
ENSG00000144824 1.028915808 0.02131388 PHLDB2 
ENSG00000132819 0.966969965 0.02131388 RBM38 
ENSG00000174130 1.200368186 0.02131388 TLR6 
ENSG00000146856 1.33197498 0.02147248 AGBL3 
ENSG00000181104 0.858124247 0.02147248 F2R 
ENSG00000151240 2.341962219 0.02156264 DIP2C 
ENSG00000166396 3.745033991 0.02188618 SERPINB7 
ENSG00000126353 2.796281752 0.02197274 CCR7 
ENSG00000115271 0.820955968 0.02241177 GCA 
ENSG00000131378 0.633102399 0.02242289 RFTN1 
ENSG00000183579 1.273929105 0.02242289 ZNRF3 
ENSG00000040608 1.278612743 0.02245122 RTN4R 
ENSG00000198517 0.668729027 0.02251869 MAFK 
ENSG00000136630 1.650197239 0.02261039 HLX 
ENSG00000090776 1.245723444 0.02290445 EFNB1 
ENSG00000154380 1.278983737 0.02290445 ENAH 
ENSG00000153071 1.460315712 0.02302634 DAB2 
ENSG00000162407 2.670792367 0.02302634 PLPP3 
ENSG00000168994 1.524469471 0.02303755 PXDC1 
ENSG00000071246 1.011032282 0.0232328 VASH1 
ENSG00000120549 2.868654568 0.02329218 KIAA1217 
ENSG00000169908 2.485377412 0.02329218 TM4SF1 
ENSG00000168615 0.884469442 0.02332229 ADAM9 
ENSG00000118276 0.689470482 0.02332229 B4GALT6 
ENSG00000121068 2.398186833 0.02362811 TBX2 
ENSG00000275379 0.752600312 0.02387794 HIST1H3I 
ENSG00000154277 1.361453927 0.024231 UCHL1 
ENSG00000106327 1.187024982 0.0242371 TFR2 
ENSG00000277632 2.885687933 0.02435385 CCL3 
ENSG00000113971 0.800731319 0.02435385 NPHP3 
ENSG00000148154 2.227104131 0.02437889 UGCG 
ENSG00000101405 2.051141871 0.02439048 OXT 
ENSG00000143776 0.797207661 0.02484114 CDC42BPA 
ENSG00000204136 1.608280626 0.02484114 GGTA1P 
ENSG00000123066 0.72348715 0.02494541 MED13L 
ENSG00000175063 0.764708509 0.02494822 UBE2C 
ENSG00000197496 1.269737243 0.02515348 SLC2A10 
ENSG00000116128 1.489534932 0.02528229 BCL9 
ENSG00000206511 2.792328807 0.02555351 GABBR1 
ENSG00000072694 1.947524446 0.02575314 FCGR2B 
ENSG00000091262 1.033050337 0.02622041 ABCC6 
ENSG00000151687 0.931861476 0.02622041 ANKAR 
ENSG00000234289 0.747390185 0.02622041 LOC102724334 
ENSG00000181192 0.617909349 0.02663675 DHTKD1 
ENSG00000198010 2.430231966 0.02682173 DLGAP2 
ENSG00000184515 3.463692789 0.02692445 BEX5 
ENSG00000197629 1.475787087 0.02723554 MPEG1 
ENSG00000160712 0.918420786 0.02735361 IL6R 
ENSG00000123146 0.992402326 0.02749539 ADGRE5 
ENSG00000105552 0.807888218 0.02749539 BCAT2 
ENSG00000278705 0.837140175 0.02771098 HIST1H4B 
ENSG00000007237 0.809180094 0.02779634 GAS7 
ENSG00000148908 1.054420946 0.02788656 RGS10 
ENSG00000131747 0.695627254 0.02788656 TOP2A 
ENSG00000129467 1.521393007 0.02788712 ADCY4 
ENSG00000145349 1.184129465 0.02822727 CAMK2D 
ENSG00000126759 1.007773149 0.02875508 CFP 
   
  258 
ENSG00000183049 0.665514536 0.02893247 CAMK1D 
ENSG00000128596 0.680803047 0.02893247 CCDC136 
ENSG00000106080 0.79734989 0.02905318 FKBP14 
ENSG00000212747 2.315203252 0.02919076 RTL8B 
ENSG00000256069 1.823018861 0.02996615 A2MP1 
ENSG00000140450 0.966447933 0.0299811 ARRDC4 
ENSG00000064989 0.661340455 0.0299811 CALCRL 
ENSG00000101665 1.940663267 0.0299811 SMAD7 
ENSG00000103056 0.852032189 0.0299811 SMPD3 
ENSG00000188486 0.75441724 0.03012787 H2AFX 
ENSG00000129993 0.662802804 0.03013946 CBFA2T3 
ENSG00000100077 0.862046345 0.03033122 GRK3 
ENSG00000053918 1.581420048 0.03129698 KCNQ1 
ENSG00000010671 0.719624917 0.03159227 BTK 
ENSG00000170485 1.80855278 0.03234712 NPAS2 
ENSG00000167100 0.917175939 0.03240218 SAMD14 
ENSG00000276644 0.714381039 0.03245803 DACH1 
ENSG00000108773 0.516475308 0.03245803 KAT2A 
ENSG00000149573 1.055697666 0.03288176 MPZL2 
ENSG00000120832 1.099406269 0.03303032 MTERF2 
ENSG00000206282 1.081265167 0.033132 RGL2 
ENSG00000134061 1.269331477 0.03337543 CD180 
ENSG00000266338 0.772594303 0.03360352 NBPF15 
ENSG00000169413 1.933867446 0.03375688 RNASE6 
ENSG00000136982 0.667189243 0.03443169 DSCC1 
ENSG00000198435 1.023074764 0.03443169 NRARP 
ENSG00000153404 1.1574279 0.0344874 PLEKHG4B 
ENSG00000188643 2.370659958 0.03465398 S100A16 
ENSG00000077782 1.126619519 0.03469929 FGFR1 
ENSG00000224103 1.749963862 0.03476704 HLA DPA1 
ENSG00000130958 1.247022263 0.03476704 SLC35D2 
ENSG00000178999 0.654592702 0.03512909 AURKB 
ENSG00000167371 2.035337192 0.03513883 PRRT2 
ENSG00000180596 0.717258638 0.03532078 HIST1H2BC 
ENSG00000273983 0.730025002 0.03532078 HIST1H3G 
ENSG00000148655 0.822850728 0.03532078 LRMDA 
ENSG00000151503 0.581779792 0.03532078 NCAPD3 
ENSG00000204301 3.366577621 0.03532078 NOTCH4 
ENSG00000182957 0.903305698 0.03532078 SPATA13 
ENSG00000188906 2.491583844 0.03540966 LRRK2 
ENSG00000161013 0.799799978 0.03550967 MGAT4B 
ENSG00000089159 0.715236345 0.03550967 PXN 
ENSG00000139687 0.532202444 0.03646247 RB1 
ENSG00000100979 0.905289811 0.03647612 PLTP 
ENSG00000205309 0.84484608 0.03650395 NT5M 
ENSG00000070190 0.759905482 0.03665458 DAPP1 
ENSG00000167419 1.393309378 0.03665458 LPO 
ENSG00000161981 0.85139453 0.03716069 SNRNP25 
ENSG00000033627 0.752451191 0.03718008 ATP6V0A1 
ENSG00000138346 0.709811694 0.03718008 DNA2 
ENSG00000137414 0.901934255 0.03718008 FAM8A1 
ENSG00000258405 1.286366623 0.03746862 ZNF578 
ENSG00000042980 0.844754131 0.03795474 ADAM28 
ENSG00000164181 1.309768972 0.03850767 ELOVL7 
ENSG00000105997 0.73893985 0.03850767 HOXA3 
ENSG00000166927 1.417303793 0.03850767 MS4A7 
ENSG00000105426 0.976543129 0.03853874 PTPRS 
ENSG00000133169 1.876715851 0.03903923 BEX1 
ENSG00000166341 0.82349782 0.0392117 DCHS1 
ENSG00000004866 1.171546226 0.039393 ST7 
ENSG00000278634 1.483853168 0.03942255 LILRA2 
ENSG00000197956 1.160697699 0.03950682 S100A6 
ENSG00000053747 1.536754502 0.03961134 LAMA3 
ENSG00000135919 1.212977919 0.04021224 SERPINE2 
ENSG00000242361 1.301942756 0.04030331 HLA DMA 
ENSG00000137501 1.033422313 0.04030331 SYTL2 
ENSG00000187815 1.161089279 0.04034202 ZFP69 
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ENSG00000176624 0.737142777 0.04046278 MEX3C 
ENSG00000165795 0.990519762 0.04075135 NDRG2 
ENSG00000136160 2.155891009 0.04086214 EDNRB 
ENSG00000198959 1.633704447 0.04086214 TGM2 
ENSG00000117877 1.063823921 0.04119215 CD3EAP 
ENSG00000263961 1.125365709 0.04119215 RHEX 
ENSG00000166510 2.163392184 0.04131026 CCDC68 
ENSG00000110077 3.134639694 0.0415144 MS4A6A 
ENSG00000183580 2.530841048 0.0421005 FBXL7 
ENSG00000187513 3.007582275 0.0423309 GJA4 
ENSG00000141698 0.755157635 0.0423309 NT5C3B 
ENSG00000274429 1.141317478 0.0427901 DLG5 
ENSG00000189057 0.806322001 0.04297813 FAM111B 
ENSG00000162711 0.730099958 0.04302265 NLRP3 
ENSG00000116604 0.703665484 0.04317401 MEF2D 
ENSG00000172380 2.322482308 0.0435403 GNG12 
ENSG00000069020 0.814557868 0.04358929 MAST4 
ENSG00000274891 0.82946935 0.04358929 TRAPPC12 
ENSG00000120217 2.108709341 0.04410523 CD274 
ENSG00000184113 1.505584845 0.04441531 CLDN5 
ENSG00000157927 1.007265073 0.04451401 RADIL 
ENSG00000082269 0.668880496 0.04460489 FAM135A 
ENSG00000128567 1.329657839 0.04476735 PODXL 
ENSG00000189337 0.939513436 0.04529112 KAZN 
ENSG00000177511 2.466032159 0.04529112 ST8SIA3 
ENSG00000198948 1.554200216 0.04600396 MFAP3L 
ENSG00000100320 0.789992909 0.04610085 RBFOX2 
ENSG00000020181 0.64149706 0.04677559 ADGRA2 
ENSG00000118971 0.600808316 0.0467928 CCND2 
ENSG00000090006 0.620077237 0.04679458 LTBP4 
ENSG00000162825 0.885126071 0.04679458 NBPF20 
ENSG00000168016 0.755141741 0.04679458 TRANK1 
ENSG00000277059 1.315204439 0.04683475 FAM30A 
ENSG00000151062 0.916395914 0.04790017 CACNA2D4 
ENSG00000130037 3.199893797 0.04815773 KCNA5 
ENSG00000140400 0.624369493 0.0484206 MAN2C1 
ENSG00000117400 0.918704441 0.04866367 MPL 
ENSG00000159335 1.178887773 0.04866367 PTMS 
ENSG00000175189 3.243698341 0.04908682 INHBC 
ENSG00000137727 1.432397173 0.04910205 ARHGAP20 
ENSG00000149782 0.633298868 0.04910205 PLCB3 
ENSG00000198734 2.065996588 0.04914069 F5 
ENSG00000157445 2.46603193 0.04920567 CACNA2D3 
ENSG00000198286 0.841900712 0.04928243 CARD11 







   
  260 
10.5 Appendix 5 
 List of genes commonly upregulated in foetal liver and neonatal/adult 
derived populations in humans and mice, described in chapter 5. 
FL human  FL Mouse CB human BM mouse 
DDX3Y  NLRC5 
AKAP12  ITPR2 
LIN28B SLC44A2 
CCNB1 SLC4A8 
ASPM  DACH1 
KIF20A ARMCX3     
KIF15 IRF7 
BUB1B  CSGALNACT2 
DLK1 CSGALNACT1 
LMNB1 CYTIP 
AURKA  RNF125 




CD33    CHST11 
UBE2C NRXN1 












COTL1 OPTN       
DLAT LGALS3BP 








MYCN    FAAH 
CCNF GADD45B 












IGSF10 BCL6       
UQCC2 IER3    






   











CKAP5   
 
DNMT3A 
 
MARCKS  
 
ITGA4 
 
IFT57 
 
SIRPA 
 
PTCD3 
 
 
 
